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A B S T R A C T
According to the World Health Organization a third of the world's population is
infected with Mycobacterium tuberculosis. The unparalleled success of M.

tuberculosis as a pathogen reflects the bacterium's extraordinary ability to per
in its host in spite of eliciting a robust immune response. Currently available

treatment is inadequate and drug resistance is rapidly spreading. New antibiotic
are desperately needed. The substrates and metabolic pathways utilized by
pathogens during infection are largely unknown and represent an under-exploited
area of investigation. Uniquely, evolution of the genus Mycobacterium has
involved extensive duplication of fatty acid metabolism genes, including two
homologs encoding prokaryotic- and eukaryotic-like isoforms of the glyoxylate
cycle enzyme isocitrate lyase (ICL). The glyoxylate cycle is employed by cells
when fatty acids are the main carbon source available. Here, we show that these

enzymes are jointly required by M. tuberculosis for growth on fatty acids and fo

virulence in experimental infections. Although deletion of icll or icl2 had litt
impact on replication of M. tuberculosis in macrophages and mice, deletion of

both genes abrogated intracellular growth, and resulted in rapid bacterial clear

from the lungs. A dual-specificity ICL inhibitor similarly blocked replication o
M. tuberculosis on fatty acids in vitro and in macrophages. The absence of ICL
orthologs in mammals, and recent findings implicating the glyoxylate pathway in
the virulence of other bacterial and fungal pathogens makes this metabolic
pathway an attractive novel target for drug development.

A R o x a n a Elias, m i madre, por su infinita abnegation y amor...
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" W h e n m e n lack a sense of awe, there will be disaster."
Lao Tsu
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P A R T I

C H A P T E R

1

Bacterial Persistence: Strategies for Survival

INTRODUCTION

Most bacteria cause acute infections that cannot withstand the onslaught of the
host's adaptive immune response. Less commonly, some bacteria such as
Salmonella typhi and Mycobacterium tuberculosis cause infections that persist,
often for the lifetime of the host. Persistence is responsible for the unusual

epidemic characteristics of diseases like tuberculosis. A relevant metric is the
"critical community size" (CCS) required for endemicity. The theoretical and
observed CCS for measles virus is a staggering 250,000 individuals; in smaller
populations, measles self-extinguishes after exhausting the pool of naive
susceptible hosts (Keeling & Grenfell 1997; Keeling, 1997). Human populations

on this scale have existed for only a few thousand years, suggesting that measle
a newcomer to the human niche. This view is supported by field studies of

epidemiologist Francis Black, who found that imported measles did not persist in
small, isolated human populations — e.g., in the South American Amazon basin

1

(Black, 1975). In contrast, tuberculosis was endemic in m a n y of these smaller
communities. Modeling studies put the CCS for tuberculosis at less than 500
individuals (McGrath, 1988), perhaps explaining its antiquity as a human disease
(Daniel et al. 1994; Haas & Haas 1996). Persistence is also reflected in the

contrasting epidemic dynamics of diseases caused by persistent and non-persisten
pathogens — e.g., measles epidemics wax and wane over wks or months (Fig.
1.1 A) (Keeling, 1997), whereas tuberculosis epidemics span centuries (Fig. LIB)
(Grigg, 1958; Blower etal, 1995).
M. tuberculosis is not unique in its ability to cause persistent infections.

Indeed, the roster of persistent pathogens continues to lengthen as technologica
advances allow the identification of previously unknown species. An important

example is the recognition that gastritis, gastric and duodenal ulcers, and gast
neoplasms and lymphomas are often linked to colonization of the human stomach

by Helicobacter pylori (Dubois et al., 2000). Via mechanisms that are only partly
understood, this Gram-negative spiral bacterium has evolved to exploit a niche
that was assumed to be devoid of microbial life. This is a remarkably successful

strategy — by current estimates, the stomachs of half the global human populatio

harbor H. pylori, often for the lifetime of the host (Blaser & Atherton, 2004). A

the list of persistent pathogens grows, so does our appreciation of the diversit
sophistication of the mechanisms that allow these microbial invaders to survive
"in the face of opposition or adversity." A comprehensive survey of persistent
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Fig. 1.1 Contrasting epidemic dynamics of measles and tuberculosis. (A) Simulation of a measles
epidemic initiated by entering one infectious case at time zero into a susceptible population of
500,000. The simulation illustrates successive waves at -6-12 month intervals (Keeling, 1997). (B)
Simulation of a tuberculosis epidemic initiated by entering one infectious case at time zero into a
population of 200,000. It illustrates the relative contribution of 3 types of disease to the overall
incidence: progressive primary, post-primary, and relapse tuberculosis. A fourth type, exogenous
reinfection (not included), presumably would increase the peak level and duration of the epidemic.
Redrawn from Blower et al. (1995). The contrasting epidemic dynamics of measles and tuberculosis
are also reflected in the "critical community size" (CCS) required for endemicity, which is roughly
250,000 for measles (Keeling, 1997) and 500 or less for tuberculosis (McGrath, 1988).

bacterial pathogens is beyond the scope of this chapter, which will focus on a few
organisms as paradigms of persistence strategies.

1.1. Treponema pallidum — Why run if you can hide?

Several spirochetes of the genus Treponema cause persistent infections in humans

including Treponema pallidum, the etiologic agent of syphilis. Spirochetes are a
phylogenetically distinct group of prokaryotes with an outer membrane and a
periplasmic space, similar to the Gram-negatives; however, the outer membrane of
treponemes has a higher lipid:protein ratio and lacks the pro-inflammatory
constituent lipopolysaccharide (LPS) (Radolf et al, 1989; Radolf, 1995). The
periplasmic space contains the flagella of these highly motile, slender, and

elongated "corkscrew" bacteria. Syphilis was first recognized in the late fiftee

century after the first European explorers returned from the Americas, where the
disease was probably endemic (Quetel, 1990). When syphilis first erupted in
Europe, it was highly virulent and usually fatal. As the spirochete spread
throughout Europe it was rapidly attenuated, and a milder, more chronic form of
disease became dominant. Why? It may be that the attenuated strains were

favored because the horrific manifestations of the early, virulent form of syphi
were a deterrent to sexual transmission. It is also tempting to speculate that
attenuated treponemes enjoyed a selective advantage because prolonged survival

of the infected host ensured greater opportunity for transmission. Field evidenc

in favor of this idea derives from the epidemic of myxomatosis that was
introduced into the feral rabbit population of Australia in 1950/51 (Fenner &
Fantini, 1999). Following an initial period of high host mortality, attenuated
strains of myxoma virus emerged and became dominant. Rabbits infected with

attenuated viruses were protected against superinfection with the virulent paren
virus, and, because they lived longer and were more active, dissemination of the
attenuated strains was favored.
The incidence of syphilis has declined steeply since the introduction of
penicillin in 1943. However, the disease continues to pose a significant health
problem worldwide. The steady decline in the incidence of syphilis from 1991 to

the present in the United States should not necessarily be interpreted as a vict

for public health because syphilis epidemics display naturally periodic dynamics
with approximately ten-year cycles. Recently, these cycles, which previously had
been attributed to changes in "environmental" factors such as sexual behavior,
have been shown to be due to intrinsic host immunity-pathogen interactions
(Grassly et al, 2005). The immunity that follows syphilis, though imperfect,

allows for exhaustion of susceptible individuals after an epidemic, leading to a
decline in incidence (Morgan et al, 2003). However, this period is typically
followed by a surge in the number of cases as a new supply of susceptible
individuals becomes available. The periodic dynamics of syphilis epidemics
underscores the need for unceasing vigilance in case detection and treatment
(Garnett & Brunham, 1999).

Syphilis is a slowly progressing, multistage disease (Singh & Romanowski,
1999). Infection is transmitted horizontally by sexual contact and vertically by
transplacental migration of treponemes. During sexual intercourse, spirochetes
present in the genital tract of the donor invade the recipient through small
abrasions in the mucous membranes or skin of the genitalia. Replication of the

organism at the site of entry triggers massive leukocyte infiltration, blood ves
damage, and tissue necrosis, resulting in the appearance of a primary lesion or
"chancre." In most patients, the chancre heals spontaneously after a few weeks

and disease progression is arrested. In the less fortunate minority, disseminati
from the primary lesion occurs a few weeks after initial infection, leading to

generalized infection of almost every tissue of the body, with a notable tropism

the vascular system. The onset of secondary syphilis is marked by the appearance

of nodular lesions or papules at these metastatic sites of infection. In most ca
of primary and secondary syphilis, infection is resolved spontaneously by the

adaptive immune response usually in less than 6 months post-exposure (Garnett et
al, 1997). However, small populations of treponemes may persist in a few

isolated lesions and eventually give rise to tertiary syphilis, a chronic diseas
usually endures for the lifetime of the host. Treatment of primary or secondary

syphilis with penicillin is highly effective, but once disease progresses to the

tertiary or latent stages it becomes refractory (Ghinsberg & Nitzan, 1992). Terti
syphilis is characterized by the persistence of mature granulomatous lesions
("gummas") containing small numbers of spirochetes. Gummas may occur in

almost any organ system, causing gradual physiological deterioration. Persistent

infection of the CNS can lead to destruction of neural tissue, loss of motor act
and paresthesia, as in the jerking movements and paroxysmal pains that are

characteristic of tabes dorsalis (sclerosis of the posterior columns of the spin
cord). Gummas occurring in other regions of the CNS may give rise to the most

dreaded manifestations of syphilis — insanity and generalized paralysis. It is n
clear how treponemes damage tissues. No bacterial toxins have been identified,

and it is possible that the pathology is due to chronic inflammatory host respon
to persistent spirochetes.
In the pre-chemotherapy era, longitudinal studies of untreated syphilis
revealed that the great majority of patients do not progress beyond the primary
stage (Gjestlaand, 1955), and reinoculation studies established that syphilitic
patients were partially protected against reinfection (Fitzgerald, 1981). Both
humoral and cellular adaptive immune responses play a role in resistance to T.
pallidum (Rich et al, 1933). Passive immunization of rabbits with immune serum

before infection with T. pallidum delays the appearance of syphilitic lesions an

attenuates their severity (Bishop & Miller, 1976a), and resistance to re-infectio
correlated with the appearance of anti-treponemal antibodies (Bishop & Miller,
1976b). Antibodies from immune rabbit serum promote complement-mediated

killing of treponemes (Blanco et al, 1984) and block the interaction of T pallid
with extracellular matrix components (fibronectin, laminin, and collagen), which

could interfere with the invasion and dissemination of spirochetes (Fitzgerald e

al, 1984). Syphilitic patients typically develop I g M and IgG responses to a slew
of treponemal antigens (Baker-Zander et al, 1985).
A role for cellular immunity is suggested by the dramatic infiltration of
lesions by mononuclear leukocytes, which occurs as early as one week postinfection in the rabbit model (Lukehart et al, 1980a; Sell et al, 1980). The
cellular infiltration peaks by two weeks post-infection and is composed
predominantly of mononuclear phagocytes and T cells, with Treponema-specific T
cells emerging early in the course of infection (Lukehart et al, 1980b; BakerZander et al, 1988; Arroll et al, 1999). Lesions of syphilitic patients contain
activated CD8+ cytolytic T lymphocytes (van Voorhis et al, 1996a) and show
evidence of a dominant type-1 CD4+ T cell cytokine response — i.e., IFN-y, IL12, and IL-2, but not IL-4 (van Voorhis et al, 1996b). Activation of macrophages

by type 1 cytokines is thought to be important for treponemal clearance and lesi
resolution (Sell et al, 1980; Lukehart et al, 1980a; Lukehart, 1982). Degraded
treponemes are found inside the phagolysosomal compartments of infiltrating
macrophages in regressing syphilitic lesions (Ovcinnikov & Delektorskij, 1972),
and rabbit peritoneal macrophages are capable of phagocytizing and killing
treponemes in vitro (Lukehart & Miller, 1978; Baker-Zander & Lukehart, 1992),

particularly in the presence of opsonizing antibodies (Baker-Zander et al, 1993).
However, both opsonized and non-opsonized treponemes are unusually resistant to
phagocytosis by macrophages, which presumably enhances bacterial survival in
inflammatory lesions (Alder et al, 1990; Lukehart et al, 1992).

In the rabbit model of syphilis, long-lasting immunity to T. pallidum does

not develop until about three months post-infection, and fails to develop altoge

if the course of infection is interrupted by antibiotic therapy (Fitzgerald, 1981

Although adaptive immunity curtails further disease progression, sterilization d
not occur, and "immune" animals continue to harbor viable treponemes

indefinitely. There is a clear parallel to human disease, in which tertiary syph
may occur years or decades after initial infection. Two key questions arise: why
does acquired immunity develop so slowly in syphilis, and why is the pathogen
not eliminated? Poor immunogenicity and immune evasion by treponemes may
provide partial answers.
Persistent treponemes harvested from rabbits at later stages of infection,

after >99% of the bacteria have been cleared, are less susceptible to phagocytos
by macrophages (Lukehart et al, 1992), suggesting that persistent infection may
be due to a subpopulation of treponemal persistent bacteria that evade
opsonization and phagocytosis. It has been suggested that this type of bacteria
might adopt a "stealth" strategy in vivo, altering their surface composition in

to reduce their antigenicity (Radolf, 1994). Indeed, ultrastructural studies reve
that the outer membrane of T. pallidum is largely devoid of membrane-associated
proteins (Radolf et al, 1989), and intact treponemes are poorly reactive with
immune rabbit serum unless the outer membrane is removed or damaged (Cox et

al, 1992). A number of cell wall-associated T. pallidum lipoprotein antigens have

been identified, but these are apparently localized to the inner (plasma) membrane
rather than the outer membrane (Radolf, 1994; Radolf, 1995).
T. pallidum is a highly invasive pathogen (Haake & Lovett, 1990), so the

paucity of surface-exposed proteins begs the question, what are the ligands that

allow the organism to attach and invade after entering the host? These presumabl
surface-exposed bacterial components are likely targets of the adaptive immune
response. Two proteins termed Trompl and Tromp2 (^Treponema pallidum rare

outer membrane proteins") were identified by freeze-fracture electron microscopy
(Blanco et al, 1997). Although localization of Tromps to the outer membrane is
disputed (Akins et al, 1997), anti-Tromp antibodies are treponemicidal and
correlate with protective immunity in rabbits (Lewinski et al, 1999). The

sequence of the T. pallidum genome reveals another group of potentially surfaceexposed molecules comprising a novel twelve-member gene family termed tpr
{"Treponema pallidum repeat") (Fraser et al, 1998). The Tpr proteins contain
central domains of variable length and sequence flanked by conserved N- and Cterminal domains, including conserved hypothetical transmembrane domains in
some family members. One of these, TprK, is surface-exposed and targeted by the
protective immune response in rabbits (Centurion-Lara et al, 1999). Antiserum
from rabbits that are immunized with TprK is opsonizing for phagocytosis and
TprK-immunized animals are partially protected against challenge with virulent
treponemes. The role of the Tpr proteins in treponemal pathogenesis is not

known, but these studies suggest that they could be attractive subunit candidate

10

for a vaccine. Strain differences in tprK copy number and sequence have been

identified, suggesting that variation of TprK might contribute to immune evasion

(Centurion-Lara et al, 2000). Possibly, the advent of a subpopulation of antigeni
variants during infection could account for the failure of adaptive immunity to

eliminate small numbers of persistent bacteria, resulting in the prolonged perio
of latency that can be observed during syphilis.

1.2. Borrelia spp. — Antigenic variation: a change of face wins the race

Many microbial pathogens control gene expression by programmed
rearrangements of specific DNA sequences (Borst & Greaves, 1987). These
"contingency loci" (Moxon et al, 1994) affect processes at the host/pathogen
interface, including colonization, invasion, adaptation to different tissue
environments, and evasion of immune defenses (Deitsch et al, 1997).
Programmed rearrangement of genes encoding surface antigens ("antigenic
variation") is essential for the evasion of humoral immunity by extracellular
pathogens such as the Borrelia spp. that cause relapsing fever and Lyme disease.

1.2.1. Relapsing fever. Relapsing fever (RF) is characterized by recurrent febri
episodes, which correspond to intervals of high bacteremia (Fig. 1.2A) (Barbour
Hayes, 1986). The causative agents are arthropod-transmitted spirochetes of the

genus Borrelia. The RF borrelias persist at titers of up to ~108 bacteria per ml
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Relapsing Fever during Borrelia infection

A)

CU2

B)

Antigenic Variation of Neisseria Pili
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Fig. 1.2. Antigenic variation in Relapsing Fever and Gonorrhoeae. (A) Relapsing Fever. Spikes of
fever are accompanied by waves of spirochetemia. In each successive wave, a new antigenic variant
dominates (indicated by different shapes). A s the bacteria are cleared by the specific humoral
response, the fever subsides. However, expansion of a newly emergent variant brings about another
febrile episode within a few days. (B) Antigenic variation of pili in Neisseria gonorrhoeae. Pilin is
encoded by one or two pilE expression loci. Variant pilin sequences are stored in silent pilS cassettes,
which lack the 5' coding and promoter sequences required for expression. Nonreciprocal
recombination between pilS and pilE sequences gives rise to expression of variant pilin subunits.
Modular recombination can generate mosaic pilE loci containing sequences derived from several
distinct pilS loci.
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blood, which ensures transmission of the pathogen to the insect vector during a

blood meal. However, extracellular bacteria residing in the blood are exposed to
the onslaught of the humoral immune response; survival in this perilous
environment requires the pathogen to keep one step ahead of the host, which the
RF borrelias accomplish by means of antigenic variation (Barbour, 1990).

Referring to the spirochete-specific antibodies generated during an episode of R

Meleney (1928) wrote: "These substances [antibodies] are specific for the strain

spirochetes which was present during the preceding attack, but have no influence

on the spirochetes of the succeeding relapse. The spirochetes of the relapse giv
rise, in turn, to immune substances which are specific for them but not for the
spirochetes of the first attack." A key question was whether a single bacterium
could give rise to the observed waves of variants, or whether relapses were due
simultaneous infection with a mixture of variants that were expanded and

eliminated in succession. This issue was resolved by infection of rats with a si

bacterium (B. turicatae) and recovery of antigenically distinct relapse populati
(Fig. 1.2A) (Schuhardt & Wilkerson, 1951). The population dynamics of borrelial

antigenic variation were clarified by the application of serotype-specific immun

sera to identify relapse isolates of B. hermsii, which arose at frequencies of ~
to IO"4 per generation (Stoenner et al, 1982). Only a small proportion of the
spirochete population converted to other serotypes; this switch was abrupt and
coincided with the clearance of the dominant (parental) population. Given the

high rate at which serotype switching occurred, it was (and still is) puzzling t
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only one or a very small number of serotypes were found in each relapse.
Inhibition of antibody production had no effect on the emergence of serotype
variants, demonstrating that humoral immunity was not driving the generation of
new spirochete serotypes, but merely selecting against pre-existing types. The
serotype-specific antibodies responsible for spirochete clearance recognize a

family of surface-exposed and serotype-specific lipoproteins, the "variable majo
proteins" (VMPs) (Barbour et al, 1982).
The high-frequency variation of VMPs was later shown to result from
programmed rearrangements of the vmp genes (Meier et al, 1985). The DNA

sequences encoding a serotype-specific VMP variant are present in all serotypes,
including those that express a different VMP variant (Plasterk et al, 1985).
However, serotypes that express a particular VMP contain not one but two DNA
loci encoding that variant, i.e., duplication of a given vmp is associated with
expression. Duplication occurs via a non-reciprocal recombination event between
a silent vmp "cassette" and a unique, unlinked "expression site". Recombination
between these non-homologous loci is targeted by homologous regions flanking
the expressed and silent vmp genes. The repertoire of vmp genes is carried on

multi-copy, linear plasmids, with silent and expressed loci located on different
plasmids (Saint Girons & Barbour, 1991; Kitten & Barbour, 1992; Wilske et al,
1992). This arrangement allows recombination to occur at high frequency without
jeopardizing chromosomal integrity. Interestingly, the vmp expression site is
linked to the telomere of the linear plasmid that carries it (Kitten & Barbour,
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1990). Although the significance of telomere linkage is unclear, it is shared by the
system responsible for high-frequency variation of the immuno-dominant "variant
surface glycoprotein" (VSG) antigen in Trypanosoma brucei (Rudenko et al,
1998).
Two additional mechanisms contribute to antigenic variation in B. hermsii.
The first involves activation of a pseudogene downstream of an expressed vmp by
intra-plasmid (rather than inter-plasmid) recombination (Restrepo et al, 1994).
The second involves the selective hyper-mutation of expressed vmps by an
unknown mechanism; polymorphisms in expressed vmp genes accumulate with
time and are absent in silent vmp genes (Restrepo & Barbour, 1994).
None of the vmp genes is expressed in the insect vector, suggesting that the

vmp system has evolved to promote bacterial survival exclusively in the vertebra
host (Schwan & Hinnebusch, 1998). What is the role of the VMP system in

pathogenesis? Is it simply to offer a constantly changing face to the vertebrate
immune system? Or do the VMPs contribute directly to infection and
dissemination within the host? Emerging evidence suggests that VMP variation
may influence the organ tropism and dissemination properties of individual
spirochetes (Cadavid et al, 1994; Cadavid et al, 1997; Pennington et al, 1999).
It is tempting to speculate that these "knock-on" effects of VMP variation could

promote the adaptation of Borrelia spp. to previously unavailable niches, possib
including new host species.
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1.2.2. L y m e disease. L y m e disease (LD) is a chronic syndrome caused by the

tick-borne spirochete Borrelia burgdorferi. The ecological cycle of the pathogen

is complex, involving several small and intermediate-sized vertebrate reservoirs
which transmit bacteria to the insect vector during blood meals (Gern & Humair,
1998). Humans are thought to be a "dead end" host. LD can be divided into three
clinical stages (Steere, 1989; Evans, 1999). The first stage is marked by a

transient skin lesion at the site of inoculation (erythema migrans). In the secon
stage, lasting up to six months, dissemination of the spirochetes gives rise to
secondary skin lesions and other intermittent and variable pathologies, such as
muscular and skeletal pain, meningitis, and carditis. These signs and symptoms

often resolve spontaneously, leading to a subclinical or latent phase of variabl
duration. The third stage of disease, occurring months to years after initial

infection, is characterized by chronic arthritis, cardiomyopathy, and neurologic
abnormalities. Borrelial persistence has been documented in clinical studies of

patients (Fikrig et al, 1994; Kuiper et al, 1994) and in animal models (Barthold
al, 1993; Pachner et al, 1995; Roberts et al, 1995; Gylfe et al, 2000). The
mechanism(s) that allow B. burgdorferi to cause persistent infection - whether
chronic or latent - remain poorly understood.
Although LD patients typically produce antibodies against a broad range of

B. burgdorferi antigens, antibody production may be significantly delayed (Steer

1989). Studies in animal models of infection also suggest that B. burgdorferi may
in some cases induce a non-protective immune response. In different strains of

16

mice, susceptibility seems to correlate with production of the "type 1" cytokine
interferon-y (IFN-y), whereas resistance correlates with production of the "type

cytokine interleukin-4 (IL-4) (Sigal, 1997). This association has also been noted
in Lyme disease patients (Oksi et al, 1996), and may reflect the importance of
antibody-mediated mechanisms of protection against borreliosis (Hu & Klempner,
1997), since type 2 cytokines are associated with dominant humoral immune
responses.
There is accumulating evidence that B. burgdorferi evades the humoral
response by antigenic variation of surface-exposed lipoproteins encoded by vis
genes (for "vmp-like sequence") (Zhang et al, 1997). The parallel to the vmp

system of the RF borrelias is striking: the vis coding sequences are carried on a
linear plasmid, and serotype switching occurs by non-reciprocal recombination

between silent vis cassettes and an expressed copy (vlsE) that is telomere-linke
(Zhang & Norris, 1998a, 1998b). Because recombination between vlsE and
segments of the silent vis cassettes is combinatorial, the number of unique VlsE

variants that could arise by shuffling of cassette segments is potentially enorm

Antigenic variation of VlsE in mice is associated with loss of seroreactivity, a

the rate of variation is higher in immune-competent mice than in immune-deficien
SCID mice (Zhang & Norris, 1998b). These observations suggest that VlsE
variation may be an important mechanism of immune evasion. However, the rate

of VlsE variation in SCID mice, although relatively low, is still much higher th
observed during in vitro passage, suggesting that VlsE variation may play an
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adaptive role in vivo in addition to its probable role in i m m u n e evasion. This idea

is supported by the observation that spirochetes lacking the vslE plasmid are le
infective to both immune-competent and SCID mice (Norris et al, 1995).
Interestingly, the fact that while most of the bacterium's chromosome is -25%
G+C in content while the vlsE region is about ~50% G+C, suggests that this 10 kb
region might not be autoctonous to B. burgdorferi species (Casjens et al, 2000).
The genome of B. burgdorferi potentially encodes as many as 150 different

lipoproteins (Fraser et al, 1997). Lipoproteins of the outer surf ace proteins fa
(OspA through OspG) are immuno-dominant and elicit potent inflammatory

responses (Sigal, 1997). B. burgdorferi does not display high-frequency variation
of Osp proteins during infection, suggesting that Osps probably do not undergo

antigenic variation (Barthold, 1993; Persing et al, 1994; Stevenson et al, 1994).
However, selection of low-frequency, spontaneous, escape mutants has been
observed in vivo, and could account for the considerable polymorphism of Osps

within natural populations of spirochetes (Fikrig et al, 1993; Marconi et al, 19

Livey et al, 1995). Strain variation in Osp serotypes could play an important rol

in enhancing survival during infection of a host who had previously been exposed
to a different antigenic variant.
In addition to high-frequency variation and population-level heterogeneity

of borrelial antigens, antigenic "modulation" may also play a role in persistenc

Expression of surface lipoproteins, e.g. OspA and OspC, fluctuates as the bacter
travel from vector to host and back again (Philipp, 1998). Spirochetes express
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high levels of O s p A in the gut of the flat tick, but precipitously down-regulate its

expression as they begin their migration to the salivary glands of the feeding t

(de Silva et al, 1996). While levels of OspA remain low in the course of infectio
expression of OspC is increased and sustained. However, this expression is not
uniform: Bacteria not expressing ospC are selected in vivo just as anti-OspC
antibodies titers emerge -17 days post-infection. Interestingly, these bacteria
regain expression of ospC in culture or when transferred to naive mice. Thus,
differential expression of ospC might represent an important mechanism of
immune evasion in Lyme disease (Liang et al, 2002). Several other genes of B.

burgdorferi that are expressed in the host but not in the tick vector or in vitr

been identified (Suk et al, 1995; Das et al, 1997; de Silva & Fikrig, 1997), some

of which are induced specifically during the persistent phases of infection (Fik
et al, 1999), but their role in the host-pathogen interaction remains to be
elucidated.
Some late manifestations of LD may not be related to persistence of viable

spirochetes. Some LD patients develop refractory arthritis. It is not clear whet

arthritis is due to local persistent infection or to autoimmune disease initiate
infection but maintained in the absence of viable bacteria (Klempner & Huber,
1999; Evans, 1999; Hemmer et al, 1999). The controversy stems from the fact
that many patients with Lyme arthritis do not respond to antibiotic therapy and
may not have detectable borrelial DNA in their synovial fluid.

19

The persistence strategies of the R F and L D borrelias are markedly similar,
but several important differences should also be noted. Both pathogens cause
septicemia, but the spirochete blood load in RF is much higher than in LD. The

waves of spirochaetemia and fever that are the signature of RF are not seen in LD

Antigenic variation and immune selection of variants occur at much lower rates i
LD than in RF. These differences likely reflect the divergent ecologies of the
causative spirochetes, their vectors, and their intermediate hosts.

1.3. Neisseria gonorrhoeae — Traveling incognito to escape recognition

Gonorrhea, caused by the Gram-negative diplococcus Neisseria gonorrhoeae, is
one of the most prevalent sexually transmitted diseases of humans — every year,
78 million infections occur worldwide (WHO, 1995). Gonorrhea is usually a self-

hmiting, uncomplicated acute infection of the urethra or the cervix with localiz
inflammation, which usually resolves within a weeks of exposure (Garnett et al,
1999). However, in some instances, acute infection is followed by more serious
sequellae, such as epididymitis in men, and pelvic inflammatory disease (PID),
salpingitis, and endometritis in women (Paavonen, 1998). Damage to the upper
reproductive tract in women can lead to infertility and ectopic pregnancy.
Mucosal colonization and invasion results in disseminated gonococcal infection

(DGI) in ~ 0.5-3.0% of cases, leading to arthritis, dermatitis, tenosynovitis, an

(rarely) carditis or meningitis (Kerle et al., 1992). Gonoccocal arthritis is the
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c o m m o n type of joint infection in sexually active adults (Cucurull & Espinoza,
1998).
"Gonorrhea in the male, as well as in the female, persists for life in certain

sections of the organs of generation, notwithstanding its apparent cure in a gre
many instances" (cited in Oriel, 1991). Thus, the persistent nature of gonorrhea
was recognized by the noted veneorologist Emil Noeggerath in 1872, seven years

before Albert Neisser identified the gonococcus as the etiologic agent. Persiste
infection can be symptomatic or subclinical; the high frequency of asymptomatic
carriers is a major obstacle to prevention and treatment. In clinical studies,
approximately half of infected males who were examined because their sexual
partners were known to have gonorrhea were aymptomatic (Handsfield et al,
1974; Crawford et al, 1977), and asymptomatic infection rates may be even
higher in women (McCormack et al, 1977).
The persistence of N. gonorrhoeae in a population is largely possible
because infection, despite eliciting massive inflammation, uniformly fails to
generate an immune response capable of conferring immunity to reinfection

(Gray-Owen et al, 2001). Infection initiates with entry of iV. gonorrhoeae into t

lower urogentital tract. Rapid attachment to the mucosal epithelium of the genit
tract is mediated by surface appendages called pili (Nassif & So, 1995). Loose
attachment is followed by a more intimate association involving the surfaceexposed opacity (Opa) proteins (Dehio et al, 1998). Certain Opa proteins also
promote the transmigration of gonococci across the epithelial layer to the
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submucosa. Colonization of the (sub)mucosa is followed by extensive bacterial
multiplication and shedding of bacteria into the genital secretions, triggering
massive localized inflammation that is responsible for the clinical signs and
symptoms of gonorrhea. The inflammatory response begins with a massive
infiltration of phagocytes, predominantly polymorphonuclear cells (PMNs), in

response to pro-inflammatory cytokines and chemokines such as interleukin-1 (IL1), IL-6, IL-8, and tumor necrosis factor-a (TNF-a (Naumann et al, 1997). These

are produced locally in response to factors released or triggered by the bacteri
including bacterial cell-wall peptidoglycan and lipooligosaccharide (LOS), and
complement component C5a.
PMNs phagocytize and kill gonococci by the oxidative burst, and other
mechanisms such as defensins, cathepsin G, and other cationic antimicrobial
proteins (Shafer & Rest, 1989). Gonococci may, however, be able to counter

these defenses. Neisserial cell-wall porins inhibit phagocytosis and degranulati
by PMNs (Bjerknes et al, 1995) and interfere with both the classical and
alternative pathways of complement activation (Ram et al, 1999; Vogel & Frosch,
1999). The critical role of complement in host defense against Neisseria spp. is
evidenced by the hyper-susceptibility of individuals with heritable complement
deficiencies to infections by these species (Figueroa & Densen, 1991). Virtually

all patients develop specific, opsonizing antibodies to the major surface protei
the gonococcus (Jarvis, 1995), but these do not necessarily prevent re-infection
(Brooks & Lammel, 1989). In part, re-infection may reflect the ability of the
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gonococcus to subvert humoral immunity. Like several other mucosal pathogens,
N gonorrhoeae produces an IgAl-specific serine protease that cleaves the hinge
region of IgA antibodies (Kilian et al, 1988; Kilian et al, 1996). The IgAl

protease may also promote the intracellular survival of gonococci by cleaving th
lysosome-associated membrane protein 1 (LAMP-1) (Lin et al, 1997), which
could be important for transcytosis of gonococci across the genital epithelium
(Hopper et al, 2000).
Antigenic variation also plays an important role in survival of N.
gonorrhoeae in the face of adaptive immunity. Variation of several cell-surface
components of the gonococcus — notably, the pili, outer membrane Opa proteins,
and LOS — is controlled by distinct and complex mechanisms. In addition to
immune evasion, the organism's ability to invade and colonize different
anatomical niches may also be determined by changes in surface components.
Furthermore, recent evidence suggests that some of these surface proteins might

be involved in active suppression of T-cell responses, which could be the reason
why infection by N. gonorrhoeae is not followed by immunity that protects from
reinfection with bacterial strains of the same serotype (Hobbs et al, 1999).
Pili. Pioneering experiments in human volunteers established the essential

role of pili in infection (Kellogg et al, 1963). Pili promote the initial coloniz

of the urethral tract by mediating adherence to the genital epithelium (Swanson,
1973) via the CD46/MCP receptor (Kallstrom et al, 1997, 1998). Pili are
immuno-dominant antigens and antibodies directed against them block gonococcal
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adherence to epithelial cells (Rothbard et al, 1985). However, high-frequency
variation of the pilin subunits that comprise pili occurs throughout the course
human infection, including early stages before the emergence of the adaptive
humoral immune response (Hagblom et al, 1985; Seifert et al, 1994). These

observations suggest that pilin variation might play two roles in the gonococcal

life cycle: persistence in an infected individual by evasion of the adaptive imm
response, and persistence at the community level by permitting transmission to
individuals who had previously encountered the parental serotype. The

mechanism of pilin variation in Neisseria is remarkably similar to the mechanism
used by the Borrelia to vary their surface antigens (Segal et al, 1985; Seifert,
1996). The gonococcal genome encodes a large number of sequence-variable pilin
genes, but only the pilin gene present at an expression locus (pilE) is actually

transcribed and translated into protein (Fig. 1.2B). The silent pilin loci {pilS)
pseudogenes that lack the 5'-terminal coding sequences and the promoter

sequences required for transcription. A pilin switch occurs when sequences store
at a pilS locus are transferred to a pilE locus by non-reciprocal recombination.
Thus, the pilE gene that is expressed at any given time is a mosaic of sequences
derived from various pilS cassettes, which can be endogenous or exogenous in

origin, since Neisseria are naturally transformable (Gibbs et al, 1989). Pili can

also undergo on/off/on... phase variation by imprecise recombination between pil
and pilE generating aberrant forms of pilin that are not assembled and exported

(Seifert, 1996). Phase variation of pili can also occur by on/off/on... switching

24

PilC, a minor constituent of pili that is essential for pilus assembly and maturation.
Phase variation of pilC occurs by "slipped-strand replication" mediated by runs
G residues near the 5' end of the gene. In addition to immune evasion, phase

variation of pili might play a role in traversal of the genital epithelium, beca
pili interfere with invasion of epithelial cells and transcytosis of epithelial
(liver et al, 1998). If non-piliated gonococci are responsible for mucosal

invasion, then reversion to the piliated state must occur rapidly, because gonoc
present in the blood of DGI patients are uniformly piliated.
Opacity (Opa) proteins. The surface-exposed Opa proteins are encoded

by a family of related but unlinked genes; a single isolate of N. gonorrhoeae may
encode as many as twelve opa genes and may express zero, one, or multiple Opa
proteins (Dehio et al., 1998; Nassif et al, 1999). Gonococci isolated from human

patients or volunteers are predominantly Opa-positive, even when initial infecti
was with Opa-negative bacteria, and simultaneous expression of multiple Opa
proteins is apparently favored (Swanson et al, 1988; Jerse et al, 1994). The Opa

repertoire expressed by a given bacterium affects invasiveness as well as tissue

tropism (Kupsch et al, 1993; Dehio et al, 1998; Nassif et al, 1999). Opa proteins

phase vary in vitro at a frequency of IO"3 to IO"4 (Stern et al, 1984, 1986) and
mechanisms involved in this variation include "strand slippage" during DNA

replication, and intergenic recombination of opa genes, from both intra- and extr
genomic sources. This promiscuous reshuffling of coding sequences is
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presumably responsible for the enormous repertoire of opa alleles observed in
natural populations of gonococci (Meyer et al, 1990).
Opa proteins might also play a role in the suppression of T-cell responses
during gonoccocal infection. Binding of bacteria expressing OPA to CEACAM1,
a surface molecule present on lymphocytes, blocks CD4+ T cell activation and
proliferation in vitro (Boulton & Gray-Owen, 2002). This likely occurs via
signaling through ITIM motifs found in the cytoplasmic tails of CEACAM1
molecules, which can recruit SHP1 and SHP2 phosphatases that can antagonize
the kinase-dependent signaling required for lymphocyte activation (Ravetch &
Lanier, 2000).
Lipo-oligosaccharide (LOS). The outer-membrane lipooligosaccharide
(LOS) of Neisseria spp. differs from the typical lipopolysaccharide (LPS) of

Gram-negative bacteria in that it lacks the repetitive O-antigen moiety. In addi

to its structural role in the cell wall, LOS is thought to facilitate mucosal in
and survival of gonococci (Dehio et al, 2000). The resemblance of the
carbohydrate moieties of LOS to host glycosphingolipids may promote immune
evasion by "molecular mimicry" (Mandrell & Apicella, 1993; Moran et al, 1996).
Extensive variation of LOS oligosaccharide moieties can result in expression of
several structurally distinct LOS molecules by a single bacterium (van Putten &
Robertson, 1995; Minor & Gotschlich, 2000). LOS variation is determined by
phase-variable expression of the LOS glycosyltransferases that sequentially add
sugars to the LOS variable chain (Gotschlich, 1994; Minor & Gotschlich, 2000).
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Individual Igt genes contain poly-G tracts that expand and contract by slipped-

strand replication, resulting in on/off/on... expression of the corresponding LO
glycosyltransferase (Danaher et al, 1995; Yang & Gotschlich, 1996; Minor &
Gotschlich, 2000). Certain LOS variants are sialylated by a bacterial sialyl
transferase using host CMP-NANA (van Putten & Robertson, 1995). This
modification promotes survival by blocking the bactericidal activity of normal

human serum and specific antibodies against cell-surface antigens such as porins
or LOS itself (Parsons et al, 1989; Smith et al, 1995; Ram et al, 1999). On the
other hand, LOS sialylation interferes with invasion of epithelial cells and
transcytosis across mucosal barriers, suggesting that modulation of LOS
sialylation could be advantageous at different stages of infection (van Putten,
1993). This idea is supported by studies in human volunteers, where sialylation

levels were low during early stages of infection (facilitating mucosal invasion)
high after colonization and traversal of the mucosal barrier (conferring serum
resistance) (Schneider et al, 1991). This temporal modulation of surface

components in the course of infection is one of the more striking examples of the
sophistication with which the Neisseria have learned to blindside the defense
mechanisms of the host.
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1.4. Salmonella typhi —

Chronic carriers, a galling problem

Typhoid fever is major threat to human health anywhere treatment of sewage and
drinking water is inadequate. The etiologic agent is the Gram-negative bacillus
Salmonella typhi. Over 16 million people suffer from the disease annually, and
about 0.6 million die from it (Pang et al, 1998). Antibiotics are available but
resistance is increasing — some regions in India report rates of multi-drug
resistance in excess of 50% (Rowe et al, 1997). A vaccine based on the capsular

polysaccharide antigen Vi is effective but its application has not been sufficie
widespread (Hessel et al, 1999). S. typhi is an exclusively human pathogen so

transmission depends on contact with an infectious case, either an acutely infec
individual or a chronic carrier. Because infection occurs via the oral route,
transmission is often mediated via contaminated foodstuffs, as in the infamous
case of Mary Mallon ("Typhoid Mary") (Scherer & Miller, 2001).
Ingested bacteria invade the intestinal wall by transcytosis of enterocytes or

M cells in Peyer's patches. Bacterial replication in the submucosa is followed b
entry into the bloodstream and dissemination throughout the body. Replication
within macrophages in the spleen and liver leads to release of bacteria into the
bloodstream. Signs and symptoms of typhoid include enterocolitis, diarrhea,

anorexia, fever, convulsions, and delirium. Much of the pathology of typhoid feve
is attributed to the massive release of cytokines triggered by bacterial LPS.

Invasion of the gallbladder leads to shedding of bacteria into the intestine. Hi

28

fevers, accompanied by constant severe abdominal pain, persist for about four

weeks, followed by slow convalescence with continued shedding of bacteria in the
feces (Hornick et al, 1970). Both humoral and cell-mediated immunity have been
implicated in the protective immune response (Jones & Falkow, 1996; Jones,
1997). Most individuals recover fully and clear the infection; however, about 1%
to 5% of those infected become asymptomatic chronic carriers and continue to

shed bacteria in their stool and urine for the remainder of their lives. Although
chronic carriers have none of the signs and symptoms of acute typhoid, they are
increased risk of developing cancer (Dutta et al, 2000; Shukla et al, 2000).
S. typhi has adopted a novel strategy to evade destruction by the host
immune response: by invading and adapting to an immune-privileged anatomical
niche (the gallbladder), the organism puts itself out of harm's way. Little is

known about its survival in the bilious environment of the gallbladder. Curiousl

persistence of S. typhi in the gallbladder is more likely if gallstones are pres

indeed, S. typhi can often be cultured from gallstones. The gallbladder also see
to provide a safe haven from the onslaught of chemotherapy. Antibiotics,

although generally effective in treating acute infection, often fail at eliminat

infection from chronic carriers: About 25-50% of carriers are never cured despite
long-term chemotherapy, and relapses are common, particularly in those with

biliary or gallbladder calculi (Hornick, 1985; Gilman, 1989). In clinical studies
chronic carriers, subsets of patients had negative stool cultures for up to two
after chemotherapy yet eventually relapsed (Kaye et al, 1967; Johnson et al,
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1973). This largely undetected source of contagion poses a formidable obstacle to

public health efforts to eliminate typhoid. Therefore, it is rather disheartenin
the carrier state has received scant attention from the scientific community.
A major obstacle to the study of typhoid fever and the carrier state has been
the lack of a suitable animal model. The related species S. typhimurium, a
significant source of food-borne gastro-enteritis in humans, produces a disease
mice that resembles typhoid in humans. Extrapolations from studies in the mouse
model to human typhoid must be made with caution, since it is not yet clear
whether the mechanisms of persistence are conserved between two bacterial
species. When mice are infected with S. typhimurium orally, survival en route
from the stomach to the intestine is dependent on the "acid tolerance response"
(ATR) controlled by the alternative sigma factor RpoS (Foster., 1995; Slauch et
al, 1997). The intestinal mucosa is breached by invasion of bacteria into

enterocytes or M cells lining the Peyer's patches. Bacterial "invasion factors" a

injected into the cytoplasm of the target cell by a type III secretion system en
by the "Salmonella pathogenicity island 1" (SPI1) (Ochman et al, 2000). Injected
factors include SopE (Hardt et al, 1998) and SptP (Fu & Galan, 1999), which
function as a GDP/GTP exchange factor (GEF) and a GTPase-activating factor
(GAP), respectively, for GTPases Cdc42 and Rac-1. The sequential
activation/deactivation of Cdc42/Rac-1 directs the transient actin cytoskeleton
reorganization and membrane ruffling that accompany invasion. Once bacteria

breach the mucosa they invade and replicate within macrophages in the underlying
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submucosa. Alternatively, bacteria m a y be phagocytized on the lumenal face of

the intestinal wall and ferried across to the submucosa, thus bypassing the SPI1
mediated invasion pathway altogether (Vazquez-Torres et al, 1999).
Once the intestinal wall is breached, the infection is rapidly generalized

throughout the reticuloendothelial system, especially in the liver and spleen. T

pathogenesis of Salmonella hinges on the ability to survive and replicate within
phagocytes of the monocyte-macrophage lineage. Salmonella inhabits a "loose"

vacuole that acidifies to the normal phagolysosomal pH of 4.5-5.0 (Rathman et a
1996), but whether this compartment is a true phago-lysosome or a modified
vacuole is controversial (Rathman et al, 1997; Sinai & Joiner, 1997). Functions

required for survival and replication within macrophages are encoded by a second
"Salmonella pathogenicity island", SPI2, which also encodes a second type in
secretion system, Spi/Ssa (Ochman et al, 1996), whose expression is activated
intracellularly (Valdivia & Falkow, 1997). The SPI2 type Ul secretion system
translocates the bacterial protein SpiC from the Salmonella vacuole into the
cytoplasm of the host cell, where it interferes with phagosome-lysosome fusion
(Uchiya et al, 1999). SPI2 also encodes the PhoP/PhoQ two-component

regulatory system that controls expression of Pho-activated genes (pag) and Phorepressed genes iprg), which are critical for intracellular survival (Groisman &
Ochman, 1997). SPI2-encoded factors are responsible for evasion of the oxidative
burst via exclusion of the NADPH-dependent phagocyte oxidase complex from
the membrane of the Salmonella vacuole (Vazquez-Torres et al, 2000). The
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foregoing discussion highlights the important contributions of the susceptible
mouse model of typhoid to our current understanding of the molecular basis of

invasion, intracellular survival, and dissemination of Salmonella spp. This model

however, has shed little light on the asymptomatic carrier state, a key aspect o
human typhoid that merits more attention.
In the past, some attempts were made to model certain aspects of persistent
Salmonella infections in susceptible mice. For instance, certain strains of S.

typhimurium are capable of causing a persistent infection in the intestine, sple
liver, and occasionally even the gallbladder of these mice that can last for up
two months, thus allowing the study of some aspects of the immune response to a

more chronic infection (Sukupolvi et al, 1997). More recently, a significant step

toward the development of a model of prolonged persistent infection was taken by
simply shifting the study of Salmonella pathogenesis from the historicallypreferred Salmonella-sensitive mouse strains to resistant ones. Monack et al.
(2004) demonstrated that infection of mice carrying the wild-type Nrampl allele

(resistant) infected orally with wild-type S. typhimurium bacteria resulted in a

chronic infection: bacteria lingered in the organs of these mice for upto a year,
mostly in macrophages of the mesenteric lymph nodes. Interestingly, IFN-ydependent immunity was found to be required for maintaining the bacteria in
check. Though, no persistence-specific bacterial genes have yet been found, two

genes, mig-14 and virK, are apparently important in both the acute and persisten
phases of the infection using this newly developed Salmonella persistence model
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(Brodsky et al, 2005). These factors promote bacterial survival in macrophages
through inhibition of the bactericidal effects of the anti-microbial peptide
(CRAMP), which is highly expressed in IFN-y-activated macrophages.

1.5. Biofilms — Staying alive by staying put

Pathogens persist in their hosts via phenotypic adaptation to a multitude of

different tissue environments. Studies of these processes in bacteria have focus

on the behavior of individual cells, but accumulating evidence suggests that thi
an overly reductionist view (Costerton et al, 1999). Many bacterial species
fluctuate between planktonic growth and sessile growth within biofilms, which
typically complex and highly structured microbial communities (Costerton et al,

1995), frequently composed of several species engaged in symbiotic relationships.

Bacteria living in biofilm communities appear to be strikingly different in thei
physiology and metabolism from those growing planktonically (Costerton et al,
1995; Costerton et al, 1999).
Biofilms begin to form when bacteria growing in nutrient-rich
environments develop adhesive behavior, leading to attachment to a surface and

the formation of a monolayer of cells, followed by aggregation into characterist
micro-colonies (Fig. 1.3) (Costerton et al, 1995; Pratt & Kolter, 1999). These
micro-colonies secrete highly hydrated exo-polysaccharides (EPS), which
compose up to 80-90% of a mature biofilm's mass (Lawrence et al, 1991) and
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Biofilm Dissolution: Programmed Disruption, Shear Forces, etc.

Planktonic Celts

*>•&

^

Mature Biofilm
Flagellar motility
Surface
attachment
Growth

Twitching motility
via type IV pili
Cell-cell
adhesion

Quorum sensing
via HSL (lasl)
EPS matrix
synthesis

**%

Fig. 1.3. Biofilm life cycle. Planktonic bacteria s w i m to a surface via flagellar motility and attach
(mediated by flagella and nutrient sensing mechanisms). Replication on the surface leads to the
formation of a monolayer of cells, which aggregate by twitching motility (mediated by type I V pili)
and adhere to each other, forming surface-attached microcolonies. These microcolonies b e c o m e
e m b e d d e d within a thick layer of secreted exopolysaccharides (EPS). A s cell density increases,
q u o r u m sensing via homoserine lactones (HSLs) synthesized by Lasl triggers the developmental
changes required for formation of the correct architecture and thickness of the fully mature biofilm.
T h e mature biofilm is penetrated by fluid-filled channels that deliver nutrients and remove waste.
Bacteria within the biofilm are less susceptible to antibodies, phagocytes, and antimicrobials than
planktonic cells. T h e steps leading to dissociation of biofilms and reversion to the planktonic form are
poorly understood, but m a y involve environmental sensing and programmed disruption, or simple
physical forces such as shear stress from fluid flow. Adapted from Costerton et al. (1999).
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form an architecturally complex E P S matrix which is essential for biofilm
formation and structure (Watnick & Kolter, 1999; Yildiz & Schoolnik, 1999), as

well as resistance to environmental insults, antimicrobials, and predation by fre

living protozoa or, in the case of biofilm infection, by host phagocytes (Jensen
al. 1990; Costerton et al, 1995). The EPS matrix is penetrated by a complex
system of fluid-filled channels that mediate nutrient distribution, elimination
metabolic waste products, and chemical communication between micro-colonies
in the biofilm. Nutrient availability is an important determining factor in the
stages of biofilm formation. In Pseudomonas aeruginosa, the carbon metabolism

sensor Cre controls the expression of functions required for biofilm genesis, su

as the type IV pili that mediate twitching motility (Wall & Kaiser, 1999; O'Tool

et al, 2000). Both flagellar motility and twitching motility are required for the

early stages of biofilm formation by P. aeruginosa and Vibrio cholera (O'Toole &

Kolter, 1998; Watnick & Kolter, 1999). Flagella are required for initial bacteria

surface contacts, while type IV pili promote the aggregation of surface-adherent
bacteria into micro-colonies.
The mechanisms that control the later stages of biofilm development
remain largely unknown, but quorum sensing via secreted homoserine lactones

(HSLs) seems to play a critical role. In P. aeruginosa, the lasl locus responsib

for HSL synthesis is dispensable for the formation of a nascent and structurally
simple biofilm, but essential for its further maturation (Davies et al, 1998).

Apparently, bacteria within the developing biofilm must talk to each other in or
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to coordinate the events that generate the complex architecture of the mature
biofilm. Production of HSLs has been demonstrated in naturally-occurring
biofilms from aquatic environments (McLean et al, 1997) and from urethral
catheters removed from patients (Stickler et al, 1998). The latter observation
suggests the possibility that inhibitors of HSL production or function might be
useful for preventing biofilm formation on indwelling medical devices.
Little is known about the mechanisms that mediate the dissolution of
biofilms and reversion to planktonic growth. Recent work in V. cholera suggests

that quorum sensing is also involved in this process. During V. cholera infectio

bacteria in an apparently superinfectious state in biofilm-like structures (Merr
al, 2002) are ingested orally. After passage through the gut (the biofilm state

needed to withstand the stomach's acidity), they must be able to exit the biofilm
order colonize the intestine. Quorum sensing is apparently essential for the

formation of a biofilm of just the right thickness so that rapid dissociation ca

place once the bacteria get to the intestine because mutants of the quorum sensi
regulator hapR, which overexpress the vps genes of EPS biosynthesis and make

thick biofilms, are poor colonizers, despite having increased acid resistance (Z
& Mekalanos, 2003).
One of the most relevant aspects of bacterial biofilms vis-a-vis infections is

the increased resistant of biofilm bacteria to killing by antimicrobials (Coster
al, 1999). Inadequate drug penetration may contribute to the problem, as well as

the altered physiology of bacteria within biofilms. The heterogeneous architectu
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of biofilms creates chemical micro-environments that support slow- and non-

growing bacterial populations (Costerton et al, 1995), which are known to be less
susceptible to antimicrobials (Eng et al, 1991; Evans et al, 1991). Indeed, the
drug susceptibility and growth rate of biofilm bacteria are inversely related
(Gilbert et al, 1990).
Among medically relevant biofilm formers, P. aeruginosa is the best
understood. This Gram-negative opportunistic pathogen afflicts immunecompromised individuals, including burn victims, neutropenic patients on cancer
chemotherapy, and particularly cystic fibrosis (CF) patients (Govan & Deretic,
1996). Inherited defects in the chloride ion channel CFTR (cystic fibrosis
transmembrane regulator) cause CF patients to suffer from buildup of dehydrated

mucus in the respiratory tree, defective mucociliary function, and other defects
lung defenses. CF patients are unusually prone to develop chronic pulmonary

infections by opportunistic pathogens, most of which respond to antibiotic thera
However, virtually all CF patients are eventually colonized by P. aeruginosa,
which resist eradication.
Flagella are required for the early stages of Pseudomonas biofilm formation
(see above) and for virulence in mouse models of burn wound sepsis (Drake &
Montie, 1988) or pulmonary infection (Feldman et al, 1998). However, flagella
can also promote non-opsonic phagocytosis of bacteria by neutrophils and
macrophages (Mahenthiralingam & Speert, 1995). This conundrum might be

resolved by temporal modulation of flagella expression in the course of infectio
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In a prospective clinical study, bacteria isolated from C F patients at early stages of
disease were flagella-positive, motile, and sensitive to phagocytosis, whereas

bacteria isolated from persistently infected patients were flagella-negative, no
motile, and resistant to phagocytosis (Mahenthiralingam et al, 1994). Flagella
phase variation could be accelerated by the emergence of hyper-mutable
subpopulations of P. aeruginosa in the CF lung (Oliver et al, 2000).
Hyper-mutation might also promote the replacement of non-mucoid strains,

which are responsible for initial colonization, by mucoid variants, which domina

later stages of infection. Mucoid variants arise by spontaneous mutations in gen

controlling synthesis of alginate, an EPS matrix component, and their appearance

is correlated with a poor prognosis for the patient. The alginate matrix shields
bacterial micro-colonies from both arms of the host immune response -humoral
and cellular. Some variants that spontaneously arise during infection have been
shown to have an enhanced ability to form biofilms as well as resistance to
multiple antibiotics (Drenkard & Ausubel, 2002). These variants, which can

readily be selected upon antibiotic exposure in vitro, might be selected in vivo

antibiotic exposure itself or as a result of exposure to host-mediated stresses.
Most CF patients develop high levels of specific antibodies to P.

aeruginosa, but these are ineffective against bacteria buried in the alginate ma
(Govan & Deretic, 1996; Costerton et al, 1999). Indeed, deposition of immune
complexes on the surface of Pseudomonas biofilms is believed to contribute to
lung inflammation and pathology in CF. Lung damage may also result from the
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chronic influx of neutrophils, which are unable to clear the infection because the

alginate matrix interferes with phagocytosis and killing. Bacterial communicatio

(quorum sensing) within the biofilm is apparently required for optimal induction
of protective mechanisms, including the superoxide dismutases (Mn-SOD and FeSOD) and catalase (KatA) that detoxify phagocyte-generated ROI (Hassett et al,
1999). Interestingly, the biofilm also supports the appearance of variants that

The study of microbial biofilms and their role in persistent infections is still
at an early stage. The environmental signals that promote biofilm formation and

dissolution, and the signals that the bacteria use to communicate with each othe
are just beginning to be deciphered. In addition to species-specific signals, a
common language of secreted pheromones is apparently used for inter-species
communication (Bassler, 1999). Elucidation of the signalling pathways that

control biofilm dynamics could point the way to novel interventions targeting no
individual bacterial cells, but their collective behavior as biofilms.

39

C H A P T E R

2

Tuberculosis a n d the tubercle bacillus

INTRODUCTION

Mycobacterium tuberculosis is arguably the single most successful pathogen
humankind has ever known. As Koch (1882) put it in The Etiology of
Tuberculosis: "If the number of victims is a measure of the significance of a

disease, then all disease, even the most dreaded infectious diseases, such as pl

or cholera, must rank far behind tuberculosis." Today, 120 years later, Presiden
Mandella tells us: "We cannot cure AIDS without curing TB."
The unparalleled penetrance of TB in the human population reflects the

extraordinary ability of M. tuberculosis to cause a lifelong persistent infectio

peculiarity which most likely is the result of a long dynamic interaction with i

host, one that may have begun before modern civilization (Morse et al, 1964; Sal
et al, 1994). Though microbial infections including those caused by highly
pathogenic bacteria tend to run an acute course, with infectious cycles of a few
weeks, mycobacterial infections such as leprosy and TB are unusually protracted
due to these pathogens' proclivity to persist in their hosts (Fig. 2.1) (Gomez &
McKinney, 2004; Britton & Lockwood, 2004). Persistence by M. tuberculosis can
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Fig. 2.1. Acute vs. chronic active and latent bacterial infections. Acute infections are rapidly
cleared by a sterilizing immune response that often protects from reinfection. Chronic infections las
much longer, can be controlled, but usually are not eradicated by immunity, which seldom protects
from reinfection. M. tuberculosis causes both chronic active and latent infections.
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occur in the form of chronic active disease and latent infection; in either form, the
biology of M. tuberculosis persistence is poorly understood (Manabe & Bishai,
2000; Gomez & McKinney 2004; Boshoff & Barry, 2005). Because available

antibiotics are inefficient in eradicating persistent bacteria, treatment must b
extended, and often lasts between 6 and 9 months. In spite of the inherent

difficulties in implementing these sorts of regimens, antibiotics have effective

led to a scale back of TB in most of the industrialized world, however, they have
had a much smaller impact in the rest of the world, where lack of resources make
implementing such cumbersome drug treatments considerably more difficult (Dye

et al, 1999). Most people live in the "developing" world," and it is in this othe
'forever-developing' world -where poverty is extreme, public health deplorable,
and malnutrition and overpopulation widespread - where TB relentlessly and
inexorably continues to exact its deadly toll (Farmer etal, 1991).
Though it is clear that combating the current TB epidemic would be greatly
facilitated by the development of new and more efficient drugs and vaccines, and
that in order to generate these, a better understanding of the biology of M.
tuberculosis during infection would be greatly beneficial (McKinney, 2000;
Andersen, 2001; Flynn, 2004; Mitchison, 2004), the major obstacle in dealing with
TB and other major infectious diseases such as malaria and HIV is the
uwillingness of the industrialized world to make the investments that would be

needed to facilitate drug discovery (Nathan, 2004) and the affordable and effici
distribution of already available drugs (Farmer, 1996; Farmer & Campos, 2004).
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2.1. Global burden of tuberculosis

2.1.1 Epidemiology. Despite improvement in the prognosis of TB in affluent
nations, the disease continues to be the leading cause of death among bacterial
infections worldwide (Dye et al, 1999; Dye et al, 2002). Furthermore, it has
been estimated that close to 2 billion people harbor latent tubercle bacilli,

constituting a reservoir that will result in about 100 million cases of reactiva
TB (Raviglione et al, 1995). According to WHO estimates, of circa 50 million
deaths occurring per year, approximately 2 million are from TB, and over 95% of
those deaths occur in the developing world (WHO, 2004).
TB epidemics are extremely slow, typically expanding over centuries
(Blower, et al, 1995) (Fig. LIB). Though the incidence of TB worldwide was in
a downtrend since the 1950's, this changed considerably in recent times: from
1985 to 1992 the incidence of TB rose by 20% in the United States (Bloom &
Murray, 1992), and a considerable percentage of the cases were drug resistant
(Moore et al, 1996). Among the most important reasons for such reversal were
the AIDS pandemic, reduction in public health resources in inner cities, and
continued immigration from areas of high TB prevalence (Zuber et al, 1997).

2.1.2. TB and AIDS. AIDS in HIV-infected individuals, e.g., low CD4+ T cells,

is one of the most important contributors to the development of TB in co-infecte
individuals in many parts of the world including the United States (Chaisson et
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1987; Modilevsky et al, 1989).

The low C D 4 + T cell counts translate into

suboptimal macrophage activation and an inability to mount a protective response
HIV-coinfection is the greatest single risk factor for progression from M.

tuberculosis infection to disease. The risk of developing disease after infectio
with M. tuberculosis in an HIV-coinfected person is about 5-15% per year,
compared to a lifetime risk of developing active TB after infection of about 10%
in immuno-competent individuals. Furthermore, the inability to mount an
effective adaptive immune response leads to a more progressive course of TB in
HIV-infected individuals (Sepkowitz, 1995; Corbett et al, 2003; Aaron, 2004).
Miliary TB, a highly disseminated form of TB that can affect multiple organs
(Mert et al., 2001), is also more frequent in AIDS patients (1990). Furthermore,

some evidence suggests that the interaction might be reciprocal, since active TB

might stimulate viral replication, thereby accelerating the onset of AIDS (Whale
et al, 1995), perhaps through TNF-a, which induces viral transcription, and/or

activation of the CD4+ T cells that support viral replication (Fauci, 1996; Bafi

al, 2003). Current estimates indicate that there are about 11 million individuals
coinfected with HIV and M. tuberculosis worldwide. A recent study found that of
an estimated 1.8 million deaths from TB, 12% were attributable to HIV, and

similarly, TB was responsible for 11% of all deaths due to AIDS in adults (Corbe
et al, 2003).
The emergence of drug resistant strains of M. tuberculosis is another
important factor modifying the current TB epidemic (Farmer et al, 1998). In
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general, a strain is considered multiple drug resistant ( M D R ) if it is resistant to at
least isoniazid and rifampicin, the two most effective drugs for TB. Rapidly

spreading MDR M. tuberculosis strains, that are resistant to all four first line
drugs, including isoniazid, rifampin, pyrazinamide and embuthal, have already
emerged (Bifani et al, 2002; Post et al, 2004). According to WHO estimates,
circa 5% of all active TB cases worldwide are caused by MDR strains. In some
parts of the world, MDR strains represent a much higher percentage of the TB
cases; in Estonia, for instance, MDR TB represents close to 15% of all cases,
while in Russia, -25% of all TB cases are MDR (Farmer, 2001).

2.2. The tubercle bacillus

Mycobacterium tuberculosis belongs to the class Actinobacteria, order
Actinomycetales, suborder Corynebacterineae, family Mycobacteriaceae. The
suborder Corynebacterineae encompasses other high G+C Gram-positive bacteria
including members of the Nocardia, Rhodococcus and Corynebacterium families.

M. tuberculosis bacilli are non-motile rod-shape bacteria with general dimension
ranging from 1 and 4 \im in length and 0.3 to 0.6 urn in diameter. Some forms of

bacilli that are smaller and round have been observed in histopathological studi
(Reviewed in Lurie, 1939a). Though M. tuberculosis requires oxygen for growth,
it can grow at low oxygen tensions and can survive complete oxygen deprivation
(Wayne & Hayes, 1996).
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2.2.1. Mycobacterial growth rates. Mycobacteria are notorious for being very
slow growers. M. smegmatis, a fast growing innocuous mycobacterial saprophyte

used as a surrogate to study M. tuberculosis, has a division time of about 3 hr i

axenic culture and takes 3-4 days to form a colony on agar. M. tuberculosis has a
doubling time of about 20 hours in culture and formation of a colony on agar
requires 18-21 days (Wayne, 1994). Pathogenic mycobacteria have adapted to
slow growth at many levels. For example, M. tuberculosis takes about 10 hours to

replicate its genome, while E. coli can do it in 0.5 hours; and while E. coli has
seven rRNA operons, M. tuberculosis has only one (Cole et al, 1998).

2.2.2. Mycobacterial cell wall. One of the most striking features of
mycobacterial cells is their tremendously complex lipid-rich envelope, which
weigths half of the cell's dry weight. This property causes mycobacterial cells

aggregate into clumps in culture, making their experimental manipulation difficu

Limited studies suggest that mycobacterial cells might be relatively less permea

to hydrophilic substrates due to the presence of mycotic acids and mycosides; th
impermeability could prevent transport of hydrophilic substrates into the cell.
This lipid "shield," which causes M. tuberculosis to retain Carbol fuchsin dye

despite acid treatment ("acid fastness"), plays an important protective functio
from physical and chemical stress, and accumulating evidence indicates that its
components mediate complex interactions with the host immune response (Manca
et al, 2004; Reed et al, 2004; Karakousis et al, 2004). These properties might
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also limit the ability of certain drugs to efficiently enter the mycobacterial cell
(Barry & Mdluli, 1996; Kolattukudy et al, 1997, Brennan, 2003).
The peptidoglycan of mycobacterial cell walls has alternating Nacetylglucosamine and muramic acid residues. The muramic acid residues are N-

acylated with glycolic acid rather than acetic acid. Arabinogalactan, a branched
chain polysaccharide made up of a galactose and an arabinose chain, is attached
the peptidoglycan. Some of the arabinose units are linked to penta-arabinose

units, which are esterified with mycolic acids. Mycolic acids, long-chain 1-alkyl

2-hydroxy fatty acids, are essential for formation of the mycobacterial cell wal
(Brennan, 2003).

2.2.3. Mycobacterial genomes. The first M. tuberculosis genome sequenced was

that of the virulent laboratory strain H37Rv (Cole et al, 1998). A recent clinica
isolate, termed CDC 1551, was sequenced shortly after (Fleischman, 2001), and a
third clinical isolate (strain 210) is near completion. The sequencing of the
genomes of several other mycobacteria has been completed or is near completion
(Gamier et al, 2003; NCBI). This wealth of information has uncovered unique
aspects about mycobacterial biology. The constant G+C content of -65%
throughout mycobacterial genomes suggests the absence of horizontally acquired
pathogenicity islands, which are widespread in other pathogenic bacteria.
Mycobacterial genomes have several novel multigene families and an unusually
high number of duplicated 'housekeeping' genes, as well as repetitive insertion
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sequences (Brosch et al, 2001).

Interestingly, though the proportion of the

genome that has arisen through gene duplication is not particularly high (-51%),
the duplicated genes show low divergence, which might contribute to functional
overlap or outright redundancy.
The most salient characteristic of the M. tuberculosis and other
mycobacterial genomes so far sequenced is the presence of a vast number of genes
dedicated to lipid metabolism, including catabolic and anabolic functions (Cole
al, 1998; Fleischman, 2001; Gamier etal, 2003). Over 8% of the M. tuberculosis
genome is made up of genes encoding proteins putatively involved in some aspect
of lipid metabolism and considering that near 40% of the dry weight of the
mycobacterial cell wall (Anderson, 1940) is made up of lipids, it is reasonable

conclude that lipid metabolism plays a major role in the biology of mycobacteria

2.3. Clinical tuberculosis

M. tuberculosis contagion occurs when a susceptible person inhales bacillicontaining infectious droplets that have been expelled from the lungs of a

tuberculous individual by sneezing, coughing or simply talking. Of those infecte
only a minority (-10%) will develop disease; about half will do so within a few
months to a couple of years immediately following infection (primary TB), while

the other half will do so only after an indeterminately long period of latency (
primary TB) (Comstock, 1982).
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2.3.1. Primary T B .

After reaching the alveoli, phagocytosis of the bacilli by

resident macrophages (Ernst, 1998; North & Jung 2004) is followed by
unrestricted bacterial exponential intracellular growth. Uptake of bacteria by
dendritic cells (DCs) and migration of infected DCs to the draining lymph nodes
for antigen presentation likely contributes to the lympho-hematogenous
dissemination of bacteria to extrapulmonary organs and uninfected parts of the
lung, leading to the formation of secondary lesions (Lurie, 1964; Dannenberg &
Rook, 1994a). Exponential bacillary growth is thought to continue in primary and

secondary lesions until a specific T-cell response is generated around each lesi
curtailing bacillary growth and likely killing some of the bacteria within

macrophages as these become mycobacterio-static or -cidal after activation (Flyn
&Chan, 2001) (Fig. 2.2).
The caseous centers of newly formed lesions are surrounded by activated
macrophages. Presumably bacterial antigens being released by the bacteria
(Beatty & Russell, 2002) or captured from them are constantly being processed
and presented to surrounding T cells in the context of IL-12 and other cytokines
that induce a Thl type of immune response. Constant presence of antigen likely
contributes to expansion of the T cell populations and continued activation of

macrophages, which avidly ingest and inhibit/kill bacilli that accumulated durin
the acute phase of the infection. In a lesion where the bacteria are effectively
controlled by CMI, the caseous center becomes surrounded by a capsule, forming
a protective granuloma. Overtime, the number of viable bacilli in these
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granulomas likely diminishes. Old caseous foci of this sort contain little to no
bacilli, and some of the old lesions can ossify and be reabsorbed (Sweany et al,

1943; Opie & Aronson, 1927). The interactions just described result in control of
the infection in most infected individuals.
For reasons poorly understood, some individuals fail to generate the
protective type of immune response just described. In these cases, bacteria
continue to replicate and the granulomas become increasingly necrotic. It is
believed that part of the tissue damage that occurs is the result of
immunopathology, i.e., an excessive host-mediated inflammatory response to
bacillary antigens (Dannenberg & Rook, 1994a). When the centers of granulomas
undergo caseating necrosis, the sheaths of monocytes and T cells which normally

suppress the intracellular growth of the bacilli can also become necrotic; as th

bacteria continue to replicate in nonactivated macrophages at the periphery of t

lesion, progressive destruction of lung tissue ensues, ultimately leading to the
death of the host. Massive inflammation and tissue damage can also be caused

directly by some components of the bacterial cell wall as well as by secreted li
and proteins; lipoarabinomannan (LAM), for instance, triggers TNF-ct secretion
by macrophages, while some secreted lipids lead to secretion of proinflammatory
IL-6 (Karokousis et al, 2003).
Although M. tuberculosis is not an obligate intracellular pathogen, it is
unclear whether it is capable of extracellular growth in the acellular necrotic
centers of caseous lesions. In contrast, solid caseum that has undergone
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Fig. 2.2. Cellular i m m u n e response to M . tuberculosis infection. Depicted are some aspects of the
innate and adaptive cellular immune responses to infection by M . tuberculosis as inferred from
studies using ex-vivo and in-vivo models of T B . The bacteria are assumed to reside mostly within
vacuoles in macrophages. Not shown are C T L - and gd T cell-mediated proposed mechanisms of
protection.
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liquefaction is believed to be permissive for bacillary replication. The coughing

up of this highly infectious material is in fact responsible for the transmissio
the bacilli. These observations illustrate how pathology is a necessary step in
life cycle of M. tuberculosis infection in humans.

2.3.2. Latent TB infection and reactivation. Little is known about the factors
that determine whether an individual that is exposed to M. tuberculosis will go
to develop primary TB or become latently infected. That the immune status of the
host is involved in both the establishment and maintenance of latency can be
inferred from the observation that HIV-M. tuberculosis coinfected individuals
have a much higher risk of developing TB after infection.
The only sign of infection in individuals with latent TB infection (LTBI) is
the appearance (between 2-6 wks post-exposure) of a detectable delayed type

hypersensitivity reaction to a mycobacterial purified protein derivative (tuberc
(PPD). By taking necropsy specimens of lung lesions from immune-competent
individuals who had died of causes other than TB and inoculating them into

guinea pigs to determine the presence of infectious bacilli, it was shown that s

individuals can harbor viable tubercle bacilli for many years without showing an
symptoms of disease (Opie & Aronson, 1927). In these early studies, it was found

that while specimens from encapsulated or calcified lesions rarely were infectio
those isolated from caseous lesions in the lung's apex generally were.

Unexpectedly, apparently healthy tissues were also often infectious. Several oth

52

studies from the pre-antibiotic era have confirmed that lung lesions from

asymptomatic individuals can harbor viable bacilli to different degrees (Feldman
& Baggentoss, 1938; 1939; Sweany et al, 1943; Manabe & Bishai, 2000; Gomez
& McKinney, 2004). Recent evidence of potential LTBI in normal human lung
tissue was provided by the finding that about 30-50% of samples from individuals
from endemic regions (Mexico and Ethiopia) could harbor M. tuberculosis DNA
(Hernandez-Pando et al, 2000). Molecular evidence of endogenous LTBI
reactivation LTBI comes from a recent case study in Denmark concerning an
individual who had become infected 30 years prior with the same strain shown to

be responsible for the reactivation and development of active TB (Lillebaek et a
2002).
Perhaps the most compelling evidence for the prevalence of LTBI has come
from the observed increased rates of TB in AIDS patients, as well as the high
reactivation TB associated with the intake of TNF-a inhibitors prescribed for

rheumatoid arthritis. These observations indicate that many individuals with LTB
accomplish life-long suppression of the bacillus, but never actually achieve
sterilization.
Reactivation TB usually presents clinically as a slowly progressive, chronic

condition; an individual with chronic sub-acute TB may infect scores of contacts
without realizing that (s)he has the disease (Hoge et al, 1994; Valway et al,
1998). Patients with cavitary TB are particularly infectious because they shed

enormous numbers of tubercle bacilli in their sputa. Cavitation is caused by the
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liquefaction of necrotic tuberculous tissue and its expulsion via the airways;
liquefaction is linked to a strong DTH response and is an important example of
immuno-pathology in TB (Dannenberg & Rook, 1994a). The molecular basis of
cavity formation has not been determined, nor is it clear whether the immune
mechanisms responsible for pathogenesis and protection are the same.

2.4. Experimental studies of tuberculosis

The Mouse model of chronic tuberculosis. Animals infected with M.
tuberculosis — mice, guinea pigs, or rabbits — typically develop a chronic,

progressive form of the disease which varies in severity depending on the specie

the guinea pig being the most susceptible, the rabbit the most resistant, and th
mouse somewhere in between.
The mouse has become the animal of choice in the study of TB. In fact,
Koch himself employed mice in his pioneering experiments over 100 years ago. A
chronic infection in mice can be established by inoculation of bacilli by
intravenous injection (Hart & Rees, 1950; McCune & Tompsett, 1956) or by
aerosol exposure (Orme & Collins, 1994). The bacilli multiply logarithmically

during the first 2-4 wks post-infection and then stop increasing in numbers in t

lung and start to slowly decline in numbers in the liver and spleen. Depending on

the titer of the initial inoculum, the chronic infection can last from months to
a year (Rhoades et al, 1997). The model is useful in that it allows host-M.
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tuberculosis interactions to be studied in the context of a prolonged persistent
infection. The maintenance of a relative high bacterial load, accompanied by
accumulating pathology, might pertain to human active TB, while the apparent
lack of bacterial replication might be relevant to both active TB and LTBI.
Among the limitations of the mouse model are differences in the composition and
organization of the granulomatous structures compared to those formed in human

lungs, and in the location of the bacilli in the infected lungs - almost exclusi
intracellular in mice, considerably more extra-cellular in humans.
Spontaneous M. tuberculosis latency in animals only occurs in nonhuman
primates (Capuano et al., 2003; Flynn et al, 2003). A drug-induced model of

latency known as the "Cornell model", in which M. tuberculosis-infected mice are

sterilized by drug treatment, and then allowed to reactivate spontaneously or by
immunesuppression, was developed in the 1950's (McCune & Tompsett 1956;
McCune et al. 1956, 1966a, 1966b). This model allows host-pathogen interactions
to be studied in the context of an infection where very low numbers of bacteria
present and has been used to study host factors involved in establishing and

maintaining this type of "latency" (Scanga et al, 1999; Botha et al., 2002; Botha
& Ryffel, 2003). However, the relevance of the model to true latency awaits
validation.
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2.5. Host-pathogen interactions in T B

Bacilli reaching the lung alveoli are phagocytosed by resident macrophages (Luri
& Zappasodi, 1942) via mannose, complement (Schlesinger et al, 1990;
Schlesinger, 1993)), and Fc receptors (in differentiated macrophages) (Malik et
al, 2000). Uptake through Fc receptors increases phagolysosomal fusion
(Armstrong & Hart, 1975) and triggers the oxidative burst (Kobzik et al, 1990),
leading to killing of bacteria in human macrophages (Malik et al, 2000; Malik et
al, 2001). Regardless of the receptor involved, uptake apparently requires

recruitment of cholesterol to the phagosome (Gatfield & Pieters, 2000). Uptake by
dendritic cells occurs via DC-SIGN (Tailleux et al, 2003).

2.5.1. Cellular interactions leading to a protective immune response. A
protective immune reponse to M. tuberculosis is mediated mainly by T-cells
(CMI) (Suter et al., 1961; MacKaness, 1968; Murray, 1999; Flynn & Chan, 2001;
North & Jung, 2004) (Fig. 2.2). As early as one wk post-infection, bacteriaspecific CD4+ and CD8+ T cells migrate to the lung (Serbina & Flynn, 1999),
peaking in numbers at around 4 wks post infection (Feng et al, 1999). Studies in

immune-deficient mice have established that IFN-y (Cooper et al, 1993; Dalton et
al, 1993; Flynn et al, 1993; Kamijo et al, 1993), TNF-a (Flynn et al, 1995;
Adams et al, 1995), and IL-12 (Flesch et al, 1995; Cooper et al, 1997) are the
main ytokines involved in a protective immune response. The relevance of
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IFN-y and IL-12 in antimycobacterial immunity is supported by h u m a n genetic

data (Altare et al, 1998); the recent association between administration of TNF-a
inhibitors used to treat rheumatoid arthritis and the reactivation of LTBI has

underscored the protective role of this cytokine in control of M. tuberculosis i
humans (Nunez-Martinez etal, 2001).
The initiation of the immune response occurs via presentation of M.
tuberculosis antigens, presumably by dendritic cells (DCs) (Guermonprez et al,
2002), on MHC class I and II molecules to naive T cells, which in the context of
IL-12 and IL-23 (Flesch et al., 1995; Fulton et al, 1996; Cooper et al, 2002;
Verreck et al, 2004) produced by infected macrophages and DCs themselves, are

instructed to differentiate into IFN-y-secreting cells (T helper type I, Thl) ce
(Trinchieri, 2003) (Fig. 2.2). Both CD4+ and CD8+ T cells contribute to the
activation of infected macrophages via IFN-y secretion (Tascon et al., 1998),
while CD8+ T cells might additionally contribute to protection by causing
apoptosis of infected macrophages through the Fas-FasL pathway, as well as via
secretion of granulysin and other microbicidal molecules (Stenger et al, 1998;
Serbina et al, 2000). However, the relative contribution of CD8+ T cells to the

overall protective CMI might not be as significant as that by CD4+ T cells since

tuberculosis-infected mice deficient in the former live almost as long as infect
wild-type mice, while those deficient in the latter are significantly more
susceptible (Sousa et al, 2000; Mogues et al, 2001).
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Natural killer ( N K ) cells might contribute to the early control of M .

tuberculosis replication by generating IFN-y and granulysin during the first few

days of the infection (innate phase), however since their depletion does not affe

bacterial loads, it is likely that other innate sources of IFN-y exist (Junqueir
Kipnis et al, 2003). In addition to NK cells, the rapid early activation of
'bystander' CD8+ T cells has been implicated as an early source of IFN-y during
bacterial infections (Lertmemongkolchai et al, 2001). The lack of early CD8+ T
cell-derived IFN-y could explain why in the lungs of CD8+ T cell-deficient mice

M. tuberculosis bacilli replicate to 1 logio higher than in wild-type mice, befo
their numbers stabilize (Mogues et al, 2001). Later on in the infection NK cells
might also help control the infection by producing granulysin or by inducing
apoptosis in infected monocytes, via a Fas-FasL independent mechanism (Brill et
al, 2001).
Mice lacking CD4+ T cells are highly susceptible to M. tuberculosis
infection (Caruso et al, 1999), and exhibit reduced macrophage activation, which

is associated with lower IFN-y production (Barnes et al, 1993; Orme et al, 1993).
Even though CD8+ T cell production of IFN-y can compensate and restore the

concentrations of IFN-y back to normal levels in CD4+ T-defecient mice, the latt

still succumb to the infection earlier than wild-type mice, suggesting a role fo

CD4+ T cell-derived IFN-y early in the infection, or perhaps an IFN-y-independen
mechanism that is important early in the infection (Caruso et al, 1999). An IFNy-independent CD4+ T cell-mediated mechanism dependent on NOS2 has recently
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been shown in vitro and suggested to be important in vivo by the demonstration
that IFN-y-deficient mice can be effectively protected by BCG vaccination in a
CD4+ T cell-dependent manner (Cowley & Elkins, 2003).
CMI to M. tuberculosis promotes the formation of granulomas - infected
macrophages surrounded by antigen-specific lymphocytes, multinucleated giant
cells, and a ring of fibrous deposition (Dannenberg & Rook, 1994b). Granulomas

typically encompass the entire infection foci and effectively isolate the bacill
from the rest of the healthy lung. Granuloma formation is largely dependent on
TNF-a and GM-CSF (Kindler et al, 1989; Shibata et al, 2001), which are
produced by infected macrophages, T cells (Saunders et al, 2003), and other
hemaetopoetic cells, and drive tissue-resident stromal cells to produce
macrophage-inflammatory protein-ip (MIP-ip), MlP-la (Czermak et al, 1999)
and other chemokines (Algood et al, 2003) needed to recruit neutrophils,
lymphocytes, and monocytes to the site of infection. TNF-a"A mice infected with
M. tuberculosis fail to form organized granulomas, are incapable of controlling
tuberculosis replication, and succumb to M. tuberculosis within 20-30 days post
infection (Flynn et al, 1995; Bean et al, 1999). The levels of TNF-a must be

tightly regulated since overproduction can lead to excessive pathology (Bekker e
al, 2000). Likewise, GM-CSF-deficient mice are highly susceptible to M.
tuberculosis infection (mean-time to death, 35 days) (Gonzalez-Juarrero et al,
2005).
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2.5.2. Survival of M . tuberculosis in the macrophage. Pathogenic mycobacteria
reside and readily replicate within tight vacuoles of non-immune-activated
macrophages (Armstrong & Hart, 1971; Rusell, 2001). Pioneering studies by
D'Arcy Hart and co-workers showed that tubercle bacilli prevent the fusion of
lysosomes to M. tuberculosis-containing vacuoles, which prevents their normal

acidification and facilitates bacterial survival and replication (Armstrong & Ha
1971, 1975). Vacuoles containing live virulent M. avium have a relatively high
pH (6.3-6.5), which correlates with a lower density of vesicular H+ ATPase pumps
on their membranes (Sturgill-Koszycki et al, 1994). Mycobacterial vacuoles
reside within the recycling/sorting endosomal compartment — markers of early
endosomes (Rab5) are retained, markers of late endosomes (Rab7) and lysosomes
(LAMP1-1 and LAMP-2) are largely excluded; communication with the
cytoplasmic membrane appears to be maintained as suggested by the cycling of
transferrin in and out of the vacuoles (Clemens & Horwitz, 1996; SturgillKoszycki et al, 1996). Diversion of the mycobacterial phagosome from the

normal maturation pathway correlates with retention of the actin-binding coronin
"TACO" on the phagosomal membrane (Ferrari et al, 1999).
Active evasion of phagolysosomal fusion by M. tuberculosis involves
bacterial "effectors" such mannose-capped lipoarabinomannan (ManLAM) which
interferes with phagolysosomal fusion by blocking the acquisition of the

lysosomal cargo and syntaxin 6 from the trans-Golgi network (Fratti et al., 2003)
LAM alone can specifically block the cytosolic Ca2+ increase necessary for a
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signaling cascade involving phosphatidylinositol (PI)3 kinase h V P S 3 4 , which is
needed for production of PI 3 phosphate (PI3P) on phagosomes (Vergne et ah,
2003).
The importance of type-1 cytokines in human immunity to M. tuberculosis
infection has been confirmed by studies of naturally occurring polymorphisms in
the genes encoding type-1 cytokines and their receptors in humans (Atare et al,
1998; Ottenhoff et al, 2002). The principle role of type-1 cytokines in anti-TB
immunity is to activate the anti-microbial functions of macrophages. IFN-y

activation and infection of murine macrophages with M. tuberculosis results in t

differential expression of some 40% of the macrophage genes, an indication of ju
how dynamic the host-M. tuberculosis interaction is (Ehrt et al, 2001). Many of
these differentially-expressed genes likely encode functions involved in the
curtailment of growth and killing of the intracellular bacilli.

2.5.3. Effector mechanisms of the immune-activated macrophage. Schaible
and colleagues (1998) found that upon activation of M. avium-infected
macrophages with IFN-y and LPS, the mycobacterial vacuoles fuse to each other,
become more acidic (pH 5.3), and as a result of fusion with lysosomes accumulate

hydrolases. These and other changes in the intracellular milieu lead to stasis a
killing of the bacilli.
One of the facilitators of phagolysosomal fusion and acidification
downstream of IFN-y that has been shown to be essential for protection in TB is
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L R G 4 7 (Feng et ah, 2004; MacMicking et ah, 2003), a m e m b e r of a family of
IFN-y-dependent GTPases that mediate fusion events in endosomal networks
(Taylor et ah, 1996). That these GTPases play different functions in response to

infection by different pathogens is suggested by the findings that IGTP-/~ and I

47_/_ mice, which are susceptible to infection by viral, bacterial, and eukaryoti

pathogens (Taylor et ah, 2000; Collazo et ah, 2001), are resistant to infection by
M. tuberculosis. In contrast, LRG47"7" mice succumb to infection by M.
tuberculosis with kinetics similar to those of NOS2_/" mice, the other major
pathway of antimycobacterial immunity (Chan et ah, 1992; Chan et ah, 1995;
MacMicking et ah, 1997).
The immune system relies on chemically reactive micromolecules as well
as enzymes to neutralize and eliminate invading pathogens and their products.

Some of the most efficient of these reactive molecules in killing and controllin
M. tuberculosis include the reactive nitrogen intermediates derived from nitric
oxide produced by nitric oxide synthase 2 (Nathan, 1992). M. tuberculosis is
killed by murine peritoneal macrophages and cell lines activated with IFN-y and
either LPS or TNF-a via RNI production, and IFN-y and TNF-a synergistically
increase NO synthesis by macrophages (Flesch & Kaufmann, 1991; Chan et ah,
1992; MacMicking et ah, 1997a; Nathan & Shiloh, 2000). The demonstration that
NOS2"A mice are highly susceptible to M. tuberculosis infection provides clear
functional genetic evidence that NOS2 is essential for the protective immune
response against M. tuberculosis (MacMicking et ah, 1997b; Scanga et ah, 2001).
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Even though macrophage activation and resulting R N I production result in

bacteriostasis, M. tuberculosis is nonetheless able to resist eradication in mou

lungs and in activated macrophages in tissue culture, despite the fact that in v
reagent NO is a potent mycobactericidal (Nathan & Ehrt, 2003). Having evolved

to infect the mammalian lung, M. tuberculosis appearently has ways of countering
the nossive effects of NO and related RNI. One such mechanism involves the
product of the mpa gene, which forms hexamers that have ATPase activity, and is
believed to be associated with a mycobacterial proteosome. Ampa M. tuberculosis

bacteria are attenuated in wild-type mice and show some revertion to virulence i
NOS2_/" (Darwin et al, 2003). It remains to be shown whether Ampa M.
tuberculosis bacteria have defects in protein degradation via this presumptive
proteasome, and whether this proposed function is involved in protecting the

bacteria from RNI. An additional strategy adopted by M. tuberculosis to deal wit
RNI appears to be simple avoidance of NOS2. Recent, microscopy studies

indicate that M. tuberculosis might be able to prevent NOS2 from being recruited
to bacteria-containing phagosomes (Miller et al, 2004).
The role of NO in protection against M. tuberculosis in humans is
somewhat controversial (Nathan & Ehrt, 2003). While some investigators have
reported NOS2 protein induction, NO, which is measured by determining the

concentration of its breakdown products nitrate (N03) and nitrite (N02), cannot b
consistently detected in M. tuberculosis-infected cultures of human
monocytes/macrophages (MacMicking et al, 1997; Nathan & Ehrt, 2003).
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Furthermore, no mutations in nosl in humans have yet been associated with
susceptibility to M. tuberculosis. However, patients with active TB apparently
exhale high levels of NO, which correlate with high expression of NOS2 and
spontaneous production of nitrite by alveolar macrophages (Wang et al, 1998).
Another reactive micromolecule that is a potent antimicrobial effector of
the immune response is the nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase (PHOX)-mediated production of reactive oxygen intermediates
(ROIs) - reduction products of 02 such as superoxide, hydrogen peroxide, and
hydroxyl radical (Nathan & Shiloh, 2000). ROI generation is an effective
antimicrobial defense against many bacterial pathogens including Salmonella
(Vazquez-Torres & Fang, 2001) and Burkholderia cepacia (Segal & Holland,
2003). However, the protective role of ROI in TB appears to be less prominent
than during Salmonellae infections. CGD patients which lack phagocyte oxidase

have not been reported to be more susceptible to M. tuberculosis infection (Nath
& Ehrt, 2003). Furthermore, gp91(phox/) mutant mice, which lack a functional

phagocyte oxidase are not more susceptible to M. tuberculosis than wildtype mice
(Hisert et ah, 2004; Ng et ah, 2004), while mice lacking the gp47 subunit of

PHOX are less able to control M. tuberculosis replication only transiently (Coop
et ah, 2000). Furthermore, M. tuberculosis appears to be able to effectively
counteract the damaging effects of ROIs. ROI detoxification mediated by the

KatG catalase is essential for bacterial persistence in mice following induction
adaptive immunity (Li et ah, 1998; Pym et ah, 2002), and an M. tuberculosis
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mutant of katG is attenuated in wild-type mice, but reverts to wildtype levels of
virulence in mice lacking PHOX (Ng et ah, 2004). The product of katG is also a
peroxynitritetase, thus it may protect M. tuberculosis from botrh RNI and ROI
(Wengenack et ah, 1999). At least one of the superoxide dismutases of M.
tuberculosis contributes to intracellular survival (Piddington et ah, 2001).

2.5.4. Immunity during M. tuberculosis chronic infection. Several of the
components that are important for generating a protective immune response to M.

tuberculosis infection are also important for maintaining the equilibrium betwee
host and pathogen during the chronic phase of the infection. As expected, Thl

maintainance is important for controlling M. tuberculosis during the chronic pha

of the infection and sustaining this type of response requires IL-12 (Feng et ah,
2005). Neutralization of TNF-a by antibodies or by infection with an adenovirus
expressing a soluble TNF-a receptor resulted in marked increases in bacterial
loads and exacerbation of disease in the mouse model of chronic TB and in a
variation of the Cornell model of drug-induced latency (Adams et ah, 1995,
Scanga et ah, 1999; Mohan et ah, 2001). Also using the Cornell model of TB,
IFN-y has been shown to be involved in preventing reactivation (Scanga et ah,
1999). Similarly, chemical inhibition of NOS2 in chronically infected mice
resulted in rapid increases in lung bacterial loads (Flynn et al, 1998). NOS2-

inhibiton also reactivated M. tuberculosis in variations of the Cornell model of
latency (Scanga et al, 1999; Botha et ah, 2002).
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2.6. M . tuberculosis mechanisms of i m m u n e evasion

Some of the bacterial mechanisms M. tuberculosis uses to directly protect itself
from ROI/RNI effectors of the immune response have already been discussed.
But like many persistent pathogens, M. tuberculosis has evolved mechanisms to
evade and subvert host immune responses at many levels (Flynn & Chan, 2003).
In addition to directly blocking phagosome maturation (See above), M.
tuberculosis interferes with IFN-y signalling via STAT1 (Ting et ah, 1999).
STAT1 deficiency in humans has been associated with increased susceptibility to
mycobacterial infection. Down-regulation of antigen-presenting (MHC class II
and CD1) and costimulatory (B7) molecules on infected macrophages may affect
activation of IFN-y-secreting T cells (Wojciechowski et al, 1999; Flynn & Chan,
2003). Macrophage activation, antigen presentation, and T cell activation may

also be inhibited by cytokines secreted by macrophages as a result of the infect
such as IL-10 (Murray, 1999), IL-6 (van Hyningen et ah 1997; Nagabhushanam et
ah, 2003), and transforming growth factor-p (TGF-p) (Vanham et ah, 1997). In
addition to blocking antimicrobial signaling pathways, many pathogens prolong
their survival by triggering apoptosis of leukocytes (Weinrauch & Zychlinsky,
1999). However, in M. tuberculosis infection apoptosis of the infected
macrophage has been implicated as a mechanism of host protection which could

deprive the bacterium of its intracellular niche of replication (Oddo et ah, 199
Gil et ah, 2004). Indeed accumulating evidence suggests that pathogenic
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mycobacteria m a y interfere with apoptosis of infected macrophages in order to

perpetuate their intracellular "safe haven" (Fratazzi et ah, 1999; Komfeld et ah
1999; Keane etal., 2000).

2.7. Extracellular persistence of M. tuberculosis in vivo

In the human lung M. tuberculosis is thought to reside both intracellularly and
extracellularly, depending on the type of lesion (Grossett, 2003; Kaplan et ah,
2003; Boshoff & Barry 2005). Pioneering work by Lurie (1964) and continued by
Dannenberg (Dannenberg & Rook, 1994b) in the rabbit model showed the
existence of extra-cellular M. tuberculosis in caseous necrotic lesions. Since
immunity to TB was thought to be mainly mediated by activated phagocytes

which kill intracellular bacteria (Mackaness, 1968; North, 1974), it was suspecte

that the extra-cellular milieu represent a safe heaven for bacterial replication

perhaps persistence. In order to study this population of bacteria directly, Lur

devised a very ingenious method of cultivating bacteria extracellularly in vivo:
Parlodion-film encased silk bags that were impervious to host cells, but not to
plasma, were inoculated with bacilli, and then implanted subcutaneously in

rabbits. These "extracellular" bacteria replicated unhindered during the first t
wks of infection, but then leveled off at circa 2 wks post infection. When
immunized animals were used, bacteria stopped growing earlier and were killed
more efficiently than in naive counterparts, strongly implicating acquired
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immunity in controlling the growth of extracellular bacteria. Since control of

growth correlated with a more rapid mobilization of mononuclear cells toward the
encased focus of infection, it was proposed that factors secreted by activated

macrophages rendered the fluids entering the infection foci inimical to bacteria
replication (Lurie, 1939a,b).
Recently, Karakousis and collagues (2004) adapted Lurie's strategy to the
widely used model of murine TB: M. tuberculosis was encapsulated in cellimpermeable hollow fibers, and these were implanted subcutaneously into mice

for in vivo cultivation. As expected, an initial period of bacterial replication

followed by curtailment of growth, followed by a considerable decline in numbers

and, interestingly, an eventual stabilization of the counts. These stationary-st

CFU counts, similarly to those in the equilibrium that characterizes the chronic
phase of infection in the mouse model of chronic TB (Rees & Hart, 1961; MufiozElias et ah, 2005) represented a somewhat static scenario: they found that about
half of the encapsulated bacilli were alive by differential staining; a highly

dynamic equilibrium would have resulted in a large accumulation of dead bacteria
and a decreasing proportion of live ones. Furthermore, indirect analysis comparison of ATP utilization and CFU at corresponding time points - indicated
that soon after implantation, bacteria decreased their metabolism. The rapid

cessation of multiplication and rather swift reduction in metabolic activity sug
that innate defenses or perhaps immune-independent mechanisms prompt these

adaptations. This was also suggested by Lurie's studies using vaccinated animals
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which implicated an unknown plasma factor in bacterial growth inhibition. This

factor could be nitric oxide, which is known to block M. tuberculosis replicatio

vitro by inhibiting bacterial respiration (Voskuil et ah, 2003). Careful analysis
the hollow-fiber's contents in this extracellular model of persistence in vivo,
including concentrations of NO, oxygen, essential elements, and nutrients might
be of value.

2.8. Chemotherapy: drug tolerance and resistance

2.8.1. Chemotherapy and drug tolerance. Current antibiotic treatment regimens
for active pulmonary TB are costly and burdensome, typically consisting of an

early phase of daily treatment with four drugs (isoniazid, rifampin, pyrazinamid
and ethambutol or streptomycin) for two months, and a prolonged four-monthlong phase of isoniazid and rifampin treatment. However, even when adequate

antibiotic therapy is completed, persistent bacilli may not be eradicated comple
(Kopanoff, 1988), and relapses are relatively frequent, especially among HIV+
individuals (Perriens et ah, 1995). Most drugs currently used to treat TB target

functions that are required for bacterial growth and division; see Table 2.1 for
list of available drugs and their proposed targets.

2.8.2. Drug Resistance. The long duration and complexity of currently available
TB drug regimens contribute to high levels of non-compliance and the emergence
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of widespread drug resistance and multiple-drag resistant ( M D R ) strains of M .
tuberculosis. The global prevalence of MDR-TB has recently been estimated at
4.3% (Heymann et al, 1999); alarmingly, almost 80% of MDR-TB strains
worldwide are resistant to 3 of 4 first-line drugs. In some eastern European and
former USSR nations, MDR-TB has reached epidemic proportions (Farmer et ah,
1998; TB alliance, 2005 report; tballiance.org).

2.8.3. Drug tolerance in vivo. It is not clear why treatment of TB is so difficul

and slow. The same antimicrobials that take months to cure a patient or to steri
the tissues of an experimentally infected animal, will sterilize a culture of M.
tuberculosis in vitro within days (Fig. 2.3B&C) (McDermott, 1958; McKinney,
2000; Mitchision, 2004). Drug penetration might be a problem, though apparently
at least for isoniazid adequate penetration does occur (Barclay et ah, 1953).
Neither increasing drug dosages (McDermott, 1958), nor giving patients more
drugs (Mitchison, 1980), led to increases in rates of killing in vivo.
Drug tolerant bacterial populations. One influential model of persistence

in the face of chemotherapy posits that the phenomenon results from physiologica

heterogeneity of mycobacteria in the tissues, which might include slow- and nondividing bacteria which resist killing by antimicrobials (Mitchison 1979, 1980).

Supporting evidence for this model was provided by a remarkable clinical study i
which tuberculous lung lesions were cultured from patients who had received
prolonged multi-drug chemotherapy (Fig. 2.3A) (Vandiviere et ah, 1956). Lesions
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Table 2.1. Currently available drugs to treat T B in h u m a n s

Drug

Cellular process

Molecular target (gene)

targeted
Isoniazid

Cell wall mycolic acid
synthesis

Enoyl-ACP reductase
(inhA)
p-Ketoacyl A C P synthase
(kasA)

Ethionamide

Cell wall mycolic acid
synthesis

Enoyl-ACP reductase
(inhA)

Pyrazinamide

Cell wall fatty acid
biosynthesis

FAS-I fatty acid synthase
(fas)

Ethambutol

Cell wall arabinogalactan
synthesis

Arabinosyltransferase
(embAB)

Cycloserine

Cell wall peptidoglycan
synthesis

D-alanyl, D-alanine ligase
(ddlA)
Alanine racemase (air)

Rifampin

R N A synthesis

Streptomycin

Polypeptide synthesis

Fluoroquinolones

D N A synthesis

D N A gyrase (gyrAB)

Folic acid synthesis

Dihydropteroate synthase

P A S (p-amino-salicylic
acid)

R N A polymerase P
subunit (rpoB)
16S r R N A (rrs)
S12 ribosomal protein
(rpsL)

(folP)

N a m e s in bold lettering indicate 1st line drugs. InhA (Banerjee et ah, 1994); kasA
(Mdluli et ah, 1998); fas (Zimhony et ah, 2000); e m b A B (Belanger et ah, 1996);
ddlA (David et ah, 1969); air (Caceres et ah, 1997); rpoB (Telenti et ah, 1993);
rrs and rpsL (Finken et ah, 1993); gyrAB (Drlica et ah, 1996); folP (Nopponpunth
et ah, 1999). Table adapted from McKinney (2000).
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A)

CLOSED
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lesion: drugsensitive
Colonies in310 months
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M . tuberculosis in vivo drug tolerance
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- X - bacterial CFU in vivo
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Fig. 2.3. In vivo drug tolerance. (A) Resected lung lesions from patients on chemotherapy were
cultured. "Open" and active cavitary lesions, with patent connections to the airways, yielded drugresistant tubercle bacilli in the normal timeframe (less than 2 months' incubation). "Closed" and
dormant encapsulated lesions, with no apparent connections to an airway, yielded drug-sensitive
bacteria only after extended incubation (3 to 10 months). Adapted from Vandiviere et al. (1956) by
Munoz-Elias & M c K i n n e y (2002). (B) In vivo drug tolerance in mice. Mice infected with M .
tuberculosis (Erdman) were put on I N H monotherapy from w k 4-12 post-infection (empty) or not
(solid). (C) In vitro vs in vivo susceptibility of M . tuberculosis isoniazid (INH) and rifampin (RTF);
(Fig. C: courtesy of J.D. McKinney).
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that were "open" and active yielded colonies of drug-resistant tubercle bacilli in
the normal time frame of 3-8 wks; in contrast, lesions that were "closed" and
inactive yielded colonies only after 3-10 months of incubation, and these
"resurrected" bacteria were fully drug susceptible.
These clinical findings parallel pioneering experiments in the mouse model
of TB by McCune, McDermott, and Tompsett (McCune & Tompsett 1956;
McCune et ah 1956, 1966a, 1966b) who established the Cornell model of druginduced latency (See above). McDermott (1958) defined in vivo "persisters" as
those "microorganisms which are drug susceptible when tested outside the body
[but] are nevertheless capable of surviving within the body despite intensive
therapy". Importantly, these persisters are not genotypically resistant (do not

higher minimal inhibitory concentrations, MICs) and are not genotypically tolera
(do not have mutations that allow survival in the absence of replication). Thus,
nature of these persisters largely remains an enigma.
The nature of 'persisters.' This type of bacterial persistence was first
recognized by Bigger (1944), who observed that penicillin treatment of a growing
culture of Staphylococcus aureus consistently failed to kill a fraction of the

population (106). Remarkably, these bacteria, which he called "persisters," could

survive exposure to multiple antibiotics and stresses and were therefore postula
to be in a modified state in which they were neither able to replicate, nor

permanently incapacitated since they retained the ability to grow like wild-type
when cultured in the absence of antibiotics.
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O n e important question regarding the nature of "persisters" is whether they
generate spontaneously or are induced by exposure to antibiotics. Recently,

Balaban et ah, (2004) took advantage of two previously described E. coli strains
which formed high numbers of persisters, hipA7 (Moyed & Bertrand, 1983) and
hipQ (Wolfson et ah, 1990), and microfluidic devices which allowed the analysis

of the history of individual cells after subjecting the population to antibiotic

mediated killing, to demonstrate the existence of at least two types of persiste
both of which were shown to be present in the population prior exposure to

antibiotic. Type I persisters are a preexisting subpopulation of non-growing cel

generated at stationary phase. The size of the population of type I persisters i
directly proportional to the number of stationary phase cells inoculated into a

culture. Type II persisters are a subpopulation of cells that multiply more slow

than the majority of the cells in the culture, a state that appears to be inheri
several generations. Since type II persisters are constantly generated during

exponential growth, the number of type II persisters present in a growing cultur
increases in step with the population, and is not influenced by the size of the
inoculum.
Since these persisters survive treatment with antibiotics but their generation
is independent of exposure to them, they are probably generated during natural

infections and might play a role in persistent infections including TB. How migh
these persisters arise during M. tuberculosis infection? Most bacteria in the

sputum of TB patients are susceptible to killing by antibiotics, as suggested by
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rapid conversion to sputum negativity soon after onset of chemotherapy; thus it is

unlikely that many of these bacteria are persisters. Since M. tuberculosis infec
involves the inhalation of infectious droplet nuclei containing between 1-10

bacilli, natural transmission of persisters is unlikely. Persisters could be gen

as the infection progresses. Type II persisters could be generated during the in
period of replication before the onset of CMI and probably in smaller numbers

during periods of active replication throughout the chronic phase of the infecti

Type I persisters could be generated during periods of no replication, which mig

be similar to stationary-phase. If bacterial replication resumes sporadically du

latency, only to be curtailed by the protective immune response, type I persiste

by virtue of their lag in coming out of stationary phase, might be protected from
such killing and enriched for. Both types of persisters would be intrinsically

tolerant to the cidal action of antibiotics, but type II persisters would be exp
to be more sensitive to killing by antibiotics than type I persisters because

replication and cell division require macromolecular synthetic processes that ar
targeted by currently available drags.
But why is M. tuberculosis so recalcitrant to eradication by the host and by

antibiotics compared to other bacteria that also have the ability to form persis

One reason might be its intrinsic resistance to chemical and physical stress, wh
could act as a barrier to the efficient penetration by drugs. Additionally, M.
tuberculosis might have evolved a high rate of generation of persisters. The

existence of high persistence mutants in other bacteria indicates that the abili

75

form persisters is under genetic control and therefore subject to evolution.

Bacterial species might have evolved specific rates for generation of persisters

which fit their particular life styles, e.g., it is possible that bacterial spec
spend a lot of time in biofilms have a high basal rate of persister generation,

that the resistance to killing displayed by bacteria in a biofilm might be due t

high fraction of persisters. M. tuberculosis, having evolved to cause chronic an

latent infections in humans, would likely benefit from having an intrinsically h

persister generation rate. In LTBI, acquired immunity, which effectively controls

and kills most of the infecting bacteria, might fail in eradicating all the bact

because surviving cells might be persisters that are phenotypically resistant to

antibacterial chemical compounds (ROIs, RNIs, acid, hydrolases, etc) as well as t
commonly used antibiotics. Interestingly, recent modeling suggests that high
persister generation might be a physiological adaptation well suited to life in
environments where antibiotics (stresses) are intermittently encountered, while

low rates of persister generation might be better suited for life in an environm
where exposure to anbiotics (stresses) is rare (Kussell et ah, 2005). Generation
persisters may be important for pathogens like M. tuberculosis which depend on
long-term survival in the dynamic environment of the immune-aware host for

transmission. Whether environmental signals might influence the manifestation of

the persister phenotype is unknown; there could be significant interplay between
the myriad of mechanisms involved in stress survival by bacteria and the
mechanism(s) of persister generation.
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C H A P T E R

3

Bacterial M e t a b o l i s m in vitro

INTRODUCTION

We have learned much about the metabolism of bacteria since the observation of
these animacules under Leeuwenhoek's crafty lenses, and their early cultivation

Pasteur's expertly sterile hands (de Kruif, 1926). Most of this knowledge has bee

gained from the study of a handful of species, mostly the enterics Escherichia c

and Salmonella enterica serovar typhimurium, and has resulted in our vast curren
understanding of physiology and metabolism. However, since most of these
studies were and continue to be conducted in the laboratory, generally under
artificially optimized conditions, much less is known about the physiology and
metabolism of bacteria living in their natural environments. This void in our
understanding extends to those few species that are arguably the most relevant

ones, those bacteria that as part of their intended or accidental life cycles in
and cause malaise in humans, and occasionally their death. This chapter is a
general discussion of bacterial metabolic pathways with an emphasis on carbon
metabolism, largely drawing from the work on enterics; however, an effort has
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been m a d e to highlight what is k n o w n to occur or might occur in M . tuberculosis
and other mycobacterial species.

3.1. General metabolic considerations

In order to sustain themselves, chemotrophic bacteria need a number of elements
in varying quantities. Some elements such as carbon (C), oxygen (O), hydrogen

(H) and nitrogen (N), which are abundant constituents of cells, as well as calci
(Ca), chloride (CI), iron (Fe), phosphorous (P), potassium (K), magnesium (Mg),
and sulfur (S), which are needed for various cell functions, are required in
relatively high concentrations (>100 \iM). A number of other elements such as
manganese and zinc are needed in trace amounts. All of these elements are
generally found in substances referred to as nutrients, which are also energy

sources since their catabolism can lead to ATP generation, the energy currency o
the cell. Some of this ATP can be produced directly from metabolic intermediates

containing high-energy phosphoryl bonds by the transferring of this group to ADP
(substrate-level phosphorylation). However, most ATP molecules are generated
through respiratory chains in which the flow of electrons from negative redox-

potential donors to more positive redox-potential acceptors is linked to the tra
of the phosphoryl groups to ADP molecules. ATP is employed to activate
metabolic intermediates for further chemical reactions necessary for cell
maintainance, growth, and genetic perpetuation. While the electron donor can be
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either an organic or an inorganic compound, the electron acceptor is in most cases
oxygen, though other electron acceptors such as carbon dioxide, nitrate, and
sulfate are sometimes used.
In addition to the elements so far listed, different types and amounts of a
variety of compounds must sometimes be obtained from the environment,
depending on whether the bacteria can synthesize them themselves. These include
prosthetic groups of various enzymes such as nicotinic acid (precursor of
coenzymes NAD+ and NADP+), lipoic acid, riboflavin B2 (precursor of flavin
mononucleotide, FMN), flavin adenine dinucleotide (FAD) and thiamine
(precursor of thiamine pyrophosphate), as well as other vitamins and some amino
acids.

3.2. Substrate uptake

Passively diffused substrates (oxygen, C02) get into cells without interaction w
cell membrane components until equilibrium is established; their transport does
not involve energy expenditure. Similarly, facilitated diffusion requires no
energy, but does involve a membrane carrier. Active transport, in contrast, is

substrate specific and requires energy. One type of active transport involves th

electron transport chain or ATP hydrolysis at the membrane and its coupling with

the carrier's ability to bind and transport the substrate into the cell. Another

involves substrate-specific binding proteins, which usually hydrolyse ATP. Group
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translocation by chemical modification of the transported substrate via formation

of a phosphate ester is also common and in this case the donor is a phosphorylate
substrate specific enzyme that traps the substrate in the membrane and frees it
the cytoplasm in the phosphorylated form. The transport of sugars in E. coli
occurs through this mechanism via the phosphoenolpyruvate:glucose
phosphotransferase system (PTS), where the phosphate donor is phosphoenol
pyruvate (PEP). This pathway is found mostly in facultative and obligate
anaerobic bacteria and is apparently absent in mycobacteria (Romano, 1970).

3.3. Carbon catabolism and cellular biosynthesis

Bacteria can either use organic (carbon heterotrophs) or inorganic compounds
(carbon autotrophs) to generate energy and cell constituents. Mycobacteria are
heterotrophs and can use a variety of carbon substrates as sources of carbon and
energy. In addition to chemotrophy, mycobacteria are also capable of
chemolithotrophy since they all contain a CO dehydrogenase and can grow on CO
(Park et ah, 2003). Bacteria can grow on a number of carbohydrates including
glucose, fructose, lactose, and pentoses, on several organic acids including

pyruvate, malate, and succinate, as well as on a number of amino acids, and fatty

acids of different lengths, including acetate and propionate. Carbon utilization
studies in vitro have shown that M. tuberculosis and other mycobacteria can
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oxidize a number of carbon substrates including carbohydrates, lipids, and amino
acids (Wheeler, 1984).
Carbon substrate catabolism provides the bacterial cell with energy in the
form of reducing equivalents to generate ATP, and with essential biosynthetic
precursors. Glucose-6-P, fructose-6-P, 3-P-glycerate, PEP, pyruvate, acetyl-CoA,
oxaloacetate and alpha-ketoglurate are all precursors of monomers such as sugar
phosphates, amino acids, vitamins, fatty acids, and nucleotides, which are then
assembled into macromolecular cellular components such as proteins,
polysaccharides, lipids, and nucleic acids that make up the cell. A partial list
provided in table 3.1.

Table 3.1. Important precursors of biosynthesis and their products
Precursor
Fructose-6-P

Product
mannose-6-P, hexoseamines (N-acetylglucosamine
of L P S and peptidoglycans)

Dihydroxyacetone
phosphate

Phospholipids

3-phophoglycerate

Glycine, Serine, Cysteine

PEP

Phenylalanine, Tryptophan, Tyrosine

Pyruvate

Alanine, Valine, Leucine

Acetyl-CoA

Fatty acids

Propionyl-CoA

Fatty acids

2-ketogluteraldehyde

Arginine, Glutamate, Glutamine, Proline

Succinyl-CoA

Porphyrins

Oxaloacetate

Asparagine,
Aspartate,
Methionine, Threonine
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Isoleucine,

Lysine,

3.4. Pathways of carbohydrate catabolism

Sugars such as glucose and other hexoses are used by many bacteria as sources of

carbon and energy. Glucose is not only a highly versatile biosynthetic precursor

but thanks to its relatively high potential energy, it is also an excellent fuel

ATP generation. A typical bacterial cell uses half of the glucose available to i
biosynthetic purposes and the other half for ATP generation (Fraenkel, 1996). In
several bacteria, the transport of glucose into the cell is linked to its
phosphorylation via the PTS, which is unique to bacteria (Anderson and Wood,
1969). Searches of the M. tuberculosis genome with the glucose-specific (or
fructose-specific) phosphotransferase enzyme IIA or other components of the PTS
systems yielded no homologues. Some bacteria, including E. coli and Salmonella
have a hexokinase (glk) and while glk mutants grow normally on glucose medium,
PTS-deficient bacteria grow slowly on glucose relying on this hexokinase. M.
tuberculosis does not have a clear glk homologue (possibly Rv0650), but it does
have a clear polyphosphate glucokinase homolog, and transposon mutants of

ppgK, encoding this putative sugar transporter, grow slowly on glycerol/dextrose
containing plates (Sassetti et ah, 2003).
The three main pathways of sugar intermediary metabolism are the
Embden-Meyerhof pathway (glycolysis), the pentose phosphate pathway, and the
Entner-Doudoroff pathway (Romano & Conway, 1996; Peekhaus and Conway,
1998).
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3.4.1. Entner-Doudoroff pathway. S o m e bacteria metabolize sugars through 6phosphogluconate via the Entner-Doudoroff pathway (EDP) (Fig. 3.1) (Entner &
Doudoroff, 1952). Though the EDP is widely distributed and apparently one of
the most ancient in evolution, its significance in carbon catabolism is only
beginning to be understood (Romano & Conway, 1996). Studies carried out over

the past few decades, most of which analyzed E. coli grown in bactch cultures and
high glucose concentrations, indicated that the EDP played a minor role in

carbohydrate metabolism. In contrast, recent functional genetic analyses suggest

that the EDP is heavily employed and is essential for the survival of E. coli in
mammalian intestine (Chang et ah, 2004). Furthermore, recent analysis of

bacterial species not routinely studied in the laboratory is uncovering a much m
central role for the EDP in bacterial sugar catabolism than previously realized
(Fuhrer et ah, 2005). Genes encoding enzymes of the EDP, namely glucose
oxidase (gcd), 6-P-gluconate dehydrase (edd), and 2-keto-3-deoxy-6-P-gluconate
aldolase (edd) are not found in M. tuberculosis or M. leprae genomes as
determined by BLASTP searches with the E. coli sequences. Likewise homologs
of genes involved in the transport of gluconate (gluconate permeases: gntP and
gntT) or its activation (gluconate kinase: gntK) are also missing.
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Fig. 3.1. Carbohydrate metabolism pathways. The best-characterized pathways of carbohydrate
catabolism are glycolysis, the pentose phosphate pathway (PPP), and the Entner Doudoroff pathway
( E D P ) . Glucose anabolism occurs via gluconeogenesis. E n z y m e s c o m m o n to glycolysis and
gluconeogenesis are indicated b y thick double-headed arrows. Irreversible reactions:
phosphofructokinase and pyruvate kinase (glycolysis), and fructose-1,6-biphosphatase and P E P
synthase (gluconeogenesis). pts, PEP:glucose phosphotransferase system; glk, glucose kinase; pgi,
phosphoglucose isomerase; pflc, phosphofructokinase; fbp, fructose- 1,6-bisphosphatase; fba,
fructose-1,6-bisphosphate aldolase; tpi, triosephosphate isomerase; gap, glyceraldehyde 3phosphatedehydrogenase; p g k phosphoglycerate kinase; p g m , phosphoglyceratemutase; eno,
enolase; pyk, pyruvate kinase; pps, P E P synthase; ppdk, pyruvate phosphate dikinase; gcd, glucose
dehydrogenase; gntK, gluconate kinase; zwf, glucose-6-phosphate dehydrogenase; pgl, 6phosphogluconolactonase; edd, 6-phosphogluconate dehydratase; eda, 2-keto-3-deoxy-6phosphogluconate aldolase; gnd, 6-phosphogluconate dehydrogenase; rpe, ribulose-5-phosphate
epimerase; tkt, transketolase; tal, transaldolase. Genes absent in mycobacteria are indicated b y
parenthesis/dashed arrows (Modified from Fraenkel, 1996).
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3.4.2. T h e pentose phosphate pathway. The pentose phosphate pathway (PPP)
(Fig. 3.1) allows the oxidation of one molecule of glucose to 3 of C02 and 1
glyceraldehyde-3-P with the concomitant generation of NADPH; NADPH is
required for reactions in which NADH cannot act as co-enzyme. The PPP also
generates pentose phosphates, which are precursors of nucleotide biosynthesis,
and erythrose-4-P, which together with phosphoenol pyruvate (PEP), are
precursors of aromatic amino acids (Romano & Conway, 1996). In B. abortus the
PPP alone can be used for sugar metabolism. M. tuberculosis has homologs of the
genes of the PPP, including glucose-6-P dehydrogenase (zwfl and zwfl),
phosphogluconolactonase (pgl), 6-phosphogluconate dehydrogenases (gndl and
gndl), transaldolase (tal) and transketolase (tkt). E. coli oxidize up to a third

the glucose available throuhg the PPP, and the rest through glycolysis. However,

other species use the PPP mostly for biosynthetic purposes. Importantly, the PPP
pathway can function as a cycle and allow aerobic growth on carbohydrates in the
absence of a functional TCA cycle (Fig. 3.1). Glucose-6-phosphate
dehydrogenase activity (GND) was long ago demonstrated in extracts from fast
and slow growing mycobacteria (Sharma et ah, 1985), and M. tuberculosis
transposon mutants in several PPP genes (gndl, tkt, tal) are impaired for growth
on standard mycobacterial medium (Sassetti et ah, 2003).

3.4.3. Embden-Meyerhof-Parnas pathway (Glycolysis). Glycolysis (Fig. 3.1) is
widely used for the degradation of glucose-6-P to pyruvate (Fraenkel, 1996).
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Lacking a P T S , M . tuberculosis likely activates glucose by phosphorylating it via
polyphosphate glucokinase (PPGK). In E. coli, the inter-conversion of glucose-6P and fructose-6-P is catalyzed by P-glucose isomerase (pgi). Apgi E. coli grow

slowly on glucose, and do so relying on the PPP since deleting either zwf or gnd
apgi-nnll background abrogates growth (Fraenkel & Levisohn, 1967). Similarly,
PGI-deficient M. smegmatis grow on glucose but at a lower rate and after a
protracted lag phase (Tuckman et ah, 1997). M. tuberculosis pgi mutants are also
impaired for growth on glucose-containing media (Sassetti et ah, 2003).
Fructose-6-P is converted to Fructose-1,6-P2 by phosphofructokinase (pfk).
E. coli has two PFK isoenzymes, neither of which is essential for growth on
glucose, however, pfkA appears to encode the main PFK in this species since pfkA
mutants are more markedly impaired for growth on glucose than mutants in pfkB
(Doelle, 1975; Vinopal & Fraenkel, 1975; Vinopal et ah, 1975). Similarly, M.

tuberculosis has two putative PFKs, which appear to overlap functionally (Sasset
et ah, 2003). Interestingly, E. coli ApfkAIApfkB mutants cannot grow on glucose,

but constitutivity of the glyoxylate cycle (GC), an anaplerotic pathway normally

employed during growth on even-chain fatty acids (C2 substrates), as a result of
mutation in the GC regulator iclR, can compensate for the partial loss of PFK
(ApfkA) (Vinopal & Fraenkel, 1974), which suggests that when there is reduced
flow of carbon into into the lower part of glycolysis, the GC might supply
sufficient PEP via PEP carboxykinase (PCK) (Romberg & Smith, 1970).
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Fructose-1,6-P2

aldolase

(fba)

splits

fructose-1,6-P2

into

dehydroxyacetone-P and glyceraldehyde-3-P, and interconversion of these two
products is catalyzed by triose-P-isomerase (tpi) (Bai et ah, 1982). As expected,
M. tuberculosis tpi mutants do not grow well on standard 7H10 plates where
glucose and glycerol are the main carbon sources (Sassetti et ah, 2003). When E.
coli use glycerol as a carbon source, its conversion to dihydroxyacetone-P must

accompanied by its isomerisation to glyceraldehyde-3-P to avoid the production o
methylglyoxal, which can be toxic to cells (Cooper & Anderson, 1970). This
might not be an issue during glycerol catabolism in mycobacteria because
methylglyoxal synthase (mgsA) seems to be absent in these species.
Glyceraldehyde-3-P is converted to glycerate-l,3-P2 by glyceraldehyde-3-P
dehydrogenase (gap); glycerate-l,3-P2 can be interconverted to 3-P-glycerate by
P-glycerate kinase (pgk), which can be interconverted to 2-P-glycerate by Pglycerate mutase (gpm), of which several homologues exist in M. tuberculosis. 2P-glycerate is dehydrated to PEP by enolase (eno). Though functional TPI, GAP,
PGK and ENO enzymes are required for growth on either glycerol or succinate
alone, if both substrates are provided, these steps are dispensable (Anderson &
Wood, 1969; Fraenkel, 1996). Up until this point in glycolysis, the only
irreversible reaction dicussed is that catalyzed by PFK.
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3.5. Conversion of P E P to pyruvate and the fate of pyruvate

Conversion of PEP to pyruvate by pyruvate kinase (PYK) is coupled to ATP
generation (Clark, 1989). E. coli lacking PYK (PYKI and PYK2) grows slowly on
glucose, relying on the PPP for sugar catabolism and energy, the PTS system for
pyruvate generation, and PEP carboxylase (PPC) for replenishment of
oxaloacetate (Ponce et ah, 1998; Peng & Shimizu, 2003). PYK-deficient E. coli
can only grow on sugars that are transported by the PTS because pyruvate is
formed when the phosphoryl group of PEP is donated (Anderson & wood, 1969).
B. subtilis PYK-deficient mutants grow slowly on glucose (Fry et ah, 2000)

despite lacking a PPC, likely because their PTS provides the necessary pyruvate.
Since M. tuberculosis lacks both a PTS and PPC, a PYK-deficient mutant
should not grow on sugars. While M. tuberculosis has a functional PYK enzyme,
the related species M. bovis lacks this activity (Gamier et ah, 2003) and cannot
grow on glycerol or dextrose (Keating et ah, 2005). M. bovis grows well on

several C2 and C3 (odd chain fatty acids) substrates in vitro (unpublished, E.J.M
Most commonly, pyruvate is oxidized through decarboxylation to acetylCoA via the pyruvate dehydrogenase (PDH) complex, which is composed of
pyruvate dehydrogenase (El), a dihydrolipoamide acetyl (succinyl-) transferase
(sucB, E2), which liberates the acetyl-CoASH molecule, and dihydrolipoamide
dehydrogenase LPD (E3), which regenerates the dihydrolipoic acceptors
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covalently attached to lysine residues on the E 2 acetyl (succinyl-) transferase
component (Argyrou & Blanchard, 2001). The PDH complex is present in almost

all aerobic heterotrophs so far studied (Neveling et ah, 1998). The LPD subunit i
the same as that in the E3 of 2-ketoglutarate dehydrogenase (a-KGDH). M.
tuberculosis LPD and the SUCB components of PDH/a-KGDH apparently
participate in the detoxification of peroxynitrite in vitro (Byrk, et ah, 2002).

3.6. The tricarboxylic acid cycle (TCA cycle)

The TCA cycle is the predominant cycle of intermediary metabolism in animal
tissues, where it oxidizes acetyl-CoA to C02 and provides several important
biosynthetic precursors. However, the TCA cycle is generally more widespread in
eukaryotes than it is in prokaryotes; bacterial genomes often lack one or more
genes of the pathway, most commonly an a-ketoglutarate dehydrogenase
component (Cordwell, 1999).
In the TCA cycle, oxaloacetate (oxaloacetate) (a C4-dicarboxylic acid)
condenses with acetyl-CoA (high potential-energy C2 compound) yielding citrate
(C6 compound) (Fig. 3.2) (Cronan & LaPorte, 1996). The cycle then oxidizes this
C6 compound back to the C4 releasing two C02 molecules and gaining ATP, GTP,
NADH+, and FADH2 molecules in the process. Acetyl-CoA, which can originate
from sugars (glycolysis and PDHC), fatty acids (P-oxidation), or through direct
synthesis from acetate (acetyl-CoA synthase) enters the TCA cycle through its
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Fig. 3.2. Tricaboxylic Acid Cycle. T h e T C A cycle allows the oxidation of acetyl-CoA to C 0 2 with
concomittant gain of reducing equivalents. Quantity and type of carbon substrate, as well as oxygen
levels, affect expression of T C A cycle enzymes; induction of the T C A cycle is most pronounced
w h e n bacteria g r o w on C 2 substrates under aerobic conditions. G e n e names are those used for M .
tuberculosis ( H 3 7 R v annotation) (TubercuList: http://genolist.pasteur.fr/TubercuListA
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condensation with oxaloacetate by action of citrate synthase. M . tuberculosis has

three genes that could encode this activity (gltAl, gltAl, citA). The isomerizati

of citrate to isocitrate is catalyzed by a two step reaction carried out by acon

(ACN, acs), which first dehydrates citrate to the enzyme-bound form cis-aconitat
and subsequently adds a water molecule to this intermediate to produce the free
isocitrate. Isocitrate is then oxidized and decarboxylated to a-ketoglutarate
by isocitrate dehydrogenase. M. tuberculosis has two isocitrate dehydrogenases

(IDHs) (icdl, icdl) (Sharma et ah, 1985). Similarly, Ralstonia species encode two
IDHs and these are functionally redundant (Wang et ah, 2003a).
The oxidation of a-ketoglutarate to succinyl-CoA is catalyzed by the aketoglutarate dehydrogenase complex (a-KGDH), which is analogous to the PDH
complex which oxidizes pyruvate to acetyl-CoA. In M. tuberculosis, PDH and aKGDH complexes apparently have in common not only the LPD (E3) component,
but also the lipoate dehydrogenase (E2) component, since the only lipoylated
protein in the M. tuberculosis proteome is SUCB (E2) (Bryk et ah, 2002). The
conversion of succinyl-CoA to succinate is catalyzed by succinate thiokinase
(sucCD) and is accompanied by the generation of an ATP molecule by substrate
level phosphorylation by taking advantage of the high energy thioester group in
succinyl-CoA. In E. coli, a-KGDH dehydrogenase genes (sucAB) and the
succinate thiokinase genes (sucCD) are in an operon (sucABCD); in M.
tuberculosis, sucCD form an operon, but sucA and sucB do not.
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Succinate dehydrogenase (SDH, sdhA-D) then oxidizes succinate to fumarate,
which is subsequently hydrated to malate by fumarase (FUM, fum). In E. coli, an
NAD-dependent malate dehydrogenase (MDH) is primarily responsible for the
oxidation of malate to oxaloacetate. Malate:quinone-oxidoreductase (MQO), an
FAD-dependent membrane-associated protein, which can also catalyse the
oxidation of malate to oxaloacetate while the electrons are donated to quinones
the electron transport chain instead of to NAD+ (Kather et ah, 2000), is only
required if MDH is missing (Molenaar et ah, 2000; van der Rest et ah, 2000). In
contrast, MQO is the principal enzyme catalyzing the oxidation of malate to
oxaloacetate in C. glutamicum, and Amqo mutants of this species cannot grow on
C2 substrates. In fact, purified C. gltuamicum MDH readily catalyzes the
reduction of oxaloacetate to malate (Molenaar et ah, 2000). Similarly, in P.
aeruginosa MQO rather than MDH oxidizes malate to oxaloacetate and is needed
for growth on acetate; the function of MDH in this species is not known
(Kretzschmar et ah, 2002). These observations suggest that in at least some

bacteria, MDH is involved in the reductive branch of the TCA cycle (See Fig. 3.3
while MQO functions in TCA cycle and/or the GC during growth on C2 substrates
(See Fig. 3.2, 3.6). Mycobacteria have both types of malate dehydrogenase.
Addition of cAMP to low-oxygen cultures of M. bovis (BCG) upregulates
expression of mdh, which could mean that mycobacteria increase flow of carbon
through the TCA and glyoxylate cycles under these conditions (Gazdik &
McDonough, 2005), or, alternatively, that the TCA cycle functions reductively
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Fig. 3.3. Branched and 'modified' T C A Cycle. The branched (biosynthetic) mode of operation of
the citric acid cycle is employed by bacteria growing under aerobic conditions in excess glucose or
anaerobically on any carbon substrate, and by bacteria that lack a-ketoglutarate dehydrogenase, the
pathway plays a strictly biosynthetic role. A T P is obtained from glycolysis and from acetyl-CoA
catabolism via the P T A / A C K pathway (not shown). The glyoxylate cycle is needed for anaplerosis.
In M . tuberculosis the T C A cycle might operate in the branched mode via K G D and G A B D
replacing a-ketoglutarate dehydrogenase. Abbreviations: CIT, citrate cynthase; ACN,aconitase;
IDH, isocitrate dehydrogenase; SUC,. succinyl-CoA synthetase; K G D , a-ketoglutarate
decarboxylase; S S A D H , succinic semialdehyde dehydrogenase; S D H , succinate dehydrogenase;
F R D , fumarate reductase; F U M , fumarase; M D H , malate dehydrogenase; M Q O , malate:quinone
oxidoreductase; ICL, isocitrate lyase;MLS, malate synthase.
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under these conditions, depending on whether mycobacterial M D H is more similar
in function to the MDH of E.coli or C. glutamicum, respectively.
All the TCA cycle enzyme activities have been demonstrated in protein
extracts from animal tissues and many bacteria (Cronan & LaPorte, 1996).
Mycobacterial genomes have homologs of every step of the cycle. Many of the
activities including those of ACN, IDH, SDH, FUM and MDH have been
demonstrated in several fast and slow growing mycobacteria including M. vaccae,
M. phlei, M. avium, and M. leprae (Sharma et ah, 1985; Katoch et ah, 1987).
Activities of the TCA cycle enzymes have also been demonstrated in M.
tuberculosis (Murthy et ah, 1973), except for a-KGDH activity, which was
extremely low; however, since the TCA cycle is an inducible pathway, several

growth conditions should be tried before railing out the presence of a particula
activity (Iuchi & Lin, 1988; 1991; Guest & Russell, 1992; Hayashi et ah, 2002;
Lorenz et ah, 2004). Recently, it has been reported that M. tuberculosis indeed
lacks a-KGDH activity, and that instead, an a-ketoglutarate decarboxylase
converts a-ketoglutarate to succinic semialdehyde, which is then converted to
succinate (Tian et ah, 2005) (Fig. 3.3).
The main factors affecting expression of TCA cycle enzymes are oxygen,

and the type and concentration of carbon source available to the cell (Gray et a
1966; Spencer & Guest, 1987, Lynch & Lin, 1996; Park et ah, 1997). TCA cycle

enzymes are expressed in low levels in anaerobiosis and in glucose-excess aerobi
growth, and in high levels during aerobic growth on C2 compounds such as fatty
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acids or acetate (Amarasingham & Davis, 1965; Ornston & Ornston, 1969; Chin et
ah, 1989; Holms, 1996; Lynch & Lin, 1996; Peng & Shimizu, 2003). Gene

expression and carbon flux analyses in C. glutamicum suggest a similar control o
the TCA cycle (Weindisch et al, 2000; Hayashi et al, 2002). Conditions
affecting the expression of key enzymes of the TCA cycle also affect the way the
cycle operates (Gray et al, 1966). As mentioned previously, during anaerobic
growth on glucose, E. coli obtains energy from glycolysis and utilizes the TCA
cycle in a bifurcated mode (Fig. 3.3) in which the oxidative branch [citrate

synthase, aconitase, isocitrate dehydrogenase] produces 2-ketoglutarate, while t
reductive branch [malate dehydrogenase, fumarase, fumarate reductase (replaces

succinate dehydrogenase), and succinate thiokinase (a.k.a succinyl-CoA synthase)
produces succinyl-CoA (Amarasingham & Davis, 1965). Interestingly, succinyl
CoA synthase activity is high in leprosy bacilli grown in vivo (Wheeler, 1984).
In the absence of a suitable electron acceptor, E. coli converts acetyl-CoA
to a mixture of acetic acid and ethanol via fermentation (Cozzone, 1998).
Whether fermentative or acetate producing pathways are employed by
mycobacteria is not known; however, genes putatively encoding fermentative
enzymes such as formate lyase (pfl) or lactate dehydrogenase (lid), as well as
acetate producing enzymes (ack, pta) are present in mycobacterial genomes.
Although much has been learnt about sugar metabolism from model

organisms such as E. coli, Salmonellae, and B. subtilis over the last century, it
becoming apparent that some of the tenets of central metabolic pathways do not
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apply to bacterial strains/species that are not laboratory-adapted. For instance,
recent carbon 13C tracer flux analysis experiments with several non-laboratory-

adapted phylogenetically distinct bacteria indicate that unlike E. coli or B. su
laboratory strains, many bacteria catabolize sugars via the EDP rather than

glycolysis, and rely on the PPP almost exclusively to fulfill biosynthetic needs
Importantly, all aerobes analyzed apparently employed a full respirative TCA
cycle for oxidation of acetyl-CoA without any significant overflow of carbon in

the form of acetate when grown in glucose under aerobic conditions (Fuhrer et ah

2005). Although these observations are only of a quantitative nature, they sugges

that the significance and function of a given metabolic route in one species in a

particular setting is likely to be much less of a generalizable characteristic t
previously thought, with different bacteria using different routes of carbon
utilization to different degrees depending on the conditions of growth.

3.7. Glycerol catabolism

Glycerol can be used as a carbon source by many bacteria, and in particular the
cultivation of mycobacteria in vitro is greatly enhanced by addition of this
carbohydrate (Katoch et ah, 1987; Wheeler, 1984). In E. coli glycerol is first
phosphorylated to glycerol-3-P by a glycerol kinase (Hayashi & Lin, 1967).
Glycerol-3-P is then oxidized to dihydroxyacetone phosphate by glycerol-P
dehydrogenase (Schryvers et ah, 1978). M. tuberculosis has a glycerol kinase
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(glpK, Rv3696c) and two putative glycerol-P dehydrogenases (glpDl, Rv2249c;
glpDl, Rv3302c). Glycerol-3-P is an important precursor of phospholipids, and in
the absence of an exogenous source of glycerol, cells make glycerol-3-P from
dihydroxyacetone phosphate employing a glycerol-3-P synthase. The proteins

encoded by the glp regulon can also be used by the cell for recycling the glycer
moiety of phospholipids and triglycerides.

3.8. Fatty acid catabolism

Cells need to metabolize fatty acids to fulfill several physiologic needs. Fatty

acids provide the building blocks for phospholipids, glycolipids and lipoprotein
and their derivatives act as hormones and messengers in many cell types.
Furthermore, fatty acids are excellent fuels. It has been estimated that 40% of
weight of a mycobacterial cell is made up of lipids (Anderson, 1940; Wheeler,
1988) and about 8% of the M. tuberculosis genome is made up of genes putatively
involved in lipid metabolism, including over 100 putative catabolic functions
(Cole et ah, 1998; Cole, 2002).
Though a permease that can transport acetate into E. coli cells has recently
been identified (Gimenez et ah, 2003), little is known about the uptake of other
short- and medium-chain fatty acids (SCFAs, MCFAs), most of which might get

into the cell by diffusion. The transport of long-chain fatty acids (LCFAs) into

coli cells is mediated by a carrier mechanism which requires fadD and fadL, whic
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encode a fatty acyl-CoA synthase (Kamede and Nunn, 1981) and an outer
membrane protein (Black et ah, 1985), respectively. The exact function of FADL
is not known, but it increases binding and uptake of MCFAs and LCFAs.
Mycobacteria lack an outer membrane and have no homologs of fadL genes;

nothing is known about how fatty acids cross the thick lipid-rich wall and plasm
membrane of a mycobacterial cell.

3.8.1. The cycle of beta-oxidation. Bacteria, like eukaryotes, degrade fatty aci
primarily via a cyclic oxidation pathway known as P-oxidation (Black & DiRusso,
1994). Some eukaryotes including plants, fungi, and mammals have a

mitochondrial as well as a peroxisomal pathway of P-oxidation, the components of

which differ depending on the type of fatty acid they oxidize (Kunau et ah, 1985)
Through P-oxidation, even-numbered fatty acids (C2 substrates) are oxidized

stepwise into acetyl-CoA subunits, while odd-chain fatty acids (C3 substrates) a
similarly catabolized into acetyl-CoA units and a terminal propionyl-CoA unit.
Acetyl-CoA and propionyl-CoA then entered central metabolism where they are
further oxidized or serve as precursors for lipid synthesis (Kolattukudy et ah,
1997; Campbell & Cronan, 2001). Under aerobic conditions, E. coli can grow on
LCFAs (>12 carbon-long acyl chains) as sole source of carbon, but growth on
MCFAs (C6-C12) can take place only after p-oxidation enzymes are induced as a
result of the transport and activation of LCFAs inside the cell (Overath et ah,
1969).
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Each turn of the P-oxidation cycle is accompanied by the reduction of one
FAD+ (acyl-CoA dehydrogenase reaction) and one NAD+ (3-hydroxyacyl-CoA
dehydrogenase reaction), and the shortening of the acyl chain by two carbons,
which are released as an acetyl-CoA (CoA-dependent thiolytic cleavage) (Fig.
3.4). The shortened fatty-acyl-CoA molecule reenters the degradation cycle.
The principal enzymatic steps are as follows:

1. Activation of the free fatty acid to an acyl-CoA thioester by acyl-CoA syntha

(Fatty acid:CoA ligase; EC 6.2.1.3). This step requires two high-energy phosphate
equivalents per molecule of free fatty acid activated. Once a fatty acid is thus

activated, no further energy expenditure is required; thus, the longer a fatty a
the more energy it can yield. While E. coli has a single acyl-CoA synthase with
broad specificity for medium and long chain fatty acids, FADD (Overath et ah,

1969; Klein et ah, 1971), M. tuberculosis has 36 putative fadDs. At least some of

these FADDs, particularly those adjacent to lipid biosynthetic genes such as the
polyketide sythases (PKS), function as long-chain fatty acyl-AMP ligases which

activate fatty acids as acyl-adenylates which might then be transferred to the P
for further processing (Trivedi et ah, 2004).
2. Next, the CoA ester is oxidized to an enoyl-CoA by a fatty acyl-CoA
dehydrogenase (FADE). Again, while E. coli has a single fadE, M. tuberculosis
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Fig. 3.4. b-oxidation pathway of fatty acid degradation in Mycobacterium tuberculosis. Based on
homology searches of the M . tuberculosis genome (H37Rv; http://genolist.pasteur.fr/TubercuList/)
using bacterial, fungal and mammalian b-oxidation genes. Gene names are those used for M .
tuberculosis. E. coli ( E C O ) and M . tuberculosis ( M T B ) enzymes are listed. Gene names are
italicized. Abbreviations: H A C D H , 3-hydroxyacyl-CoAdehydrogenase; S C - H A D H , short-chain 3hydroxyacyl-CoA-dehydrogenase. (Modified from Clark and Cronan, 1996).
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has 34 fadE homologs, resembling eukaryotic cells in which m a n y acyl-CoA
dehydrogenases with different specificities are present (Kunau et ah, 1995).
3-5. The remaining steps are catalyzed by enoyl-CoA hydratases (ECHs), which
hydrate the enoyl-CoA to 3-hydroxy(OH)-acyl-CoAs, 3-hydroxyacyl-CoA
dehydrogenases (FADBs), which oxidize the 3-OH-acyl-CoA to 3-keto-acyl-CoA,
and 3-ketoacyl-CoA thiolases (FADAs), which cleave away the terminal acetyl-

CoA, freeing the already activated fatty acyl-CoA, which enters another oxidativ
round. The M. tuberculosis genome contains 22 echA genes putatively encoding
enoyl-CoA hydratases/isomerases. It also has two short 3-OH-butyryl-CoA
dehydrogenases (fadBl and fadB3), as well as a putative multifunctional long
FADB (fadB), which has ECH and hydroxyacyl-CoA dehydrogenase (HADH)
domains. FADB2 and FADB3 belong to a large family of short chain hydroxy 1acyl dehydrogenases (SC-HADH) with members in the mitochondrial P-oxidation
systems of eukaryotes, belonging to the superfamily of short-chain alcohol
dehydrogenases (Krozowski, 1994).
M. tuberculosis has many genes potentially encoding SC-HADHs (Cole et
ah, 1998), including around 30 or so SC-HADHs with homology to fungal
peroxisomal p-oxidation SC-HADHs. A. nidulans mutants lacking a peroxisomal
SC-HADH (AfoxA) are impaired for growth on long chain fatty acids, but grow
normally on C6 fatty acids relying on a mitochondrial short chain P-oxidation
system (Maggio-Hall & Keller, 2004), and interestingly, the dehydrogenases of
these mitochondrial pathways are homologous to the E. coli and M. tuberculosis
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canonical fadB products. Thus, considerable functional overlap exists between

FADBs and non-canonical short chain dehydrogenases in fungi; whether this is the
case in M. tuberculosis remains to be determined.

3.8.2. Catabolism of short chain fatty acids as carbon substrates. In some
bacteria, including E. coli, growth on SCFAs (C4-C6) requires, in addition to

some P-oxidation enzymes, the induction of an additional set of activities encod
by the atoA, D, B and C genes (Pauli & Overath, 1972). AtoA and atoD encode
the subunits of an acetoacetyl-CoA transferase involved in the activation of
acetoacetate and short-chain fatty acids into acyl-CoAs; atoB encodes a
ketohydroxylacyl thiolase. In addition to repression by FadR (a regulator of

LCFA utilization), these genes are subject to transcriptional control by a posit
regulator encoded by atoC (Overath et ah, 1969). Wild-type E. coli cannot grow
on SCFAs unless FadR is released by activated LCFAs and the ATO system is
induced by SCFAs.
In contrast to enterics, mycobacteria readily grow on SCFAs without
requiring prior exposure to LCFAs. In fact, both M. smegmatis (Munoz-Elias et
ah, in preparation) and M. tuberculosis (Munoz-Elias & McKinney, 2005) grow
comparably well in SCFAs and glucose. M. tuberculosis scoA and scoB genes
have homology to atoD and atoA genes, respectively, and fadA genes have some
homology to atoB. Thus, it is possible that scoAlB gene products are involved in
activating SCFAs to acyl-CoAs. Alternatively, one or more of the FADD acyl-

102

C o A synthases could perform this function. After processing by a F A D E and an
ECH, the 3-OH-acyl-CoA could then be oxidized by a FADB or one of the other
SC-HADHs, into the keto form, which might then be cleaved by a FADA thiolase.
Given that the scoB/A genes are in an operon with accAl/accDl genes, which

putatively encode acetyl-/propionyl-CoA carboxylases, it is also possible that t
degradation of some SCFAs might be linked to the metabolism of propionyl-CoA
via the methylmalonyl-CoA pathway.

3.8.3. Regulation of fatty acid utilization. In E. coli the genes encoding the
functions involved in the transport and p-oxidation of MCFAs and LCFAs form

the fad regulon, which is under the transcriptional control of the negative regu
FadR, which in the absence of LCFAs, represses oxidation and induces fatty acid
biosynthesis instead (Cronan & Subrahmanyan, 1998; Black et ah, 2000). In E.
coli, the fadBA operon has a FadR binding site in its promoter, and binding of
acyl-CoAs (>11 carbons in length) to FadR, releases it from the fadBA promoter
and allows the synthesis of P-oxidation enzymes. Utilization of fatty acids

requires the anaplerotic GC, the expression of which is indirectly controlled by
FadR through IclR (see below) (Ornston & Ornston, 1969). A homolog of fadR is
absent in M. tuberculosis and essentially nothing is known about the regulation
fatty acid catabolism in mycobacteria.

3.8.4. Utilization of acetate and propionate.
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Acetate. Acetate might diffuse freely or be transported into the E. coli cell
by a permease (Gimenez et ah, 2003), and after activation to acetyl-CoA by an
inducible acetyl-CoA synthase (ACS) (Brown et ah, 1977), it either enters
biosynthesis or is oxidized to C02 via the TCA cycle (Fig. 3.5A). In Salmonella,
the histone deacetylase SIR2 is required for ACS activity, and for growth on
acetate and propionate (Starai et ah, 2003). Growth on acetate, similarly to
growth on other C2 substrates, requires the GC for anaplerosis (Romberg &
Krebs, 1957; Romberg & Sadler, 1960).
E. coli and C. glutamicum growing in high concentrations of glucose
employ the PTA/ACK pathway, which is composed of a phosphotransacetylase
(PTA) that reversibly converts acetyl-CoA and Pi to acetyl-P and CoASH, and
acetate kinase (ACK), which reversibly converts acetyl-P and ADP to acetate and
ATP (Rose et ah, 1954) (Fig. 3.5A) to produce acetate from acetyl-CoA (Kakuda
et ah, 1994). However, the pathway can function in the opposite direction,
especially during growth in high concentrations of acetate, and allows Aacs
mutants to grow, though poorly, on low concentrations of acetate (Kumari et ah,
1995) (Fig. 3.5B); Aacs/Apta/Aack mutants cannot grow on acetate (Kumari et ah,
1995). In addition to eliminating excess acetyl-CoA in the form of acetate, the
PTA/ACK pathway also provides acetyl-P, which has been proposed as a
signaling molecule based on in vitro studies using two-component systems and

acetyl-P as phosphate donor, though the significance of these observations is no

clear since signaling in wild-type strains with normal two-component systems has
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Acetate metabolism:
A)
acetate + A T P + C o A - S H -» acetyl-CoA + A M P + PPi (acetyl-CoA
synthase, acs)
B)
acetyl-CoA + Pi < — > acetyl-P + C o A S H (acetate kinase, ac/r)
acetyl-P + A D P < — > acetate + A T P (phosphotransacetylase, pta)
C)
Propionate metabolism:

propionate
Methylcitrate cycle ( M C C )
(prpE), acs
ACS
Propionyl-CoA
oxaloacetate

Succinate pyruvate

r

(prpB/MICL)

prpC, M C S
2-methylcitrate

2-methylisocitrate

2-methylaconitate
acn, ACN

prpD, M C D

T

Fig. 3.5. Pathways of acetate and propionate metabolism. (A-B) Acetate metabolism. (A)
Acetate is assimilated via acetyl-CoA synthase. A C S can also use propionate as a substrate. (B)
P T A / A C K is used for acetate production and also provides the acetyl-P signaling molecule. Enzyme
names are indicated next to corresponding reaction. (C) Odd-chain carbon substrate metabolism via
the methyl citrate cycle ( M C C ) . The M C C pathway essentially converts propionyl-CoA into
pyruvate. Enzymes involved: acetyl/propionyl-CoA synthase (ACS, acs), 2-methylcitrate synthase
(prpC, M C S ) , 2-methylcitrate dehydratase (prpD, M C D ) , and 2-methyl-isocitrate lyase (prpB,
M I C L ) . Aconitase (ACN, acn) is in c o m m o n with the T C A cycle, as are the enzymes converting
succinate to oxaloacetate (not shown). Gene/enzyme names are based on the M . tuberculosis genome
(Tuberculist.org), although not always annotated as such; when missing, the E. coli name is used (in
parentheses). (C) Adapted from Tabuchi & Uchiyama (1975).
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not been found to be affected by loss of either ackA or pta (Cleary & Stock, 1994;
Chamnongpol & Groisman, 2000). More recently, acetyl-P has been implicated in
glucose-starvation (Chang et ah, 1999), osmoregulation (Bang et ah, 2002),
biofilm development (Wolfe et ah, 2003), as well as in nitrogen and phosphate
assimilation (Reviewed in Wolfe, 2005).
Mycobacteria have homologs encoding functions of both acetate

metabolism pathways. It appears that similarly to E. coli, in mycobacteria ACS is
the major pathway involved in acetate utilization as a carbon source, since Aacs
mutants of M. smegmatis cannot grow on acetate (L. Merkov, personal
communication). The function of the PTA/ACK pathway and acetyl-P
intermediate in mycobacteria is unknown.
Propionate. In mammalian cells, the metabolism of propionate-, branchedchain amino acids-, and odd-chain fatty acids-derived propionyl-CoA takes place
via propionyl-CoA carboxylase (PCCA), a mitochondrial enzyme that
carboxylates propionyl-CoA to d-methylmalonyl-CoA, which is then rearranged to
succinyl-CoA. Mutations in PPCA are the cause of propionic acidemia, the most
frequent autosomal recessive disorder of organic acid metabolism in humans
(Wolf et ah, 1981). This pathway is also used by several bacterial species
(Halarnkar & Blomquist, 1989) and has been proposed to function in E. coli
(Evans etal., 1993).
However, mounting evidence indicates that several bacteria including E.
coli (Textor et ah, 1997), S. typhimurium (Horswill & Escalante-Semerena, 1997;
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1999), C. glutamicum (Claes et ah, 2002), and Ralstonia eutropha (Bramer &
Steinbuchel, 2001), catabolize propionate via a pathway known as the
methylcitrate cycle (MCC). The role of the MCC in C3 substrate catabolism was
discovered three decades ago in Candida lipolytica (Tabuchi & Serizawa, 1975;
Tabuchi & Uchiyama, 1975), and has more recently been demonstrated in two

other fungi, S. cervisiae (Pronk et at., 1994) and A. nidulans (Brock et ah, 2001
In the MCC, a molecule of propionyl-CoA is condensed with oxaloacetate by
methylcitrate synthase (MCS, prpC) to form methylcitrate, which is then
isomerized by the combined action of a dehydratase (MCD, prpD) and aconitase

(ACN, acs) into methylisocitrate, which is cleaved into succinate and pyruvate b
methylisocitrate lyase (MICL, prpB) (Tabuchi & Uchiyama, 1975) (Fig. 3.5C).
The M. tuberculosis genome has homologs of prpC (MCS) and prpD (MCD), in
addition to the other TCA cycle enzymes in common with the MCC; however, a
prpB (MICL) is apparently missing.
The first step in propionate utilization is its activation to propionyl-CoA.
This can occur via a specific propionyl-CoA synthase (PRPE) as in Salmonellae
(Horswill & Escalante-Semerena, 1999), or by ACS which, in addition to acetate,
can use propionate as a substrate. However, not all ACS can use propionate; for
example S. cereviase has 2 ACS, and while one can use both acetate and
propionate as a substrate, the other can only use acetate (van den Berg et ah,
1996). Mycobacteria have only one ACS (acs), whose specificity is unknown.
Alternatively, propionate activation can occur via the PTA/ACK pathway, which
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usually operates in the reverse orientation (acetate production). The first step can
be catalyzed by a specific propionate kinase - tdcD gene in E. coli and

Salmonellae - which produces propionyl-P. The closest homolog to either of these

kinases in M. tuberculosis is ackA. ACK from E. coli can function as a propionate

kinase but is less efficient than the canonical propionate kinase. In the second
in the activation of propionate, propionyl-P is converted to propionyl-CoA by
PTA.
In E. coli and Salmonellae, the prp genes are subject to catabolite
repression by glucose (Lee et ah, 2005). In M. tuberculosis, transcription of
prpDC is upregulated after phagocytosis by macrophages and in vivo
(Schnappinger et ah, 2003).

3.9. PEP generation and gluconeogenesis

Regardless of whether carbohydrates are available as carbon sources or not,
bacteria need to generate several glycolysis intermediates that serve as
biosynthetic precursors. In the absence of sugars as carbon sources, cells
accomplish this via gluconeogenesis, which is essentially glycolysis backwards

since most glycolytic enzymes readily catalyze the reverse reactions (Fig. 3.1).

Only the conversion of fructose- 1,6-P2 to fructose-6-P requires a non-glycolyti

enzyme and this is because the PFK-catalyzed reaction is not readily reversible.

This strictrictly gluconeogenic enzyme is called fructose-1,6-biphosphatase (fbp)
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and mutants lacking this activity fail to grow on acetate, dicarboxylic acids and
other gluconeogenic substrates (Fraenkel & Horecker, 1965). In M. tuberculosis,

this reaction is carried out by a class II fructose 1,6-bisphosphatase encoded b
glpX (Movahedzadeh et ah, 2004). The transcriptional activator/repressor Cra
(era) is apparently responsible for controlling the direction of carbon flow in
coli and Salmonellae and mutants of cra cannot grow on glucogeogenic substrates
(Saier & Ramseier, 1996). No such regulator has been identified in mycobacteria.
The starting point of gluconeogenesis varies depending on the carbon
source available for growth but it is usually pyruvate or PEP. The most common
precursor of PEP is oxaloacetate, but PEP can also be generated by reactions
around pyruvate (Fig. 3.6). During growth of E. coli on C2 substrates or
dicarboxylic acids, PEP carboxykinase (PCK) decarboxylates oxaloacetate to PEP.
PCK-deficient E. coli can grow on glucose or pyruvate, but not on succinate,
fumarate, or malate (Anderson & Wood, 1969). PEP can also be generated from
pyruvate by PEP synthase (PPS), and E. coli lacking PPS cannot grow on
pyruvate, lactate, or alanine (Cooper & Romberg, 1965; Oh et ah, 2002),
indicating that E. coli cannot use the pyruvate-oxaloacetate-PEP route (via PCA
and PCK) for PEP generation under these conditions. Growth of E. coli on
glucose or PEP requires upregulation of the anaplerotic PEP carboxylase (PPC),
and downregulation of PCK and PPS; PCK is induced by acetyl-CoA, while PPS
is induced by pyruvate (Cooper & Kornbeg, 1967). M. tuberculosis and M. bovis
do not have a PPS homolog, but have a putative pyruvate phosphate dikinase
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( P P D K ) , which could generate P E P via phosphorylation of pyruvate as in E. coli,
thus possibly replacing PPS (Cooper & Romberg, 1965).
An alternative route for generating PEP from C2 substrates is via malic
enzyme (MEZ), which decarboxylates malate to pyruvate (Fig. 3.6) (Hansen &
Juni, 1975). During growth of E. coli on dicarboxylic acids, MEZ produces
pyruvate, which is oxidized to obtain necessary acetyl-CoA (Pertierra & Cooper,
1977). In B. subtilis, the pyruvate produced by MEZ apparently also serves as as
substrate for pyruvate carboxylase (PCA). In this species, MEZ and PCA form a
"pyruvate shunt" whose function might be to provide pyruvate during growth on
gluconeogenic substrates and then recycle back the pyruvate left to acetyl-CoA
(Diesterhaft & Freese, 1973). A recent quantitative carbon flux study found that

several non-model bacteria substantially (up to ~30% of carbon flow) relied on t
pyruvate shunt to obtain oxaloacetate during growth on glucose (Fuhrer et ah,
2005). M. tuberculosis has both pea and mez genes, but while pea transposon
mutants are impaired for growth on glucose-containing plates, mez mutants are
not, suggesting that M. tuberculosis might not need to generate pyruvate from
malate during growth on glucose (Sassetti et ah, 2003).
In E. coli, both PCK and MEZ/PPS(PPDK) pathways can be used to
generate PEP from gluconeogenic substrates. While single ApckA or Apps
mutants grow on acetate, a double mutant cannot. Likewise, deletion of both
genes encoding malic enzymes (sfcA and maeB) does not abrogate growth on
acetate, unless pckA is also missing (Oh et ah, 2002). In C. jejuni, the absence
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Ill

P P S / P P D K makes P C K essential for gluconeogenesis (Velayudhan &

Kelly,

2002). In C. glutamicum, the purified MEZ favors the decarboxylation reaction
(toward gluconeogenesis), but deletion of malE (MEZ) has no effect on growth on
C2 substrates, suggesting that the absence of mez might be compensated by PCK
as in E. coli (Gourdon et ah, 2000). During growth on glucose, C. glutamicum
generates oxaloacetate from PEP by PPC, making PCA or the MEZ-PCA pyruvate
shunt dispensable. Though the function of mez has not been investigated in
mycobacteria, M. smegmatis seems to rely mainly on PCK to generate PEP during
growth on C2 or gluconeogenic substrates because a Apck mutant could not grow
on acetate, pyruvate, succinate or malate, but grew normally on dextrose or
glycerol (A. Upton, personal communication). This indicates that MEZ and PPDK
cannot compensate for the loss of PCK in gluconeogenesis. Furthermore, a PCKdeficient mutant of M. bovis grows normally on standard media where glycerol

and dextrose are the main carbon substrates, suggesting that PCK is not needed f

anaplerosis during growth on carbohydrates (Liu et ah, 2003b); the mutant was not
tested for growth in C2 substrates.

3.10. Anaplerosis: the replenishment of intermediary metabolites

In addition to its role in energy generation, i.e., ATP production by substrate
phosphorylation and reducing power in the form of reduced pyridine and flavine
nucleotides (NADH, FADH2) which are oxidized through the respiratory chain to
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generate more A T P , the T C A cycle also provides essential biosynthetic precursors
and does so in the form of its intermediates such as oxaloacetate and aketoglutarate. If these C4-dicarboxylic acids of the TCA cycle were not

replenished, the cycle would quickly run out of intermediates and come to a stop.
Cells avoid such a fate by constantly replenishing such intermediates from the

outside directly. Reactions of this sort, which allow net carbon gain, are terme
anaplerotic reactions (Romberg, 1966). The anaplerotic route an organism

employs depends on the type and concentration of carbon substrates, as well as o

the electron acceptor(s) available to it (See Fig. 3.6). Some of these anaplerot
routes will be discussed in the next sections.

3.10.1. Anaplerosis during growth on sugars. When E. coli grow on sugars in
batch culture (standard sugar concentrations ~ 0.1-0.5% w/v), oxaloacetate is
replenished by carboxylation of PEP by PEP-carboxylase (PPC). PPC-deficient
Salmonellae grow poorly on glucose unless TCA cycle intermediates are provided
(Theodore & Englesberg, 1964). Interestingly, the slow growth on glucose of E.
coli Appc mutants (~20% slower than wild-type bacteria) is facilitated by

upregulation of the GC, since when PPC-deficient mutants are grown in relatively

high glucose (0.4-0.5% w/v), they increase carbon flow through the GC in order t
obtain sufficient oxaloacetate (Peng et ah, 2004). Thus the anaplerotic function
PPC on dextrose can be compensated by the GC. During growth on

carbohydrates, other bacteria, including B. subtilis and C. glutamicum, replenis
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TCA

cycle intermediates via carboxylation of pyruvate to oxaloacetate by

pyruvate carboxylase (PCA) (Diesterhaft & Freese, 1973; Peters-Wendisch et ah,
1998;). Inspection of recently published genome sequences from enterics
indicates that pea is missing in this group of bacteria. M. tuberculosis and M.
lack a ppc homolog and Apca transposon mutants are impaired for growth on

standard 7H10 plates (glucose and glycerol) (Sassetti et ah, 2003), suggesting th
M. tuberculosis employs PCA for anaplerosis on carbohydrates and that
compensation by the GC may not occur. Other mycobacteria, including M.
smegmatis, do have homologs of PPC, suggesting that the loss of ppc might have
been a recent event in the Mycobacterium genus.

3.10.2. The Glyoxylate Cycle: anaplerosis during growth on fatty acids and
other substrates metabolized via acetyl-CoA. As discussed above, many

bacterial species can utilize short, medium and long fatty acids including aceta
and propionate, as sources of carbon and energy. Acetyl-CoA produced by fi-

oxidation of fatty acids (Fig. 3.4), is further oxidized to C02 via the TCA cycle

(Fig. 3.2). When fatty acids are the only carbon source available, replenishment
TCA cycle intermediates cannot be accomplished via PPC or PCA. Under these
conditions, an anaplerotic pathway called the GC becomes indispensable
(Romberg & Krebs, 1957; Romberg, 1966; Omston & Ornston, 1969) (Fig. 3.6).

In the first step of the GC, isocitrate lyase (ICL) cleaves isocitrate into glyo
and succinate, and in the second step, malate synthase (MLS) condenses the
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glyoxylate with another molecule of acetyl-CoA to form malate (Vanni et ah,
1991). The succinate is oxidized to fumarate by succinate dehydrogenase (SDH),
or converted to succinyl-CoA by succinyl-CoA synthase (SUCCD). ICL and
MLS-catalyzed reactions together with the TCA cycle enzymes SDH, fumarase
(FUM), malate dehydrogenase (MDH), citrate synthase, and aconitase (ACN)

constitute the cycle (Fig. 3.6). In addition to mediating the incorporation of t
new molecules of acetyl-CoA per turn of the cycle, the GC also bypasses the
decarboxylation reactions of the TCA cycle (IDH and aKGDH steps, Fig. 3.3),
which further contributes to carbon conservation.
In E. coli, the genes encoding ICL (aceA) and MLS (aceE) are in an operon
with aceK (aceBAK), which encodes a regulator of IDH (see below). In M.
tuberculosis ICL and MLS are encoded by aceA (a.k.a. icll) and glcB,
respectively, and they are not together in the chromosome (Cole et ah, 1998). A
gene encoding another putative ICL (ic/2) is present in the genome of all

mycobacteria. Interestingly, in at least one strain of M. tuberculosis icll migh

a pseudogene (Cole et ah, 1998), while in M. leprae icll is a pseudogene (Cole et
ah, 2001). Cell-free extracts from in viYra-grown M. tuberculosis, M. smegmatis
and armadillo-grown M. leprae have both ICL and MLS synthase activities
(Kannan et ah, 1985; Bharadwaj et ah, 1987). The data on M. leprae indicates
that the product of icll is expressed in vivo and that it indeed encodes an ICL.
The control of carbon flow through the GC. Isocitrate can serve as
substrate for either IDH (TCA cycle) or ICL (GC), and thus constitutes a branch
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point in central metabolism, where two enzymes are competing for the same
substrate. Given the kinetic constants of the E. coli enzymes (IDH's Km = 8 [xM;
ICL's Km = 600 \iM), it is not surprising that during growth in excess glucose

most of the isocitrate is preferentially oxidized by IDH. Carbon flux into the G
is facilitated in two ways: the GC genes are induced and IDH is deactivated
(Walsh & Koshland, 1984). In E. coli, aceK of the aceBAK operon encodes an
IDH kinase/phosphatase which can phosphorylate IDH and thereby drastically
deactivate the enzyme, thus shifting the flow of carbon toward ICL. Addition of
glucose to a culture of bacteria growing on acetate, despite increasing growth,
rapidly lowers carbon flow through the TCA cycle (by 5 fold). Simultaneously,
the IDH kinase/phosphatase dephosphorylates IDH, which rapidly increases its
activity and almost completely stops carbon flux through the GC (Walsh &
Koshland, 1985). It is not clear how glucose mediates these effects (Corzone et
ah, 1998).
Expression of the GC in enterics is under the indirect transcriptional control

of FadR (of fatty acid catabolism) and the direct control of IclR, a repressor w
binds to its own promoter and that of the aceBAK operon, thereby repressing
expression of the GC (Maloy & Nunn, 1982; Gui et ah, 1996a). This binding is
inhibited by PEP (Cortay et ah, 1991). Transcription of iclR is positively
regulated by binding to its promoter by FadR (Gui et ah, 1996b). No homologs of
either FadR or IclR have been identified in M. tuberculosis. In C. glutamicum, a

transcriptional repressor called RamB that binds to the promoter of the aceA (IC
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and aceB ( M S L ) genes and partially prevents their expression has been described
recently. However, mutation of ramB does not significantly impair growth on

acetate or glucose, suggesting that other regulators exist (Gerstmeir et ah, 2004
Interestingly, M. tuberculosis apparently has two putative transcriptional
regulators that have homology to RamB. One of these, Rv0465c, is upstream of
icll, and the promoter of icll has a motif that is a close match to the well
conserved motif recognized by RamB in C. glutamicum promoters (Gerstmeir et
al, 2004). The other putative regulator, Rvll29c, is located upstream of
homologs of prpC and prpD, which are putatively involved in metabolism of C3
substrates (see above & Chapter 10). A second repressor of the GC has been
found in C. glutamicum and it is called GlxR. GlxR bears homology to the cAMP
receptor-binding protein (CRP) regulator from E. coli. In E. coli, cAMP is the
mediator of catabolite repression: when glucose is low, intracellular cAMP
increases, binds CRP and cAMP-CRP activates transcription of several genes
involved in the utilization of alternative sources of carbon (Lin, 1996). To the
contrary, in C. glutamicum, growth on glucose leads to high cAMP intracellular
concentrations, and cAMP-GlxR complexes exert transcriptional repression of
genes encoding enzymes involved in utilization of alternative carbon substrates
including GC genes. During growth on acetate, cAMP levels are low, and since
the repressor cannot bind cAMP, it remains inactive (Kim et al, 2004). ORF
Rv3676 of M. tuberculosis is over 75% homologous to glxR.
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3.11. Alternative routes of C2/glyoxylate metabolism

The glyoxylate produced by the GC is most commonly condensed with acetylCoA by malate synthase to generate malate. However, other routes of glyoxylate
metabolism exist; some of these are discussed below.

3.11.1. Glycerate Pathway. In the glycerate pathway, glyoxylate carboligase
catalyzes the condensation of two molecules of glyoxylate into one molecule of
tartronate semialdehyde (Gupta & Vennesland, 1964), which is then
phosphorylated to 3-phosphoglycerate by tartronate semialdehyde reductase and
glycerate kinase; 3-P-glycerate is then catabolized via glycolysis to pyruvate.
smegmatis can grow on glyoxylate, though poorly (unpublished observations).
Since this pathway results in the net conversion of two molecules of glyoxylate
one of PEP/pyruvate, which could then be converted to oxaloacetate by PCA, this
routing of the carbon could bypass the need for malate synthase during growth on
C2 substrates. Though the genes of this pathway appear to be present in several

mycobacteria, they are apparently absent in M. tuberculosis. In E. coli glyoxyla

can alternatively be reduced to glycolate by a constitutive glyoxylate reductase
(ycdW) (Ornston & Ornston, 1969; Nunez et al, 2001).
In E. coli, glycolate can be metabolized by the enzymes encoded by the glc
operon, which includes glycolate oxidase (GOX) and a glyoxylate-induced malate

synthase (MLSG, glcB). In this bacterium, either acetate or glyoxylate can induce
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the glc and ace operons and the glcB- and aceB-encoded malate synthases can
compensate for each other (Pellicer et al, 1999). M. tuberculosis has a putative
GOX and its only malate synthase is closer in homology to the glcB-encoded MLS
than to the aceB encoded enzyme (acetate-induced).

3.11.2. The Dicarboxylic Acid Cycle. Using a citrate synthase E. coli mutant,
Romberg & Sadler (1960) demonstrated that oxidation of glyoxylate could take
place independently of a complete functional TCA cycle as long as glutamate was
provided. Cells given labeled acetate rapidly labeled oxaloacetate, PEP, and
pyruvate in the presence of unlabeled glyoxylate indicating that acetyl-CoA was
preferentially metabolized via the GC to oxaloacetate. Oxaloacetate was then
decarboxylated (presumably by PCK) to PEP, which was subsequently oxidized
(via PYK) to pyruvate, which could then be dehydrogenated to acetyl-CoA to keep

the cycle running. Interestingly, it has been recently shown that in contrast to

coli grown in batch culture in excess glucose (~0.1-0.5 w/v), starving bacteria

(<0.002% glucose) grown in a chemostat, preferentially metabolize glucose via th
dicarboxylic acid cycle rather than the TCA cycle (Fischer & Sauer, 2003).

3.12. Catabolism of amino acids

Amino acids are often catabolized by converting them to intermediates of central
intermediates of metabolism. In general, amino acids are first converted to the
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corresponding amino acid via oxidative deamination reactions catalyzed by amino
acid specific dehydrogenases (e.g., CH3-CH(NH2)-COOH (alanine) -> CH3-COCOOH (pyruvate). The catabolism of certain amino acids, e.g., threonine,
methionine, valine, and isoleucine results in the generation of propionyl-CoA
(Hesslinger et al, 1998).
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C H A P T E R

4

Bacterial M e t a b o l i s m d u r i n g Infection

INTRODUCTION

In order to successfully infect, grow, and survive in their hosts, pathogens must

able to find appropriate and sufficient sources of carbon and energy (Rhen et al
2000). With few exceptions, little is known about the nutrient sources and
metabolic pathways utilized by pathogens during infection (Smith, 2000). Even

though the importance of microbial metabolism in vivo might appear self-evident,

it is an area of research that has received little attention in the past, largel
it has been assumed that we know more than we actually do know about microbial
metabolism and also because interfering with central metabolic pathways was
deemed unfeasible due to structural conservation of the enzymes involved.
However, evidence is emerging that pathogens acquire nutrients from the host
utilizing factors (transporters, enzymes, cofactors, etc.) that are sufficiently

distinct, and in some cases altogether absent, from those in their mammalian hos

to warrant targeting such factors for chemotherapeutic intervention (Walsh, 2003
Fidock et al, 2004; Nathan, 2004). In fact, some of these microbial pathways
could be viewed as important "virulence" determinants in at least two senses.
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Firstly, they are almost certainly needed by pathogens to adapt to the specific
"metabolic niches" they inhabit, and thereby provide the pathogen with the
constituents and energy required to be able to counteract, evade or deactivate,

antimicrobial effectors. Secondly, emerging evidence indicates that at least som

metabolic enzymes, possibly bifunctional, might be directly involved in chemical

reactions that deactivate host antimicrobial effector molecules (Bryk et al, 200
Lundberg et ah, 1999).
Defining the way parallel and opposing metabolic pathways operate is a
difficult task, especially because, as discussed in the previous chapter, the
functions of these pathways are highly dependent on environmental conditions,
e.g. growth parameters and nutrients available. The challenge becomes
considerably more formidable when the goal is to determine which metabolic
pathways are relevant in the highly dynamic environment of an infection. The

following paragraphs review our current, rather scant, understanding of metaboli

pathways of carbon utilization employed by bacterial pathogens during infection.

4.1. Escherichia coli

Even though our knowledge of E. coli metabolism during axenic growth in the

laboratory is extensive, little is known about nutrient acquisition and metaboli

of E. coli living in the intestines as a commensal or as a pathogen. The intesti
epithelium is covered by mucus, a complex of glycoproteins and glycolipids that
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includes acetylglucosamine, Af-acetylneuraminic acid, iV-acetylgalactosamine,

galactose, glucuronate, galacturonate, mannose, fucose, sialic acids, and ribose.
Accumulating evidence indicates that carbohydrate metabolism is important for
survival of E. coli in the mammalian large intestine as first suggested by the
finding that E. coli mutants that cannot grow on mucus fail to colonize the
intestine of mice (Peekhaus & Conway, 1998). In support of this view, Aeda
mutants of the Entner-Doudoroff pathway (EDP) are defective in intestinal

colonization in the streptomycin-treated mouse model, and a gluconate transporte
(GntP) mutant was also impaired for intestinal growth (Sweeny et ah, 1996b).
The utilization of glucuronate is suggested by the severe (100 fold < wildtype)
colonization defect of AuxuA, which lacks a dehydratase involved in the
catabolism of this compound (Sweeny et ah, 1996b).
Recently, gene expression studies of E. coli grown in glucose versus mucus
revealed that during growth in mucus bacteria upregulate, as expected, genes
involved in the catabolism of amino sugars, pentoses, and amino acids (Chang et
ah, 2004). Less expectedly, E. coli also upregulates genes involved in
phospholipid degradation as well as the gluconeogenic genes pckA and ppsA (pps).
Genes involved in the synthesis of purines, pyrimidines and several amino acids

are in contrast repressed suggesting E. coli scavenges these from mucin (Chang e

ah, 2004). These investigators also evaluated several metabolic mutants for their

ability to colonize the mouse intestine, and their findings largely confirmed th
importance of the EDP for in vivo growth and survival. However, these studies
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also revealed that mutants differentially deficient in their ability to utilize

carbohydrates had different in vivo phenotypes. For instance, mutants of the EDP

which could not use gluconate, failed to grow and to persist in the host. However
those incapable of using fucose, mannose, or ribose were impaired specifically
during persistence. Mutants of the pentose phosphate pathway (Agnd), TCA cycle
(AsdhB) and gluconeogenesis (Apps, ApckA) did not show an in vivo phenotype.
Interestingly, in a separate subsequent study, Apps or ApckA mutants were found
to be impaired for persistence in the context of a co-infection with wild-type
bacteria (Miranda et ah, 2004).
Together these data support the notion that during its sojourn in the
intestine, E. coli bacteria largely use carbohydrates for growth and survival.

However, to do so they apparently must be able to use a wide variety of substrat
This could be because these different substrates become variably available

throughout the infection and in particular might become more limiting during the
persistent phase of the infection and/or in the context of a co-infection.

4.2. Helicobacter pylori

A large fraction of the world's population is believed to be persistently infect
H. pylori (Blaser & Atherton, 2004). Nothing is known about the type of carbon
sources used by H. pylori in the stomach of its host. However, the H. pylori
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genome sequence indicates that it has a modified T C A

cycle in which the

conversion of a-ketoglutarate to succinyl-CoA is carried out via a keto-glutarat
ferredoxin oxidoreductase instead of via the canonical a-ketoglutarate
dehydrogenase (Tomb et ah, 1997). Interestingly, the a-ketoglutarate ferredoxin

oxidoreductase appears to be essential, making this enzyme of central metabolism

an attractive target for drug discovery (Hugues et ah, 1998). The korA-D genes of
M. tuberculosis are homologous to those that encode the aforementioned enzyme
complex in H. pylori. H. pylori lacks the genes encoding the GC, making it

unlikely that these bacteria use fatty acids or gluconeogenic substrates are car
sources in the stomach.

4.3. Listeria monocytogenes

Virulence of L. monocytogenes requires entrance into intestinal epithelial cells
escape from the phagosome into the cytoplasm, replication therein, and actin-

based motility which eventually facilitates infection of neighboring cells (Lecu

Cossart, 2002). Some of these events are regulated by the transcriptional activat
PrfA (Kreft et ah, 2002). Based on the observation that in vitro conditions that
activated the expression of prfA, and of PrfA-dependent virulence genes, also
endowed Listeria with the ability to utilize glucose-1-P as a carbon substrate,
the fact that glucose-1-P is a breakdown product of glycogen which might be
readily available in the cytosol of host cells, it was hypothesized that hexose
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phosphates could be used by Listeria as carbon substrates during infection (Ripio
et ah, 1997). Indeed, while wild-type Listeria microinjected directly into a
mammalian cell's cytosol could readily grow and replicate, a mutant in htp,
encoding a hexose transporter, could not (Goetz et ah, 2001). Furthermore, this
Ahtp mutant could not utilize several glucose-1-P-related sugars including
glucose-6-P, fructose-6-P, and manose-6-P in vitro (Chico-Calero et ah, 2002),
and was attenuated during infection in mice, e.g, mutant bacteria grew more

slowly and killed infected mice later than wild-type. This adaptation by Listeri

the intracytoplasmic niche it inhabits might be shared by other pathogens. An Hp
homolog is also found in Shigella, which like Listeria escapes from the
phagosomal vacuole and grows in the cytoplasm of host cells.

4.4. Salmonellae

Our understanding of Salmonella carbon metabolism in vivo is rather rudimentary.

The Salmonellae vacuole is likely limiting in essential elements such as Mg++ an
Ca++, since the mtgC gene encoding a Mg++ transporter is required for virulence
(Buchmeier et al, 2000), and the two-component system PhoP/PhoQ, which
regulates transcription of genes whose function is required for intracellular
survival is activated by low concentrations of Mg++ (Miller et al, 1989). Amino

acids and purines also appear to be limiting since auxotrophs are attenuated for
intracellular survival (Hoiseth & Stocker, 1981; Fields et al, 1986).
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Based on a comprehensive examination of Salmonellae gene expression

isolated from infected macrophages, it has been suggested that these bacteria us
gluconate, galactone and similar sugars as carbon sources during infection

(Eriksson et al, 2003). This was based on the finding that although expression of
genes of the EDP pathway was unchanged, some genes encoding transporters of
gluconate were upregulated. The fact that both glycolysis and the pentose
phosphate phosphate pathway were drastically downregulated was interpreted as

suggesting specificity in the types of sugars metabolized by the bacteria. These
observations, though informative, are not sufficient to establish the relevance
sugar metabolism during infection of Salmonellae. Furthermore, some puzzling
observations in the same study -that several genes encoding enzymes of amino
acid biosynthesis were downregulated, some of which are known to be essential
for Salmonellae survival in the macrophage vacuole (Hoiseth & Stocker, 1981;
Fields et al, 1986) - need to be clarified.
Alternatively, it has been suggested that Salmonella may depend on C2
substrates during infection. An S. typhimurium (SR-11) mutant that could not
grow on C2 substrates in vitro was found to be attenuated in mice (Utley et al,

1998), and was later shown to be a mutant of the catabolite activator/repressor c

(Allen et al, 2000). Cra positively controls genes involved in the utilization of
gluconeogenic substrates including the GC and gluconeogenesis (Saier &
Ramseier, 1996). Suggestively, a mutant of malic enzyme (Amez), which converts
malate to pyruvate, was also found to be attenuated in vivo (Valentine et al,
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1998). Recently, an S. typhimurium isocitrate lyase (AaceA) mutant of the G C was
found to be attenuated "late" in the infection (day 10) in the susceptible mouse

model, despite growing similarly to wild-type early on in the infection, or duri
24 hr macrophage infection (Fang et al, 2005). The mutant also showed impaired

survival during the chronic phase of infection when tested in a recently describ
Salmonellae persistence model in resistant mice (Monack et al, 2004), however,
for this experiment, the AaceA was combined with an aroA mutation, complicating
the interpretation of the results. Though clearly the issue merits further
investigation, considerable evidence supports the idea that C2 substrates might

play an important role in the metabolism of Salmonellae in vivo, especially in t
persistence phase of the infection.

4.5. Mycobacterium tuberculosis

M. tuberculosis is an intracellular pathogen that chiefly resides within vacuole
macrophages (Armstromg & Hart, 1971; 1975; Clemens et ah, 2002). Although

some aspects of the mycobacterial vacuole such as its pH in resting and activate
macrophages or its interaction with other components of the endosomal network
such as lysosomes have been partially characterized (Clemens & Horwitz, 1995;
Clemens, 1996; Russell & Sturgill-Koszycki, 1996; Russell, 2001), other aspects

such as its chemical composition in terms of essential elements and nutrients th
might be available to the bacterium within it, remain poorly understood.
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S o m e lines of evidence indicate the tubercle bacillus resides in a nutrientlimited environment in vivo. Amino acid and purine auxotrophs isolated in both
M. tuberculosis and M. bovis are impaired for growth in macrophages and/or
animal models of infection (Hondalus et ah, 2000; Smith et ah, 2001; Jackson et
ah, 2003). The fact that AmbtB mutants, which lack the high affinity siderophore
mycobactin and cannot grow in medium containing low iron in vitro, are also
incapable of replication in human (THP1) macrophages (De Voss et ah, 2000)
suggests that M. tuberculosis might also experience some iron-limitation during
infection. Siminarly, magnesium also appears to be limiting within the
mycobacterial vacuole (Rodriguez & Smith, 2003, Buchmeier et ah, 2000).
Some evidence gathered over the years regarding carbon utilization by M.
tuberculosis suggested a slowing down of metabolism and the prevalence of C2
(fatty acid) catabolism in vivo. M. tuberculosis and M. bovis bacteria isolated
from -20 day-infected mouse lungs respired at much lower levels than in vitrogrown bacteria, which suggested reduced metabolism. Curiously, it was also

observed that fatty acids but not carbohydrates significantly stimulated the abi
of these bacteria to reduce a tetrazolium dye; in viYra-grown bacteria readily
oxidized both (Segal & Bloch, 1956; Kanai & Rondo, 1974). Kondo et ah, (1970)

also found that mycobacteria harvested from infected lungs appeared to be closel

associated with lipids, and showed that M. tuberculosis could digest liposomes i
suspension, releasing fatty acids (Kondo & Kanai, 1976; Kondo et ah, 1985).

Mycobacteria apparently have extracellular lipases that might have this function
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(Casal & Linares, 1984; Kannan et ah, 1987) including four partially redundant
phospholipases C (Raynaud et ah, 2002), which jointly are required for virulence
of M. tuberculosis. Furthermore, some 20 genes annotated as putative lipases
(UpC-lipW genes) are also present in the genome.
The glyoxylate cycle and persistence of M. tuberculosis. As reviewed in

Chapter 3, many bacteria can utilize fatty acids as sources of carbon and energy,

and to do so bacteria specifically require the /2-oxidation cycle and the GC (GC
Early studies seeking to determine the metabolic capabilities of mycobacteria
revealed that both fast and slow growing mycobacteria including M. tuberculosis
and M. leprae encoded activites of the TCA cycle and the GC (Murthy et ah,
1973; Seshadri et al, 1972; 1976; Kannan et al, 1985; Katoch et al, 1987;
Bharadwaj et al, 1987). Analysis of M. leprae, M. microti and M. avium grown in
vivo also revealed the presence of GC enzymes isocitrate lyase and malate
synthase (Bharadwaj et al, 1987; Wheeler & Ratledge, 1988). These findings

together with the demonstration that activity of ICL increased in late stationar
phase M. tuberculosis cultures (Murthy et al, 1973), led some of these early
investigators to suggest that GC-mediated metabolism might represent a strategy
employed by pathogenic mycobacteria such as M. leprae and M. tuberculosis to
persist in the host in such ill-defined states as dormancy (Segal & Bloch, 1956;
Bharadwaj et al, 1987; Gupta & Ratoch, 1997). This "alternate" (to
carbohydrates) mode of metabolism based on the GC, it was speculated, could be
linked to phenotypic drug tolerance and the common failure of antitubercular
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drugs to kill recalcitrant 'persisters' (Murthy et al, 1973; Kannan et al, 1985;
Gupta & Katoch, 1997).
Functional genetic evidence supporting the hypothesis that fatty acids and
specifically the GC might indeed be relevant to the metabolism of the tubercle
bacillus during infection was first provided by McKinney and colleagues (2000).
An M. tuberculosis mutant lacking ICL1 (Aicll) was impaired for survival

specifically during the persistence phase of the infection in the mouse model of

chronic tuberculosis, despite growing indistinguishably from the parental strain

during the acute phase (Fig. 4.1 A). The mutant also elicited less pathology tha
wild-type bacteria (Fig. 4.1B&C).
The extensive duplication of genes encoding fatty acid P-oxidation
enzymes in M. tuberculosis (Cole et al, 1998) presents a major obstacle to the
genetic analysis of the role of fatty acid catabolism in TB pathogenesis due to
potential functional redundancy between homologs. In contrast, the GC in M.

tuberculosis apparently comprises a single gene encoding malate synthase and two
genes encoding isocitrate lyases (icll and icll) (Cole et al, 1998). Thus, we

decided to focus our efforts on investigating the role of this latter pathway in
pathogenesis of M. tuberculosis.
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Fig. 4.1. iWl is required for persistence and virulence of M . tuberculosis in mice. (A) Bacterial
loads in the lungs of B 6 X 1 2 9 F 1 mice infected with IO6 j'c/7-deficient (filled circles) or wild-type
(circles) M T B cells. (B-C) Lung pathology in B 6 X 1 2 9 F 1 mice infected with (B) wild-type or (C)
Aicll mutant bacteria at 16 weeks post-infection. (Data, courtesy of J. D. McKinney).
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P A R T II

CHAPTER 5

M y c o b a c t e r i u m tuberculosis Replication D y n a m i c s in vivo

INTRODUCTION

In the mouse model of TB a predominantly pulmonary infection is established

after intravenous inoculation or exposure to aerosolized bacteria (North & Young
2004). The acute phase of infection lasts a few wks and is characterized by

exponential bacterial growth in the lungs. The transition to the chronic phase o
infection is brought about by the emergence of acquired cell-mediated immunity
(CMI), which is mediated by antigen-specific T cells and and immune-activated

macrophage and results in the stabilization of bacterial loads in the infected o
(Flynn & Chan, 2001). A long-standing question has been whether this plateau in
the bacterial growth curve during chronic infection represents a "static"
equilibrium in which bacterial replication is slow or absent, or a "dynamic"

equilibrium in which continued rapid bacterial replication is precisely balanced
an equally rapid rate of killing by the host immune response (Sever & Youmans,
1957). This issue has important implications for anti-mycobacterial drug therapy
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because drugs that are currently used to treat T B are more effective against
bacteria undergoing rapid growth and cell division (McKinney, 2000; Mitchison,
2004).
In a classic study, Rees and Hart (1961) sought to distinguish between
"static" and "dynamic" models of the host-pathogen equilibrium in persistent TB
by enumerating "viable counts" (CFU) and "total counts" (microscopically

detectable acid-fast bacilli (AFB)) in the lungs of chronically infected mice. T
authors reasoned that if the dynamic model were correct the viable counts and
total counts should diverge over time due to progressive accumulation of dead
bacilli, which would contribute to the total counts (AFB) but not to the viable
counts (CFU). Instead, they found that the viable and total counts were

remarkably congruent throughout the course of infection, a result that favored t

static model. They acknowledged, however, that loss of acid-fast staining by dea

bacilli could result in an underestimate of the true number of total counts. Los

acid-fastness might also explain their observation that the total counts gradual
declined in animals treated with the anti-mycobacterial drug isoniazid (INH),
which is known to interfere with acid-fast staining (Middlebrook, 1952). It has

also been suggested that acid-fast staining might be lost in tubercle bacilli pr
in latently infected human tissues (Seiler et al, 2003).
In this chapter we describe experiments addressing this important aspect of

the host-pathogen interface in persistent TB. First, we measured and compared M.
tuberculosis viable counts (CFU), and total counts, represented by the number of
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bacterial chromosome equivalents (CEQ), in the lungs of chronically infected
mice. Our experimentally determined values were then compared with values

obtained from an in silico model that was used to simulate bacterial growth curv
(CFU accumulation) and to predict the extent of accompanying bacterial CEQ

accumulation over time at different rates of bacterial cell division. Alternativ
scenarios were modeled in which the immune response was bacteriostatic,

bactericidal, or both. Our results support the static equilibrium model, in which

entry into the chronic phase of infection is accompanied by a marked reduction i

the bacterial cell division rate. (The results discussed in this chapter are the
of a conceited effort by Wai-Tsing Chan, Jim Gomez, John McKinney, Juliano
Timm, and the author and have been reported [Munoz-Elias et al, 2005]).

RESULTS

5.1. Modeling the host-pathogen equilibrium in infected mice

In the mouse model of TB, the chronic phase of infection is characterized by
progressive lung pathology despite relatively stable numbers of viable bacteria
enumerated as colony-forming units (CFU) (Rhoades et ah, 1997). The plateau in

the bacterial growth curve could represent a "static" equilibrium in which the r

of bacterial cell division is very slow, or a "dynamic" equilibrium in which rap

bacterial cell division continues unabated, balanced by an equal rate of bacteri
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death effected by host immune mechanisms (Rees & Hart, 1961).

The latter

scenario would be akin to the highly dynamic equilibrium observed in HIV
infection prior to the onset of AIDS (Simon and Ho, 2003). We reasoned that the

two scenarios -static vs. dynamic- could be distinguished by comparing the "viab
counts" (CFU) and "total counts" (bacterial chromosome equivalents (CEQ)) at

various stages in chronically infected animals. The static model predicts that C
and CEQ will not diverge over time, whereas the dynamic model predicts that
bacterial CEQ will accumulate over time while CFU remain stable.
To illustrate these alternative scenarios, we devised a simple in silico model
that can be used to generate CFU and CEQ curves representing a static
equilibrium in which CMI is strictly bacteriostatic (Fig. 5.1 A), or a dynamic

equilibrium in which CMI is strictly bacteriocidal (Fig. 5.IB). The derivation of
our model is described in the Materials and Methods.
In the "static" scenario, the model predicted that both viable counts (CFU)
and total counts (CEQ) would remain stable and would not diverge over time (Fig.

5.1 A). In the "dynamic" scenario, the model predicted that although viable coun
would remain stable over time, the total counts would gradually rise due to the
accumulation of dead bacteria; in the modeled experiment depicted in Fig. 5.IB,
the CEQ/CFU ratio increased by ~ 100-fold between 2 wk and 16 wk postinfection. We also modeled semi-dynamic scenarios where CMI exerted both
bacteriostatic and bacteriocidal effects resulting in stable numbers of CFU but
gradual accumulation of CEQ. The semi-dynamic scenarios could reflect a partial

136

A)

B)

9-i
87-

7o>6o
-i 5-

g)6-

° 5- /
4- /
31
c)

9-

8-

4-

4

1 ' ' T —i
8
12
Weeks

16

3r
2.
0

4

8
Weeks

12

11

C)

Fig. 5.1. Modeling static and dynamic scenarios of the host-pathogen equilibrium in chronic
murine TB. Mice are infected with 200 CFU. Acute-phase infection (0-2 wk) is characterized by an
exponential increase in viable counts (CFU) with a 24.6 h population doubling time. Chronic phase
infection (2-16 wk) is characterized by stable viable counts. (A) Static scenario. Acquired immune
response halts bacterial replication after the acute phase of infection. Viable counts (CFU, dotted
lines) and total counts (CEQ, solid lines) do not diverge over time. (B) Dynamic scenario. Bacterial
replication continues at an undiminished rate (24.6 h doubling time) throughout the chronic phase,
but bactericidal acquired immune response kills 5 0 % of the bacteria after each round of cell division.
Balanced growth and death results in stable viable counts while total counts accumulate, resulting in
rapid divergence of C E Q and CFU. (C & D ) Semi-dynamic scenarios where the rate of bacterial cell
division is reduced by (C) 5 0 % or (D) 9 0 % from the acute-phase rate, resulting in a more gradual
divergence of C F U and CEQ.
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effect of C M I on the entire bacterial population, or variable efficacy of C M I
against different bacterial sub-populations (Fig. 5.1C, D); our model cannot

distinguish between these possibilities. The semi-dynamic scenarios were modeled

by varying the rate of bacterial cell division and death during the chronic phas

described in the Materials and Methods. When the rate of cell division during the
chronic phase was reduced by 50% (Fig. 5.1C) or 90% (Fig. 5.ID) as compared to

the cell division rate during the acute phase, the CEQ/CFU ratio nonetheless ros
appreciably—by ~ 40-fold (Fig. 5.1C) or ~ 8- fold (Fig. 5.ID), respectively—
between 2 wk and 16 wk post-infection. Our model will also accommodate more

complex scenarios, such as fluctuating rates of cell division or cell death duri

the course of infection (see Fig. 5.2). A key assumption is that non-viable bact
(and their chromosomes) are not removed or degraded over time; here we provide
experimental support for this assumption (see below), in agreement with evidence
adduced previously by others (Rees & Hart, 1961).

5.2. Comparison of modeled and experimentally determined CFU and CEQ
curves in infected mice

In order to generate experimental values for bacterial CFU and CEQ during the
course of a murine infection, C57B1/6 mice were aerosol-infected with -200 CFU

of M. tuberculosis (Erdman) and groups were sacrificed at selected time points f

quantitative analysis of bacillary loads. Viable counts (CFU) were enumerated by
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plate-culture of lung homogenates and total counts ( C E Q ) by quantitative realtime PCR (QPCR).
During the acute phase of infection (0-2 wk post-infection), the viable
counts in the lungs increased exponentially with an average population doubling

time of 24.6 hr (Fig. 5.2), which is typical in the mouse model of TB. During the

chronic phase of infection (2-16 wk post-infection), there was a much slower ris

in the viable counts with an average population doubling time of 1,676 hr (~ 70 d
(Fig. 5.2). The CEQ/CFU ratio showed little change during the chronic phase of

infection (Fig. 5.2; inset numbers indicate CEQ/CFU ratios/time point), indicatin
that there was minimal accumulation of chromosomes from dead bacteria. These

observations resemble the predicted curves generated by the "static" scenario in
our model (Fig. 5.1 A), and differ markedly from those of the "dynamic" scenario

(Fig. 5. IB), and support the idea that the rate of bacterial cell division is v
during the chronic phase of infection. In order to provide a more direct
comparison between our modeled and experimental results, we modeled the

"dynamic" and "static" scenarios using the growth rate constants derived from th

experimental data depicted in Fig. 5.2, taking into account any changes in bacte
CFU between time points by varying the growth rates constants (K values)

appropriately. The experimentally determined CEQ values (Fig. 5.2, open circles)
diverged sharply from the modeled CEQ values in the "dynamic" scenario (Fig.

5.2, blue line) or the "semi-dynamic" scenario where replication of bacteria dur

the chronic phase was reduced by 50% (Fig. 5.2, green line), and fell between the
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Fig. 5.2. Comparison of modeled and experimentally determined C F U and C E Q curves in
mice. (A) Wild-type (C57B1/6) mice were aerosol-infected with M. tuberculosis (-200 CFU/mouse).
At indicated time points, mice were sacrificed and viable counts (CFU) were quantified by plating
lung homogenates (closed squares); total counts (CEQ) were quantified by Q P C R (open circles).
Modeled C E Q values were derived using the static (red line) or dynamic (blue line) equilibrium
scenarios, or semi-dynamic scenarios in which the rate of cell division during chronic infection was
reduced by 5 0 % (green line) or 9 0 % (orange line) compared to acute infection. Symbols represent
mean C F U or C E Q values (n = 4 mice/group); inset numbers = CEQ/CFU ratios at time point. P
values for pairwise comparisons of the experimental and modeled C E Q values at 16 wk:
experimental vs. dynamic or semi-dynamic (50%) scenarios, P < 0.001; experimental vs. static or
semi-dynamic (10%) scenarios, P > 0.05. Results are representative of two experiments. (B)
Standard curve for the fadE15 primer-beacon set used to quantify bacterial C E Q in tissue
homogenates. Threshold cycle (Ct) values (y-axis) were obtained by Q P C R of target D N A (x-axis).
Symbols (open circles) indicate mean Ct values of three independent experiments; error bars
indicate STDEV. The trendline drawn through the data points indicates the linear regression curve,
which was calculated using the least-squares method.
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modeled C E Q

values for the "static" scenario (Fig. 5.2, red line) and the

"semidynamic" scenario where replication of bacteria during the chronic phase

was reduced by 90% (Fig. 5.2, orange line). The parallel rise in experimental CFU
and CEQ values between 2 and 16 wk post-infection indicates that stasis is not
complete, although the doubling time of the bacterial population during the

chronic phase is increased nearly 70-fold (1,676 hr) compared to the acute phase

(24.6 hr). Thus, although it is likely that bacterial growth continues at a redu
rate during the chronic phase of infection, our results are not consistent with

model in which rapid bacterial cell division is balanced by equally rapid cell d

5.3. Large numbers of bacterial chromosomes can be quantified in infected
mice

We considered the possibility that our inability to detect a divergence of CFU a
CEQ during the chronic phase of infection might be due to technical limitations
our methods for extraction and quantification of bacterial chromosomes from
infected lungs. In order to confirm that there was no ceiling on the number of
chromosomes per lung that we could accurately quantify, we enumerated CFU and
CEQ in aerosol-infected IFN-y deficient mice, which are unable to control
replication of M. tuberculosis (Cooper et ah, 1993; Flynn et ah, 1993). By 4 wk
post-infection, shortly before the IFN-y7" mice became moribund, the bacterial
load in the lungs had reached ~109 CFU per mouse; the number of CEQ detected
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by Q P C R corresponded very closely to the number of C F U detected by plate
culture (not shown). The close correspondence of CFU and CEQ spanning a range

of > 5 log10 confirms that our inability to detect a divergence of bacterial CFU

CEQ trajectories in chronically infected mice (Fig. 5.2) was not due to a techni
limitation of the QPCR assay.

5.4. Persistence of dead bacteria in mouse lungs

We considered the possibility that our inability to detect a substantial
accumulation of bacterial chromosomes during the chronic phase of infection
might be due to rapid removal or degradation of killed bacteria. In order to
address this issue using QPCR to quantify bacterial chromosomes in the lungs, we
assessed the impact of isoniazid (INH) therapy on the viable (CFU) and total
(CEQ) bacterial counts in chronically infected C57BL/6 mice. Untreated controls
showed relatively stable viable and total counts between 4 and 12 wk postinfection (Fig. 5.3B). In contrast, mice treated with INH for 8 wk (from 4 to 12
wk post-infection) showed a marked reduction in viable counts (3.6 logio),

whereas the total counts remained stable (Fig. 5.3A). These observations indicate

that non-viable tubercle bacilli (and their chromosomes) are not subject to rapi
removal or degradation, in agreement with previous reports (de Wit et ah, 1995;
Rees and Hart, 1961).
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Fig. 5.3. Chromosomes of non-viable M. tuberculosis in mouse lungs are not removed or
degraded rapidly. C57B1/6 mice were infected i.v. with M. tuberculosis (~1 x IO6 C F U per mouse).
One group (A) received INH (25 mg kg"1 d'1) for 8 wk starting at 4 wk post-infection; a control
group (B) was left untreated. At 4 , 8, and 12 wk post-infection, mice from INH-treated and
untreated groups were sacrificed and viable counts (CFU) were quantified by plating lung
homogenates (open bars); total counts (CEQ) were quantified by Q P C R (shaded bars). Bars
represent mean C F U or C E Q values (n = 4 mice per group); error bars indicate S T D E V from the
means. In pairwise comparisons of C F U values in the INH-treated group for 4 wk vs. 8 wk or 4 wk
vs. 12 wk post-infection, differences were highly significant (P < 0.005), while those of C E Q values
in the INH-treated group for 4 wk vs. 8 wk or 4 wk vs. 12 wk post-infection were not (P > 0.05).
Results are representative of two experiments.
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CHAPTER 6

A n Investigation into the Role of icll a n d icll in C a r b o n
Metabolism and Pathogenesis of Mycobacterium tuberculosis

INTRODUCTION

Microorganisms that invade, replicate, and persist within other host organisms

must acquire and assimilate carbon substrates from their hosts' tissues. With fe
exceptions, little is known about the sources of nutrients or the metabolic
pathways utilized by pathogens to use such nutrients during infection (Smith,

2000). Metabolic adaptations to tissue environments are almost certainly essentia

for the ability of pathogens to survive in the host in spite of acquired immunit

These adaptations might also contribute to the difficulty in eradicating microbe

the host despite prolonged therapy with drugs to which the pathogen, when tested
in vitro, is susceptible (McDermott, 1958). In vivo drug tolerance is a major

reason why tuberculosis (TB) therapy requires administration of multiple drugs f

at least six months, resulting in high rates of patient non-adherence, treatment
failure, and acquired drug resistance (Gomez & McKinney, 2004). Elucidation of

the metabolic pathways required for growth and persistence of M. tuberculosis in
the mammalian lung could suggest new avenues of intervention against this
recalcitrant pathogen (Stewart et ah, 2003; Boshoff & Barry, 2005).
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Several lines of evidence suggest that pathogenic mycobacteria primarily

utilize fatty acids, rather than carbohydrates, as carbon substrates during infe
(Chapter 3). Previously we reported that disruption of icll in M. tuberculosis

impairs the ability of the bacteria to survive at wildtype levels during the chr

phase of infection in mice, but has little effect on replication during the firs
wks of the infection (McKinnney et ah, 2000; Chapter 3). The genome of M.
tuberculosis has a gene homologous to icll, termed icll (MT1966, Rvl915/16),

which encodes a second putative isocitrate lyase (ICL2) (Cole et ah, 1998). Here,

we report that icll and icll provide overlapping and essential functions in grow

and survival of M. tuberculosis in vivo. Deletion of icll or icll alone had litt
effect on bacterial catabolism of fatty acid substrates or multiplication in
macrophages and mice. In contrast, bacteria lacking both genes were unable to
grow in fatty acid-containing media or in macrophages, and were rapidly
eliminated from the lungs of infected mice. Virulence of the Aicll Aicll strain
not restored in mice lacking macrophage activation pathways mediated by
interferon-y (IFN-y) or tumor necrosis factor-a (TNF-a), indicating that the

essentiality of the gGC) at the onset of the infection is largely independent of
host immune response. Using a dual-specific ICL inhibitor, we adduce evidence
that chemical inhibition of ICL activity might be a feasible and effective
therapeutic approach.
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RESULTS

6.1. ICL isoenzymes of M. tuberculosis

Previously, we reported that isocitrate lyase (ICL1) facilitates persistence of
tuberculosis in chronically infected mice and macrophages (McKinney et ah,
2000; Fig. 4.1). The genome sequence of a virulent clinical isolate of M.
tuberculosis (CDC1551) identified a second id gene (MT1966, Rvl915/16; here
designated icll) (Fleischmann et ah, 2002) with limited homology to icll
(MT0483, Rv0467); the predicted gene products are 27% identical overall, and
differ significantly in size (ICL1 = 428 AA; ICL2 = 766 AA). Recombinant ICL2

displays isocitrate lyase activity in vitro although it is less active than ICL1
zu Bentrup et al, 1999). Sequence alignments revealed three distinct groups of
ICL proteins (Fig. 6.1), which differed in length and domain organization (Fig.
6.2A). Group I ICLs comprised eubacterial short ICLs, including M. tuberculosis
ICLL Group II ICLs included plant and fungal medium-length ICLs, which

contained a central domain (Domain II) absent in group I. Group III ICLs, so far
identified only in Mycobacterium, had a long C-terminal domain absent in groups
I and II; they also contained a central region with significant homology to the
central domain of the eukaryotic ICLs and were overall -35% identical to them
(Fig. 6.1&6.2). In silico modeling of the three-dimensional structure of ICL2,

based on the X-ray crystal structures of ICL1 from M. tuberculosis (Sharma et al
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and genome databases (NCBI). N a m e is followed by accession number or unique gene identifier in
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Fig. 6.2 I C L 1 and I C L 2 are evolutionarily divergent structurally related proteins . (A) D o m a i n
organization of isocitrate lyases in eubacteria and eukaryotes. Alignments were generated using the
Conserved D o m a i n Database ( C D D vl.62, N C B I ) . Domains I and III are present in all ICLs.
D o m a i n I contains the conserved catalytic motif K K C G H . D o m a i n II is present in fungal and plant
ICLs and in mycobacterial ICL2, but absent in mycobacterial I C L L D o m a i n I V is unique to
mycobacterial ICL2. (B) ICL1 and ICL2 are structurally related isocitrate lyases. Structural
modeling of M . tuberculosis ICL2. Superimposition of the model of I C L 2 m o n o m e r (red) and the
X-ray crystal structure of an ICL1 m o n o m e r (blue). Encircled: I C L catalytic signature motif
K K C G H ( A A 193-203 in ICL1; A A 213-217 in ICL2). The I C L 2 model was generated using
M O D E L L E R , based on the predicted A A sequence of I C L 2 (Gl: 50952459) and coordinates from
the crystal structure of ICL1 ( P D B 1 F 8 M , Gl: 15607608) (Sharma et al., 2000). D o m a i n II of I C L 2
( A A 269-365) is absent in ICL1, and was modeled after the crystal structure of I C L from Aspergillus
nidulans (Gl: 49096622)24. D o m a i n IV (not depicted) had no homology to any k n o w n sequences.
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2000) and I C L from Aspergillus nidulans (Britton et al, 2000), revealed a striking

level of structural concordance (Fig. 6.2B). Significantly, the active site loops
ICL1 and ICL2, containing the conserved catalytic motif (KKCGH), were nearly
superimposable (Fig. 6.2B, encircled). Thus, despite the limited homology
between ICL1 and ICL2, conservation of tertiary structure and enzymatic activity
suggested these enzymes might subsume overlapping biological roles.

6.2. Generation of Mycobacterium tuberculosis id mutants

Microorganisms use the GC to replenish TCA cycle intermediates during growth
on fatty acids because under these conditions the concentrations of PEP and
pyruvate are insufficient to support anaplerosis via their conversion to
oxaloacetate by PEP carboxylase (PPC) or pyruvate carboxylase (PCA),

respectively (Fig. 3.6). To assess the role of the GC in mycobacterial pathogene
and fatty acid metabolism, M. tuberculosis (Erdman) strains were constructed in
which icll, icll, or both were deleted. The mutants were generated by allelic
exchange as illustrated (Fig. 6.3A), using a replicative plasmid and sucrose
counterselection as described previously (Pavelka & Jacobs, 1999). The icll gene
was disrupted by deletion of two internal MscI fragments and insertion of a

kanamycin resistance cassette. The same construct was used to disrupt icll in th
chromosome of wild-type and Aicll mutant bacteria, thereby generating A/c/2 and
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Fig. 6.3. Disruption of icl2 in the genome of wild-type M . tuberculosis (Erdman and H 3 7 R v ) &
in the icll mutant background (Erdman). (A) Scheme for disruption of icl2 in the chromosome of
M . tuberculosis (Erdman). (B) Genomic D N A preparations from M . tuberculosis wild-type
(Erdman) (lane 1), H 3 7 R v (19), plasmid p E M 0 2 7 carrying wild-type icl2 (lanes 2 & 11), deletion
construct p E M 0 2 9 (lanes 3 & 12), mutant candidate clones in Erdman (lanes 4-8), in H 3 7 R v
(lanes 12-17) and (C) Genomic D N A preparations f r o m M . tuberculosis wild-type (lane 1), plasmid
p E M 0 2 7 carrying wild-type icl2 (lanes 2 & 8 ) , deletion construct p E M 0 2 9 (lanes 3 & 9 ) , Aicll
(Erdman) (lane 7), Aicl2 (Erdman) (lane 4), Aic/2 (H37Rv) (lane 5), candidate clones for icl2
disruption on the Aicll (Erdman) background (lanes 10-19) were digested with ApaLI, separated in
1 % T B E agarose gels, denatured with 0.5 N a O H , transferred to Hybond N membrane, and probed
with an 610 bp P C R fragment from p E M 0 2 7 (indicated by diamond-headed marks) labeled with 32P
using a random priming labeling kit. Hybridization and washings were carried out under stringent
conditions (65 C ) ; specific hybridization was detected by autoradiography. See materials and
methods for further details.
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AicllAicl2 mutants, respectively. Disruptions were confirmed by Southern blot
(Fig. 6.3B&C).
Disruption of icll in M. tuberculosis (Erdman) and its complementation
with an episomal plasmid carrying a wild-type copy of icll gene were previously
described (McKinney et ah, 2000). In the genome of M. tuberculosis, the ORF
immediately downstream of icl2 appears to be transcribed in the opposite

orientation thus making it unlikely that the disruption of icl2 would affect the
expression of this downstream gene. However, another potential complication in

the analysis of a mutant is that unintended mutations may be introduced elsewher
in the chromosome inadvertently during its construction. Thus, reversal of a
mutant's phenotype by complementation with a functional copy of the gene that
was disrupted is always desirable. Since in the AiclllAicU mutant strain we had

generated icll had been disrupted by deletion of part of the ORF and insertion o
hygromycin resistance cassette, while the icl2 gene had been replaced by a
kanamycin resistance cassette, complementing plasmids carrying a streptomycin
resistance cassette and either icll (pEM263-4/pICLl) or icl2 (pEM3E4-8/pICL2)
were constructed and transformed into the AiclllAicU (see Materials & Methods).

151

6.3. Characterization of M . tuberculosis id mutants in standard media

M. tuberculosis lacking icll, icl2, or both grew equally well and indistinguishab
from wild-type bacteria in 7H9 broth in either rolling (Fig. 6.4A) or shaking
bottles (Fig. 6.4B). Rolling bottles afforded better growth presumably because
they allowed better aereation. The ability to form colonies on standard 7H10
plates was somewhat different for the different id deficient strains. While the

single Aicl2 mutant grew like wildtype (CFU in 3 wks), formation of a colony of a
size comparable to that of wild-type bacteria at 3 wks by Aicll and AiclllAicU

mutant bacteria required four and six wks of incubation, respectively (not shown)

6.4. Determining in vitro growth conditions to test utilization of C2 substrates

In most bacterial species studied so far, the GC is essential for growth solely
the only carbon substrates available are ones that enter central metabolism as

acetyl-CoA (C2 substrates); such carbon sources are primarily fatty acids (Crona

& LaPorte, 1996). In order to assess the contribution of ICL 1 and ICL2 to carbon
metabolism in M. tuberculosis, we set sought to establish culture conditions

permitting the assessment of the contribution of these enzymes to bacterial carb
metabolism.
Mycobacteria are notoriously slow-growing fastidious organisms (Wheeler,
1984; Honer zu Bentrup & Russell, 2001). M. tuberculosis can be
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Fig. 6.4. Characterization of M . tuberculosis id mutant strains in standard 7H9 broth, M 9 based and 7H9-based defined liquid media. (A-B) M. tuberculosis (Erdman) bacteria were
cultured in standard (std.) 7H9 broth: (A) in rolling bottles; (B) in shaking bottles. (C-E) M9-based
defined media: (C) no carbon; (D) glucose; (E) acetate (C2FA). (F-H) 7H9-based defined media:
(F) no carbon; (G) glucose; (H) acetate (C2FA). Both M 9 - & 7H9- based defined media contained
Tween-80 (0.05%), Albumin fraction V (0.5%), and NaCl (0.08%). Growth was monitored by
measuring culture turbidity (OD600 nm) at the indicated time points. Results are representative of at
least two experiments.
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grown axenically, but its optimal cultivation requires relativelyrichmedia (Dubos
& Middlebrook, 1947). In liquid, M. tuberculosis is routinely grown in
Middlebrook 7H9 powder (DIFCO)-based broth supplemented with "ADS" (w/v:
0.5% albumin, 0.2% glucose, 0.085% saline, 0.05% Tween-80, and 0.5% glycerol.
On solid media, M. tuberculosis is grown on 7H10 agar (DIFCO)-based media
supplemented with glycerol (0.5% w/v) and 10% OADC (DIFCO). OADC
(DIFCO) is a commercial supplement containing oleic acid, albumin, glucose, and
catalase at the same concentrations used by Middlebrook and Dubos (Dubos &
Middlebrook, 1947), which are the same as those used in ADS for
supplementation of 7H9 broth. In order to define conditions that would allow the
study of carbon utilization of M. tuberculosis on solid media, we repeatedly
attempted to use non-commercial (home-made) stocks of OADC to culture M.

tuberculosis, but these media preparations consistently resulted in a drastic de
in colony formation (colonies took circa 8 wks to appear, not shown). This fact
made studies of M. tuberculosis on defined solid media impractical.
Therefore, we took a two-pronged approach to study carbon utilization in
mycobacteria. The first approach consisted in generating mutants in the same
genes we were interested in studying in M. tuberculosis, namely GC genes, in M.
smegmatis, a fast-growing saprophyte that is readily cultured in minimal media.
The mutants were then complemented with the homologous M. tuberculosis genes

to study their function as it pertains to carbon utilization. This work is repor
Chapter 9. The second approach was to find growth conditions in which a given
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carbon substrate was the sole or at least the main carbon substrate present in liquid

media for M. tuberculosis cultivation. Cultivation of M. tuberculosis in minimal
M9 salts liquid media supplemented with different single carbon substrates

resulted in very poor growth, clumping, and attachment of the tubercle bacilli t
the walls of the culture flask (not shown). We next attempted to grow M.
tuberculosis in M9 salts liquid media supplemented with albumin, saline and
Tween-80 (same concentrations used for standard 7H9 broth) and a single carbon
source at 0.1% (w/v). Encouragingly, M9-based media supplemented with either
the short chain fatty acid acetate (C2FA) or glucose allowed significant growth
(Fig. 6.4D&E). Some initial background growth was observed in media
containing "no carbon;" this we attributed to the presence of Tween-80 (0.05%),
which at low concentrations can be metabolized by mycobacteria (Saito et ah,
1983). Nonetheless, the growth obtained in M9-based media was very limited (the
bacterial doubling time was ~ 5-6 days, compared to ~1 day in standard 7H9
broth). So we next replaced the M9 salts with 7H9 powder; 7H9 powder
(DIFCO), in addition to basic salts, contains citrate (0.01%, w/v) and glutamate
(0.05%, w/v), and traces of other elements that enhance bacterial growth. 7H9based media supplemented with glucose (0.1%, w/v) or C2FA (0.1%, w/v)

supported significantly better and faster growth of M. tuberculosis (doubling ti
3-4 days) than similarly supplemented M9-based defined media (Fig. 6.4G&H).
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6.5. Functional redundancy of icll and icl2 in fatty acid metabolism in vitro

Importantly, we observed that while both M9- and 7H9-based defined glucose
media supported the growth of the AiclllAicU mutant (Fig. 6.4D&G), C2FAsupplemented media did not (Fig. 6.4E&H). Interestingly, the AiclllAicU mutant
failed to grow even to background levels in M9- or 7H9-based media without

added carbon, perhaps reflecting the inability of the mutant to grow on fatty ac
derived from Tween-80 (Fig. 6.4C&F). These growth conditions were used to
analyze the ability of the id mutants to grow on different carbon substrates.
Deletion of icll or icU alone had little effect on bacterial replication

kinetics in media containing glycerol (Fig. 6.5A), glucose (Fig. 6.5B), short-cha
fatty acids (Fig. 6.5C-G), or long-chain fatty acids (Fig. 6.6A-E) as carbon

sources. In contrast, deletion of both icll and icU eliminated growth on fatty ac

while having little effect on utilization of carbohydrates (Fig. 6.5&6.7). A sli
but reproducible lag was observed for growth of the AiclllAicU strain in
carbohydrate-containing media (Fig. 6.5B), suggesting carbon flux through the GC
under these conditions in wild-type M. tuberculosis. A similar observation has
been made in Corynebacterium glutamicum (Wendisch et ah, 2000). In the
experiments shown in Fig. 6.5 & 6.7, growth was determined by monitoring the

optical absorbance of the cultures, except for Fig. 6.6D, where the ability of t
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Fig. 6.5. Overlapping roles of ICL1 and ICL2 in short chain fatty acid metabolism. (A-G) M .
tuberculosis (Erdman) bacteria were cultured in liquid media containing (0.1% w/v): (A) glycerol;
(B) glucose; (C) acetate (C2FA); (D) propionate (C3FA); (E) butyrate (C4FA); (F) valerate (C5FA);
(G) hexanoate (C6FA). Growth was monitored by measuring culture turbidity (OD600 n m ) at the
indicated time points. Results are representative of at least two experiments.
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Fig. 6.6. Overlapping roles of ICL1 and ICL2 in long-chain fatty acid metabolism. (A-C) M.
tuberculosis (Erdman) bacteria were cultured in liquid media containing (0.1% w/v): (A)
polyoxyethylene sorbitan mono-laurate (C12FA); (B) polyoxyethylene sorbitan mono-palmitate
(C16FA); (C) polyoxyethylene sorbitan mono-stearate (C18FA). Growth was monitored by
measuring culture turbidity (OD600 nm) at the indicated time points. (D) Growth on palmitate
(C16FA) was measured by BACTEC, which quantifies [14C]-C02 released by oxidation of [14C]palmitate. (E) Growth on dipalmitoyl-phosphatidylcholine (DPPC, C16FA), an abundant
phospholipid in the lung, was determined by plating for CFU. Results are representative of at least
two experiments.
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bacteria to metabolize a C 1 6 F A was determined in a B A C T E C apparatus in which
the evolution of C02 from media containing radiolabeled palmitate is measured,
and for Fig. 6.6E, where growth was determined by plating for CFU after the
bacteria had been cultured for 15 days in media supplemented with dipalmitoylphosphatidylcholine (DPPC), a major phospholipid component of pulmonary
surfactant (pulmonary surfactant is typically 90% lipids, 10% proteins)
(Santangelo et ah, 1999).

6.6. ICL activities in vitro and icll and icll mRNA levels during infection

Next, we determined ICL activities present in extracts from bacteria grown on
different carbon substrates to get an idea of the relative contribution of each
isoenzymes to the overall ICL activity (Table 6.1). Extracts prepared from

glucose-grown wild-type bacteria had basal levels of ICL activity, those from th
single Aicll and A/c/2 mutants each had some activity as well, while Aicll Aicll

extracts had no activity. The ICL activity in wild-type acetate extracts was abo
10 fold higher compared to glucose, but unexpectedly, the activity in the Aicll

mutant was barely detectable (similar to ICL levels in glucose), while that in th
A/c/2 was higher than wild-type. Unexpectedly, growth on the C3 fatty acid
propionate resulted in ICL activity which was -10 fold higher than on acetate.
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T o get an idea of the regulation of ICL expression during infection, w e next
sought to determine the relative levels of mRNA for each of the id homologs.
Previously, Timm and colleagues (2003) reported up-regulation of icll in M.

tuberculosis (strain H37Rv) isolated from mouse lungs relative to bacteria grown

in vitro. Confirming this previous observation, we found that icll was highly up
regulated in bacteria isolated from mouse lungs that had been infected with M.
tuberculosis Erdman, the strain used throughout

Table 6.1. Isocitrate lyase activity in M. tuberculosis icl mutants
M.

tuberculosis

Glucose

Acetate

Propionate

Wildtype

2.10+/-0.11

26.20 +/- 2.48

406.47 +/- 28.25

Aicll

0.35 +/- 0.16

0.54 +/-0.25

2.35 +/-1.11

Aicll

1.68+/-0.13

40.07 +/- 5.95

495.44 +/- 65.09

Aiclllicll

0.09 +/- 0.31

ND

ND

strain

Bacteria were grown in defined 7 H 9 broth at 37 °C with shaking (65 rpm), and
harvested at late log phase. Carbon substrates were used at 0.2 % w/v, each.
Values correspond to specific activities (nmol/min/mg) in total cell-free extracts:
isocitrate-stimulated activity using 1 m M isocitrate, 0.1 m M N A D H at 25 °C. All
strains are M . tuberculosis (Erdman). N D = not done. Data represent the average
of 3 measurements from one set of extracts.

our studies. A peak in expression occurred at around 20 days post-infection, but
relative high expression levels were maintained throughout (60 and 180 day time
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Fig. 6.7. Expression of glyoxylate cycle enzymes during infection. (A) icll and (B) icl2 m R N A
levels in M . tuberculosis grown in vitro (gray bars), in mouse lungs at 21 d (black bars), 60 d (black
and white checkered bars) and 180 d (black circles-filled bars). Bars represent ratios of icll or icl2
levels relative to sigA, a gene whose expression remains relatively unchanged during the infection
(Timm et al, 2003). Number of transcript copies was determined by Q R T - P C R using gene specific
molecular beacons as detailed in materials and methods. Results are representative of least two
experiments using samples from the same infection. Mice were infected i.v. with M . tuberculosis
Erdman (1 x 106 CFU/mouse).
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points) (Fig. 6.7). Expression of icll was also higher in vivo compared to in vitro,

but the levels of expression were significantly lower (-10 fold) than those of i

at all time points (Fig. 6.7). Together these observations suggest that while IC

is inducible, being upregulated in vitro in response to C2/C3 substrates, and at

level of mRNA in the lungs of mice. ICL2 appears to be constitutive in vitro, and
subjected to some, but relatively low upregulation compared to ICL1 in vivo.

6.7. Long-term survival of icll -deficient M. tuberculosis

In order to assess the contribution of ICL1 and ICL2 to growth and survival of M.

tuberculosis in vivo, we infected wild-type (C57BL/6) mice with bacteria lacking
icll, icll, or both. Confirming our previous observations (McRinney et ah, 2000),

by 4 wks post-infection, bacterial loads in the organs of mice infected with Aic

M. tuberculosis were 5-10 fold lower than those that had been infected with wild

type bacteria (Fig. 6.8). However, here, by following the fate of the Aicll muta
for much longer than previously, we noted that despite significant prolonged
attenuation and reduced tissue pathology (Fig. 6.9), Aicll mutant bacteria were
actually capable of long-term persistence in the lungs of mice (at around 105
CFU/lung), and late in the infection resumed growth (compare CFU/lung at 16 vs

52 wk, post-infection), leading to pathology and death of the infected mice at c

75 wks post-infection (Fig. 6.10). Mice infected with wild-type bacteria died at
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Spleen

Fig. 6.8. Loss of I C L 1 attenuates M . tuberculosis in chronically infected mice. Wild-type mice
(C57BL/6) were infected with M . tuberculosis (Erdman) wild-type or Aicll mutant (IO6 C F U , i.v.).
Bacteria in the (A) lung, (B) spleen, and (C) liver were enumerated by plating organ homogenates
for C F U at indicated time-points. Error bars indicate S T D E V for each group (n=4-5).
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Fig. 6.9. L u n g pathology in m i c e infected with ICLl-deficient M . tuberculosa.
L u n g sections ( H & E stain) at 16 w k post-infection in C 5 7 B L / 6 mice infected with M . tuberculosis
( E r d m a n ) (~5xl05, i.v.) ( A - C ) wild-type, (D-F) Aicll. N u m b e r s o n right margin indicate total
magnification.
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about 40 wks post-infection (Fig. 6.10), while uninfected mice lived longer than
104 wks (not shown). Based on our in vitro carbon utilization experiments
indicating that the absence of either id was not enough to impair growth on C2

substrates, we hypothesized that the observed ability of the Aicll mutant to per

in the organs of mice and resume growth late in the infection might be due to the
presence of ICL2.

6.8. icll is dispensable for M. tuberculosis growth and persistence in mice

To directly assess the contribution of ICL2 to M. tuberculosis pathogenesis, we

evaluated the ability of the A/c/2 mutant to grow and persist in mice. Similarly
the Aicll mutant, the A/c/2 mutant replicated like wild-type during the first 2
of infection. However, in contrast to the Aicll mutant, bacteria lacking ICL2

remained at wild-type levels during the chronic phase of the infection (wk 2-16)

(Fig. 6.11), and elicited comparable pathology (Fig. 6.12). The fact that deletio
of each id individually resulted in limited (Aicll) or no phenotype (Az'c/2) is
consistent with the hypothesis of partial redundancy between the two homologs
and our studies carbon utilization studies (Fig. 6.4-6.6).
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Fig. 6.10. Survival of mice chronically infected with ICLl-deficient M . tuberculosis. Time-todeath of wild-type (C57BL/6) mice infected with M . tuberculosis (Erdman) wild-type or Aicll
mutant (5xl05 C F U , i.v.). (n=10). (CFU data corresponding to this figure are shown in Fig. 6.9).
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Fig. 6.11. I C L 2 is dispensable for M . tuberculosis growth and persistence in chronically
infected mice. Wild-type (C57BL/6) mice were infected with M . tuberculosis (Erdman) wild-type
or Aicll mutant (5xl05 C F U , i.v.). Bacteria in the (A) lung and (B) spleen were enumerated by
plating organ homogenates for C F U at indicated time-points. Error bars indicate S T D E V for each
group (n=4-5).
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Fig. 6.12. L u n g pathology in mice infected with ICL2-deficient M . tuberculosis.
L u n g sections ( H & E stain) at 16 w k post-infection in C 5 7 B L / 6 mice infected with M . tuberculosis
(Erdman) (~5xl05, i.v) (A-C) wild-type, (D-F) A/c/2.
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6.9. Partial functional redundancy between icll and icll in vivo

Indeed, in contrast to A/c/7 or A/c/2 mutant bacteria, AiclllAicU M. tuberculosi

mutants failed to replicate in lungs, spleens and livers of mice, and were cleare
from the lungs by 4 wks post-infection, as seen in two independent experiments
(Fig. 6.13A-C; Fig. 6.14 A&B). We observed no spontaneous relapse, and no
bacilli could be recovered from any infected organ 48 wks post-infection (Fig.
6.13A-C; limit of detection = 2 CFU per organ) suggesting sterilization. Mice
infected with the AiclllAicll mutant did not show any discemable splenomegaly
(Fig. 6.15) or lung pathology (Fig. 6.16), and remained healthy until the
experiment was terminated 2 years post-infection, whereas mice infected with
wild-type bacteria uniformly succumbed between 8 and 9 months post-infection.
The experiment was repeated a third time using the aerosol route of infection.
Mice received 10 CFU/mouse as determined by plating lung homogenates for
CFU at 24 hours post-infection. By 2 wks post-infection, AiclllAicll mutant
bacteria had been eradicated from the lungs and had bacteria were unable to
disseminate to the spleen as indicated by plating organ homogenates at 2 and 4
wks post-infection (limit of detection = 1 CFU/time-point). Complementation of

the AiclllAicll mutant with an episomal plasmid carrying a wild-type copy of icl

restored bacterial growth in both lung and spleen (Fig. 6.17A&B), as well as lun
tissue pathology (Fig. 6.18); late-stage persistence was largely, although not
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Fig. 6.13. I C L 1 and I C L 2 are jointly required for growth and survival of M . tuberculosis in
mice . (A-C) Wild-type (C57BL/6) mice were infected with M . tuberculosis (Erdman) wild-type or
Aicll/Aicl2 (~106, i.v.). Bacterial loads in the (A) lung, (B) spleen, and (C) liver were enumerated by
plating organ homogenates for C F U at indicated time-points. Error bars indicate S T D E V for each
group (n=4-5). Limit of detection: 40 CFU/organ/mouse (dotted line), except for 48 w k time-point, 1

CFU.
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Fig. 6.14. ICLl/ICL2-deficient bacteria are eradicated from mouse lungs within 4 weeks of
infection. (A-B) Wild-type (C57BL/6) mice were infected with M . tuberculosis (Erdman) wild-type
or Aicll/Aicl2 (5xl05, i.v.). Bacterial loads in the (A) lung and (B) spleen were enumerated by
plating organ homogenates for C F U at indicated time-points. Error bars indicate S T D E V for each
group (n=4). This experiment only differs from the experiment shown in Fig. 6.13 in that a lower
infection dose was used in this one. Limit of detection: 2 CFU/lung/mouse.
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Fig. 6.15. ICLl-/ICL2-deficient M. tuberculosis is avirulent in mice. Spleens of C57BL/6 mice
collected 2 weeks post-infection (~ IO6 CFU, i.v.) with wild-type (6.11 ± 0.15), Aic/7 (5.92 ± 0.12),
A/c/2 (6.24 ± 0.08), or AicllAicl2 (3.58 + 0.22) bacteria. Numbers in parentheses indicate Log10CFU
± S T D E V at 2 wk post-infection. Scale is in cm.
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Fig. 6.16. Lung pathology in mice infected with ICLl-/ICL2-deficient M. tuberculosis.
Lung sections (H&E stain) at 16 wk post-infection in C57BL/6 mice infected with M. tuberculosis
(~5xl05, i.v.) (A-C) wild-type, (D-F) AiclllAicU.
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Fig. 6.17. Growth of ICLl/ICL2-defkient M . tuberculosis in mice is restored by
complementation with pICLl. Wild-type (C57BL/6) mice were infected with M . tuberculosis
(Erdman) AiclllAicU, or Aic/i/A/c/2::pICLl (5xl05 C F U , i.v.). Bacteria in the (A) lung and (B)
spleen were enumerated by plating organ homogenates for C F U at indicated time-points. Error bars
indicate S T D E V for each group (n=4-5).
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Fig. 6.18. Lung pathology in mice infected with ICLl-/ICL2-deficient M . tuberculosis
complemented with ICLl. Lung sections ( H & E stain) at 16 w k post-infection in C57BL/6 mice
infected withM. tuberculosis (~5xl05, i.v.) (A-C) wild-type, (D-F) A/c///A/c/2::pICLl.
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completely, restored as well. A n in vivo experiment with the AiclllAicll mutant
that had been complemented with a plasmid carrying a wild-type copy of icll was
not performed.

6.10. AiclllAicll M. tuberculosis mutant is avirulent in immune-deficient mice

TB case fatality rates are higher in AIDS patients than in HlV-negative individu
despite appropriate anti-mycobacterial therapy, suggesting that antimicrobials
might be less efficacious in immune-compromised hosts (El-Sadr et ah, 2001).
We asked what effect ICL inactivation would have on growth and survival of M.
tuberculosis in immuno-deficient hosts by infecting mouse strains lacking

interferon-y (IFN-y7") or tumor necrosis factor-cc receptor 1 (TNF-a-Rl"7"), whic

are highly susceptible to M. tuberculosis infection (Cooper et ah, 1993; Flynn e
ah, 1993; Flynn et ah, 1995). Importantly, we found that AiclllAicll bacteria

were incapable of replicating in IFN-y"7" mice (Fig. 6.19) or TNF-ocRT7" mice (Fi
6.20). These experiments suggest that targeting ICLs might be effective even in
immune-compromised individuals.
Previously we had seen that the attenuation of Aicll bacteria in C57BL/6

mice was largely reversed in IFN-y"7" mice as well as in mice deficient in other
components of the immune response, suggesting that the in vivo requirement for
ICL activity might be triggered by T-cell-mediated activation of macrophages
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Fig. 6.19. ICLl/ICL2-deficient M. tuberculosis is avirulent in immune-deficient (IFN-y'-) mice.
IFN-y-deficient (C57BL/6) mice were infected with M. tuberculosis (Erdman) wild-type or
Aicll/AicU (IO6 CFU, i.v.). Bacteria in the (A) lung and (B) spleen were enumerated by plating
organ homogenates for C F U at indicated time-points. Individual symbols represent C F U in the
organs of individual mice (n=3-5).

177

Lung

A)
]WT

3
LL
o
o

14
Days

Lung

B)
8
7
6
D 5
LU
O 4

• icl1/2

O)

5 2
3
1
0
56
Days

Fig. 6.20. ICLl-/ICL2-deficient M . tuberculosis is avirulent in immune-deficient (TNF-aRT/_)
mice. TNF-aRI-deficient (C57BL/6) mice were infected with M . tuberculosis (Erdman) (A) wildtype or (B) Aicll/AicU (5xl05 C F U , i.v.). Bacteria in the lung were enumerated by plating organ
homogenates for C F U at indicated time-points. Limit of detection at 56 days: 40 CFU/organ
(indicated by dotted line). Error bars indicate S T D E V for each group (n = 4).
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(Chapter 7; McRinney et ah, 2000). Our results with AiclllAicll mutant bacteria
are largely inconsistent with this idea and suggest that dependence of M.
tuberculosis on ICL activity for early growth in vivo is largely independent of
these components of the immune response. Nonetheless, even though clearance of
AiclllAicll bacteria from the infected lungs of IFN-y7" mice (Fig. 6.19A) was
observed by wk 16 post-infection, the die off occurred more slowly than in
immune-competent mice (Fig. 6.13 & 6.15) and little evidence of it was observed

in the spleen (Fig. 6.19B), where AiclllAicll bacteria persisted without growing,

perhaps reflecting organ specific differences in the environment of the infectio

6.11. Growth of /c/-deficient M. tuberculosis in macrophages

We next investigated whether the requirement for ICL-mediated metabolism by

M. tuberculosis to growth and survive in mice could also be seen at the level of
parasitized macrophage. In marked contrast to either Aicll or A/c/2 bacteria,
which replicated like wild-type, AiclllAicll M. tuberculosis was incapable of
intracellular replication in resting macrophages (Fig. 6.21).
Stimulation by mycobacterial products and certain cytokines activates
macrophage effector mechanisms including phagocyte-oxidase-mediated

generation of ROI, inducible nitric oxide (NOS2)-mediated generation of RNI, and
LRG47-mediated phagolysosomal fusion and acidification (Nathan & Shiloh,
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2000; Russell, 2001; MacMicking, 2005). T o determine the impact of host cell

activation on the survival of ICLl-/ICL2-deficient M. tuberculosis, bone marrowderived macrophages were activated with IFN-y (100 U mL") prior to and during
intracellular infection. While macrophage activation was bacteriostatic to

intracellular wild-type M. tuberculosis as expected, it was markedly bactericida

AiclllAicll M. tuberculosis (Fig. 6.21). M. tuberculosis lacking icll, but not icl
deficient bacteria also were slightly attenuated for growth and survival within
macrophages (Fig. 6.21). Complementation of the AiclllAicll mutant with wild-

type copies of icll (Fig. 6.22 A&B) or icll (Fig. 6.22 C&D) restored replication
non-activated macrophages (Fig. 6.22 A&C) and survival in IFN-y-activated
macrophages (Fig. 6.22 B&D).

6.12. Growth of /c/-deficient M. tuberculosis in human macrophages

To extend our observations to human cells, human blood monocyte-derived
macrophages were infected ex-vivo. Similarly to wild-type, Aicll and A/c/2 M.
tuberculosis readily replicated in human primary macrophages as determined by

CFU (Fig. 6.23) and4',6'-diamino-2-phenylindole (DAPI)-staining of intracellular
bacteria (Fig. 6.24). In contrast, AiclllAicll bacteria were incapable of any

intracellular replication (Fig. 6.23-6.25). These data suggest that M. tuberculo
might depend on the GC during infection of its natural host.
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Activated Mac

Fig. 6.21. Replication and survival of icl mutants of M . tuberculosis in murine macrophages.
Non-activated (A,C,E) and IFN-Y-activated (B,D,F) macrophages were infected with M .
tuberculosis wild-type, Aicll, A/c/2 or Aicll/AicU as indicated ( M O I 2:1). At the indicated time
points, cells were lysed (n = 4 wells) and plated to enumerate C F U . Symbols represent means; error
bars indicate S T D E V . Results are representative of two experiments.
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Fig. 6.22. Replication and survival of M . tuberculosis AiclllAicU complemented with p I C L l or
p I C L 2 in murine macrophages. Murine bone marrow-derived macrophages, (A,C,) non-activated
or (B,D) IFN-y-activated were infected with M . tuberculosis wild-type, A/c/7/A/c/2::pICLl or
A/c/i/A/c/2::pICL2 strains as indicated ( M O I 2:1). At indicated time points, cells were lysed (n = 4
wells) and plated for C F U enumeration. Symbols represent means; error bars indicate S T D E V .
Results are representative of two experiments.
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Fig. 6.23. Replication and survival of id M . tuberculosis mutants in h u m a n macrophages. (A-B)
H u m a n blood monocyte-derived macrophages were infected with M . tuberculosis wild-type, Aicll,
AicU, Aicll/AicU or A/c///A/c/2::pICLl strains as indicated ( M O I 1:1). At indicated time points,
cells were lysed (n = 4 wells) and plated to enumerate C F U . Symbols represent means; error bars
indicate S T D E V . Results are representative of two experiments.
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Fig. 6.24. M . tuberculosis id mutants in h u m a n macrophages . (A-D) H u m a n blood monocytederived macrophages seeded on round cover slips were infected with M . tuberculosis (Erdman) (A)
wild-type, (B) Aicll, (C) A/c/2, (D) AiclllAicU; ( M O I 1:1). At 6 days post-infection, bacteria were
fixed and stained with DAPI. Results are representative of two experiments.
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Together, these observations suggest that fatty acids might be the principle carbon
source used by mycobacteria to grow and survive intracellularly.

6.13. The ICL inhibitor 3-nitropropionate blocks replication of M.
tuberculosis on fatty acids and in macrophages

Our demonstration that ICL activity is essential for replication and survival of

tuberculosis in vivo suggested that chemical inhibition of ICL1 and ICL2 might b

an effective therapeutic strategy. We therefore tested the ability of the protot
ICL inhibitor 3-nitropropionate (3-NP) (Schloss & Cleland, 1982; Honer zu
Bentrup et ah, 1999; Sharma et ah, 2000) to block growth of M. tuberculosis in

media containing specific carbon substrates (Fig. 6.25) and in macrophages (Fig.
6.26).
Growth of M. tuberculosis on glycerol (Fig. 6.25A) or glucose (Fig. 6.25B)
was only slightly affected by the addition of 0.1 mM 3-NP, comparable to the

slightly reduced growth kinetics of the AiclllAicll strain under these condition

In contrast, 3-NP prevented growth of M. tuberculosis on fatty acids (Fig. 6.25C
F). When M. tuberculosis was grown in murine macrophages (Fig. 6.26), addition

of 3-NP resulted in inhibition of intracellular replication (58-fold reduction i
CFU at day 7) (Fig. 6.26B), comparable to the growth inhibition resulting from
deletion of icll and icll (54-fold reduction in CFU at day 7) (Fig. 6.26A).
Inhibition of mycobacterial growth in macrophages by 3-NP was dose-dependent

185

Fig. 6.25. Chemical inhibition of I C L blocks growth of M . tuberculosis on fatty acids. Wild-type
M . tuberculosis (Erdman) bacteria were cultured in liquid media containing (0.1% w/v) (A) glycerol;
(B) glucose; (C) propionate (C3FA); (D) polyoxyethylene sorbitan mono-laurate (C12FA); (E)
polyoxyethylene sorbitan mono-palmitate (C16FA); (F) polyoxyethylene sorbitan mono-stearate
(C18FA) with (asterisks) or without (filled squares) the ICL inhibitor 3-NP (0.1 m M ) . Growth was
monitored by measuring OD600 n m at the indicated time points. Wild-type bacteria: squares;
ICLl/ICL2-deficient bacteria: diamonds; ICLl/ICL2-deficient bacteria complemented with episomal
plasmid carrying ICL1: asterisks. Results are representative of three experiments.
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Fig. 6.26. Chemical inhibition of I C L blocks intracellular growth of M . tuberculosis in
macrophages. Growth in murine bone marrow-derived macrophages ( A - C ) and in h u m a n blood
monocyte-derived macrophages (D). Macrophages were infected with wild-type (squares) without
(filled), with (empty) 3-NP, or AiclllAicU mutant M . tuberculosis (diamonds) After 4 hr, cells were
washed to remove non-cell-associated bacteria and incubated in fresh m e d i u m with or without 3-NP
(numbers in parentheses indicate m M concentrations). A t the indicated time points cells were lysed
(n = 4 wells) and plated to enumerate C F U . Symbols represent means; error bars indicate S T D E V .
Results are representative of two experiments.
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(Fig. 6.26C).

Growth of M . tuberculosis in h u m a n macrophages was also

inhibited by 3-NP in a dose-dependent manner (Fig. 6.26D), although inhibition
was somewhat less effective in human as compared to murine macrophages,
perhaps due to differences in the uptake or metabolism of the compound.
Consistent with our interpretation that growth inhibition by 3-NP was due

to inhibition of ICL per se, bacteria that over-expressed ICL1 from a plasmid (~
fold higher expression under in v/fro-inducing growth conditions) were less
sensitive to growth inhibition by 3-NP than wild-type bacteria in vitro (Fig.
6.27A&B) and ex-vivo during growth in murine macrophages (Fig. 6.27C). These

results provide a proof of concept for the potential development of ICL inhibito
as antimycobacterial drugs.
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Fig. 6.27. M . tuberculosis strain over-expressing I C L is resistant to growth inhibition by 3nitropropionate. M . tuberculosis (A) wild-type or (B) ICL 1-over-expressing bacteria were grown
in liquid media containing (0.1% w/v) propionate (C3FA) in the presence of increasing
concentrations of 3-NP (as indicated, numbers in m M ) . Growth was monitored by measuring ODfinn
n m at the indicated time points. (C) Bone marrow-derived mouse macrophages were infected with
M . tuberculosis wild-type without (filled squares) or with (empty squares) 3-NP (10 m M ) or with an
ICL 1-over-expressing strain without (x) or with (*) 3-NP (10 m M ) .
( A & B ) results are
representative of two experiments. (C) results of one experiment.
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A link b e t w e e n the I m m u n e R e s p o n s e , Bacterial M e t a b o l i s m , a n d

Persistence of M. tuberculosis in the Host

INTRODUCTION

The immune system has evolved a number of strategies to curtail the replication
and survival of intracellular pathogens. One important strategy involves a

remodeling of the infected area so as to isolate it from healthy tissue as it oc
during granuloma formation. As this occurs, the host cells that harbor the

infecting bacteria are also altered (activated) or even killed in an effort to l
growth of the bacteria within them. Activation of effector mechanisms within
cells involves the production of noxious molecules such as reactive oxygen and

nitrogen intermediates (ROI and RNI), which are thought to directly block or kil
the infecting bacteria.
In dealing with M. tuberculosis, our immune system engages a number of
mechanisms of defense (Flynn and Chan, 2001; Nathan & Ehrt, 2003;
MacMicking 2005). In addition to the production of ROI and RNI, during
activation of infected cells other changes in the chemical composition of the
intracellular space the pathogen inhabits take place. Macrophage activation via
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interferon g a m m a

(IFN-y) leads to increased phagolysosomal

fusion

and

acidification, which at least in part is mediated by IFN-y-induced GTPase LRG47
(MacMicking et ah, 2003; MacMicking, 2005). Although some evidence
indicates that the mycobacterial vacuole in macrophages is devoid of certain
amino acids (Smith et ah, 2001; Parish & Stoker, 2002), and limiting in some
essential elements such as iron and magnesium (Buchmeier et ah, 2000;
Rodriguez & Smith, 2003), little is known about the carbon substrate vacuolar
contents or how the concentrations of any of these elements or carbon substrates
might be influenced by immune-mediated activation of the macrophage.
We showed previously that M. tuberculosis required ICL to grow and
survive in mice from the onset of the infection, suggesting that the ability to

metabolize C2 substrates during infection is essential for this pathogen. Our da
also showed that either of the two isoenzymes could provide enough activity for
growth and survival during the acute phase of the infection (~wk 0-2). However,
during the persistent phase of the infection, Aicll mutant bacteria were unable
maintain wild-type levels of bacterial loads in the lung, while A/c/2 mutant
bacteria behaved like wild-type (Chapter 6; McKinney et ah, 2000; Munoz-Elias
& McKinney, 2005). Thus, the functional overlap between the two homologs is
only partial: loss of icll is fully compensated by icll during both acute and

persistent phases of the infection, while loss of icll is only fully compensated
icll during the acute phase of the infection.
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The fact that the in vivo phenotype of the A/c/7 mutant coincided with the
time at which acquired immunity to M. tuberculosis normally emerges in the
mouse model of tuberculosis suggested a causal link. Can acquired immunity
bring about changes in the infection milieu that prompt M. tuberculosis to rely

ICL to a greater degree during the persistent phase of the infection than during

acute phase? To shed light on this question, we carried out a series of experime

analyzing the ability of ICL 1-deficient M. tuberculosis to grow in mice deficie
in several known anti-tubercular pathways (Flynn & Chan, 2001; North & Jung,
2004; MacMicking, 2005).
Here we show that the host immune response is largely responsible for the

attenuation phenotype of ICL 1-deficient bacteria during the chronic phase of th
infection in immune-competent mice. While T cells, IFN-y, and TNF-a played a

role in bringing about this phenotype, the downstream effectors inducible nitric
oxide (NOS2) and LRG47 were only partially involved, and phagocyte oxidase
(PHOX) was completely dispensable. Our results suggest that in an immunecompetent host, the emergence of acquired immunity might cause M. tuberculosis
to increase its reliance on the GC, implicating carbon restriction as an
antimycobacterial mechanism specific to persistence.

RESULTS

7.1. icll -deficient M. tuberculosis regains virulence in T cell-deficient mice
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The adaptive i m m u n e response to M . tuberculosis infection is largely mediated by

antigen-specific CD4+ and CD8+ T cells, which exert their protective effects via
secretion of the macrophage-activating cytokine IFN-y (Flynn & Chan, 2001;
North & Jung, 2004). Thus, we started evaluating our hypothesis by testing the

ability of Aicll bacteria to grow in Rag 1-deficient mice (Mombaerts et ah, 1992)
which were expected to be highly susceptible to M. tuberculosis infection.
The attenuation of the Aicll mutant seen in wild-type mice was largely

reversed in Ragl"7" mice. Aicll mutant bacteria replicated similarly to wild-type
bacteria, and were almost as virulent (Fig. 7.1) (mean time-to-death for Ragl"7"
mice infected with Aicll mutant and wild-type bacteria were 34 and 19 days,

respectively). Thus, the persistence-specific attenuation of Aicll mutant bacteri
appears to be driven by an interaction with components of the host's acquired
immune response.

7.2. IFN-y-dependent mechanisms contribute to killing of icll -deficient
bacteria

Studies using mice deficient in CD4+ and CD8+ T cells have established that the

contribution of CD4+ T cells to the protective immune response to M. tuberculosi
infection is more crucial than that of CD8+ T cells (Caruso et ah, 1999; Serbina
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Fig. 7.1. ICLl-deficient M . tuberculosis regains virulent in T cell-deficient mice. (A-B) Ragl"'~
mice are highly susceptible to M . tuberculosis infection. Wild-type mice (dotted lines, empty
squares) and Ragl"/_ mice (solid lines/filled squares) were infected with M . tuberculosis (Erdman, ~ 5
x IO6 C F U , i.v.) . (A-C). Aicll mutant reverts to virulence in Ragl"A mice. Ragl"A mice were
infected with wild-type (solid lines/filled squares) or Aicll mutant bacteria (solid lines/filled circles).
Bacteria in the (A) lung and (B) spleen were enumerated by plating for C F U at indicated time-points.
Error bars indicate S T D E V (n=4). C ) Survival of Ragl_/" mice infected with wild-type (squares) or
Aicll mutant bacteria (circles) (n=7).
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Flynn, 1999; Serbina et ah, 2001).

C D 4 + T cells contribute to anti-tubercular

immunity largely through the production of IFN-y, which turns on several antimycobacterial defense mechanisms (Flynn & Chan, 2001; North & Jung, 2004;
MacMicking, 2005). Therefore, we next asked whether A/c/7 bacteira could also
"revert" to virulence in mice lacking IFN-y.
Similarly to our observations in Ragl"A mice, A/c/7 bacteria showed a clear
reversal toward virulence in IFN-y7" mice, growing in all organs analyzed

similarly to wild-type bacteria (Fig. 7.2A-C), and killing these mice by -33 days
post infection (Fig. 7.2D). As expected, IFN-y/_ mice infected with wild-type M.
tuberculosis succumbed by -17 days post-infection (Fig. 7.2D).
The reversal of the Aicll mutant we saw in both Ragl"A and IFN-yA (Fig. 7.1&7.2)
was not complete. While wild-type bacteria grew unabated in the organs of both
of these mice, the A/c/7 mutant noticeably slowed down at about 7-10 days post-

infection (Fig. 7.1&7.2). This difference was underscored by the delayed kinetics
with which mice infected with A/c/7 bacteria succumbed to infection compared to
those infected with wild-type bacteria (Fig. 7.1C&7.2D). These observations
suggest that other host factors which are T cell/IFN-y-independent, likely
contribute to the attenuation of A/c/7 M. tuberculosis in an immune-competent
wild-type host.

195

A)

Lung

10

Spleen

B)
10

9

9

8
3 8
LL 7 -I
O
en 6
o
5

LL 7
O
O) 6
o 5
4

4

3
10

15

20

25

30

35

10

15

20

25

30

35

Days

Days

C)

10

Liver

9
Lt 8
O
S)
o

15

20

25

30

35

Days

Fig. 7.2. ICLl-deficient M . tuberculosis regains virulence in IFN-y'" mice. IFN-y"'" mice
(C57B1/6) were infected with M . tuberculosis (Erdman) wild-type (squares) or Aicll (circles)
bacteria (0.5-1 x IO6 C F U , i.v.). Bacteria in the (A) lung, (B) spleen, and (C) liver were enumerated
by plating organ homogenates for C F U at indicated time-points. Error bars indicate S T D E V for each
group (n=4). D ) Survival (n=10).
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7.3. I m m u n e effector mechanisms that contribute to the control of iclldeficient M. tuberculosis

We next turned our attention to effector mechanisms downstream of IFN-y that

could be responsible for the persistence-specific attenuation of ICL 1-deficient
tuberculosis observed in wild-type mice (McKinney et ah, 2000; Munoz-Elias &
McKinney, 2005). IFN-y induces expression of Ca++-independent nitric oxide
synthase (NOS2) through the JAK/STAT pathway (Xie et al, 1992; Nathan &

Xie, 1994; Darnell, 1997). Nitric oxide and other reactive nitrogen intermediates
(RNI) are key components in the host's anti-tubercular arsenal (MacMicking et
al, 1997; Nathan & Shiloh, 2000). To address the contribution of this host
defense pathway to the attenuation of A/c/7 M. tuberculosis, we infected NOS2"7"

mice with wild-type or A/c/7 bacteria and monitored bacterial growth and surviva
in their lungs. Unexpectedly, NOS2"A mice were capable of stabilizing A/c/7
mutant bacterial loads in the lungs at about -106 CFU from day 20-70 post-

infection, only losing control of the infection after -112 days (Fig. 7.3A-C). In
contrast, wild-type bacteria multiplied to about -109 CFU per lung in only -40
days in these mice, in accordance with previous results (MacMicking et al, 1997;
Scanga et al, 2001). Moreover, while NOS2"7" mice infected with A/c/7 mutant
bacteria survived up to - 135 days, those infected with wild-type bacteria
succumbed within -40 days (Fig. 7.3D).
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Fig. 7.3. Nitric oxide synthase contributes to the attenuation of ICLl-deficient M . tuberculosis.
(A-D) NOS2"'" (C57BL/6) mice were infected with M . tuberculosis (Erdman) wild-type or Aicll
(5xl05 C F U , i.v.). Bacteria in the (A) lung, (B) spleen, and (C) liver were enumerated by plating
organ homogenates for C F U at indicated time-points. Error bars indicate S T D E V for each group
(n=4). (D) Survival (n=8).
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The fact that A/c/7 mutant bacteria did revert to some degree in N O S 2 " "

mice - a slight increase in bacterial loads in both lungs and spleens was observ
suggests that NOS2, presumably via RNI production, does contribute to the
phenotype of the A/c/7 mutant during the persistence phase of the infection in
wild-type mice. However, that the A/c/7 mutant's reversal was not nearly as
dramatic as that observed in IFN-y-deficient mice suggests that other IFN-ydependent mechanisms exist that are capable of inhibiting the growth of the
mutant, but do not impair wild-type bacteria to the same degree.
Another IFN-y-dependent mechanism that plays a key role in the control of
M. tuberculosis infection is the LRG47 GTPase-mediated increase in lysosomal

fusion and acidification of the M. tuberculosis vacuole (MacMicking et al, 2003).
When LRG47"7" mice were infected with the A/c/7 mutant, some reversal of the
mutant's persistence defect was observed. However, similarly to NOS2"/_ mice,
LRG47"/_ mice were also capable of controlling the growth of the A/c/7 mutant
and, in fact, did so more efficiently than NOS2"/_ mice (N. Dhar & J.D.
MacMicking, personal communication).
Mice lacking phagocyte oxidase (PHOX) are highly susceptible to

infections by several fungi and bacteria including intracellular Salmonellae spp
(Nathan & Shiloh, 2000). However, M. tuberculosis is relatively resistant to ROI
ex vivo (Manca et ah, 1999), and gp91(PH0X"/") mice control M. tuberculosis
infection as efficiently as their wild-type counterparts (Nathan & Shiloh, 2000;
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et ah, 2004). Nevertheless, w e considered it possible that lower ICL activity in the
ICL 1-deficient strain might interfere with the bacteria's ability to generate
effective defenses against ROI, and make them more susceptible to a hostmediated mechanism to which wild-type bacteria are normally resistant. To test

this hypothesis, we monitored the growth of A/c/7 mutant bacteria in gp91(PH0X/)
mice.
Interestingly, we failed to see any reversal of the A/c/7 mutant's
attenuation, and instead observed a slight increase in its attenuation. PHOX-

deficient mice killed A/c/7 mutant bacteria more efficiently than wild-type mice
(Fig. 7.4A-C). The bacterial requirement for ICL1 in these mice might even

appear earlier on because only 2 wks into the infection, the lung bacterial load
the A/c/7 mutant were about 10X lower than wild-type bacteria (Fig. 7.4A);

further, the A/c/7 mutant only replicated slightly in the spleen (Fig. 7.4B) and

at all in the liver (Fig. 7.4C) during the acute phase. These data argue that the
phenotype of the A/c/7 mutant in wild-type mice is unlikely to be driven by ROI.

7.4. TNF-ocRI-mediated immunity contributes to the attenuation of iclldeficient bacteria

The cytokine tumor necrosis factor alpha (TNF-a) is a major player in the immune
response to M. tuberculosis infection (Flynn et ah, 1995; Adams et ah, 1995;
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Fig. 7.4. Phagocyte oxidase is dispensable for control of ICLl-deficient M. tuberculosis. (A-C)
gp91phox-/- (C57B1/6) mice were infected with M . tuberculosis (Erdman) wild-type or Aicll bacteria
(~5xl05 C F U , i.v.). Bacteria in the (A) lung, (B) spleen, and (C) liver were enumerated by plating
organ homogenates for C F U at indicated time-points. Error bars indicate S T D E V for each group
(n=4).
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Flynn &

Chan, 2001).

Together with IFN-y, T N F - a synergistically activates

macrophages inducing production of higher levels of RNI and ROI, which results
in higher anti-mycobactericidal activity (Flesch & Kaufman, 1990; Chan et ah,
1992; Flynn & Chan, 2001). However, TNF-a exerts its antimycobacterial effects
through both iNOS-dependent and independent mechanisms (Flynn et ah, 1995;
Adams et ah, 1995; Bean et ah, 1999; Ehlers et ah, 1999; Bekker et ah, 2001).
Since we had found that NOS2 and LRG47 appeared to be only partially

responsible for the attenuation of the A/c/7 mutant, we next asked whether TNF-a
mediated mechanisms might be involved.
To this end, we evaluated the ability of the A/c/7 mutant to grow in mice
lacking TNF-aRI. Signaling through this receptor is thought to mediate most of
the anti-tubercular effects attributed to this cytokine (Algood et ah, 2003).
Surprisingly, we found that the attenuation of A/c/7 mutant bacteria was almost
completely reversed in these mice (Fig. 7.5A-C). Growth of the A/c/7 mutant was

essentially indistinguishable from that of wild-type bacteria, and only a slight
delay in death in the mice infected with the A/c/7 mutant compared to wild-type
bacteria was observed (Fig. 7.5D). This experiment was carried out with slightly
higher dose of bacteria than previous ones (-2-3 x IO6 CFU/mouse versus - 5 to

10 x 105 CFU/mouse by i.v.), thus it is possible that the high number of bacteria
overwhelmed the immune response and prevented discerning any residual
attenuation of the A/c/7 mutant in the experiment shown in Fig. 7.5. In fact, in
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Spleen

Fig. 7.5. TNF-ocRI-deficient mice fail to control the growth of ICLl-deficient M . tuberculosis.
(A-D) TNF-aRI(p55"'") (C57BL/6) mice were infected with M . tuberculosis (Erdman) wild-type or
Aicll (~2xl06 C F U , i.v.). Bacteria in the (A) lung, (B) spleen, (C) liver were enumerated by plating
organ homogenates for C F U at indicated time-points. Error bars indicate S T D E V for each group
(n=4). (D) Survival (n=10).
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second experiment in which bacteria were administered by aerosol (-100 C F U ) ,
the reversal of the phenotype of the A/c/7 mutant was less dramatic (not shown)
and was more reminiscent of the pattern of growth we saw in IFN-y-deficient mice
(Fig. 7.2 & Dahr & MacMicking, personal communication). Nonetheless, these
data together suggest that TNF-a is a major factor contributing to the immune

response that causes M. tuberculosis to rely on ICL 1-mediated metabolism during
infection.
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Assessing the Potential of Inhibiting I C L 1 in E n h a n c i n g

Chemotherapy of Tuberculosis in Mice

INTRODUCTION

During the persistent phase of the infection in the mouse model of chronic

tuberculosis (TB) bacilli are thought to undergo limited replication (Rees and H

1961; Munoz-Elias et ah, 2005; Chapter 5). Not surprisingly, drugs like isoniazi

(INH) that preferentially kill replicating bacteria are relatively less efficien

administered to infected mice late rather than early in the infection (McCune et
1956). Nonetheless, even if M. tuberculosis is only replicating slowly during

infection, it must maintain some metabolic activity in order to support basic ce

functions, and to counteract the constant onslaught of host immune effectors. Th
type of metabolism characterizing M. tuberculosis during persistence might be

different from that in periods of rapid bacterial growth, such as during the acu
phase of the infection.
Largely based on the fact that antibiotics have dramatically different antitubercular effects depending on when during the infection and in what
combination they are given when treating TB, it has been proposed that the
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physiology/metabolism of the tubercle bacillus in the lung might be radically
different from that of bacteria growing in vitro and that different populations

bacteria might exist, which differ metabolically/physiologically from each other
well (Mitchison, 1979, 1980). These phenotypic changes might contribute to the
ability of drug-susceptible bacteria to persist in vivo despite adequate
chemotherapy, a phenomenon known as in vivo drug tolerance and a major
obstacle to the eradication of TB (McDermott, 1958).
Based on our finding that ICL 1-deficient bacteria are specifically attenuated
during persistence in immuno-competent mice (McKinney et ah, 2000; Chapters
6&7), and that expression of /c/7 is highly induced throughout the infection in
mouse lungs (Timm et ah, 2003; Fig. 6.7), we hypothesized that ICLl-mediated

metabolism might be particularly relevant to the persistent phase of the infecti
Thus, we set out to test the effect that lack of ICL1 alone would have on the
treatment of chronically infected mice, and on the ability of ICL 1-deficient

bacteria to reactivate from "latency" in a chemotherapy-induced model of latency
in mice.

RESULTS

8.1. A n additive anti-mycobacterial effect between I N H and lack of I C L 1
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The early anti-tubercular bactericidal activity of isoniazid (INH) is attributed to its

efficacy in killing actively multiplying bacilli (McKinney, 2000; Mitchison, 2004
It is thought that INH's initial rate of killing subsequently declines because

residual organisms replicate and metabolize more slowly or differently (Mitchiso
2004; Boshoff & Barry, 2005). Since our results with the A/c/7 mutant suggested
that the GC might be required during both the acute and chronic phases of the
infection, we asked whether treatment of INH and lack of ICL1 alone would
synergize in killing bacteria specifically during the persistent phase of the

infection. This would be akin to assessing the effect that a potential inhibitor
ICL1 would have on TB chemotherapy if co-administered with INH. To this end
we infected mice (C57BL/6) with A/c/7 mutant or wild-type bacteria and

compared the in vivo susceptibility of the two strains to INH treatment. Mice we
inoculated intravenously with wild-type or A/c/7 bacteria and the infection was
allowed to proceed normally for 4 wks (Fig. 8.1). At that point groups of mice
infected with either strain were placed in monotherapy with LNH (25 mg/kg/day)
(Canetti, 1960) for the next 8 wks; every 2 wks, 4 mice from each group (treated
and untreated, infected with either strain) were sacrificed and the numbers of
bacteria in their organs were determined by plating for CFU. As expected, by wk
4 post infection, the counts for the A/c/7 mutant in the lung were already about
fold lower than those of wild-type bacteria and remained between -0.75 and 1
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log10 lower than wild-type throughout the experiment in lungs, spleens, and livers
(Fig. 8.1A&Fig. 8.2A&B).
INH treatment sharply reduced bacterial loads in the lungs (2 log drop/4

wks) (Fig. 8.1 A), spleens and livers (Fig. 8.2A-B) of mice infected with wild-

bacteria during the initial 4 wks of the infection; a similar but more pronounce
drop in the census of the A/c/7 mutant (2.5 log drop/4 wks) was observed during
this period. Interestingly, the killing kinetics over this early period of

chemotherapy indicated an additive bactericidal effect between INH treatment and
ICL1 deficiency (Fig. 8.1 A&B): By the end of the second wk of INH treatment,
99% of A/c/7 bacteria had been killed compared to -90 % of wild-type bacteria.
This enhancement of killing suggests that the eventual use of ICL 1-specific

inhibitors in the treatment of TB might not interfere with the action of bacteri
drugs like INH, an important consideration when evaluating the potential of a

bacterial target for antibiotic development (Mitchison, 1979; 1980; Nathan, 2004)

8.2. Lack of ICL1 does not reduce M. tuberculosis in vivo drug tolerance

That ICL 1-deficiency led to increased susceptibility to killing by INH during t
early phase of chemotherapy was consistent with the idea that ICL-mediated

metabolism is essential for M. tuberculosis throughout the infection (Chapter 6)
However, the increased susceptibility of ICL 1-deficient bacteria to INH we

observed during the first 4 wks of treatment was not seen later on in the infect
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Fig. 8.1. Isoniazid therapy of mice infected with icll -deficient M . tuberculosis.
Widltype (C57BL/6) mice infected with wild-type or Aicll M . tuberculosis (Erdman) (~106 C F U , i.v.).
Beginning on week 4 post infection, mice were treated with I N H (25 mg/kg/day) for 8 weeks. Bacteria
in the (A) lung were enumerated by plating organ homogenates for C F U at indicated time-points. (B)
Data from INH-treated mice from (A) plotted as % survival. Error bars indicate S T D E V for each
group (n=4).
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Liver

Fig. 8.2. Isoniazid therapy of mice infected with icll -deficient M . tuberculosis.
Wild-type (C57BL/6) mice infected with wild-type or Aicll M . tuberculosis (Erdman) (~106 C F U ,
i.v.). Beginning on week 4 post infection, mice were treated with I N H (25 mg/kg/day) for 8 weeks.
Bacteria in the (A) spleen and (B) liver were enumerated by plating organ homogenates for C F U at
indicated time-points. Error bars indicate S T D E V for each group (n=4).
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I N H treatment during wks 4-8 did not further significantly reduce bacterial loads
of either wild-type or ICL 1-deficient bacteria (Fig. 8.1&8.2). Importantly,
bacteria surviving these 8 wks of INH treatment were largely drug susceptible
because only 0.25% of wild-type and no A/c/7 mutant bacteria found in the lungs
after the 8 wks of chemotherapy were resistant to INH (INH, 0.5 [xg/mL; limit of

detection, 1 CFU/lung). Thus, the great majority of these bacteria belonged to th
category McDermott (1958) termed "in vivo drug tolerant."
That the lack of ICL1 did not significantly enhance the ability of INH to

eradicate the bacteria from the organs of mice suggests that if in vivo LNH-tole
bacteria depend on C2-metabolism for persistence, ICL2 is capable of providing
enough ICL activity to the bacteria so that they can persist on C2 substrates.

8.3. A Potential role for ICL1 during reactivation from latency

We next considered the possibility that M. tuberculosis dependence on ICL1
during persistence might pertain to the bacterial population(s) responsible for
latency. Latency in humans is the most common outcome of M. tuberculosis

infection and the result of a partially effective immune response. Since no good
animal model of such scenario exists apart from the monkey (Capuano et ah,
2003; Flynn et ah, 2003), we decided to use a modified version of the "Cornell

model" of drug-induced latency (See Chapter 6) to test the possibility that ICL1

mediated metabolism might be important for the establishment and/or reactivation
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from latency. T o this end w e adapted a recently described aerosol model of drug

induced latency in which mice are treated with INH and rifampin (RIF) starting a

2 wks post-infection and then treated with a NOS2 inhibitor to induce reactivati
(Botha et al, 2002). Since we had observed that IFN-y-dependent/NOS2independent factor(s) could, at least transiently, keep A/c/7 bacteria in check

during the persistent phase of the infection (Chapter 7), we decided to carry ou
the drug-induced latency study in NOS2"7" mice. In preliminary experiments, we

confirmed that A/c/7 bacteria were attenuated during the persistence phase of th

infection compared to wild-type bacteria when given via the respiratory route (F
8.4 C), confirming our previous results via the intravenous route. NOS2"A mice

were infected by aerosol with either wild-type or A/c/7 bacteria (-30 CFU/mouse,
aerosol) and at 2 wks post-infection, a group of mice infected with each strain
put on an 8-wk long INH-RIF combination. Bacterial counts were determined
throughout, at 1-wk intervals during the first 4 wks of treatment, and at 2-wk

intervals from wks 6-10. 8 wks of chemotherapy resulted in drastic reductions in
wild-type and A/c/7 mutant bacterial loads in the lungs (CFU decreased from 106

to - 50 CFU, and in some mice, to zero) (Fig. 8.3). The killing rates of wild-typ

and A/c/7 bacteria during antibiotic treatment phase were indistinguishable. Thi
observation suggests that NOS2 might contribute to the slightly increased early
killing of A/c/7 mutant we had observed before (Fig. 8.1 A & B). However, since
in that experiment only INH was administered, the two experiments cannot be
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Fig. 8.3. Evaluating the role of ICL1 in the drug-induced model of latent tuberculosis in mice
(Modified "Cornell Model"). NOS2"'" (C57BL/6) mice infected by aerosol with wild-type or Aicll
M. tuberculosis (Erdman, -30 CFU/mouse) received isoniazid plus rifampin (25 mg/kg/day, each)
from week 2-10 post infection (drugs were given in drinking water and withdrawn 24 hr before each
time-point). Bacteria in the lungs were enumerated by plating organ homogenates for CFU at
indicated time-points. Error bars indicate STDEV for each group (n=4).
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compared directly.
In the models of drug-induced latency, if one assumes that the bacteria

remaining after treatment are in a state akin to "latency," then the relapse pha
equivalent to reactivation from "latency." If ICLl-mediated metabolism were

important for the survival of bacteria in this state "latent" state, the A/c/7 m

would be expected to survive less well, perhaps be incapable of reactivating fro

such state. As expected based on previous reports (Botha et ah, 2002; Flynn et ah
1998; Scanga et ah, 1999), NOS2-deficiency hasten the kinetics of reactivation

significantly. Only 4 wks after drug withdrawal, wild-type bacterial numbers had
bounced back one thousand fold and by 8 wks had climbed to about IO5 CFU per

lung (Fig. 8.3). Interestingly, growth of wild-type bacteria during this reactiv

phase was clearly slower than earlier in the acute phase of the infection. Durin

similar time interval in NOS2"/_ mice, wild-type bacterial loads increased from -

to about IO9 CFU per lung, which killed the mice within 9 wks of infection (Fig.
8.4 A&B). These observations suggest the existence of NOS2-independent
mechanism(s) that may contribute to the control of M. tuberculosis during
persistent infection and that perhaps together with NOS2 play a role in
maintaining latency, as proposed before (Flynn et ah, 1998).
During this initial 8 wks after drug withdrawal, ICL 1-deficient bacteria
reactivated with indistinguishable kinetics from wild-type (Fig. 8.3).
Nevertheless, over the ensuing 8 wks (wks 18-26 post infection), while wild-type
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Fig. 8.4. Comparison of growth of M. tuberculosis ic/7-deficient mutant in wild-type and NOS2"
'• mice. (A&B) NOS2"'~ and (C) wildtype (C57BL/6) mice were infected by aerosol with wild-type
(squares) or Aicll (circles) M. tuberculosis (Erdman, -30 CFU/mouse). Bacteria in the lungs were
enumerated by plating organ homogenates for C F U at indicated time-points. Error bars indicate
S T D E V for each group (n=4). (B) Survival of NOS2"'" mice infected with wild-type or Aicll mutant
(n=8).
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bacteria continued to grow, reaching between 107-108 C F U per lung, A/c/7 mutant

bacteria hovered at around IO5 CFU per lung (Fig. 8.3). In addition, reactivated
wild-type bacteria killed infected mice between wk 30-34 post-infection, while

A/c/7 mutant bacteria allowed much longer survival (mice started to die at 38 wk
post-infection and some mice survived up to 54 wks post-infection) (not shown).
Bacterial CFU during the survival part of the experiment were not determined.
These data suggest that NOS2-independent antimycobacterial mechanism(s) exist

that can more effectively control ICL 1-deficient bacteria compared to wild-type

and these might be important during reactivation from "latency." It is unclear i
this mechanism(s) is the same that transiently controlled the growth of A/c/7
mutant bacteria in the standard mouse model of chronic TB also using NOS2deficient mice (Fig. 8.4A; see also Chapter 7).
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C H A P T E R

9

T h e R o l e of the Glyoxylate C y c l e in the G r o w t h of M y c o b a c t e r i a

on Fatty Acids & Carbohydrates

INTRODUCTION

Previously, we reported that AiclllAicll M. tuberculosis bacteria are unable to
replicate in vivo and are rapidly cleared from the lungs of mice (Chapter 6;
Munoz-Elias & McKinney, 2005). As expected based on what is known about the
canonical role of the GC in carbon metabolism, AiclllAicll bacteria were unable

to grow on C2 substrates, but unexpectedly, they were also incapable of growth o

propionate and other C3FAs. (3-oxidation of odd-chain fatty acids generates both

acetyl-CoA (C2) and propionyl-CoA (C3); the latter can be metabolized via one of
several possible oxidative pathways (Halarnkar & Blomquist, 1989). Biochemical

and functional genetic evidence indicates that several bacteria including E. col
(Textor et ah, 1997), S. typhimurium (Horswill & Escalante-Semerena, 1997;
1999) and C. glutamicum (Claes et ah, 2002), catabolize propionate via the
methylcitrate cycle (MCC), whose role in C3 substrate catabolism was discovered
in fungi three decades ago (Tabuchi & Uchiyama, 1975) (Chapter 3).
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The M . tuberculosis genome has homologs of methylcitrate synthase
(prpC) and methylcitrate dehydratase (prpD), while methylisocitrate lyase (MICL,
prpB), which catalyzes the breakdown of methylisocitrate into pyruvate and
succinate, is apparently missing. However, ICLs show limited homology to
MICLs and can have weak MICL activity, i.e. use methylcitrate as a substrate

(Luttik et ah, 2000), while MICLs show negligible activity on isocitrate (Brock e

ah, 2001). These observations led us to consider the possibility that ICL1, ICL2,
or both might substitute for MICL in the MCC of mycobacteria, thus explaining
the inability of the Aiclllicll M. tuberculosis mutant to grow on C3 substrates
(Chapter 6). Alternatively, the mutant's phenotype could be interpreted to mean
that the GC is required for anaplerosis during growth on C3 substrates, as
apparently is the case in E. coli (Textor et ah, 2003).
To differentiate between these two possibilities, we first turned our

attention to the fast-growing avirulent saprophyte M. smegmatis, which has genes
putatively encoding both, an intact GC (/c/7, icll, glcB), and an intact MCC,
including all three prp genes in an operon (prpDBC). Here, we report the
generation and characterization of M. smegmatis Aicll, Aicll, and AiclllAicll
mutant strains. In parallel studies, we have directly studied the contributions
the prp genes to M. smegmatis (A. Upton, personal communication) and M.
tuberculosis C3 metabolism and pathogenesis (Chapter 6).

RESULTS
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9.1. Cloning and disruption of glyoxylate cycle genes in M . smegmatis

By performing BLAST database searches of the unfinished genome sequence of
M. smegmatis (tigr.org) with the amino acid sequences of M. tuberculosis ICL1,
ICL2 and MLS, we identified contigs encompassing /c/7, icll and glcB putative
open reading frames. The predicted /c/7 gene product encodes a 428 amino acid
protein that is 95, 93, 93, 92 and 92 % identical to the predicted sequences of
from M. marinum, M. avium, M. avium paratuberculosis, M. bovis, and M.

tuberculosis, respectively; the predicted product of the icll gene encodes a 769

amino acid product that is 80, 80, 78, 77, 77, and 77 % identical to ICL2 from M.
avium, M. avium paratuberculosis, M. marinum, M. leprae, M. bovis, and M.
tuberculosis, respectively. The amino acid identity between the M. smegmatis
ICL1 and ICL2 isoenzymes is -27% (over the entire length of the protein), which

is similar to that between all mycobacterial ICL1 and ICL2 protein sequences (no
shown).

9.2. Generation of Aicll, Aicll, AiclllAicll M. smegmatis mutants

To assess the function of the id genes in M. smegmatis carbon metabolism, we
constructed in-frame unmarked A/c/7, A/c/2, AiclllAicll deletion mutants. These
were generated by allelic exchanged delivered via suicide plasmids as described
(Pavelka & Jabcobs, 1999); see materials and methods for details. The A/c/7
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mutant was generated and kindly provided by L. Merkov.

All chromosomal

disruptions were confirmed by S. blot analysis (not shown).

9.3. Carbon utilization of Aicll, Aicll, AiclllAicll M. smegmatis mutants

Disruption of either /c/7 or icll singly or jointly did not affect the ability o
smegmatis to grow axenically in standard 7H9 broth, 7H10 plates (not shown) or
minimal M9 liquid media supplemented with either glycerol (not shown) or
glucose (Fig. 9.1A,D) as sole carbon source. As expected, AiclllAicll M.
smegmatis bacteria did not grow on even-chain (C2) fatty acids (Fig. 9.1B-D). In
contrast to the single A/c/2 mutant, which grew similarly to wild-type on all C2

fatty acids tested, the single A/c/7 mutant did not (Fig. 9.1B&C). Previously, we
had made a similar observation using a chemical putative /c/7 mutant (McKinney
et ah, 2000) that has been confirmed to have a point mutation in /c/7 (A. Upton,

personal communication). The finding that in M. smegmatis deletion of /c/7 alone
abrogated growth on C2 substrates contrasts with our carbon utilization
experiments in M. tuberculosis where deletion of /c/7 alone did not abrogate
growth on C2 substrates (Chapter 6; Munoz-McKinney, 2005).
One advantage of working with M. smegmatis as opposed to the more
fastidious M. tuberculosis is that carbon utilization studies can be done under
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Fig. 9.1. Non-overlapping roles of I C L 1 and I C L 2 in M . smegmatis fatty acid metabolism. (AD ) Bacteria were cultured in minimal M 9 liquid media containing (0.1% w/v): (A) glucose; (B)
acetate (C2FA); (C) butyrate (C4FA). (A-C) Growth was monitored by measuring culture turbidity
(OD600 n m ) at the indicated time points. (D) M . smegmatis wild-type (filled columns) or
AiclllAicU mutant (empty columns) were grown in minimal M 9 liquid media supplemented with
(0.1% w/v) Glu (glucose) or C 2 F A (acetate) for 60h and then plated for C F U . Results are
representative of two experiments.

221

stringent conditions with minimal M 9 salts and single carbon substrates on solid

media. Echoing our results in liquid media, all id mutants grew on glucose plate
(Fig. 9.2). However, while wild-type and /c/2-deficient bacteria grew on all C2

substrates tested, including acetate, butyrate, and palmitate, neither A/c/7 nor
AiclllAicll mutant bacteria were capable of growth on C2 substrates (Fig. 9.2).

9.4. Complementation of M. smegmatis id mutants with M. tuberculosis genes

Both /c/7 and icll genes from M. smegmatis provided separately restored the
ability of the AiclllAicll M. smegmatis mutant to grow on acetate (Fig. 9.3B&C)
and other C2 substrates (not shown). Importantly, either /c/7 or icll from M.

tuberculosis also restored the ability of the M. smegmatis AiclllAicll mutant to
grow on C2 substrates (Fig. 9.3D&E). That the A/c/7/A/c/2 ::pICL2 strain grew on

C2 substrates (Fig. 9.3B&E), while the A/c/7 single mutant did not (Fig. 9.1&9.2)

might be due to higher ICL activity in the complemented strain resulting from th
fact that the episomal plasmid used to complement it was medium-copy.

9.5. Dispensability of ids for odd-chain fatty metabolism in M. smegmatis

The observation that M. tuberculosis AiclllAicll mutant bacteria were unable to

grow on propionate and that ICL activity was highly up-regulated in total protei
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Fig. 9.2. G r o w t h of ic/ mutants of M . smegmatis on minimal solid media. M . smegmatis wildtype, Aicll, AicU or AiclllAicU strains were grown in 7 H 9 broth to late log phase, serially diluted in
P B S and plated on minimal M 9 solid media supplemented with 0.1% (w/v) carbon substrates. N C :
no carbon; Glu: glucose; Ace: acetate; But: butyrate; Pal: methyl-palmitate. Plates were incubated at
37 °C for 5 days. Results are representative of three experiments.
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ZV/c/t/A/c/2: :vector

A/c/7/A/c/2::plCL1
M. smegmatis

A/c/f/A/c/2::plCL2
M. smegmatis

Aicl1/Aicl2:: plCL1
M. tuberculosis

bicMbicI?.: plCL2
M. tuberculosis

Fig. 9.3. M. tuberculosis icll or icl2 genes restore ability to grow on acetate to ICL-deficient M .
smegmatis. M. smegmatis AiclllAicU mutant was transformed with (A) empty vector; (B) icll (M.
smegmatis); (C) icU (M. smegmatis); (D) icll (M. tuberculosis); (E) icU (M. tuberculosis). Bacteria
were grown in 7H9 broth to late log phase and plated on minimal M 9 solid media supplemented with
0.1% (w/v) acetate and incubated at 37 °C for 5 days.
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extracts of M . tuberculosis grown on propionate compared to glucose (Table 6.1),
suggested that ICLs might play a dual role in mycobacterial metabolism, perhaps
functioning as methylisocitrate lyases (MICL) in the methyl citrate cycle (MCC),
in addition to the GC. Alternatively, M. tuberculosis might require ICLs for
growth on C3 substrates because the anaplerotic function of the GC might be
needed under such growth conditions.
Since M. smegmatis has at least one putative prpB gene encoding a
dedicated MICL, AiclllAicll M. smegmatis mutants should only be impaired for
growth on C3 substrates if the GC is required for C3 metabolism. Thus, we tested
the ability of the different M. smegmatis id mutants to grow on C3 substrates as
sole carbon sources. Wild-type M. smegmatis grew very efficiently on the C3

fatty acid propionate. In sharp contrast to our findings with M. tuberculosis, i
genes appeared completely dispensable for growth of M. smegmatis on C3
substrates. Wild-type, A/c/7, A/c/2 and AiclllAicll M. smegmatis mutants grew
indistinguishably from each other in glucose (Fig. 9.4A), propionate (Fig. 9.4B)
valerate (Fig. 9.4C) liquid media, or propionate plates (Fig. 9.4D).
These observations suggest that if the MCC is required for C3 utilization by
M. smegmatis, MICL encoded by prpB is probably sufficient for catalyzing this
step of the pathway. They could also mean that the GC is not required for C3
metabolism in mycobacteria, and that replenishment of TCA cycle intermediates

during growth on C3 substrates likely takes place via conversion of pyruvate, th
product of the MCC, to oxaloacetate by pyruvate carboxylase (PCA). This
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Fig. 9.4. id genes are dispensable for odd-chain fatty acid metabolism in M . smegmatis. (A-C)
Bacteria were cultured in minimal M 9 liquid media containing (0.1% w/v): (A) glucose; (B)
propionate (C3FA); (C) valerate (C5FA). Growth was monitored by measuring culture turbidity
(OD600nm) at the indicated time points. (D). M . smegmatis wild-type, Aicll, AicU or AiclllAicU
strains were grown in 7 H 9 broth to late log phase and plated on minimal M 9 solid media
supplemented with (0.1% w/v) propionate (C3FA). Plates were incubated at 37 °C for 5 days.
Results are representative of three experiments.
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suggestion is further supported by the finding that a mutant of glcB, encoding
malate synthase (second step of the GC), grew indistinguishably from M.
smegmatis wild-type on C3 substrates (L. Merkov, personal communication).

9.6. ICL activity during growth on C2/C3 substrates

In M. tuberculosis, id and icll axe separately dispensable but jointly required

growth on C2 substrates (Chapter 6). Interestingly, while M. tuberculosis extrac

from A/c/2 mutant bacteria had ICL activity levels that were comparable or highe
than those from wild-type, those from A/c/7 bacteria had only very low basal
levels of activity (Table 6.1). To study the regulation of ICLs in M. smegmatis,
we grew the different id mutants on different C2 and C3 substrates to late-log

phase and prepared cell-free extracts for analysis of ICL activity. Extracts fro

wild-type M. smegmatis grown on glucose had considerable levels of ICL activity,

which increased about 5 fold when the bacteria were grown in glucose plus acetat
(Table 9.1). Extracts from dextrose-grown A/c/7 mutant had about 14% of the
activity of extracts from glucose-grown wild-type cells. However, extracts from
glucose/acetate-grown A/c/7 mutant had almost no activity. Interestingly, and

reminiscent of our observations in M. tuberculosis, all extracts prepared from t
A/c/2 mutant had ICL levels that were higher (-2X) than those of wild-type. No
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Table 9.1. Isocitrate Lyase Activity of M . smegmatis id mutants
Strain
Wild-type
AiclllAlicll

Glu
17.13
(3.40)
0.071
(0.12)

Glu/Ace

Ace

Pro

But

78.88 (8.79)

39.33
(15.20)

35.99
(4.03)

56.68
(2.73)

0.154(0.24)

ND

0.75

ND

(1.07)

Aicll

2.38 (1.09) 0.94 (0.77)

ND

0.63
(0.49)

ND

Aicll

20.53
(1.29)

64.55
(13.77)

69.07
(7.44)

90.88

128.43
(21.53)

(0.47)

Bacteria were grown in minimal M 9 broth at 37 °C with shaking (100 rpm), and
harvested at late log phase. Carbon substrates (0.1 % w/v, each): Glu = glucose;
A c e = acetate; Pro = propionate; But = butyrate. Data represent the average of 2
independent cultures from which 3 measurements were made. Total protein:
isocitrate stimulated specific activity (nmol/min/mg) using 1 m M isocitrate, 0.1
m M N A D H at 25 °C (Data were kindly provided by A. Upton).

ICL activity was detected in extracts from AiclllAicll bacteria grown on glucose

or glucose plus acetate. Extracts of acetate-, propionate-, or butyrate-grown wil

type M. smegmatis bacteria had 2-3 fold higher levels of ICL activity than extra
from glucose-grown bacteria (Table 9.1).

9.7. A role for the glyoxylate cycle in carbon utilization in mixed substrates

Under standard conditions, E. coli requires the GC only when C2 substrates are
the sole carbon source (Komberg, 1966; Cronan & LaPorte, 1996). However, our

finding that extracts from M. smegmatis grown on a mixture of glucose and acetat
had considerably higher ICL activity than extracts from glucose-grown bacteria,
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and similar observations made in M . avium (Honer zu Bentrup et ah, 1999),
suggest mycobacteria might employ the GC in mixed substrates. Indeed, we
found that M. smegmatis AiclllAicll had a significant lag during growth on 1:1
mixtures of acetate and glucose (not shown). We sought to extent these
observations to M. tuberculosis by assessing the ability of /c/-deficient M.

tuberculosis to grow on mixed carbon substrates. While wild-type M. tuberculosis

grew on C2 substrates alone, glucose alone, or mixtures of the two, unexpectedly,
the AiclllAicll mutant was unable to grow on glucose plus any C2/C3 substrate
tested including acetate (Fig. 9.5A), propionate (Fig. 9.5B), C12FA (Fig. 9.5C),
and C16FA (Fig. 9.5D). These experiments suggest in order to grow on mixed
substrates M. tuberculosis requires ICL. Thus, the GC requirement by M.
tuberculosis during infection might not indicate absolute inaccessibility to
carbohydrates.

9.8. Inhibition of M. tuberculosis ICL1 or ICL2 in whole cell assays

The absence of ICL orthologs in mammals should facilitate the eventual
development of GC inhibitors as drugs for the treatment of TB. Using the ICL
inhibitor 3-nitropropionate (3-NP) (Schloss and Cleland, 1982; Honer zu Bentrup

et ah, 1999; Sharma et ah, 2000), we provided evidence suggesting the feasibility
of blocking ICL1 and ICL2 in M. tuberculosis, and that such inhibition prevented
bacterial growth on fatty acids and in macrophages (Chapter 6). Screening for
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C3FA + Glucose

Fig. 9.5. M . tuberculosis relies on glyoxylate cycle I C L for growth on fatty acid/carbohydrates
mixed substrates. Bacteria were cultured at in liquid media containing (0.1% w/v each): (A)
acetate (C2FA) + glucose; (B) propionate (C3FA) + glucose; (C) polyoxyethylene sorbitan monolaurate + glucose; (D) polyoxyethylene sorbitan mono-palmitate + glucose. Growth was monitored
by measuring culture turbidity ( O D 6 0 0 n m ) at the indicated time points. Results are representative of
two experiments.
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ICL inhibitors would be greatly facilitated if initial testing could be done in M .
smegmatis. Here, we show that AiclllAicll M. smegmatis mutant strains carrying
the heterologous /c/7 or icll M. tuberculosis paralogs can be used for such
purpose. Addition of 3-NP to C2FA, but not to glucose minimal liquid media,

prevented the growth of wild-type M. smegmatis, as well as that of AiclllAicll M.
smegmatis carrying either /c/7 or icll genes from M. tuberculosis (Fig. 9.6).
Similarly, addition of 3-NP to M9 plates abrogated bacterial growth on C2FA but
not on glucose (Fig. 9.6).
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Fig. 9.6. Whole cell screening assay for dual inhibitors of M . tuberculosis ICL1 and ICL2
isoenzymes. (A-D) ICL inhibitor 3-nitropropionate (3-NP) (empty symbols) inhibits growth of M .
smegmatis (A) wild-type, (B) Aicll A£c/2.vpICLl (M. tuberculosis), C ) Aicll/AicU::plCL2 (M.
tuberculosis) on acetate (circles) but not on glucose (squares), (D) M. smegmatis AiclllAicU mutant.
Bacteria were cultured in minimal M 9 broth supplemented with (0.1% w/v) glucose (Glu) (filled
squares), glucose plus 3-NP (empty squares), C 2 F A (acetate) (filled circles) or C 2 F A (acetate) plus
3-NP (empty circles). Growth was monitored by measuring OD600 n m at the indicated time points
(E-J) Plate assay. Growth inhibition of M . smegmatis ( E & H ) wild-type, (F&I) Aicll /Aicl2::pICLl
(M. tuberculosis) (G&J) Aicll /Aicl2::pICL2 (M. tuberculosis) by 3-NP on (0.1% w/v) (E-G) acetate
but not on (H-J) dextrose, as carbon source in minimal M 9 plates. 3-NP was included in the
medium at 5 m M . Results are representative of three experiments.
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C H A P T E R

10

T h e M e t h y l Citrate C y c l e in M . tuberculosis

INTRODUCTION

In the foregoing chapter (Chapter 9), we presented evidence that ICL1 and ICL2
are dispensable for growth of M. smegmatis on C3 substrates, ruling out an
essential role for ICLs in the methylcitrate cycle (MCC) in this species (Fig.
10.1). Since M. smegmatis has a prpB homolog that putatively encodes a
canonical methylisocitrate lyase (MICL), these findings are not surprising.

Furthermore, since glcB, encoding malate synthase, is also dispensable for growth
on C3 substrates (L. Merkov, personal communication), the GC is apparently not
required for M. smegmatis growth under these conditions either. In contrast, M.
tuberculosis id genes are jointly required for both C2FA and C3FA metabolism
(Chapter 6). The M. tuberculosis genome has homologs of methylcitrate synthase
(prpC) and methylcitrate dehydratase (prpD), while methylisocitrate lyase (MICL,
prpB), which catalyzes the breakdown of methylisocitrate into pyruvate and
succinate, is apparently missing. However, ICLs show limited homology to
MICLs and can have weak MICL activity, i.e. use methylisocitrate as a substrate

(Luttik et ah, 2000), while MICLs show negligible activity on isocitrate (Brock e
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Fig. 10.1. Methyl citrate cycle ( M C C ) in M . tuberculosis. Even- and odd-chain fatty acids are
degraded to acetyl-CoA (C2) and propionyl-CoA (C3), respectively, via the beta-oxidation pathway.
Propionyl-CoA can be metabolized through the methylcitrate cycle. The glyoxylate cycle permits the
net synthesis of C 4 intermediates, which can serve directly as biosynthetic precursors or can be
further metabolized to C 3 precursors. Glyoxylate cycle specific enzymes: isocitrate lyase 1 (ICL1),
isocitrate lyase 2 (ICL2) and malate synthase (MLS). ICL1 and ICL2 could function as
methylisocitrate lyases in the methylcitrate cycle together with the methylcitrate cycle-specific
enzymes 2-methylcitrate synthase ( G L T A 1 ) and 2-methylcitrate dehydratase ( M C D ) . Glyoxylate
cycle enzymes in c o m m o n with the T C A cycle: Citrate synthase I ( G L T A 2 ) ; citrate synthase II
(CITA), aconitase ( A C N ) , succinate dehydrogenase (SDH), fumarate ( F U M ) , malate dehydrogenase
( M D H ) and malate:quinone oxidoreductase ( M Q O ) . Phosphoenol pyruvate (PEP) can be produced
by decarboxylation of oxaloacetate by P E P carboxykinase (PCK). Pyruvate can be generated from
malate by malic enzyme ( M E Z ) , from P E P by pyruvate kinase (PYK), or through the M C C by the
action of ICL1/ICL2 on 2-methylisocitrate producing succinate and pyruvate. Gene names are in
italics.
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ah, 2001). These observations led us to consider the possibility that ICL1, ICL2,
or both might substitute for MICL in the MCC of mycobacteria, thus explaining
the inability of the Aiclllicll M. tuberculosis mutant to grow on C3 substrates
(Chapter 6). Alternatively, the mutant's phenotype could be interpreted to mean
that the GC is required for anaplerosis during growth on C3 substrates, as
apparently is the case in E. coli and Ralstonia (Textor et ah, 1997; Wang et ah,
2003a).
Here we present evidence indicating that ICLs are induced during growth

on propionate and are bifunctional enzymes that can use both isocitrate (ICA) an
methylisocitrate MICA) as substrates. The ability of ICL1 to function as a MICL
was superior to that of ICL2, since even overexpression of ICL2 resulted in only
low levels of MICL activity. Furthermore, ICLs appeared to function together
with methylcitrate synthase and methylcitrate dehydratase encoded by prpC and
prpD M. tuberculosis genes, respectively, to form a functional MCC, which we is
required by M. tuberculosis to grow on odd chain fatty acids in vitro. A
requirement for the MCC by M. tuberculosis during infection was suggested by
the inability of a AprpDC mutant to grow in murine macrophages, but was not
supported by in vivo evidence indicating the dispensability of these genes for

growth and persistence in mice. The work presented in this chapter is the result
collaborative work with A. Upton in the laboratory.

RESULTS
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10.1. id genes of M . tuberculosis encode isocitrate/methylisocitrate lyases

To test the hypothesis that one or both of the id genes in M. tuberculosis encode
a bifunctional ICL/MICL, we cultured M. tuberculosis (Erdman) wild-type and
AiclllAicll bacteria in defined media containing glucose or propionate and
measured ICL and MICL activity in cell-free extracts. MICA was not available
commercially and was chemically synthesized starting with mesaconic acid by
modifying previously published methods (Brock et ah, 2001; Plaut et ah, 1975);
this was done in collaboration with J. Cherian and T. Kapoor at Rockefeller
University (see materials & methods).
Extracts prepared from wild-type M. tuberculosis demonstrated ICL and
MICL activity, both of which where much higher in extracts from bacterial
cultures grown on propionate (Fig. 10.2A) compared to glucose (not shown).
Extracts from wild-type bacteria grown on propionate had very high activity on

ICA and high, though significantly lower (3 fold), activity on MICA (Fig. 10.2A).
The AiclllAicll mutant grown on glucose had no detectable activity (not shown).
The finding that propionate extracts prepared from the A/c/7 mutant (which,

though impaired, grew sufficiently to allow preparation of cell-free extracts) h
very low levels of activity (Fig. 10.2A&B), while propionate extracts from the
A/c/2 mutant had ICL and MICL levels of activity comparable to those from

236

ICA
MICA
substrate

D)

ICA
MICA
substrate

E)

I icl1-/icl2(PICL1)

ICA
MICA
substrate

I icl1-icl2(PICL2)

2500

ICA

MICA

substrate

ICA
MICA
substrate

Fig. 10.2. I C L a n d M I C L activities of propionate-grown M . tuberculosis cell-free extracts. (AE ) M . tuberculosis (Erdman) bacteria were grown at 37 °C with shaking to late log phase in liquid
media containing ( 0 . 2 % w/v) propionate ( C 3 F A ) . Cell-free extracts were assayed for activity on
isocitrate (ICA) or methylisocitrate ( M I C A ) as indicated. (A) Wild-type, (B) Aicll, ( C ) Aicl2, ( D )
Aicll/AicU transformed with an episomal plasmid carrying icll, (E) Aicll/AicU transformed with an
episomal plasmid carrying icU. Assays were done in triplicates from two set of extracts. Date are
from one experiment.
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wild-type (Fig. 10.2A&C) suggested that ICL2 was not as efficient as ICL1 as a
MICL. In addition, propionate extracts of a strain overexpressing /c/7 from an
episomal multicopy plasmid on an AicllAicll background had markedly higher

levels of expression of both ICL (-6.5 fold) and MICL activity (~9 fold) compare
to wild-type (Fig. 10.2A&D), while overexpression of icll in the same background

resulted in a large increase in ICL actitvity (10 fold higher than in extracts o

A/c/7 mutant) (Fig. 10.2D), but a minimal increase in MICL activity (Fig. 10.2E).
These data indicate that at least in vitro, ICL1 is a bifunctional ICL/MICL

enzyme, and suggest that it might function in the MCC cycle of M. tuberculosis in
that capacity. The ability of ICL2 to function as a MICL is more limited.

10.2. Cloning and disruption of the putatitve methylcitrate cycle genes in M.
tuberculosis

The inability of the AiclllAicll M. tuberculosis mutant to use propionate as
substrate and the lack of MICL and ICL activities in extracts from this strain

(grown on glucose), together with the induction of ICL and MICL activities during
growth on propionate, suggested that M. tuberculosis might require the MCC and
the MICL function encoded by /c/7 and/or icU genes for propionate metabolism.

However, the possibility remained that in M. tuberculosis, unlike in M. smegmatis
the GC was required for anaplerosis during propionate metabolism either via the
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M C C or another pathway, and the inability of the AiclllAicll mutant to grow on

propionate was due to anaplerotic deficiency rather than impairment of propionat
metabolism per se. To distinguish between these scenarios, we constructed a
strain of M. tuberculosis (Erdman) in which the genes unique to the MCC, prpD
and prpC, were deleted. Homologs of prpD and prpC are found together in the M.

tuberculosis genome such that the final codon of prpD overlaps the first of prpC.
Although annotated as a 526 amino acid protein in the genome (H37Rv), ORF
analysis of the prpDC region revealed 3 possible start sites for prpD that would
give rise to proteins of 526, 505 or 502 amino acids in length. The 3 possible
peptides, conceptually translated, were aligned using BLASTP to all PRPD
peptide sequences available in NCBI databases, and the most probable was chosen
based on similarity to enzymes reported to be functional (Horswill & EscalanteSemerena, 1999). This ORF, which encoded the shortest PRPD peptide (502AA),
was defined as the prpD gene sequence for the present study.
M. tuberculosis with an in-frame unmarked deletion in the prpD and prpC
ORFs was generated by homologous recombination such that the wild-type prpDC
locus was replaced with sequence encoding a 9AA peptide. The deletion was
confirmed by PCR analysis and Southern blot (not shown). For complementation
studies of the AprpDC mutant, the strain was transformed with an integrating
plasmid derived from pMV361 (Stover et ah, 1991) carrying a wild-type copy of
the putative prpDC operon.
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10.3. T h e methylcitrate cycle is required for propionate metabolism and
growth of M. tuberculosis on odd-chain fatty acids

Deleting prpDC had no effect on bacterial growth on glucose or glycerol (Fig.
10.3A&B). Unlike the parental strain, the AprpDC mutant was unable to grow

with propionate or any other odd-chain fatty acid given as substrate (Fig. 10.3).
Unlike the AiclllAicll mutant (Chapter 6), the AprpDC mutant exhibited growth

on even chain fatty acids that was comparable to that of the parental strain (Fi
10.3). Complementation of the AprpDC mutant with an integrating plasmid
carrying the wild-type putative prpDC operon largely restored growth on
propionate media. Thus, the prpDC genes and hence the MCC are required

specifically for in vitro growth on odd-chain fatty acids by M. tuberculosis. Th
ability of this mutant to grow using C2 carbon sources indicates that the MCC is
not required for growth on C2 substrates as expected. Together these results
suggest that ICL1 and perhaps ICL2 might function as MICL in the MCC.

10.4. The methylcitrate cycle is required for survival and replication of M.
tuberculosis in resting and activated murine macrophages

We next investigated whether the requirement by M. tuberculosis for the MCC
could be seen at the level of the parasitized macrophage. In marked contrast to
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Fig. 10.3. Indispensable role of prpC and prpD in C3 fatty acid metabolism. (A-G) M.
tuberculosis bacteria were cultured at 37 °C in liquid media containing (0.1% w/v): (A) glycerol; (B)
glucose; (C) acetate (C2FA); (D) propionate (C3FA); (E) butyrate (C4FA); (F) valerate (C5FA);
(G) hexanoate (C6FA). Growth was monitored by measuring culture turbidity (OD60 n m ) at the
indicated time points. Results are representative of two experiments with similar results.
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tuberculosis wild-type bacteria which grew nearly one log over the 7 day time
course of an infection of bone marrow-derived murine macrophages, AprpDC
mutant bacteria were incapable of any growth (Fig. 10.4A). To determine the
impact of host cell activation on the survival of MCC-deficient bacteria,

macrophages were activated with IFN-y (100 U mL") prior and during intracellular

infection. While macrophage activation was bacteriostatic to intracellular wild-

type M. tuberculosis, it was slightly bactericidal to AprpDC bacteria (Fig. 10.4B
Complementation of the AprpDC mutant strain with a copy of wild-type prpDC

genes restored growth in resting macrophages and wild-type levels of survival in
activated macrophages (Fig. 10.4C&D).

10.5. The methylcitrate cycle is dispensable for growth and persistence of M.
tuberculosis in the mouse model of chronic tuberculosis.

Since our data suggested that ICL1 and to a lesser extent ICL2 could function as
MICL, we considered the possibility that the in vivo phenotype of the iclllicll
single A/c/7 mutants could be due to their function as a MICL instead of or in
addition to their role as ICLs. To directly address this question and the
contribution of the MCC to the pathogenesis of M. tuberculosis in vivo, we
evaluated the ability of the AprpDC mutant to grow and persist in mice. Unlike
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Fig. 10.4. Methylcitrate cycle genes prpC and prpD are required for intracellular replication of
M . tuberculosis. (A-D) Murine bone marrow-derived macrophages (A&C) non-activated or (B&D)
rFN-y-activated (100 U/mL) were infected with (A-D) wild-type, AprpD/AprpC, or (C&D)
AprpD/AprpC::PprpDC+ M. tuberculosis (Erdman), (MOI 2:1). Monolayers were incubated at 37 °C
in 5 % C02. At indicated time points, cells were lysed (n = 4 wells) and lysates were plated to
enumerate CFU. Symbols represent means; error bars indicate STDEV. This experiment was done
twice.
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AiclllAicll mutant bacteria which are impaired for growth from the onset of the
infection, or A/c/7 mutant bacteria, which become impaired at around 2-3 wks

post-infection, AprpDC mutant bacteria replicated and persisted indistinguishabl
from wild-type bacteria throughout the infection in both lungs (Fig. 10.5A) and
spleens (Fig. 10.5B), and elicited comparable pathology (Fig. 10.6). Thus, the
requirement for ICL during infection appears to be due to a requirement for a
functional GC rather than a MCC.
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Fig. 10.5. prpC and prpD are dispensable for growth and persistence of M . tuberculosis in
mice. ( A & B ) Wild-type (C57BL/6) mice were infected with wild-type or A p r p D C M . tuberculosis
(Erdman) (-100 C F U , aerosol). Bacteria in the (A) lung and (B) spleen were enumerated by
plating organ homogenates for C F U at indicated time-points. Error bars indicate S T D E V for each
group (n=4). Experiment was done once.
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Fig. 10.6. Lung pathology in mice infected with A p r p D C M . tuberculosis. (A-F) Histopathology
of H & E (haematoxylin-eosin)-stained lungs from C57BL/6 mice infected with M . tuberculosis
(Erdman) (-100 C F U , respiratory route) at 10 weeks post-infection. Bacterial strains: (A-C) wildtype, (D-F) AprpDC. Corresponding CFUshown in Fig. 10.5.
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P A R T III

CHAPTER 11

Discussion

INTRODUCTION

Some of the most devastating diseases known to man, including syphilis,

gonorrhea, typhoid fever, and tuberculosis (TB) are caused by bacteria capable o

persisting in their hosts often for life. To our detriment, we know little about
interactions between hosts and pathogens that allow the establishment of such
persistent infections (Munoz-Elias & McKinney, 2002; Stewart et ah, 2003;
Monack et ah, 2004). Regardless of whether a persistent infection is clinically

active or latent, the establishment of such infection means that the pathogen wi
most likely succeed in being transmitted to a new host, even if it must wait,
sometimes, for a lifetime. Investigation into the nature of bacteria during

infection, including the bacterial characteristic in vivo physiology and elicite
immune responses, and the way pathogens evade and counteract these defenses
successfully, might provide a foundation on which to base efforts toward
developing new drugs and vaccines against these foes.
Persistence of M. tuberculosis in the host is the result of the pathogen's
interaction with a partially effective immune response, i.e., one that controls
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bacterial growth but fails to eradicate the infection (Flynn & Chan, 2001; Nathan
& Ehrt, 2003; North & Jung, 2004). In order to persist, M. tuberculosis must
adapt to environmental conditions that are complex, and at least in the case of

chronic active disease, constantly changing as a result of lesion-specific varyi
degrees of ongoing inflammation, cellular infiltration, tissue destruction, and

further bacterial replication and dissemination (Vandiviere et ah, 1956; Wayne &
Salkin, 1956; Kaplan et ah, 2003). The bacterial factors involved in survival in
vivo have begun to be identified through a combination of reverse genetics
(Glickman & Jacobs, 2001; Gomez & McKinney, 2004; Boshoff & Barry, 2005)
and differential gene expression in macrophages of murine and human origin
(Dubnau & Smith., 2003; Schnappinger et ah, 2003; Voskuil et ah, 2003).
Bacterial gene expression studies of mouse lung-grown bacteria suggest
that the adaptation of M. tuberculosis to the in vivo environment involves the
differential expression of genes responsive to iron limitation, specific carbon
metabolism, and cellular hypoxia (Shi et ah, 2003; Timm et ah, 2003); limited

studies with infected human samples suggest that some of these adaptations might
also occur in the human lung (Timm et ah, 2003).
Despite having preoccupied the mind of early investigators of tuberculosis

during the first half of the 20th century, two major aspects of the in vivo biol
M. tuberculosis are still poorly understood: 1) the replicational status of M.
tuberculosis during active, and latent infection, and 2) the metabolic activity
tuberculosis during growth and survival in the host. The work I have carried out
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over the last few years, and which I have presented in this thesis, was performed
with the intention of shedding some light on these two major issues.

11.1. The replication status of M. tuberculosis in experimentally infected mice

Bacteriologic and pathologic studies of tuberculous human and animal lesions

indicate that M. tuberculosis in the lung resides in different types of lesions,

differ from each other in terms of cellular organization, degree of inflammation
and necrosis, as well as apparent bacterial burden (Lurie & Zappasodi, 1942;
Medlar, 1948; Medlar et ah, 1952; Dannenberg & Rook, 1994a; Kaplan et ah,

2003). The replicational status of the M. tuberculosis in such lesions has not be
determined, but it is thought to vary between active replication and stasis.

Replication is believed to occur on the surface of open cavities and to take pla
intracellularly within macrophages there (Kaplan et ah, 2003), and within the

softened center of liquefied cavities, where bacteria might multiply extracellul
(Lurie, 1964; Dannenberg & Rook, 1994a; Grossett, 2003). In Chapter 5, we
presented data from experiments performed to explore this question in the mouse
model of chronic TB. It has been established that immediately after M.

tuberculosis enters the host, robust bacterial multiplication is necessary to en

the establishment of the infection and the steady plateau of viable bacteria tha

characterizes the persistent phase of the infection in lungs of mice (Orme, 1994)
However, little is known about growth rates during this phase of the infection.
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first suggested by Severs and Y o u m a n s (1956), fluctuations in bacterial viable

populations can be readily measured, but these presumably represent the net resu

of multiplication and destruction by host defenses. In a pioneering work, Rees a

Hart (1961) addressed this question by tallying total bacterial counts determine
by staining bacterial bodies and comparing these to viable counts (CFU). Based
on the finding that total and viable bacterial counts overlapped throughout the

persistent phase of infection in mice, they concluded that persistent bacteria w
not actively replicating, and favored a model of "static" equilibrium. However,

those experiments, the lack of accumulation of bacterial bodies that was observe
may have been due to loss of acid-fast staining of dead bacterial bodies, a
phenomenon that has been reported by other investigators (McCune et ah, 1956;
Middlebrook, 1952). Thus, we revisited this question.
Viable counts (CFU) obtained from mouse lungs at intervals during the
chronic phase of a mouse infection were compared with total counts determined
by quantitative real time PCR. Amplification of chromosome equivalents (CEQ)

was performed directly from infected lungs by adapting a recently developed real
time PCR technique used for the precise molecular quantification of mRNA
(Manganelli et ah, 1999; Timm et ah, 2003). Remarkably, we found that at all
points analyzed (4, 8, 12 and 16 weeks post-infection) CFU and CEQ curves
closely matched each other. If constant bacterial turnover during persistence

occurred, we would have detected the resulting accumulation of bacterial genomes
(CEQ), assuming that the genomes were not removed/degraded soon after the
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bacteria were killed. Since w e did not observe significant build-up of dead bacilli
in any of the chronically infected mouse lungs analyzed, we conclude that most
bacilli in the persistent phase of infection are likely undergoing Utile or no
replication.
The assumption that genomes of killed bacteria are relatively stable was
based on control experiments where genomes from dead bacteria were shown to
linger in infected lungs (Fig. 5.3). INH therapy started at the onset of the
persistence phase (4 weeks post-infection) relatively rapidly reduced viable
bacterial counts (CFU) by ~2 and 4 login by 4 and 8 weeks of treatment,
respectively. In contrast, CEQ did not diminish after 4 weeks of treatment
compared to those in lungs of concomitantly infected but untreated mice, and did
so only slightly after 8 weeks of treatment (Fig. 5.3). The waxy coat of the
tubercle bacillus, made up of unique glycol-lipids (Brennan, 2003), likely
contributes to the permanence of bacterial bodies and their DNA content (de Wit
etal., 1995; Rees and Hart, 1961; Seiler et ah, 2003).
It is possible that killing of bacilli by immune mechanisms as opposed to
drugs as done here, may lead to genome degradation. However, this possibility
could not be tested using the mouse model of chronic TB because the immune

response against M. tuberculosis infection is not bactericidal, but bacteriostat
Also, our results also do not rule out the possibility that the stable number of

viable counts in the lungs of chronically infected mice is due to replication in
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balanced by trafficking of organisms out of the lungs, resulting in failure of both
CFU and CEQ to accumulate over time.
A key question in the context of any persistent infection is the replication
status of the pathogen over time. Dynamic pathogens such as the human
immunodeficiency virus (HIV) and hepatitis C virus (HCV) replicate at very high
rates throughout the course of infection. In persistently HIV- and HCV-infected

individuals a dynamic equilibrium is achieved in which a relatively stable viral
load is maintained by balanced production and immune-mediated destruction of

virions (Pawlotsky, 2004; Simon & Ho, 2003). Viral persistence is also facilitate

by antigenic variation, involving sequential emergence of variants that temporar
escape surveillance by the adaptive immune response. Antigenic variation is an
essential persistence strategy of many slower-replicating pathogens as well,
including parasites and bacteria; well-characterized examples include African
trypanosomes, Plasmodium falciparum and Borrelia spp. These pathogens

display oscillating population kinetics in vivo, representing sequential waves o
antigenic variants that (temporarily) escape destruction by the adaptive immune
response (Deitsch et ah, 1997; Reviewed in Chapter 1).
Although antigenic variation is a common feature of many persistent

pathogens, there is little evidence to support a role for antigenic variation in
tuberculosis persistence in chronically infected individuals (Cole, 2002). We
propose that M. tuberculosis represents a third persistence strategy, where
exponential replication of the organism during the acute phase of infection is
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followed by a relatively static equilibrium, a state of slow- or nonreplicating

persistence, during the chronic phase. The hypothesis that persistent mycobacter

are in a slow- or non-replicating state is consistent with several observations:

the induction of a gene expression program that is characteristic of non-replica
bacilli during the chronic phase of murine infection (Shi et ah, 2003); (ii) the
relatively poor efficacy of drugs that target cell wall synthesis (such as INH)
administered to chronically infected mice as compared to acutely infected mice
(McCune et ah, 1956); (iii) the increased thermal stress resistance of M.
tuberculosis (characteristic of stationary-phase cells) in chronically infected
as compared to acutely infected mice (Wallace, 1961); (iv) the lack of
accumulation of microscopically visible AFB in chronically infected mice (Rees
and Hart, 1961); (v) the lack of accumulation of bacterial chromosomes in
chronically infected mice we described here (Mufioz-Elias et ah, 2005). Kanai

(1966) provided direct proof of the ability of non-replicating M. tuberculosis t

survive for extended periods in vivo by showing that continued administration of
streptomycin was not necessary for persistence of a streptomycin-growth
dependent strain of M. tuberculosis in chronically infected mice.
The ability of M. tuberculosis to persist without replicating does not imply

that bacterial replication is entirely absent in chronically infected individual
animals, nor does it imply that persistent bacteria are metabolically inactive.
Indeed, slow fluctuations in the bacterial load over time, which are typically
observed in chronically infected mice, presumably reflect slow or intermittent
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replication of at least some bacilli (Sever & Youmans, 1957), and the dramatic
increase in bacterial load in late-stage infected mice (Orme, 1988) can only be
explained in terms of bacterial replication. Evidence from the M. marinumleopard frog model also supports the idea that chronic mycobacterial infections
involve some ongoing bacterial cell division (Bouley et ah, 2001). What seems

increasingly likely, however, is that M. tuberculosis persistence in chronically
infected mice does not represent a highly dynamic equilibrium in which rapid

bacterial growth is balanced by equally rapid immune-mediated killing, but rathe
a relatively static equilibrium in which the rate of bacterial cell division is
slow. It is unknown to what extent this conclusion can be extrapolated to humans
with chronic TB or latent TB infection. Studies on TB lesions in humans suggest

that the replicative state of the bacteria vary depending on the histopathologic

characteristics of the individual lesions (Kaplan et ah, 2003; Medlar et ah, 1952
Vandiviere etah, 1956; Wayne & Salkin, 1956).
The replicative status of bacilli during persistent infection has important

implications for the development of more effective interventions against persist
M. tuberculosis infections. Treatment of TB is notoriously difficult and
protracted, requiring a minimum of 6-9 months of multi-drug therapy to prevent
post-therapy relapse (El-Sadr et ah, 2001). Most of the drugs currently used to
treat TB are known to target cellular processes involved in cell growth, such as
cell wall biogenesis and DNA replication; consequently, these drugs are less

effective against bacteria that are not undergoing rapid cell division (McKinney
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2000; Stewart et ah, 2003; Mitchison, 2004; Boshoff and Barry, 2005).
Elucidation of the mechanisms required for persistence of M. tuberculosis in a
slow- or non-replicating state in chronically infected individuals with active
tuberculosis or latent infection might suggest new strategies for targeting
persistent bacteria.

11.2. The Glyoxylate Cycle and the Pathogenesis of M. tuberculosis

All pathogens must acquire nutrients from their hosts in order to replicate and
survive long enough to ensure their transmission to a new host. Most facultative
intracellular bacteria grow in specialized phagosome-derived vacuoles (Sinai &
Joiner, 1997); only a few species can escape the phagosomal compartment and
grow freely in the cytoplasm. It is not clear whether facultative vacuolar
pathogens do not grow in the cytosol simply because they lack the machinery to

break free from their vacuoles. Some evidence suggests that even if they reached
the cytosol, these pathogens would not be able to grow in it readily, suggesting

that the cytosol is not a very permissive compartment for growth and that specia

adaptations are required to occupy this niche. By microinjecting several bacteri
species into the cytosol of host cells, Goetz and colleagues (2001) found that
pathogens that normally reside in a vacuole, e.g., Salmonella, could not freely

replicate in the cytosol, while those that infect the cytosol as part of their n
life cycles such as Shigella or Listeria could. M. marinum, a mycobacterial
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pathogen of fish, apparently can escape the phagosome and m o v e around in the
cytosol, however, it is unclear whether it can replicate in this compartment
(Stamm et ah, 2003).
The high level of specialization required by a pathogen to successfully
inhabit a given niche likely involves mechanisms that allow it to acquire and

metabolize the nutrients available in that environment. With few exceptions, the

substrates pathogens utilize during infection and the mechanisms involved in the
acquisition and assimilation are unknown (Reviewed in Chapter 4).
Carbohydrates comprise the principal carbon source for bacteria occupying
such diverse niches as the intestinal lumen (Peekhaus & Conway, 1998; Chang et
ah, 2004), the cytoplasm of infected host cells (Chico-Calero et ah, 2002), and
perhaps the modified vacuoles within macrophages (Eriksson et ah, 2003). In

contrast, pathogenic mycobacteria isolated from lung tissues preferred to oxidiz
fatty acids rather than carbohydrates (Segal & Bloch, 1956). Of the activities
required for fatty acid catabolism, GC enzymes ICL and MLS were demonstrated

in extracts of both slow and fast growing mycobacteria including M. tuberculosis
and M. leprae (Murthy et ah, 1973; Kannan et ah, 1985; Bharadwaj et al, 1987;
Wheeler & Ratledge, 1988). That these activities were found in in vivo grown

bacteria, as well as upregulated specifically in stationary phase "old" cultures
some of these early investigators to suggest that GC-mediated metabolism might
be the basis of alternate types of metabolism employed by M. tuberculosis to
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persist in the host and to avoid eradication by drugs (Murthy et al, 1973; Kannan
et al, 1985; Bharadwaj et al, 1987; Gupta & Katoch, 1997).
More recently, mycobacterial genes and enzymes involved in fatty acid

utilization including the GC and fatty acid P-oxidation have been shown to be up
regulated during infection of mice (Timm et al, 2003; Dubnau et ah, 2005), and
macrophages of mouse and human origin (Graham & Clark-Curtiss, 1999; Dubnau
& Smith, 2003; Schnappinger et ah, 2003). A central role for fatty acid
metabolism is also suggested by the extensive duplication of genes involved in

lipid breakdown and assimilation in M. tuberculosis, M. bovis and M. leprae (Col
1998; Cole et ah, 2001; Fleischmann et ah, 2002; Gamier et ah, 2003). Induction
of multiple genes encoding analogous functions in P-oxidation (multiple fadDs,
fadBs and fadAs) suggests that these might be involved in the degradation of
different types of C2 substrates, as it occurs in mammalian cells (Kunau et ah,
1995).
The M. tuberculosis genome encodes only two homologous genes encoding

isocitrate lyases which catalyze the first step in the GC required for anapleros
during growth on fatty acid substrates. Previously, we reported that /c/7 is

dispensable for acute-phase growth but essential for persistence at wild-type le
during the chronic phase of infection in M. tuberculosis-infected mice, and
proposed that M. tuberculosis might switch to fatty acid catabolism at the

transition from the acute to the chronic phase of infection (McKinney et ah, 2000
Chapter 4).
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O n the essential role of isocitrate lyase (ICL) in M . tuberculosis in vivo
growth and survival. In Chapter 6, we present evidence that ICL1 and ICL2
provide overlapping and essential roles in metabolism of M. tuberculosis during

infection. Deletion of /c/7 or icll alone did not impair replication in macropha
or in the lungs of mice. In contrast, deletion of both /c/7 and icll abrogated
growth, and led to rapid clearance of the AiclllAicll mutant bacteria from the
lungs of mice. Our new findings that ICL activity is required from the onset of

infection indicate that ICL-mediated metabolism and fatty acid catabolism have a
more fundamental role during infection than we had previously envisioned.
Although the essentiality of the GC for growth and survival of M.

tuberculosis in the host suggests primacy of fatty acid metabolism, this does no
rule out the possibility that M. tuberculosis might also have access to
carbohydrates. Irrespective of the carbon source, anaplerosis is necessary to
replenish intermediates of the TCA cycle, such as oxaloacetate , succinyl-CoA,

and a-ketoglutarate, which are siphoned off to biosynthetic pathways (Fig. 11.1;
See also Chapter 3). However, the anaplerotic pathways bacteria employ depend
on carbon availability and growth conditions (Komberg & Krebs, 1957; Romberg
& Sadler, 1960; Omston & Ornston, 1969; Cronan & LaPorte, 1996; Holms, 1996;
Fischer & Sauer, 2003). For instance, in batch culture in excess glucose medium,
E. coli replenishes oxaloacetate by carboxylation of phosphoenolpyruvate (PEP)
or pyruvate, via PEP carboxylase (PPC), or pyruvate carboxylase (PCA),
respectively (Anderson & Wood, 1969; Peng & Shimizu,
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2003). However, during slow growth in glucose-limited medium, E. coli employs
the GC for C4 anaplerosis (Emmerling et ah, 2002; Fischer & Sauer, 2003).
Likewise, the GC is the predominant anaplerotic pathway during growth of C.

glutamicum on mixed substrates (glucose and short-chain fatty acid) (Wendisch et
ah, 2000). Interestingly, A. nidulans growing on carbohydrate and acetate

mixtures maintains ICL activity comparable to that seen during growth on acetate
alone, which is much higher than on carbohydrates alone (Arrnitt et ah, 1970).
Studies of carbon flux in nonmodel bacteria suggest that during growth on

glucose bacteria rely on shunting of malate, which can be generated by the GC, to
pyruvate and then to oxaloacetate, as preferred way of replenishing TCA cycle
intermediates. A potential role the GC in anaplerosis during growth on glucose
was suggested long ago based on the fact that the slow growth on glucose of a

Apfk E. coli mutant -likely the result of reduced carbon flow into glycolysis- c
be compensated by constitutive expression of id (Vinopal & Fraenkel, 1974)
probably by restoring PEP concentrations to optimal levels (Kornberg & Smith,
1970). Thus, the GC might be required for M. tuberculosis metabolism in vivo,
regardless of whether carbohydrate concentrations are limiting or not.
Carbon utilization studies of Mycobacteria. Though studies of carbon
metabolism, mostly utilizing 14C-labeled carbon substrates, indicate that M.

tuberculosis and other mycobacteria readily respire a variety of carbon substrat
including including glucose, glucose 6-phosphate, 6-phosphogluconate, pyruvate,
citrate, succinate, glutamate, and palmitate (Wheeler, 1984), few, if any studies
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have

actually

documented

carbon

substrate-specific

growth.

Carbon

utilization/metabolic studies in mycobacteria have been greatly limited by our

inability to grow these slow-growing fastidious bacilli in defined minimal media
(Kondo & kanai, 1976; Katoch et ah, 1987). Even in the standard relatively rich
Middlebrook/Dubos media the tubercle bacillus has a doubling time of ~ 20 hours.
Our initial experiments on defined media supplemented with different

C2/C3 fatty acid substrates indicate that deletion of the first step of the GC r
in an inability to grow on C2 substrates. Unexpectedly, however, the mutants are
also impaired on combinations of carbohydrates and fatty acids (Chapter 9),

indicating that in vitro M. tuberculosis relies on the GC for fatty acid metabol
even in the presence of carbohydrates. That M. tuberculosis lacking both ICL1
and ICL2 shows a slight lag during growth on glucose suggests that some carbon
might flow through the GC even when glucose is the major carbon substrate
present (Chapter 6). We cannot rule out that the slight phenotype of the
AiclllAicll mutant observed is due to the presence of Tween-80 (0.05 w/v) in the
media, which is included to prevent clumping. However, we see no such lag
during growth of the AiclllAicll on glycerol media. Furthermore, we have
observed that the AiclllAicll M. smegmatis mutant is also impaired for growth on
mixed substrates where it shows a lag phase compared to dextrose or glycerol
media (not shown).
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The central role of the G C

in M . tuberculosis metabolism is further

suggested by the apparent absence of PEP carboxylase (PPC) (Cole et ah, 1998;
Fleischman et ah, 2002). PPC is the canonical enzyme used for C4 anaplerosis
from sugars in prokaryotes (Anderson & Wood, 1969; Peng et ah, 2004) (Fig.
11.1). Adaptation to low concentrations of glycolytic substrates might also

involve reduced flux of carbon through glycolysis to conserve glucose-6-P and it
derivatives for biosynthetic pathways (Fig. 11.1). In agreement, genes encoding a

putative high-affinity carbohydrate transporter (IpqY, sugA-C) and a glucokinase
(ppgK) are important for in vivo growth of M. tuberculosis (Sassetti & Rubin,
2003), whereas the glycolytic steps catalyzed by triosephosphate isomerase (tpi),
glyceraldehyde 3-phosphate dehydrogenase (gap), and phosphoglycerate kinase
(pgk), which are important for in vitro growth on standard 7H10 plates
supplemented with glucose (Sassetti et ah, 2003), might be dispensable in vivo
(Sassetti & Rubin, 2003). These observations suggest that during infection, PEP,
which is required for the biosynthesis of aromatic amino acids and the
peptidoglycan precursor UDP-N-acetylmuramic acid, might be generated not by
glycolysis but by conversion of oxaloacetate to PEP by PEP carboxykinase (PCK)
(Fig. 11.1). Consistent with this idea, expression of pckA encoding PCK (Fig.
11.1) is upregulated in the lungs of M. tuberculosis-infected mice (Timm et ah,
2003). Further, M. bovis pckA mutants are highly attenuated in guinea pigs
(Collins et ah, 2002), and an M. bovis BCG pckA mutant is attenuated in SCID
mice and in murine macrophages (Liu et al, 2003b).
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P E P not consumed in biosynthesis could flow into gluconeogenesis to

provide essential precursors such as glucose-6-P. Alternatively, it could be fur
oxidized to C02 through the PEP-glyoxylate cycle (Fischer & Sauer, 2003) (Fig.

11.2A), a pathway described similar to one described long ago as the dicarboxylic
acid cycle (Romberg & Sadler, 1960). The PEP-GC has been shown to operate in

E. coli cells when these bacteria are shifted to slow growth in very low levels o
glucose (<0.002%) - below concentrations that exert cAMP-mediated catabolite
repression (Notley-McRobb et al, 1997; Matin & Matin, 1982). Under these
conditions, up to 80% of the cell's oxaloacetate is provided by the GC. During

this shift, E. coli cells drastically downregulate PPC (-12 fold) and IDH (-4 fol
while upregulating ICL (-15 fold) and PCK (-10 fold). Other than the TCA
cycle, the PEP-GC cycle is the only known energy-yielding pathway capable of
complete oxidation of PEP to C02 (Fischer & Sauer, 2003) (Fig. 11.2A). If the
major carbon substrate available to the cell is acetyl-CoA (as during growth on
fatty acids), this routing of carbon would allow the oxidation of acetyl-CoA to
C02, while also providing PEP and pyruvate for biosynthesis. Under these
conditions reactions of the TCA cycle might be needed mostly to supply
glutamtate (Romberg & Sadler, 1960). Alternatively, the pyruvate produced from
PEP might instead be recycled back to oxaloacetate, as it occurs during the
operation of the pyruvate shunt in B. subtilis (Diesterhaft & Freese, 1973) and
several other less studied bacterial species (Fuhrer et al, 2005).
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Potential sources of fatty acids for M . tuberculosis during infection.
The sources and chain-lengths of fatty acids utilized by M. tuberculosis during
infection are unknown. A possible supply is long-chain phospholipids freed from
cell (phagosomal) membranes by phospholipases. In C. neoformans, extracellular

phospholipases, which avidly digest naturally occurring phospholipids of the lun
surfactant such as dipalmitoyl phosphatidylcholine and phosphatidyl glycerol

(Santangelo et al, 1999), are required for virulence (Cox et al, 2001). In accord
with this idea, four M. tuberculosis genes encoding cell wall-associated
phospholipase C isoforms are up-regulated during infection of macrophages and

are jointly essential for normal growth in the lungs of mice (Raynaud et al, 2002
In addition to phospholipids, Triacylglycerols (TAGs) present in most
mammalian cells are also a potential exogenous source of carbon that could be
used by M. tuberculosis during infection. TAGs are highly reduced molecules

with very high energy content, e.g., 1 gram of triacylglycerol can provide as mu

as 6 times the energy found in 1 gram of glycogen, and are well suited for energy
storage. TAGs could also constitute an internal lipid reserve which M.
tuberculosis might draw upon when external supplies of carbon become limiting.
Though TAGs are common in eukaryotes, their occurrence in prokaryotes is rare.
In fact, the only bacteria known to produce and store large amounts of TAGs are
members of the actynomycete family which includes Mycobacterium,
Rhodococcus and Nocardia, among other genera (Alvarez & Steinbuchel, 2002).
Remarkably, fatty acids from endogenous TAGs can make up to 78% of the dry
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weight of a Rhodococcus cell (Alvarez et al, 1996). Recent evidence suggests

that M. tuberculosis encodes several functional TAG synthases (tgs) (Daniel et a
2004). These synthases are upregulated when M. tuberculosis bacteria are
subjected to an in vitro model of persistence in which bacteria enter a

nonreplicative state induced by slow oxygen reduction and exposure to low nitric

oxide (Daniel et al, 2004). Interestingly, Nocardia species initiate synthesis an
accumulation of TAGs during late log phase and continue accumulating the
compounds throughout stationary phase for as long as carbon sources are

available. The in vitro model used by Daniel and colleagues (Voskuil et al, 2003)

and stationary phase in vitro growth conditions are known to elicit M. tuberculo
gene expression patterns that significantly overlap (Muttucumaru et ah, 2004;
Voskuil et ah, 2004). Thus, the stimulus for TAG synthesis might be carbon
substrate availability and/or replication rates rather than levels of oxygen in
flasks of the "non-replicational persistence" model (Wayne & Sohaskey, 2001)
used by Daniel and colleagues (2004).
When external carbon sources become unavailable, Rhodococcus species
readily begin to mobilize their internal reserves of TAGs, eventually breaking
down up to 90% of such reserves (Alvarez et ah, 2000). The initial breakdown of
TAGs requires serine hydrolases known as lipases (Gupta et ah, 2004), and M.

tuberculosis has circa twenty genes that could encode such functions (UpC-lipW).
Although these genes are not induced during the initial 24-48 hr of infection in
macrophages (Schnappinger et ah, 2003), this might be expected if TAGs are
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needed only during the persistent phase of the infection after external carbon
substrates become unavailable. Fatty acids released from TAGs are likely
oxidized via P-oxidation, in much the same way it occurs during early

development of some plant seedlings. For instance, A. thaliana seedlings lacking

a peroximal 3-ketoacyl-thiolase do not grow normally because they cannot oxidize
TAG-derived long chain fatty acids, which end up accumulating in their cells.

Interestingly, postgerminative growth and seedling establishment in oilseed plan
is dependent not only on p-oxidation but also on the GC. Seedlings lacking ICL
are impaired during seedling establishment (Eastmond et ah, 2000), and ICL is

upregulated specifically during the first days of seedling development (Runquist
Kruger, 1999). Thus, utilization of fatty acids resulting from TAG hydrolysis
might well require a functional GC regardless of whether glycerol or other
carbohydrates are present.
It is tempting to speculate that the phenotype of A/c/7 M. tuberculosis

mutant might result from an increased bacterial reliance on these stored sources

fatty acids during the persistence phase of the infection. At the beginning of t
infection mixed substrates might be available requiring limited carbon flux
through the GC, which our data suggests could be provided by either ICL1 or

ICL2. Later on, as the bacteria switch entirely to fatty acids, their reliance on
might increase accordingly. That M. tuberculosis experiences nutritional stress

during persistence is suggested by the finding that a mutant lacking relA - a ge

267

of the stringent response to starvation - is severely impaired for persistence (Dahl
et ah, 2003).
The methylcitrate cycle of M. tuberculosis, p-oxidation of odd-chain
fatty acids generates both acetyl-CoA (C2) and propionyl-CoA (C3). PropionylCoA can be metabolized via several routes including the citramalate,
methylmalonyl-CoA, and methylcitrate pathways (Halarnkar & Blomquist, 1989).

Mounting evidence indicates that the methylcitric acid cycle (MCC) (Fig. 10.1) i
required for propionate catabolism in several eubacteria and fungi (Tabuchi &
Uchiyama, 1975; Horswill & Escalante-Semerena, 1999; Brock et ah, 2001). In
all these species, a dedicated MICL is present, which cannot function as an ICL
(e.g. has no activity on isocitrate) (Luttik et ah, 2000; Brock et ah, 2001). The
tuberculosis genome contains homologs of the enzymes catalyzing the first two
steps of the MCC. These are methylcitrate synthase (prpC, Rvll31) and
methylcitrate dehydratase (prpD, Rvll30), and they are up-regulated during
infection of macrophages and in vivo (Schnappinger et ah, 2003).
Since a methylisocitrate lyase (MICL, prpB) homolog is apparently absent
from M. tuberculosis, and ICL1 and ICL2 are essential for growth of M.
tuberculosis on propionate as the sole carbon source (Chapter 6), we postulated
that ICL1 and ICL2 might subsume this function. ICLs and MICLs share -25%
sequence homology and while all predicted ICLs have the catalytic site residues
K[KQ]CGH, which constitute a signature motif , methylisocitrate lyase enzymes
(prpB) have the signature sequence KRCGH at their catalytic site; mycobacterial
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ICL1 and ICL2 predicted proteins have the motif K K C G H .

Nonetheless, I C L

from S. cerevisiae has weak MICL (Luttik et ah, 2000). Here, we provide
evidence that ICLs and in particular ICL1 can function as MICL (Chapter 10).

The idea that prpB is indeed missing, and that ICL1 and/or ICL2 substitute for t
enzyme in M. tuberculosis is suggested by the lack of MICL activity in extracts
from the AiclllAicll mutant. Furthermore, an Aicll mutant and a strain
overexpressing ICL1 had normal and elevated levels of MICL, respectively, while
a A/c/7 mutant extracts had negligible activity on methylisocitrate.
Some bacteria, including E. coli and Ralstonia eutropha, which require the
MCC for propionate metabolism and have a dedicated MICL (prpB), depend on
the GC presumably for anaplerosis (Textor et ah, 1997; Bramer & Steinbuchel,
2001). However, Salmonella mutants lacking ICL or MLS are not impaired for
growth on propionate media (Horswill & Escalante-Semerena, 1999). In these
cases, anaplerosis during MCC-mediated propionate metabolism is probably
carried out by PCA, or perhaps via PPS together with PPC, rather than the GC.
Data presented in Chapter 9 indicating that the GC is dispensable for growth on
propionate by M. smegmatis, which unlike M. tuberculosis encodes a dedicated

MICL (prpB), suggest that mycobacteria, similarly to Salmonella, does not require

the GC for anaplerosis on propionate, and instead likely carry out anaplerosis v
PCA (Mukhopadhyay & Purwantini, 2000) during growth on C3 subtrates.
Experiments directly assessing the role of the MCC in M. tuberculosis
C3FA utilization and pathogenesis are presented in Chapter 10. Here we provide
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evidence that metabolism and growth on C 3 substrates such as propionate and

valerate by M. tuberculosis requires the genes putatively encoding methylcitrate
synthase (PRPC) and methylcitrate hydratase (PRPD). The requirement for this
pathway in vivo is less clear. In an ongoing experiment, the AprpDC M.
tuberculosis mutant showed no difference compared to wild-type up until wk 10

post-infection in both bacterial burden and pathology (Chapter 10). However, the
AprpDC mutant was impaired for growth intracellularly in mouse primary
macrophages. These contrasting findings underscore the fact that significant
differences exist between the metabolic requirements of bacteria depending on
whether they are grown in vitro, ex-vivo, or in vivo.
It is possible that C3FAs are used as carbon sources during growth in

macrophages in tissue culture, but that in vivo other substrates become availabl
thus lessening bacterial dependence on C3 substrates. Alternatively, during
infection M. tuberculosis might be able to turn on alternative pathways of C3
metabolism, which it fails to engage during growth in the macrophage model. M.
tuberculosis has several putative propionyl-CoA carboxylases (accD genes), and
methylmalonyl-CoA mutase genes (mutA and mutB), which may allow propionylCoA utilization via the methyl-malonate-CoA pathway. Several of these putative
propionyl-CoA carboxylases are found in the vicinity of fadD and fadE genes,
suggesting they might be involved in C2/C3 catabolic pathways.
Potential of ICL1 and ICL2 as drug targets. The complete reliance on

ICL for replication of M. tuberculosis in vivo suggests that inhibiting both ICL
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might have potent therapeutic activity. Experiments presented in Chapter 8 in
which the effect of blocking only one ICL (ICL1) in the context of chemotherapy
with isoniazid, in the mouse model of chronic TB, and with isoniazid and
rifampin, in a modified Cornell model of drug-induced latency, indicate that

inhibition of ICL1 alone would not significantly improve currently available dru
regimens. Thus, both ICL1 and ICL2 will likely need to be blocked by any future

ICL-inhibiting drug for it to be effective. The feasibility of blocking ICL duri
infection as a therapeutic approach is supported by our demonstration that the
prototype ICL inhibitor 3-nitropropionate (Schloss & Cleland, 1982; Sharma et

ah, 2000), which inhibits both ICL1 and ICL2 in the tube (Honer zu Bentrup et ah,
1999), effectively impedes replication of M. tuberculosis on fatty acids and in
macrophages (Chapter 6). M. smegmatis Aicll/AicU mutant bacteria expressing
wildtype M. tuberculosis icll and icll genes have been constructed and their

usefulness as tools for testing potential inhibitors of ICLs is supported by dat
presented in Chapter 9. These strains are currently being employed to test lead
compounds identified in high-through put screens that are being conducted by
collaborators in industry (GlaxoSmithKline).
The importance of ICL and the GC as a target for therapeutics development
is enhanced by findings implicating the GC in the pathogenesis of several other
microorganisms including the bacteria Rhodococcus fascians (Vereecke et ah,
2002), S. typhimurium (Fang et ah, 2005) and the fungi Leptosphaeria maculans
(Idnurm & Howlett,, 2002); Magnaporthe grisea (Wang et ah, 2003b), and
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Candida albicans (Lorenz & Fink, 2001). Thus, although the G C is probably not

universally required for pathogens' survival in the host, as suggested by finding
in C. neoformans (Rude et ah, 2002) and Y. pestis (Sebbane et ah, 2004), a
growing number of organisms are being identified which at some point in their
infection cycle require the GC for growth or survival during infection.

11.3. Future Studies

The role of ICL in M. tuberculosis persistence in vivo. The fact that
either ICL1 or ICL2 can sustain the metabolism of M. tuberculosis early in the
infection, even though ICL2 is likely providing considerably less activity than
ICL1, together with our previous observation that A/c/7 mutant bacteria are

attenuated specifically during the persistent phase of the infection (McKinney e
ah, 2000), and, in particular, that this attenuation results from an interaction
the immune response (Chapter 7), suggest that at the onset of persistence, the
infection milieu changes in a way that forces M. tuberculosis to increase its
reliance on ICL-mediated metabolism. One way in which this could happen is by
immune-mediated restriction in access to carbohydrates. However, the phenotype
of the A/c/7 mutant, though stage-specific in appearance, is not a demonstration

that the function of ICL1 is specifically required during persistence. The funct
of ICLs could be performed early in the infection but the effect of lacking such
function may not manifest itself until later. The possibility that ICLs are
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dispensable for M . tuberculosis remains and ought to be explored. T o address this

issue, conditionally ICL-expressing strains of M. tuberculosis are being built u
AiclllAicll mutant bacteria and recently developed methods of conditional
expression of M. tuberculosis genes (Blokpoel et ah, 2205; Ehrt et ah, 2005).
The role of the fatty acid p-oxidation cycle in M. tuberculosis
metabolism in vivo. If lipid-derived fatty acids are indeed the main carbon

substrates employed by M. tuberculosis in the host, regardless of the source, the
pathways involved in their oxidation should be essential for the growth and
survival of the bacteria during infection. As discussed in detail in Chapters 3

4, testing this prediction might be difficult because of the potential for redun
in many of the steps of P-oxidation. A survey of these putative homologous genes
indicates that the group with the lowest number of homologues is that of the
ketoacyl thiolases encoded by the fadA genes, of which there are six. Though the
oxidation of 3-hydroxyacyl-CoAs might only involve the products of 3 annotated
fadBs, the presence of some 30 or so, other short-chain hydroxyacyl
dehydrogenases, which though closer in homology to eukaryotic enzymes, might
nevertheless functionally overlap with the canonical FADBs (Maggio-Hall &
Keller, 2004), makes this group a less attractive target.
The role of malate synthase in M. tuberculosis metabolism in vivo.
We hypothesize that the joint essentiality of ICL1/ICL2 in vivo is attributable
their canonical function in the GC. However, it is possible that ICL-mediated

cleavage of isocitrate into succinate and glyoxylate functions together with oth
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pathways capable of oxidizing the generated glyoxylate. In bacteria such as P.
denitrificans, glyoxylate is converted to oxaloacetate via the beta-hydroxy
aspartate pathway in which glyoxylate is first converted to glycine through a
reductive amination reaction catalyzed by glycine dehydrogenase (GCV),
followed by condensation with another glyoxylate to form erythro-beta-hydroxy
aspartate, which is then dehydrated to oxaloacetate (Liu et ah, 2003a). Another
route for the metabolism of glyoxylate through a glycine intermediate could
involve a serine-glyoxylate aminotransferase pathway, which would lead to

formation of glycerate and sugars. This routing of carbon occurs in MLS-deficien
seedlings (Cornath et ah, 2004) and is analogous to the glycerate pathway (See
Chapter 3). In this pathway, two glyoxylates are condensed by glyoxylate

carboligase (GCL) to form tartronate, ultimately generating glycerate (Fig. 11.2B

It is not known whether any of these pathways operate in M. tuberculosis since no
clear homologs of the enzymes involved can be found in its genome. However,
the reductive amination of glyoxylate to glycine catalyzed by glycine
dehydrogenase has been demonstrated in extracts of M. tuberculosis H37Ra
(Goldman & Wagner, 1962). This reaction not only would allow the metabolism
of glyoxylate but would also aid in the regeneration of NAD+, which might be
important if bacteria experience hypoxic conditions in vivo (Wayne et al, 1982;
Boshoff & Barry, 2005).
In E. coli, the genes encoding ICL (aceA) and MLS (glcB) are in an operon
(aceBAK). In contrast, in M. tuberculosis they are not in the proximity of each
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other in the chromosome, and while /c/7 is upregulated in vivo, glcB is not ( T i m m
et al, 2003; Fig. 6.7); furthermore while ICL is massively upregulated in vitro
C2 substrates, MLS is not. Though these differences might not be important, and
constitutive levels of MLS might be sufficient for the function of the GC, they

could also be a hint that other pathways involved in the metabolism of glyoxylat
might be operative. Two types of malate synthase enzymes have been described:
type A and type G. Most micro-organisms have only one type but it is not
uncommon to find species that have both. In E. coli, which has both, MLS-A is
induced by acetate, while MLS-G is induced by glycolate (Molina et al, 1994).
However, there is cross-induction of the two enzymes by acetate and glycolate
(Pellicer et al, 1999). Mycobacteria have only one MLS and it is closer to the
MLS-G type, encoded by glcB.
To study the role of MLS in M. tuberculosis, deletion of the single-copy
gene glcB in M. tuberculosis was attempted. Two different strategies for gene
disruption in M. tuberculosis - plasmid-mediated (Pavelka & Jacobs, 1999) and
phage-mediated (Bardarov et al, 1997) homologous recombination - were used in
separate attempts to make marked deletions in glcB in both Erdman and H37Rv M.

tuberculosis strains. All of these attempts were unsuccessful. We considered the

possibility that disruption of glcB could have polar effects on downstream genes
and therefore, tried to generate the mutant using unmarked in-frame deletion
constructs with different flanking lengths (pEM304-306 series). In all cases,
homologous recombination was obtained, but resolution of the plasmid after
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sucrose counterselection always resulted in regeneration of the wild-type locus.

These results suggest that glcB might be essential. If this is the case, this co
formally shown by obtaining the mutation in a merodiploid strain in which the
chromosomal deletion is facilitated by the presence of a second wild-type copy
either episomally or integrated into the chromosome. Efforts are ongoing to do

just that. If glcB indeed proves to be essential in vitro, determining the role o
MLS in the biology of M. tuberculosis might still be feasible by adapting

methodologies used for conditional gene expression (Blokpoel et al, 2205; Ehrt e
al, 2005).
Determining the contributions of glycolysis and gluconeogenesis to M.
tuberculosis metabolism during infection. Based on our data, we hypothesize

that carbohydrates are not available, or available in only in low concentrations

M. tuberculosis during infection, and furthermore suggest that their availabilit
might change overtime, decreasing during the chronic phase of the infection.

However, several alternative scenarios are possible, and thus it will be importa
to evaluate the role of sugar metabolism-specific pathways in infection.
If carbohydrates are completely inaccessible, then the ability to catabolize

carbohydrates (glycolysis) should be dispensable, while the ability to synthesiz

carbohydrates de novo (gluconeogenesis) should be essential. If this scenario is

correct, then the functions of PCK and GLPX ought to be essential, while those of
PPGK/GLK and PFK1/2 ought to be dispensable for bacterial growth in vivo.
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Alternatively, if some carbohydrate is available, perhaps enough to provide
glucose-6-P and related biosynthetic precursors, but not enough to be used for
energy, and most of the carbon and energy is derived from fatty acid breakdown,

then it is possible that the upper and lower branches of glycolysis/gluconeogene

are 'disconnected'. In this scenario, only enzymes in the upper part of glycolys
would be required (PGI, PFKs, FBA, GLPX) as well as sugar transporters
(PPGK), but not enzymes that connect the upper part of glycolysis to PEP (TPI,
GAP, PGK, GPMs). PCK would be needed to provide PEP. It is possible that
both scenarios hold true at different times during the infection. Early on,

glycolysis might play a role while carbohydrates are available, but as the bacte
lose access to them, bacteria might have to switch to split C2/carbohydrate
metabolism (no connection between GC/TCA and upper part of glycolysis). Later
still, they may become strictly lypolytic and gluconeogenic.
Lastly, M. tuberculosis could have access unimpeded access to sugars,
perhaps low levels, and similarly to E. coli growing on very low levels of
glucose/carbohydrates rely on the GC to do so. In this scenario, the requirement

for ICL would be due to its role in oxidation of sugar- instead of fatty acid-de
acetyl-CoA. PCK would still be needed for PEP generation (Fischer & Sauer,
2003), but GLPX ought to be dispensable. Furthermore, PPGK/GLK and all
glycolytic activities ought to be needed as well.
The finding that M. bovis lacks a functional PYK (Garnier et al, 2003;
Keating et al, 2005) has been cited as evidence that glycolysis is likely

277

dispensable in pathogenic mycobacteria for growth in vivo since M . bovis causes
disease in bovines and humans. However, it is possible that in this species the
of PYK has been compensated by upregulation of either MEZ or PCA, or both. In

order to evaluate the role of glycolysis in mycobacterial metabolism both PFK an
PYK need to be lacking because PYK could be needed for the metabolism of PEP
that has been produced via PCK.
As detailed in Chapter 3, bacteria have enormous metabolic flexibility. In

E. coli, deletion of ppc results in the upregulation of the GC for anaplerosis d
growth on glucose, and a mutation on PFK can be compensated by a mutation that
upregulates the GC as well. Examples of this sort abound. Studies of gene

expression in different carbon sources have now been carried out on a global sca
in E. coli and C. glutamicum grown in specific carbon sources (acetate vs

dextrose); similar studies in M. tuberculosis ought to be feasible using the gro
conditions we have established (See Chapter 6 and Chapter 12 (Materials &

Methods)), and might be informative in aiding our understanding of carbon flux in
M. tuberculosis. Carbon flux analysis with radiolabeled carbon substrates would
also greatly enhance our understanding of mycobacterial metabolism. As we have
learned, metabolism is less well understood than sometimes assumed.

278

11.4. Conclusions

We ignore much about the metabolic pathways specifically employed by

microorganisms to use the nutrients available in the environment of the infectio
a prerequisite for pathogenesis. Uniquely, mycobacterial genomes encode an
unprecedented number of putative fatty acid metabolism genes including several

paralogs of fatty acid P-oxidation and two genes encoding isocitrate lyases (ICL
an enzyme generally needed when fatty acids are the principle sources of carbon

and energy available to bacteria. While single A/c/7 and A/c/2 mutants are capab

of growth on C2 substrates, intracellularly in both mouse and human macrophages,

and in the lungs of mice during the acute phase of infection, a Aicll/Aicll muta

is incapable of growth on C2 substrates, or in macrophages, and is avirulent, bei

cleared from lungs within 2 weeks of infection. This functional overlap uncovere
between ICL1 and ICL2 makes developing dual specificity inhibitors a desirable
goal. That this is feasible is suggested by the high conservation between the
proteins' active sites revealed by in silico structural modeling of ICL2, and by
abrogation of wild-type M. tuberculosis growth on C2 substrates and in
macrophages by an ICL inhibitor. These findings establish an essential
requirement for ICL from the onset of infection. A role for the GC during

persistence of M. tuberculosis remains an attractive possibility that is support

the phenotype of the single /c/7 mutant and gene expression data, as well as by a
considerable body of data from other groups. The potential of the GC as a novel
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target for drug development is enhanced by its apparent absence in mammalian
cells, and by emerging evidence that the pathway is important for virulence in
various bacterial and fungal pathogens. These include major causes of human
morbidity, such as Candida albicans, for which the existing therapeutic options
are suboptimal. The lengthy chemotherapeutic regimens prescribed to treat TB
and the emergence of rapidly spreading multiple-drug resistant M. tuberculosis
makes finding more effective drugs an imperative. A novel drug targeting both

rapidly dividing bacteria and slow growing or non-replicating 'persisters' would

likely reduce the number of antibiotics prescribed, shorten duration of treatmen
improve compliance, and contribute to controlling the current TB epidemic.
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P A R T

IV

CHAPTER 12

Materials and Methods

12.1. Bacterial strains and growth conditions

Standard media. M. tuberculosis Erdman and M. smegmatis mc2155 were
stored at -80°C in 15% glycerol. Bacteria were grown with aeration at 37°C in
Middlebrook 7H9 broth (DIFCO) containing 10% OADC (DIFCO), 0.5%
glycerol, and 0.05% Tween-80, or on Middlebrook 7H10 agar (DIFCO)
containing 10% OADC and 0.5% glycerol. Antibiotics (Sigma) were hygromycin
(50 [xg ml"1), kanamycin (25 u.g ml"1) and streptomycin (20 [xg ml"1).
Defined media. Carbon-source defined media (CDM) contained (w/v):
0.47% Middlebrook 7H9 powder (DIFCO), 0.5% albumin, 0.085% NaCl, and
0.05% Tween-80. Carbon substrates were used at 0.1% (w/v) or as indicated.
pH was adjusted to 6.8. Growth curves were done as follows: bacteria were
inoculated into standard 7H9 media and grown to late log phase (OD600 1-2).
These cultures were used to inoculate dextrose-CDM cultures at an initial OD600

~ 0.025; these were grown for 7-10 days till late log phase (OD600 0.8-1) and t
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used to inoculate "experimental" C D M

supplemented with the desired carbon

substrates.
In one set of experiments, M9 salts (DIFCO) supplemented with (0.1 mM)
CaC12, (2mM) MgS04, 0.5% albumin, 0.085% NaCl and 0.05% Tween-80 were
used. However, CDM supplemented with glucose (0.1%, w/v) or C2FA (0.1%,

w/v) supported significantly better and faster growth of M. tuberculosis (doubli
time 3-4 days) than similarly supplemented M9-based defined media (~6 day
dobling time). M. tuberculosis extracts were prepared from CDM (7H9-based)
where carbon substrates were used at (w/v) 0.2%.
Minimal media for carbon utilization experiments with M. smegmatis: M9
salts (DIFCO), (0.1 mM) CaC12, (2mM) MgS04 without (liquid) or with (solid)
agar (15 g L"1). Carbon substrates were used at 0.1% (w/v). M. smegmatis
extracts were made from minimal M9 liquid media where carbon substrate
concentrations were (w/v) 0.1%. Distilled water was used in all cases. Media

were sterilized by either by autoclaving (solid) or filtering (0.2 micron) (liqui
BACTEC. Degradation of [14C]-palmitate to [14CJ-C02 was measured
using the BACTEC system (Becton Dickenson) per the manufacturer's
instructions.

12.2. Mouse infections/animal models
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M o u s e strains. All mice used were either male or female (3-5 w k s of age)
on the C57BL/6 background and were purchased from Jackson Laboratories. Mice
were housed under specific pathogen free conditions at Rockefeller University,
and were routinely tested and found to be free of common mouse pathogens. All
experiments with live mice were performed in accordance with the National
Institutes of Health Guidelines for the Care and Use of Laboratory Animals, and
were approved by Rockefeller University's Institutional Animal Care and Use
Committee.
Mouse infections. Bacteria were grown to mid-log phase (OD60o ~ 0.5) in
7H9 broth, collected by centrifugation, washed with PBST, adjusted to ~ 1 x IO7
CFU ml"1, and sonicated briefly in a cup-horn sonicator to disrupt aggregates.
Mice were infected by injection of 0.1 ml (~ 1 x 106 CFU) of the bacterial
suspension into a lateral tail vein.
For respiratory infections, bacteria were grown in 7H9 broth to mid-log
phase (OD600 ~0.5), collected by centrifugation, washed once with PBST,
centrifuged at low speed for 5 min to remove clumps and the supernatant was
suspended at -106-108 CFU ml-1 (adjusted by OD600), depending on the dosage
required (101-103 CFU per mouse); aerosol exposure of mice was carried out for
15 min, followed by a 20 min purge with room air, using a custom-built aerosol
exposure chamber (University of Wisconsin, Madison), as described (MacMicking
et al, 2003)
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Chemotherapy of mice. Where appropriate, M . tuberculosis-infected mice
received isoniazid (0.1 mg/mL - 25 mg per kg body weight per day) or isoniazid
plus rifampin (0.1 mg/mL - 25mg/kg/day) delivered ad libitum in the drinking
water. Drugs were replaced by fresh water 24 h before mice were sacrificed at
each time-point.

12.3. Bacterial quantification

Quantification of M. tuberculosis colony forming units (CFU) in organs
from infected mice. Infected mice were euthanized by C02 overdose (n = 4-5 per
group). M. tuberculosis CFU were enumerated by homogenizing the left lung of
each mouse in 5 ml PBST using a Polytron tissue homogenizer, plating the diluted
homogenates on 7H10 agar, and scoring colonies after 3-4 wk (or 6-8 wk, in the

case of A/c/7 A/c/2 bacteria) at 37°C. Portions of tissue were fixed in phosphat
buffered formalin (10%) for histopathology. Histopathology staining was
performed at Cornell University Pathology Laboratory (New York, NY).
Quantification of M. tuberculosis CEQ in lungs of infected mice. M.
tuberculosis chromosomal DNA was prepared by homogenizing the right lung of
each mouse in 5 mL PBST, collecting the bacteria by centrifugation at 3000 g for

10 min at 4 °C, resuspending the bacterial pellet in 1 mL TE, adding 0.25 ml warm
(70 °C) phenol/chloroform/isoamyl alcohol (25:24:1) (Sigma) and 0.25 mL
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zirconia-silica beads (Biospec Products), and breaking the bacteria in a beadbeater (Biospec Products). Cell debris was removed by centrifugation at 12,000 g
for 10 min, 50 jo.1 5 M NaCl was added to the clarified supernatant, extraction
phenol/chloroform/isoamyl alcohol was repeated, and genomic DNA was
precipitated by addition of isopropanol. The precipitated genomic DNA from a
single infected mouse was ethanol-washed, air-dried, resuspended in 300 [xL of
water, and stored at -20 °C. Quantitative PCR (QPCR) reactions were carried out
as described (Timm et ah, 2003). Each reaction was in a volume of 50 [xL
containing lx Taqman buffer A (Perkin Elmer), 4 mM MgC12, 0.25 mM dNTPs,
2.5 units of AmpliTaq Gold polymerase (Perkin-Elmer), 0.5 \iM of the fadE15
primers, 0.3 [xM of the fadE15 molecular beacon, and the template DNA.

Typically, 1-2 [xl of template DNA (representing 0.33-0.67% of the total genomic
DNA extracted from a single mouse) was used per reaction. In some cases (where
bacterial loads were very high), template DNAs were diluted before amplification
in order to obtain QPCR threshold cycle (Ct) values in the range 25-35; control

reactions confirmed that dilution of the template had no effect on the linearity
amplification (data not shown). The set of primers and the molecular beacon used
to quantify bacterial chromosomes had the following sequences (hybridizing to
sequences in the fadE15 gene): FAM-5'-GCAGCC
CGCATGACCATCGGAGTTAAGT GGCTGC-3' (molecular beacon); 5'GATTGCGCAGATGTTCACGG-3' (forward primer); 5'GCCCTGCACCCGCTCCTTGG-3' (reverse primer). Real-time QPCR reactions
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were run and analyzed on an A B I 7900 machine per the manufacturer's
instructions. PCR conditions were: Amplitaq Gold activation step 95 °C (10 m),

followed by 40 cycles of 95 °C (30 s), 57 °C (30 s, data collection), 72 °C (30 s

Standard curves were generated using serial dilutions of M. tuberculosis genomic

DNA of known concentration. Quantitative analysis of the data was carried out as
described (Timm et ah, 2003).

12.4. Tissue culture.

12.4.1. Infection of bone-marrow-derived murine macrophages with M.
tuberculosis.

Isolation of cells. Bone marrow cells were flushed from mouse femurs and
cultured for 7 days in DMEM (Cellgro) containing 0.58 g l"1 L-glutamine, 1 mM
sodium pyruvate, 10% heat-inactivated fetal bovine serum (HIFBS; Hyclone), 10
mM Hepes 7.55, 100 U ml"1 penicillin G, 100 [xg ml"1 streptomycin, and 20% L929
cell-conditioned medium (Ehrt et ah, 2001). Adherent cells were harvested,

seeded in 12-well plates (2 x IO5 cells per well), and incubated at 37 °C, 5% C02
Where indicated, macrophages were activated by addition of 50 U ml"1 rlFN-y
(R&D) to the medium 16 h prior to infection and thereafter.
Bacterial Infection. Bacteria were grown to mid-log phase (OD60o ~ 0.5) in
7H9 broth, washed in PBS containing 0.05% Tween-80 (PBST), and centrifuged 5
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min at low speed to remove aggregates. Macrophage monolayers were infected at
an MOI of 2:1 in DMEM containing 0.58 g l"1 L-glutamine, 1 mM sodium
pyruvate, 5% HIFBS, and 5% horse serum (Gibco); after 4 h monolayers were
washed to remove non-cell-associated bacteria, and incubated (37°C, 5% C02)
with medium changes every 36 h. Where indicated, 3-NP was included in the
medium from 4 h post-infection onwards; addition of 3-NP had no detectable
effect on adherence or viability (trypan blue exclusion) of macrophages. At the
indicated time points, infected monolayers were washed, lysed with 0.5% Triton
X-100, and cell-associated bacteria were enumerated by plating lysates on 7H10
agar and scoring CFU after 3-4 wks incubation at 37 °C.

12.4.2. Infection of human blood monocyte-derived macrophages with M.
tuberculosis. Monocyte/lymphocytes were purified from whole human blood

(New York, Blood Center) by the Ficoll-plaque differential centrifugation method
as per manufacturer's instructions (Pharmacia Biotech). Cells were seeded in
tissue culture 12- well plates (Corning) at a density of 2.4 million cells/well
cultured for 2 h in 10% PHS-RPMI = RPMI-1640 (Life Technologies) containing
10% heat inactivated pool human serum (Labquib, Ltd.), 10 mM Hepes, and
gentamicin (20 ug/mL). Non-adherent cells were removed by 4 washes with plain
RPMI (37 °C). Adherent monocytes were cultured for 1 wk in 10% PHS-RPMI.
Before bacterial infections, monolayers were washed 3X with 37 °C PBS.
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Infections of h u m a n cells with M . tuberculosis were carried out identically to
those in murine macrophages, except that 10% PHS-RPMI was used throughout
the experiments.

12.4.3. DAPI Staining of macrophages and intracellular Bacteria. Human
primary monocytes derived as described above were seeded on round cover slips
fitted in the bottom of 24-well plates. At desired-time points, monolayers were
washed 3X with cold PBS, and 500 |xL of 4% paraformaldehyde in IX PBS was
added per well. After fixing for , wells were washed 3X with PBS and 300 [xL of
4',6'-diamino-2-phenylindole (DAPI stain (l[xg/mL final concentration in PBS)
were added per well. The wells were then incubated in the dark for -30 min at 4
°C. Wells were then washed 3X with PBS and the cover slip was mounted on a
microscope slide for observation using a fluorescent microscope.

12.5. Molecular microbiology

12.5.1. Construction and complementation of id mutants in M. tuberculosis.
For disruption of icll, a Kpnl fragment containing icll was sub-cloned into
pBSKS- (Stratagene) to generate pEM027-14. A 1.8 kbp MscI fragment internal
to icll was replaced with an oph kanamycin resistance (Kmr) cassette (1.3 kbp
BamHI fragment from pUC4) to generate pEM028; the deletion encompassed AA
2-612 including the catalytic motif KKCGH (AA 213-217). The Kpnl fragment
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containing the icllr.aph allele was cloned into the unique Sail site of p E M 0 2 5 , an
E. coli-Mycobacterium episomal shuttle vector containing the pAL5000
replication origin (Ranes et ah 1990), aadA streptomycin resistance (SmR) marker
(1.9 kb Dral fragment from pHP4547), and sacB counter-selection marker to
generate pEM029-l. The icllr.aph allele was recombined into the M. tuberculosis
chromosome by selection of pEM029-l (KmR) transformants followed by counterselection on 5% sucrose as described (Pavelka & Jacobs 1999). The AiclllAicll
mutant was generated by disrupting icll in the chromosome of the previously
generated A/c/7 (icllrhpt) strain (McKinney et ah, 2000). Replacement of the
wild-type icll gene with the icllr.aph allele was confirmed by PCR analysis and
Southern blot (Fig. 6.3). pICLl (pEM263-4) was constructed by sub-cloning a 1.6

kb Spel fragment containing /c/7 into the Hpal site of pEM262, an episomal vecto
derived from the shuttle vector pMV261 (Stover et ah, 1991) by replacing the
KmR cassette with the aadA SmR cassette. pICL2 (pEM3E4-8) was constructed by
inserting a 6.1 kbp Kpnl fragment (from an M. tuberculosis Erdman genomic
library cosmid, gift of M. Glickman, Sloan Kettering Institute) containing icll
the Hpal site of pEM262.

12.5.2. Construction and complementation of id M. smegmatis mutants. M.

smegmatis (strain mc2155) mutant strains with in-frame unmarked deletions in /c/
or icll or both ORFs were generated by homologous recombination using suicide
constructs based on vectors pJGHOO and pJGlOOl, respectively (gift of J.
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Gomez).

For disruption of /c/7 (carried out by L. Merkov), a 2.3kb fragment

containing the entire icll gene of M. smegmatis was amplified by PCR from
genomic DNA using primers smicllupxhol: 5CTCGAGCTTCGACCACATGAACAACG-3; smiclldnxhol: 5CTCGAGGATCTTCATGATCGGGATGC-3. The PCR product was subcloned
into pCR2.1 (to give pLM217s) and sequenced. A 2.3kb EcoRI fragment
containing the PCR product was subcloned into EcoRI digested pBSKS
(pBluescript) to give pLM218s. pLM218s was digested with Sfol to remove an
855 bp fragment internal to the /c/7 gene (removes 285 AAs from the ICL protein,

including the catalytic site, and results in an in frame deletion). The other (5.
Sfol fragment from pLM218s was religated to give pLM219s, which was then
digested with Xhol to excise the 1.5kb band containing the truncated icll gene.
This 1.5kb fragment was subcloned into Xhol digested pJGHOO vector to create
pLM220s, which was electroporated into smegmatis.
For disruption of icll, a 3.9kb Agel fragment from cosmid pEM353 (M.
smegmatis cosmid genomic library was a gift of B. Subramanian) carrying icll
was cloned into pSL301 to generate pEM701, which was EcoRV-digested to
obtain a 3.5kb fragment carrying icll, which was then cloned into the Pmel site
pJGlOOl to generate pEM902. pEM902 was BstEII-digested to remove a 660-bp
fragment, which generated an unmarked in-frame deletion after relegation into
pEM903; The deletion encompasses AA 307 to 526 of the icll ORF. pEM903
was electroporated into wild-type M. smegmatis. Counter selection was performed
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as described (Pavelka & Jacobs, 1999). A AiclllAicll M . smegmatis mutant was
generated by transforming the A/c/2 mutant with pML220s (described above).

12.5.3. Construction and complementation of AprpDC M. tuberculosis
mutants.
Disruption of the prpdc ORFs. M. tuberculosis (strain Erdman) with an
in-frame unmarked deletion in the prpd and prpc ORFs was generated by
homologous recombination using a suicide construct based on the vector pJGl111.
This vector was derived from pJG1004, a derivative of the kanamycin and
ampicillin resistant pMV261 (Stover et ah, 1991) into which hygromycin
resistance and sucrose sensitivity cassettes had been inserted (Gomez & Bishai,
2000). Additional restriction sites (Spel, BstBI, Sspl, Avrll, Ndel, Xhol, and
AflU) were added between the pJG1004 Pad and AscI sites via a PCR-generated
polylinker, to generate pJGHOO. A 39894 bp Smal/Nral fragment excised from
pGOAL19 (Parish & Stoker, 2000) containing the E. coli lacZ gene under the
control of the M. tuberculosis Antigen 85 promoter was cloned into the unique
Pmel site of pJGl 100 to generate pJGl 111 by L. Merkov. 1 kb regions upstream
and downstream of the putative prpDC ORFs were PCR-amplified (with a M.
tuberculosis genomic library cosmid as template), using primers designed to

introduce the restriction sites Pacl/Avrll into the 573' termini of the upstream
region (primers used were ttaattaactgctctgcggcacggtg and cctaggatgcatcaacat
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aatccg) and Avrll/AscI sites into the 573' termini of the downstream region (using
primers cctaggggcaccttctagtcttat and ggcgcgccagcagaccatgatcgtcg). The resulting

PCR products were subjected to restriction digestion and cloned together into th
Pad and AscI sites of pJGllll such that the 2 insert fragments were ligated to

each other at their Avrll sites (the 3' terminus of the upstream region to the 5'
terminus of the downstream region). Homologous recombination into the M.
tuberculosis chromosome would result in the replacement prpDC with an ORF
encoding a fusion protein consisting 9 AA. This construct was recombined into
the M. tuberculosis genome by selection of white, hygromycin and kanamycin

resistant transformants followed by counter-selection on 5% sucrose as described
(Pavelka & Jacobs, 1999). Replacement of prpDC with the sequence encoding the
9aa peptide was confirmed by PCR analysis and Southern blot (not shown).

12.6. Gene expression analysis by real time RT-PCR

RNA preparation from infected tissues was done as described (Timm et ah,
2003). Bacteria were from mouse lungs of wild-type (C57BL/6) mice infected
with M. tuberculosis Erdman (1 x IO6 CFU/mouse, i.v.) or from cultures grown in
7H9 following standard conditions and harvested at mid-log phase.

12.6.1. Primers and Molecular Beacons. Primers with similar melting
temperatures (60-66°C) were designed by using PRIMER 3 software (Rozen &
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Skaletsky, 2000).

Primers were tested in P C R s with 100 Erdman genome

equivalents as template and the amplification products were evaluated by gel
electrophoresis. Molecular beacons (Tyagi & Kramer, 1996) were designed as
described (www.molecular-beacons.org); The beacon for icll was purified by J.
Timm at PHRI, NY. Standard curves were generated by using serial dilutions of
Erdman genomic DNA as template. The sequences of the beacon and primers for
icll gene expression analysis were the following:
Beacon: 5' -GCAGGCTGACGATGCCGCGGTGCTGGGCCTGC-3'
RT primer: 5'-CGGATCAGGTTGCGTACGTG-3'
Primerl: 5'-GCTCCAGCACCGAAGATCC-3'
Primer 2: 5' CTGTCGCTCGCTCATCTGC-3'
(Those for /c/7 have been reported before (Timm et ah, 2003)).

12.6.2. Reverse Transcription (RT) and QRT-PCR. QRT-PCRs were as
described (Manganelli et ah, 2001). Mock reactions (no RT) were done on each
RNA sample to rule out DNA contamination. Control reactions with uninfected
murine and human tissues were performed to rule out cross-hybridization. RT
reactions were performed with Klenow DNA polymerase from Carboxydothermus
hydrogenoformans (Roche Applied Science): annealing, 95°C (1 min), 65 °C (3

min), and 57 °C (3 min); polymerization, 60 °C (30 min); RT inactivation, 95°C (5
min). Real-time PCRs were run and were analyzed on an ABI7900 real-time PCR
machine. PCR conditions: AmpliTaq Gold activation, 95 °C (10 min); 15 cycles of
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95 °C (30 sec), 65 °C (0.5° stepdown each cycle, 30 sec), and 72°C (30 sec); 25
cycles of 95°C (30 sec), 57°C (30 sec), and 72°C (30 sec).

12.6.3. Normalization of Transcripts. For each RNA sample, the control
transcripts (sigA mRNA) and target mRNAs were reverse-transcribed together in
one reaction, and the resulting cDNAs were quantified by real-time PCR. The
target cDNA was normalized internally to the sigA cDNA levels in the same
sample and expressed as (Target rnRNA)/(.s/gA).

12.7. Biochemical procedures

12.7.1. Preparation of total cell extracts from mycobacterial cultures Cultures

of the different strains of M. tuberculosis (100-150 mL in roller bottles; OD600
0.7-1) or M. smegmatis (30 mL in shaking flasks; OD600 = 0.7-1.2) were grown to
late-log phase in 7H9-based CLDM broth (M. tuberculosis) or M9-broth (M.
smegmatis) supplemented as indicated above. Bacteria were washed three times in
PBS-Tween80 (0.05%) and resuspended in MOPS buffer (50mM
morpholinepropane sulfonate, 5mM MgC12, pH 6.8, supplemented with a protease

inhibitor cocktail (Sigma P-8465)) in 1/75* vol. of culture (M. tuberculosis) or
l/20th vol. of culture (M. smegmatis). Bacterial cells were disrupted by bead
beating (high power) for 3 cycles of 1 min pulses followed by 30 seconds of rest

(on ice). The cell-debris was removed by centrifugation, the extracts were filte
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(M. tuberculosis) (0.45 micron low-protein binding SpinX", Corning) and the
concentration of protein in the supernatants was measured using a Biorad (M .
smegmatis) or BCA (M .tuberculosis) protein assay kit (Pharmacia).

12.7.2. Isocitrate lyase assay. ICL activity was measured by following the lactat
dehydrogenase (LDH) mediated reduction of glyoxylate to glycolate, with
concomitant oxidation of NADH (Warren et ah, 1970). Reactions were performed
at room temperature in a 1ml assay volume containing: cell-free extract (10-100
Ug total protein in 5-50 |iL), 0.1 mM NADH and 7U LDH (Roche), in 50 mM
MOPS/5 mM MgC12 buffer. Reactions were preincubated for 5 min at room
temperature before being started by the addition of ImM threo-D-L-isocitrate
(Sigma). Isocitrate-stimulated NADH oxidation was determined
spectrophotometrically at 340nm using the standard extinction coefficient 6.22
mM-1 for a path length of 1cm.

12.7.3. Methylisocitrate lyase assay. Me-ICL activity was measured in
analogous fashion by following LDH mediated reduction of pyruvate to lactate,
with concomitant oxidation of NADH in a 1 mL reaction containing: cell-free
extract (10-100 [xg total protein in 5-50 u.L), 2 mM DTT, 0.2 mM NADH and 7U
LDH (Roche) in 50 mM MOPS/5mM MgC12 buffer. Reactions were started by
addition of 1 mM threo-D-L-2-methylisocitrate.
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12.7.4. Synthesis of threo-D-L-2-methylisocitrate. The following procedure is
based on those described in Plaut et ah, 1975 and Brock et ah, 2001, with
modifications.
Step 1. Trans-epoxymethylsuccinic acid. Mesaconic acid (10.0 gm, 76.8
mmol) was suspended in water (40 mL) and NaOH (6.1 g, 153.7 mmol) was added
portionwise. The resulting solution was cooled to 0 °C and Na2W04.2H20 (0.760
g, 2.3 mmol) was added, followed by dropwise addition of H202 (30% aqueous
solution, 9.6 mL, 84.55 mmol). After stirring at 0 °C for 1 h, the mixture was
heated at 65 °C. After 8 h, the reaction mixture was allowed to cool to RT and
evaporated to dryness. The residue was partitioned between water (10 mL), ethyl
acetate (100 mL) and ether (100 mL). Cone. H2S04 (8 mL) dissolved in ether (70
mL) was added and the mixture stirred at RT for 3 h. The organic layer was

separated, dried (Na2S04) and evaporated to obtain the epoxide as a white powder
(9.0 g).
lR NMR (Acetone-d6, 400 MHz): 5 1.58 (s, 3 H), 3.84 (s, 1 H).
Step 2. Dimethyl trans-epoxymethylsuccinate. S02C12 (5.6 mL, 75.3
mmol) was added to a solution of the epoxide (5 g, 34.2 mmol) in anhydrous
MeOH (50 mL) at 0 °C and the mixture stirred at RT for 8 h. The reaction mixture

was concentrated in vaccuo and the residue partitioned between ether and sat. aq
NaHC03. The ether layer was separated, dried and evaporated to afford the
dimethyl ester (5.2 g) which was used directly for the next reaction.
XH NMR (CDC13, 400 MHz): 8 1.63 (s, 3 H), 3.79, (s, 3 H), 3.83 (m, 4 H).
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Step

3.

2-Methyl-5-oxo-tetrahydrofuran-2,3,4-tricarbomethoxytetra-

hydrofuran. Sodium metal (0.69 g, 28.7 mmol) was added to previously cooled
anhydrous MeOH (15 mL) under argon atmosphere at 0 °C stirring until the metal
had dissolved. Dimethyl malonate (3.2 mL, 28.7 mmol) was added to the sodium
methoxide thus formed and the resulting mixture stirred at RT until a white
precipitate formed (20-30 min). Epoxide obtained in step II (5.0 g, 28.7mmol)
was added and the mixture stirred for 3 days at RT. Cone. HC1 was added and the
stirring continued for another 2 h. The solid formed (NaCl) was filtered, the

filtrate concentrated to afford crude lactone which was direcly used for the nex
reaction.
Step 4. 2-Methyl-5-oxo-tetrahydrofuran-2,3-dicarboxylic acid. To the
crude furan obtained (1.5 g) was added 6 N HC1 (50 mL) and the mixture refluxed
for 3 h. The reaction mixture was concentrated and to remove traces of HC1 the

residue was redissolved in water and evaporated. The brown residue thus obtained

was dissolved in water and treated with activated charcoal at 60 °C. After 30 mi
the mixture was filtered and the filtrate evaporated to afford colourless crude
lactone.
lH NMR (Acetone-d6, 400 MHz): 8 1.78 (s, 3 H), 2.78 - 2.84 (m, 1 H), 3.02 3.08 (m, 1 H), 3.60-3.63 (m, 1 H), 11.61 (S, 2H).
Step 5. Methyl Isocitrate. Water (10 mL) and NaOH (0.95g, 23.9 mmol)
were added to the compound obtained in the previous step (1.5 g) and the mixture
heated at 80 °C. At the end of 12 h, the solution was neutralised with Amberlite
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H + resin at p H 7. After the removal of the solvent, the residue was redissolved in
10 mL of water and treated with activated charcoal. The mixture was filtered and
the filtrate evaporated to afford the methyl isocitrate.

!H NMR (D20, 400 MHz): 8 1.32 (s, 3 H), 2.55-2.67 (m, 2 H), 3.14-3.16 (m, 1 H)

12.7.5. Southern Blots. -2 |ig of genomic DNA from the different strains
analyzed were digested with restriction enzymes (NEB), separated in 1% TBE
agarose gels, denatured with 0.5 NaOH, transferred to Hybond N membrane
(Amersham Labs.), and probed with inserts/PCR products from appropriate
plasmids/genomic DNA, labeled with 32P using a random priming labeling kit
(Boehringer Mannheim). Stringent conditions were used for hybridization (2 h at
65° C) and washings (20 min in 2X SSC, 0.1%(w/v) SDS at RT; 2X 15 min in IX
(1st) and 0.1X (2nd) SSC, 0.1% (w/v) SDS at 65° in rolling in oven). Specific
hybridization was detected by autoradiography.

12.8. Computer modeling and bioinformatics

12.8.1. Sequence Alignments. Guide tree of isocitrate lyases amino acid
sequences generated using Vector NTI Advance 9.0 AlignX, which uses the
Clustal W algorithm (Thompson et ah, 1994) to create an alignment from which a
tree is generated using the Neighbor Joining method (Saitou & Nei, 1987).

298

12.8.2. Bioinformatics and modeling. Nucleotide sequences of /c/7 (MT0483)
and icll (MT1966) ('http://www.tigr.org) were conceptually translated; protein
domains were identified with Pfam (http://www.sanger.ac.uk/Software/Pfam/) and
domain alignments were generated with CDD vl.62 (NCBI). Protein sequences
were aligned with PSI-BLAST (NCBI), and an ICL2 structure model.was
generated with MODELLER (http://salilab.org/modeller/modeller.html) by
threading on the structures of ICL1 (Sharma et al. 2000) and A. nidulans ICL
(Britton et al. 2000).

12.8.3. Static and dynamic models of host-pathogen equilibrium. A simple in
silico model of in vivo bacterial growth dynamics and host-pathogen equilibrium
was generated using Microsoft Excel (spreadsheet available upon request).
Figures referred to in this section are those in chapter 5. The following input

parameters were selected for generating the curves depicted in Fig. 5.1: inoculu
= 200 CFU; acute phase = 0-2 wk post-infection; chronic phase = 2-16 wk post-

infection; replication rate (population doubling time) during acute phase growth

24.6 h. These input parameters were selected in order to match the experimentall
determined parameters shown in Fig. 5.2A, but the model will accommodate any

set of input parameters. In our model (Fig. 5.1), the curves depicting viable CF
incorporate the potentially bactericidal impact of the immune response by

calculating pre- and post-killing CFU values on a daily basis. Different types o

equilibria (from fully static to fully dynamic or semi-dynamic scenarios) can be
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modeled by varying the growth rate and the killing rate during the chronic phase

of infection; in our specific case, the chronic phase was defined as 2-16 wk post
infection, although these parameters can also be varied as appropriate. "Prekilling" CFU values (CFUpre) on each successive day were calculated according
to the formula CFUpre = CFUi«eK-T, where CFUi is the number of CFU on the
preceding day (postkilling), K is the growth rate constant (in d-1) before
adjustment for host-mediated killing, and T = 1 d. "Post-killing" CFU values
(CFUpost) on each successive day were calculated according to the formula
CFUpost = CFUi»eK'«T, where CFUi is the number of CFU on the preceding day

(postkilling), K' is the growth rate constant (in d-1) after adjustment for immun
mediated killing, and T = 1 d. The "static" scenario (Fig. 5.1 A) was modeled by

setting K at 0 d-1 (^doubling time) during the chronic phase of infection (2-16
The "dynamic" scenario (Fig. 5.IB) was modeled by setting K at 0.6764 d-1 (24.6
h doubling time, identical to the acute-phase rate). The "partially dynamic"
scenarios, with bacterial cell division rates reduced by 50% (Fig. 5.1C) or 90%

(Fig. 5.ID) compared to the acute-phase rate, were modeled by setting K at 0.338

d-1 (49.2 h) or 0.0676 d6 (246.0 h), respectively. For illustrative purposes, th
curves in Fig. 5.1 were generated by setting K' = 0 during the chronic phase of
infection (2-16 w) in order to maintain a stable plateau in CFU numbers; more
complex scenarios (rising or falling CFU over time) can be modeled by
independently varying K and K' (as in Fig. 5.2A). Numbers of total chromosome
equivalents (tCEQ) on each successive day were calculated by summing the CEQ
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from viable bacteria ( v C E Q ) with those from dead bacteria (dCEQ), according to
the formula tCEQ = vCEQ + dCEQ, where vCEQ = CFUpost, and dCEQ = Sum
of (CFUpre - CFUpost) for each successive day inclusive of the current day. The
chromosomal ploidy of M. tuberculosis under different growth conditions is
unknown; in M. tuberculosis-infected mice the experimentally determined
bacterial CEQ/CFU ratio at 2 wk post-infection is typically 1-3 (Fig. 5.2, 5.3,

5.4; our unpublished results). For illustrative purposes, a ploidy value of 2 was

arbitrarily used to generate the curves in Fig. 5.1 in order to avoid overlap of
CFU and CEQ curves in Fig. 5.1 A. The ploidy value was conservatively set at 1

for the modeled curves depicted in Fig. 5.2A; higher ploidy values would lead to
more rapid divergence of the CEQ and CFU curves.

12.9. Statistical analysis

Data are represented as means; error bars indicate standard deviations from
the means. Student's Mest (two-tailed) was used to evaluate differences in
bacterial CFU and CEQ obtained from infected mouse lungs or from in silico
modeling. Trendlines were computed using the least-squares method.

301

P A R T V

CHAPTER 13

Bibliography

Aaron, L., D. Saadoun, I. Calatroni, O . Launay, N . M e m a i n , V- Vincent,
G . Marchal, B. Dupont, O . Bouchaud, D. Valeyre, and O . Lortholary.
2004. Tuberculosis in HIV-infected patients: a comprehensive review. Clin
Microbiol Infect 10:388-398.
Adams, L. B., C. M. Mason, J. K. Kolls, D. Scollard, J. L. Krahenbuhl,
and S. Nelson. 1995. Exacerbation of acute and chronic murine Tuberculosis
by administration of a tumor necrosis factor receptor-expressing adenovirus. J
Infect Dis 171:400-5.
Akins, D. R., E. Robinson, D. Shevchenko, C. Elkins, D. L. Cox, and J. D.
Radolf. 1997. Trompl, a putative rare outer membrane protein, is anchored by
an uncleaved signal sequence to the Treponema pallidum cytoplasmic
membrane. J Bacteriol 179:5076-86.
Alder, J. D., L. Friess, M. Tengowski, and R. F. Schell. 1990. Phagocytosis
of opsonized Treponema pallidum subsp. pallidum proceeds slowly. Infect
I m m u n 58:1167-73.
Algood, H. M., J. Chan, and J. L. Flynn. 2003. Chemokines and
Tuberculosis. Cytokine Growth Factor Rev 14:467-77.
Allen, J. H., M. Utley, H. van den Bosch, P. Nuijten, M. Witvliet, B. A.
M c C o r m i c k , K . A . Krogfelt, T. R. Licht, D. B r o w n , M . Mauel, M . P.
Leatham, D. C. Laux, and P. S. Cohen. 2000. A Functional cra Gene Is
Required for Salmonella enterica Serovar Typhimurium Virulence in B A L B / c
Mice. Infect. I m m u n . 68:3772-3775.
Altare, F., A. Durandy, D. Lammas, J. F. Emile, S. Lamhamedi, F. Le
Deist, P. Drysdale, E . Jouanguy, R. Doffinger, F. Bernaudin, O . Jeppsson,
J. A . Gollob, E . Meinl, A . W . Segal, A . Fischer, D. Kumararatne, and J. L.
Casanova. 1998. Impairment of mycobacterial immunity in h u m a n
interleukin-12 receptor deficiency. Science 280:1432-5.

302

Alvarez, H . M., and A . Steinbuchel. 2002. Triacylglycerols in prokaryotic
microorganisms. Appl Microbiol Biotechnol 60:367-76.
Alvarez, H. M., F. Mayer, D. Fabritius, and A. Steinbuchel. 1996.
Formation of intracytoplasmic lipid inclusions by Rhodococcus opacus strain
PD630. Arch Microbiol 165:377-86.
Alvarez, H. M., R. Kalscheuer, and A. Steinbuchel. 2000. Accumulation and
mobilization of storage lipids by Rhodococcus opacus P D 6 3 0 and
Rhodococcus ruber N C I M B 40126. Appl Microbiol Biotechnol 54:218-23.
Amarasingham, C. R., and B. D. Davis. 1965. Regulation of alphaketoglutarate dehydrogenase formation in Escherichia coli. J Biol C h e m
240:3664-8.
Andersen, P. 2001. TB vaccines: progress and problems. Trends Immunol
22:160-8.
Anderson, A. B., and W. A. Wood. 1969. Carbohydrate metabolism in
bacteria. Annu. Rev. Microbiol. 23:539-578.
Anderson, R. 1940. The chemistry of lipids of tubercle bacilli. Harvey Lect
35:271-313.
Argyrou, A. and J. S. Blanchard. 2001. Mycobacterium tuberculosis
lipoamide dehydrogenase is encoded by Rv0462 and not by the lpdA or lpdB
genes. Biochemistry 40:11353-63.
Armstrong, J. A. and P. D. Hart. 1971. Response of Cultured Macrophages
to Mycobacterium tuberculosis, with Observations on Fusion of Lysosomes
with Phagosomes. J Exp M e d 134:713-740.
Armstrong, J. A. and P. D. Hart. 1975. Phagosome-Lysosome Interactions in
Cultured Macrophages Infected with Virulent Tubercle Bacilli. J Exp M e d
142:1-16.
Arroll, T. W., A. Centurion-Lara, S. A. Lukehart, and W. C. Van Voorhis.
1999. T-Cell responses to Treponema pallidum subsp. pallidum antigens
during the course of experimental syphilis infection. Infect I m m u n 67:4757-63.
Ashworth, J. M., and H. L. Romberg. 1966. The anaplerotic fixation of
carbon dioxide by Escherichia coli. Proc R Soc Lond B Biol Sci 165:179-88.
Bafica, A., C. A. Scanga, M. L. Schito, S. Hieny, and A. Sher. 2003. Cutting

303

edge: in vivo induction of integrated HF/-1 expression by mycobacteria is
critically dependent on Toll-like receptor 2. J Immunol 171:1123-7.
Bai, N. J., M. R. Pai, P. S. Murthy, and T. A. Venkitasubramanian. 1982.
Fructose-bisphosphate aldolases from mycobacteria. Methods Enzymol 90 Pt
E:241-50.
Baker-Zander, S. A., and S. A. Lukehart. 1992. Macrophage-mediated
killing of opsonized Treponema pallidum. J Infect Dis 165:69-74.
Baker-Zander, S. A., E. W. d. Hook, P. Bonin, H. H. Handsfield, and S. A.
Lukehart. 1985. Antigens of Treponema pallidum recognized by IgG and I g M
antibodies during syphilis in humans. J Infect Dis 151:264-72.
Baker-Zander, S. A., J. M. Shaffer, and S. A. Lukehart. 1993.
Characterization of the serum requirement for macrophage-mediated killing of
Treponema pallidum ssp. pallidum: relationship to the development of
opsonizing antibodies. F E M S Immunol M e d Microbiol 6:273-9.
Baker-Zander, S. A., M. J. Fohn, and S. A. Lukehart. 1988. Development
of cellular immunity to individual soluble antigens of Treponema pallidum
during experimental syphilis. J Immunol 141:4363-9.
Balaban, N. Q., J. Merrin, R. Chait, L. Kowalik, and S. Leibler. 2004.
Bacterial persistence as a phenotypic switch. Science 305:1622-5.
Banerjee, A., E. Dubnau, A. Quemard, V. Balasubramanian, K. S. Um, T.
Wilson, D. Collins, G . de Lisle, and W . R. Jacobs, Jr. 1994. inhA, a gene
encoding a target for isoniazid and ethionamide in Mycobacterium
tuberculosis. Science 263:227-30.
Barbour, A. G. 1990. Antigenic variation of a relapsing fever Borrelia
species. A n n u Rev Microbiol 44:155-71.
Barbour, A. G. and S. F. Hayes. 1986. Biology of Borrelia species.
Microbiol Rev 50:381-400.
Barbour, A. G., S. L. Tessier, and H. G. Stoenner. 1982. Variable major
proteins of Borrelia hermsii. J Exp M e d 156:1312-24.
Barclay, W. R., R. H. Ebert, G. V. Le Roy, R. W. Manthei, and L. J. Roth.
1953. Distribution and excretion of radioactive isoniazid in tuberculosis
patients. J A M A 151:1384-1388.

304

Bardarov, S., J. Kriakov, C. Carriere, S. Y u , C . V a a m o n d e , R. A .
M c A d a m , B. R. Bloom, G. F. Hatfull, and W . R. Jacobs, Jr. 1997.
Conditionally replicating mycobacteriophages: a system for transposon
delivery to Mycobacterium Tuberculosis. Proc Natl Acad Sci U S A 94:109616.
Barnes, P. F., J. S. Abrams, S. Lu, P. A. Sieling, T. H. Rea, and R. L.
Modlin. 1993. Patterns of cytokine production by Mycobacterium-reactive
h u m a n T-cell clones. Infect I m m u n 61:197-203.
Barry, C. E., 3rd and K. Mdluli. 1996. Drug sensitivity and environmental
adaptation of mycobacterial cell wall components. Trends Microbiol 4:275-81.
Barthold, S. W. 1993. Antigenic stability of Borrelia burgdorferi during
chronic infections of immunocompetent mice. Infect. Immun.6l:4955-496l.
Barthold, S. W., M. S. de Souza, J. L. Janotka, A. L. Smith, and D. H.
Persing. 1993. Chronic L y m e borreliosis in the laboratory mouse. A m J Pathol
143:959-71.
Bassler, B. L. 1999. How bacteria talk to each other: regulation of gene
expression by quorum sensing. Curr Opin Microbiol 2:582-7.
Bean, A. G., D. R. Roach, H. Briscoe, M. P. France, H. Korner, J. D.
Sedgwick, and W . J. Britton. 1999. Structural deficiencies in granuloma
formation in T N F gene-targeted mice underlie the heightened susceptibility to
aerosol Mycobacterium Tuberculosis infection, which is not compensated for
by lymphotoxin. J Immunol 162:3504-11.
Bekker, L. G., A. L. Moreira, A. Bergtold, S. Freeman, B. Ryffel, and G.
Kaplan. 2000. Immunopathologic effects of tumor necrosis factor alpha in
murine mycobacterial infection are dose dependent. Infect I m m u n 68:6954-61.
Bekker, L. G., S. Freeman, P. J. Murray, B. Ryffel, and G. Kaplan. 2001.
TNF-alpha controls intracellular mycobacterial growth by both inducible nitric
oxide synthase-dependent and inducible nitric oxide synthase-independent
pathways. J Immunol 166:6728-34.
Belanger, A. E., G. S. Besra, M. E. Ford, K. Mikusova, J. T. Belisle, P. J.
Brennan, and J. M . Inamine. 1996. The e m b A B genes of Mycobacterium
avium encode an arabinosyl transferase involved in cell wall arabinan
biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc

305

Natl Acad Sci U S A 93:11919-24.
Bharadwaj, V. P., V. M. Katoch, V. D. Sharma, K. B. Kannan, A. K.
Datta, and C . T. Shivannavar. 1987. Metabolic studies on mycobacteria. IV.
Assay of isocitrate lyase and malate synthase activity in M . leprae. Indian J
Lepr 59:158-62.
Bifani, P. J., B. Mathema, N. E. Kurepina, and B. N. Kreiswirth. 2002.
Global dissemination of the Mycobacterium tuberculosis W-Beijing family
strains. Trends Microbiol 10:45-52.
Bigger, J. W. 1944. Treatment of staphylococcal infections with penicillin.
Lancet 2:497-500.
Bishop, N. H., and J. N. Miller. 1976a. Humoral immunity in experimental
syphilis. I. The demonstration of resistance conferred by passive immunization.
J Immunol 117:191-6.
Bishop, N. H., and J. N. Miller. 1976b. Humoral immunity in experimental
syphilis. IT. The relationship of neutralizing factors in i m m u n e serum to
acquired resistance. J Immunol 117:197-207.
Bjerknes, R., H. K. Guttormsen, C. O. Solberg, and L. M. Wetzler. 1995.
Neisserial porins inhibit h u m a n neutrophil actin polymerization, degranulation,
opsonin receptor expression, and phagocytosis but prime the neutrophils to
increase their oxidative burst. Infect I m m u n 63:160-7.

Black, F. L. 1975. Infectious diseases in primitive societies. Science 187:5158.
Black, P. N., N. J. Faergeman, and C. C. DiRusso. 2000. Long-chain acylCoA-dependent regulation of gene expression in bacteria, yeast and m a m m a l s .
J Nutr 130:305S-309S.
Blanco, D. R., J. N. Miller, and P. A. Hanff. 1984. Humoral immunity in
experimental syphilis: the demonstration of IgG as a treponemicidal factor in
i m m u n e rabbit serum. J Immunol 133:2693-7.
Blanco, D. R., J. N. Miller, and M. A. Lovett. 1997. Surface antigens of the
syphilis spirochete and their potential as virulence determinants. Emerg Infect
Dis 3:11-20.
Blaser, M. J., and J. C. Atherton. 2004. Helicobacter pylori persistence:

306

biology and disease. J. Clin. Invest. 113:321-333.
Blokpoel, M. C, H. N. Murphy, R. O'Toole, S. Wiles, E. S. Runn, G. R.
Stewart, D. B. Young, and B. D. Robertson. 2005. Tetracycline-inducible
gene regulation in mycobacteria. Nucleic Acids Res 33:e22.
Bloom, B. R., and C. J. Murray. 1992. Tuberculosis: commentary on a
reemergent killer. Science 257:1055-64.
Blower, S. M., A. R. McLean, T. C. Porco, P. M. Small, P. C. Hopewell, M.
A . Sanchez, and A . R. Moss. 1995. The intrinsic transmission dynamics of
Tuberculosis epidemics. Nat M e d 1:815-21.
Bodnar, K. A., N. V. Serbina, and J. L. Flynn. 2001. Fate of Mycobacterium
tuberculosis within murine dendritic cells. Infect I m m u n 69:800-9.
Borst, P., and D. R. Greaves. 1987. Programmed gene rearrangements
altering gene expression. Science 235:658-67.
Boshoff, H. I., and C. E. Barry, 3rd. 2005. Tuberculosis - metabolism and
respiration in the absence of growth. Nat Rev Microbiol 3:70-80.
Botha, T., and B. Ryffel. 2003. Reactivation of Latent Tuberculosis Infection
in TNF-Deficient Mice J Immunol 171:3110-3118.
Bouley, D. M., N. Ghori, K. L. Mercer, S. Falkow, and L. Ramakrishnan.
2001. Dynamic nature of host-pathogen interactions in Mycobacterium
marinum granulomas. Infect I m m u n 69:7820-31.
Boulton, I. C. and S. D. Gray-Owen. 2002. Neisserial binding to CEACAM1
arrests the activation and proliferation of C D 4 + T lymphocytes. Nat Immunol
3:229-36.
Bramer, C. O., and A. Steinbuchel. 2001. The methylcitric acid pathway in
Ralstonia eutropha: n e w genes identified involved in propionate metabolism.
Microbiology 147:2203-2214.
Brennan, P. J. 2003. Structure, function, and biogenesis of the cell wall of
Mycobacterium tuberculosis. Tuberculosis 83:91-97.
Brill, K. J., Q. Li, R. Larkin, D. H. Canaday, D. R. Kaplan, W. H. Boom,
and R. F. Silver. 2001. H u m a n natural killer cells mediate killing of
intracellular Mycobacterium

tuberculosis H 3 7 R v

307

via granule-independent

mechanisms. Infect I m m u n 69:1755-65.
Britton, K., S. Langridge, P. J. Baker, K. Weeradechapon, S. E.
Sedelnikova, J. R. D e Lucas, D. W . Rice, and G. Turner. 2000. The crystal
structure and active site location of isocitrate lyase from the fungus Aspergillus
nidulans. Structure Fold Des 8:349-62.
Britton, W. J., and D. N. Lockwood. 2004. Leprosy. Lancet 363:1209-19.
Brock, M., D. Darley, S. Textor, and W. Buckel. 2001. 2-Methylisocitrate
lyases from the bacterium Escherichia coli and the filamentous fungus
Aspergillus nidulans: characterization and comparison of both enzymes. Eur J
Biochem 268:3577-86.
Brodsky, I. E., N. Ghori, S. Falkow, and D. Monack. 2005. Mig-14 is an
inner membrane-associated protein that promotes Salmonella typhimurium
resistance to C R A M P , survival within activated macrophages and persistent
infection. M o l Microbiol 55:954-72.
Brooks, G. F. and C. J. Lammel. 1989. Humoral immune response to
gonococcal infections. Clin Microbiol Rev 2 Suppl:S5-10.
Brosch, R., A. S. Pym, S. V. Gordon, and S. T. Cole. 2001. The evolution of
mycobacterial pathogenicity: clues from comparative genomics. Trends
Microbiol 9:452-8.
Brown, T. D., M. C. Jones-Mortimer, and H. L. Kornberg. 1977. The
enzymic interconversion of acetate and acetyl-coenzyme A in Escherichia coli.
J G e n Microbiol 102:327-36.
Bryk, R., C. D. Lima, H. Erdjument-Bromage, P. Tempst, and C. Nathan.
2002. Metabolic enzymes of mycobacteria linked to antioxidant defense by a
thioredoxin-like protein. Science 295:1073-7.
Buchmeier, N., A. Blanc-Potard, S. Ehrt, D. Piddington, L. Riley, and E.
A . Groisman. 2000. A parallel intraphagosomal survival strategy shared by
Mycobacterium tuberculosis and Salmonella enterica. M o l Microbiol 35:137582.
Caceres, N. E., N. B. Harris, J. F. Wellehan, Z. Feng, V. Kapur, and R. G.
Barletta. 1997. Overexpression of the D-alanine racemase gene confers
resistance to D-cycloserine
179:5046-55.

in Mycobacterium

308

smegmatis. J Bacteriol

Cadavid, D., D. D. T h o m a s , R. Crawley, and A . G . Barbour. 1994.
Variability of a bacterial surface protein and disease expression in a possible
mouse model of systemic L y m e borreliosis. J Exp M e d 179:631-42.
Cadavid, D., P. M. Pennington, T. A. Kerentseva, S. Bergstrom, and A. G.
Barbour. 1997. Immunologic and genetic analyses of V m p A of a neurotropic
strain of Borrelia turicatae. Infect I m m u n 65:3352-3360.
Campbell, J. W. and J. E. Cronan, Jr. 2001. Bacterial fatty acid
biosynthesis: targets for antibacterial drug discovery. A n n u Rev Microbiol
55:305-32.
Canetti. 1960. Studies of bacillary populations in experimental Tuberculosis
of mice treated with isoniazid. A m . Rev. Resp. Dis. 82:295-313.
Capuano, S. V., Ill, D. A. Croix, S. Pawar, A. Zinovik, A. Myers, P. L. Lin,
S. Bissel, C. F u h r m a n , E . Klein, and J. L. Flynn. 2003. Experimental
Mycobacterium tuberculosis Infection of Cynomolgus macaques Closely
Resembles the Various Manifestations of H u m a n M . tuberculosis Infection.
Infect. I m m u n . 71:5831-5844.
Caruso, A. M., N. Serbina, E. Klein, K. Triebold, B. R. Bloom, and J. L.
Flynn. 1999. Mice deficient in C D 4 T cells have only transiently diminished
levels of IFN-y, yet succumb to Tuberculosis. J Immunol 162:5407-16.
Casal, M., and M. J. Linares. 1984. Enzymatic profile of Mycobacterium
tuberculosis. Eur J Clin Microbiol 3:155-6.
Casjens, S., N. Palmer, R. van Vugt, W. M. Huang, B. Stevenson, P. Rosa,
R. Lathigra, G. Sutton, J. Peterson, R. J. Dodson, D. Haft, E . Hickey, M .
G w i n n , O . White, and C . M . Fraser. 2000. A bacterial genome in flux: the
twelve linear and nine circular extrachromosomal D N A s in an infectious
isolate of the L y m e disease spirochete Borrelia burgdorferi. M o l Microbiol
35:490-516.
Centurion-Lara, A., C. Castro, L. Barrett, C. Cameron, M. Mostowfi, W.
C . V a n Voorhis, and S. A . Lukehart. 1999. Treponema pallidum major
sheath protein homologue Tpr K is a target of opsonic antibody and the
protective i m m u n e response [published erratum appears in J Exp M e d 1999
189(11): 1852]. J Exp M e d 189:647-56.
Centurion-Lara, A., C. Godornes, C. Castro, W. C. Van Voorhis, and S. A.

309

Lukehart. 2000. The tprK gene is heterogeneous among Treponema pallidum
strains and has multiple alleles. Infect I m m u n 68:824-31.
Chaisson, R. E., G. F. Schecter, C. P. Theuer, G. W. Rutherford, D. F.
Echenberg, and P. C. Hopewell. 1987. Tuberculosis in patients with the
acquired immunodeficiency syndrome. Clinical features, response to therapy,
and survival. A m Rev Respir Dis 136:570-4.
Chamnongpol, S., and E. A. Groisman. 2000. Acetyl phosphate-dependent
activation of a mutant PhoP response regulator that functions independently of
its cognate sensor kinase. J M o l Biol 300:291-305.
Chan, J., K. Tanaka, D. Carroll, J. Flynn, and B. R. Bloom. 1995. Effects
of nitric oxide synthase inhibitors on murine infection with Mycobacterium
tuberculosis. Infect I m m u n 63:736-40.
Chan, J., Y. Xing, R. S. Magliozzo, and B. R. Bloom. 1992. Killing of
virulent Mycobacterium tuberculosis by reactive nitrogen intermediates
produced by activated murine macrophages. J Exp M e d 175:1111-22.
Chang, D.-E., D. J. Smalley, D. L. Tucker, M. P. Leatham, W. E. Norris, S.
J. Stevenson, A . B. Anderson, J. E . Grissom, D. C. Laux, P. S. Cohen, and
T. C o n w a y . 2004. Carbon nutrition of Escherichia coli in the mouse intestine.
Proc Natl Acad Sci U S A 101:7427-7432.
Chang, D.-E., S. Shin, J.-S. Rhee, and J.-G. Pan. 1999. Acetate Metabolism
in a pta Mutant of Escherichia coli W 3 1 1 0 : Importance of Maintaining Acetyl
Coenzyme A Flux for Growth and Survival. J. Bacteriol. 181:6656-6663.
Chen, L., Q. W. Xie, and C. Nathan. 1998. Alkyl hydroperoxide reductase
subunit C (AhpC) protects bacterial and h u m a n cells against reactive nitrogen
intermediates. M o l Cell 1:795-805.
Chin, A. M., D. A. Feldheim, and M. H. Saier, Jr. 1989. Altered
transcriptional patterns affecting several metabolic pathways in strains of
Salmonella typhimurium which overexpress the fructose regulon. J Bacteriol
171:2424-34.
Claes, W. A., A. Puhler, and J. Kalinowski. 2002. Identification of two
p r p D B C gene clusters in Corynebacterium glutamicum and their involvement
in propionate degradation via the 2- methylcitrate cycle. J Bacteriol 184:272839.

310

Clark, D. P. 1989. The fermentation pathways of Escherichia coli. F E M S
Microbiol Rev 5:223-34.
Clemens, D. L. 1996. Characterization of the Mycobacterium tuberculosis
phagosome. Trends Microbiol 4:113-8.
Clemens, D. L., and M. A. Horwitz. 1995. Characterization of the
Mycobacterium tuberculosis phagosome and evidence that phagosomal
maturation is inhibited. J Exp M e d 181:257-70.
Clemens, D. L., and M. A. Horwitz. 1996. The Mycobacterium tuberculosis
phagosome interacts with early endosomes and is accessible to exogenously
administered transferrin. J Exp M e d 184:1349-55.
Clemens, D. L., B. Y. Lee, and M. A. Horwitz. 2002. The Mycobacterium
tuberculosis phagosome in h u m a n macrophages is isolated from the host cell
cytoplasm. Infect I m m u n 70:5800-7.
Cole, S. T. 2002. Comparative and functional genomics of the Mycobacterium
tuberculosis complex. Microbiology 148:2919-28.
Cole, S. T., K. Eiglmeier, J. Parkhill, K. D. James, N. R. Thomson, P. R.
Wheeler, N . Honore, T. Garnier, C. Churcher, D. Harris, K . Mungall, D.
B a s h a m , D. B r o w n , T. Chillingworth, R. Connor, R. M . Davies, K . Devlin,
S. Duthoy, T. Feltwell, A . Fraser, N . Hamlin, S. Holroyd, T. Hornsby, K .
Jagels, C . Lacroix, J. Maclean, S. Moule, L. M u r p h y , K . Oliver, M . A .
Quail, M . A . Rajandream, K . M . Rutherford, S. Rutter, K . Seeger, S.
Simon, M . S i m m o n d s , J. Skelton, R. Squares, S. Squares, K . Stevens, K .
Taylor, S. Whitehead, J. R. W o o d w a r d , and B. G. Barrell. 2001. Massive
gene decay in the leprosy bacillus. Nature 409:1007-11.
Cole, S. T., R. Brosch, J. Parkhill, T. Garnier, C. Churcher, D. Harris, S.
V . Gordon, K . Eiglmeier, S. Gas, C. E . Barry, 3rd, F. Tekaia, K . Badcock,
D. B a s h a m , D. B r o w n , T. Chillingworth, R. Connor, R. Davies, K . Devlin,
T. Feltwell, S. Gentles, N . Hamlin, S. Holroyd, T. Hornsby, K . Jagels, B.
G . Barrell, and et al. 1998. Deciphering the biology of Mycobacterium
tuberculosis from the complete genome sequence. Nature 393:537-44.
Collins, D. M., T. Wilson, S. Campbell, B. M. Buddie, B. J. Wards, G.
Hotter, and G . W . D e Lisle. 2002. Production of avirulent mutants of
Mycobacterium bovis with vaccine properties by the use of illegitimate
recombination

and

screening of stationary-phase cultures. Microbiology

148:3019-27.

311

Cordwell, S. J. 1999. Microbial genomes and "missing" enzymes: redefining
biochemical pathways. Arch Microbiol 172:269-79.
Comstock, G . W . 1982. Epidemiology of Tuberculosis. A m Rev Respir Dis
125:8-15.
Cooper, A. M., A. Kipnis, J. Turner, J. Magram, J. Ferrante, and I. M.
O r m e . 2002. Mice lacking bioactive IL-12 can generate protective, antigenspecific cellular responses to mycobacterial infection only if the IL-12 p40
subunit is present. J Immunol 168:1322-7.
Cooper, A. M., C. D'Souza, A. A. Frank, and I. M. Orme. 1997. The course
of Mycobacterium tuberculosis infection in the lungs of mice lacking
expression of either perforin- or granzyme-mediated cytolytic mechanisms.
Infect I m m u n 65:1317-20.
Cooper, A. M., D. K. Dalton, T. A. Stewart, J. P. Griffin, D. G. Russell,
and I. M . O r m e . 1993. Disseminated tuberculosis in interferon g a m m a genedisrupted mice. J Exp M e d 178:2243-7.
Cooper, A. M., J. E. Pearl, J. V. Brooks, S. Ehlers, and I. M. Orme. 2000.
Expression of the nitric oxide synthase 2 gene is not essential for early control
of Mycobacterium tuberculosis in the murine lung. Infect I m m u n 68:6879-82.
Cooper, R. A., and A. Anderson. 1970. The formation and catabolism of
methylglyoxal during glycolysis in Escherichia coli. F E B S Lett 11:273-276.
Cooper, R. A., and H. L. Kornberg. 1965. Net formation of
phosphoenolpyruvate from pyruvate by Escherichia coli. Biochim Biophys
Acta 104:618-20.
Corbett, E. L., C. J. Watt, N. Walker, D. Maher, B. G. Williams, M. C.
Raviglione, and C. Dye. 2003. The growing burden of tuberculosis: global
trends and interactions with the H I V epidemic. Arch Intern M e d 163:1009-21.
Cornah, J. E., V. Germain, J. L. Ward, M. H. Beale, and S. M. Smith.
2004. Lipid utilization, gluconeogenesis, and seedling growth in Arabidopsis
mutants lacking the G C enzyme malate synthase. J Biol C h e m 279:42916-23.
Cortay, J. C, D. Negre, A. Galinier, B. Duclos, G. Perriere, and A. J.
Cozzone. 1991. Regulation of the acetate operon in Escherichia coli:
purification and functional characterization of the IclR repressor. E m b o J
10:675-9.

312

Costerton, J. W . , P. S. Stewart, and E . P. Greenberg. 1999. Bacterial
biofilms: a c o m m o n cause of persistent infections. Science 284:1318-22.
Costerton, J. W., Z. Lewandowski, D. E. Caldwell, D. R. Korber, and H.
M . Lappin-Scott. 1995. Microbial biofilms. A n n u Rev Microbiol 49:711-45.
Cowley, S. C, and K. L. Elkins. 2003. CD4+ T Cells Mediate IFN-yIndependent Control of Mycobacterium tuberculosis Infection Both In Vitro
and In Vivo. J Immunol 171:4689-4699.
Cox, D. L., P. Chang, A. W. McDowall, and J. D. Radolf. 1992. The outer
membrane, not a coat of host proteins, limits antigenicity of virulent
Treponema pallidum. Infect I m m u n 60:1076-83.
Cox, G. M., H. C. McDade, S. C. Chen, S. C. Tucker, M. Gottfredsson, L.
C . Wright, T. C . Sorrell, S. D. Leidich, A . Casadevall, M . A . G h a n n o u m ,
and J. R. Perfect. 2001. Extracellular phospholipase activity is a virulence
factor for Cryptococcus neoformans. M o l Microbiol 39:166-75.
Cozzone, A. J. 1998. Regulation of acetate metabolism by protein
phosphorylation in enteric bacteria. A n n u Rev Microbiol 52:127-64.
Crawford, C, J. S. Knapp, J. Hale, and K. K. Holmes. 1977. Asymptomatic
gonorrhea in men: caused by gonococci with unique nutritional requirements.
Science 196:1352-3.
Cronan Jr., J. E., and D. LaPorte. 1996. Tricarboxylic Acid Cycle and
Glyoxylate Bypass. In: F. C. Neidhardt, J. L. Ingraham, K. B. L o w , B.
Magasanik, M . Schaechter, and H. E. Umbarger (Ed.), Escherichia coli and
Salmonella: cellular and molecular biology, 2nd ed., vol. 1. A S M Press,
Washington, D.C.
Cronan, J. E., Jr., and S. Subrahmanyam. 1998. FadR, transcriptional coordination of metabolic expediency. M o l Microbiol 29:937-43.
Cucurull, E. and L. R. Espinoza. 1998. Gonococcal arthritis. Rheum Dis Clin
North A m 24: 305-322.
C z e r m a k , B. J., V . S a r m a , N . M . Bless, H . Schmal, H . P. Friedl, and P. A .
W a r d . 1999. In vitro and in vivo dependency of chemokine generation on C 5 a
and TNF-alpha. J Immunol 162:2321-5.
Dahl, J. L., C. N. Kraus, H. I. Boshoff, B. Doan, K. Foley, D. Avarbock, G.

313

Kaplan, V . Mizrahi, H . Rubin, and C. E . Barry, 3rd. 2003. The role of
RelMtb-mediated adaptation to stationary phase in long-term persistence of
Mycobacterium tuberculosis in mice. Proc Natl Acad Sci U S A 100:10026-31.
Dalton, D. K., S. Pitts-Meek, S. Keshav, I. S. Figari, A. Bradley, and T. A.
Stewart. 1993. Multiple defects of i m m u n e cell function in mice with
disrupted interferon-gamma genes. Science 259:1739-42.
Danaher, R. J., J. C. Levin, D. Arking, C. L. Burch, R. Sandlin, and D. C.
Stein. 1995. Genetic basis of Neisseria gonorrhoeae lipooligosaccharide
antigenic variation. J Bacteriol 177:7275-9.
Daniel, T. M., J. H. Bates, and K. A. Downes. 1994. History of Tuberculosis,
p.13-24. In: B. R. Bloom (Ed.) Tuberculosis: Pathogenesis, Protection and
Control. A S M Press, Washington, D.C.
Dannenberg Jr., A. M., and G. A. W. Rook. 1994a. Pathogenesis of
pulmonary tuberculosis: an interplay of tissue-damaging and macrophageactivating i m m u n e responses-dual mechanisms that control bacillary
multiplication, p. 459-484. In: B.R. Bloom (Ed.), Tuberculosis, Pathogenesis,
Protection and Control. A S M Press, Washington D.C.
Dannenberg Jr., A. M., and G. A. W. Rook. 1994b. Rabbit Model of
Tuberculosis, p. 149-156. In: B.R. B l o o m (Ed.), Tuberculosis, Pathogenesis,
Protection and Control. A S M Press, Washington D.C.
Darnell, J. E., Jr. 1997. STATs and Gene Regulation. Science 277:16301635.
Darwin, K. H., S. Ehrt, J. C. Gutierrez-Ramos, N. Weich, and C. F.
Nathan. 2003. The proteasome of Mycobacterium tuberculosis is required for
resistance to nitric oxide. Science 302:1963-6.
Das, S., S. W. Barthold, S. S. Giles, R. R. Montgomery, S. R. Telford, 3rd,
and E . Fikrig. 1997. Temporal pattern of Borrelia burgdorferi p21 expression
in ticks and the mammalian host. J Clin Invest 99:987-95.
David, H. L., K. Takayama, and D. S. Goldman. 1969. Susceptibility of
mycobacterial D-alanyl-D-alanine synthetase to D-cycloserine. A m Rev Respir
Dis 100:579-81.
Davies, D. G., M. R. Parsek, J. P. Pearson, B. H. Iglewski, J. W. Costerton,
and E . P. Greenberg. 1998. The involvement of cell-to-cell signals in the

314

development of a bacterial biofilm. Science 280:295-8.
de Kruif, P. 1926. Microbes Hunters. Pocket Books, Inc., New York. NY.
de Silva, A. M., and E. Fikrig. 1997. Arthropod- and host-specific gene
expression by Borrelia burgdorferi. J Clin Invest 99:377-9.
de Silva, A. M., S. R. Telford, 3rd, L. R. Brunet, S. W. Barthold, and E.
Fikrig. 1996. Borrelia burgdorferi O s p A
is an arthropod-specific
transmission-blocking L y m e disease vaccine. J Exp M e d 183:271-5.
De Voss, J. J., K. Rutter, B. G. Schroeder, H. Su, Y. Zhu, and C. E. Barry,
3rd. 2000. The salicylate-derived mycobactin siderophores of Mycobacterium
tuberculosis are essential for growth in macrophages. Proc Natl Acad Sci U S A
97:1252-7.
de Wit, D., M. Wootton, J. Dhillon, and D. A. Mitchison. 1995. The
bacterial D N A content of mouse organs in the Cornell model of dormant
tuberculosis. Tuber Lung Dis 76:555-62.
Dehio, C, S. D. Gray-Owen, and T. F. Meyer. 1998. The role of neisserial
O p a proteins in interactions with host cells. Trends Microbiol 6:489-95.
Dehio, C, S. D. Gray-Owen, and T. F. Meyer. 2000. Host cell invasion by
pathogenic Neisseriae. Subcell Biochem 33:61-96.
Deitsch, K. W., E. R. Moxon, and T. E. Wellems. 1997. Shared themes of
antigenic variation and virulence in bacterial, protozoal, and fungal infections.
Microbiol M o l Biol Rev 61:281-93.
Diesterhaft, M. D. and E. Freese. 1973. Role of Pyruvate Carboxylase,
Phosphoenolpyruvate Carboxykinase, and Malic E n z y m e during Growth and
Sporulation of Bacillus subtilis. J. Biol. Chem. 248:6062-6070.
Doelle, H. W. 1975. ATP-sensitive and ATP-insensitive phosphofructokinase
in Escherichia coli K-12. Eur J Biochem 50:335-42.
Drake, D. and T. C. Montie. 1988. Flagella, motility and invasive virulence
of Pseudomonas aeruginosa. J G e n Microbiol 134:43-52.
Drenkard, E. and F. M. Ausubel. 2002. Pseudomonas biofilm formation and
antibiotic resistance are linked to phenotypic variation. Nature 416:740-3.

315

Drlica, K., C. X u , J. Y . W a n g , R. M . Burger, and M . Malik. 1996.
Fluoroquinolone action in mycobacteria: similarity with effects in Escherichia
coli and detection by cell lysate viscosity. Antimicrob Agents Chemother
40:1594-9.
Dubnau, E. and I. Smith. 2003. Mycobacterium tuberculosis gene expression
in macrophages. Microbes Infect 5:629-37.
Dubnau, E., Chan, J., Mohan, V.P., and Smith, I. (2005) Responses of
Mycobacterium tuberculosis to growth in the mouse lung. Infect I m m u n 73:
3754-3757.
Dubois, A., A. Welch, D. E. Berg, and M. J. Blaser. 2000. Helicobacter
pylori, p. 263-280. In: J. P. Nataro, M . J. Blaser, and S. Cunningham-Rundles
(Ed.), Persistent Bacterial Infections. A S M Press, Washington, D. C.
Dubos, R. J. and G. Middlebrook. 1947. Media for tubercle bacilli. J Exp
M e d 56:334-345.
Dutta, U., P. K. Garg, R. Kumar, and R. K. Tandon. 2000. Typhoid carriers
among patients with gallstones are at increased risk for carcinoma of the
gallbladder. A m J Gastroenterol 95:784-7.
Dye, C, B. G. Williams, M. A. Espinal, and M. C. Raviglione. 2002.
Erasing the world's slow stain: strategies to beat multidrug-resistant
tuberculosis. Science 295:2042-2046.
Dye, C, S. Scheele, P. Dolin, V. Pathania, and M. C. Raviglione. 1999.
Consensus statement. Global burden of tuberculosis: estimated incidence,
prevalence, and mortality by country. W H O Global Surveillance and
Monitoring Project. J A M A 282:677-86.
Eastmond, P. J., V. Germain, P. R. Lange, J. H. Bryce, S. M. Smith, and I.
A . G r a h a m . 2000. Postgerminative growth and lipid catabolism in oilseeds
lacking the glyoxylate cycle. Proc Natl Acad Sci U S A 97:5669-74.
Ehlers, S., J. Benini, S. Kutsch, R. Endres, E. T. Rietschel, and K. Pfeffer.
1999. Fatal granuloma necrosis without exacerbated mycobacterial growth in
tumor necrosis factor receptor p55 gene-deficient mice intravenously infected
with Mycobacterium avium. Infect I m m u n 67:3571-9.
Ehrt, S., D. Schnappinger, S. Bekiranov, J. Drenkow, S. Shi, T. R.
Gingeras, T. Gaasterland, G . Schoolnik, and C . Nathan. 2001.

316

Reprogramming of the Macrophage Transcriptome in Response to Interferon-y
and Mycobacterium tuberculosis: Signaling Roles of Nitric Oxide Synthase-2
and Phagocyte Oxidase. J. Exp. M e d . 194:1123-1140.
Ehrt, S., X. V. Guo, C. M. Hickey, M. Ryou, M. Monteleone, L. W. Riley,
and D. Schnappinger. 2005. Controlling gene expression in mycobacteria
with anhydrotetracycline and Tet repressor. Nucleic Acids Res 33:e21.
El-Sadr, W. M., D. C. Perlman, E. Denning, J. P. Matts, and D. L. Cohn.
2001. A review of efficacy studies of 6-month short-course therapy for
tuberculosis among patients infected with h u m a n immunodeficiency virus:
differences in study outcomes. Clin Infect Dis 32:623-32.
Emmerling, M., M. Dauner, A. Ponti, J. Fiaux, M. Hochuli, T. Szyperski,
K . Wuthrich, J. E . Bailey, and U . Sauer. 2002. Metabolic Flux Responses to
Pyruvate Kinase Knockout in Escherichia coli. J. Bacteriol. 184:152-164.
Eng, R. H., F. T. Padberg, S. M. Smith, E. N. Tan, and C. E. Cherubin.
1991. Bactericidal effects of antibiotics on slowly growing and nongrowing
bacteria. Antimicrob Agents Chemother 35:1824-8.
Entner, N. and M. Doudoroff. 1952. Glucose And Gluconic Acid Oxidation
O f Pseudomonas saccharophila. J. Biol. Chem. 196:853-862.
Eriksson, S., S. Lucchini, A. Thompson, M. Rhen, and J. C. D. Hinton.
2003. Unravelling the biology of macrophage infection by gene expression
profiling of intracellular Salmonella enterica. M o l Microbiol 47:103-118.
Ernst, J. D. 1998. Macrophage receptors for Mycobacterium tuberculosis.
Infect I m m u n 66:1277-81.
Evans, C. T., B. Sumegi, P. A. Srere, A. D. Sherry, and C. R. Malloy. 1993.
[13C]propionate oxidation in wild-type and citrate synthase mutant
Escherichia coli: evidence for multiple pathways of propionate utilization.
Biochem J 291:927-32.
Evans, D. J., D. G. Allison, M. R. Brown, and P. Gilbert. 1991.
Susceptibility of Pseudomonas aeruginosa and Escherichia coli biofilms
towards ciprofloxacin: effect of specific growth rate. J Antimicrob Chemother
27:177-84.
Evans, J. 1999. Lyme Disease. Current Opinion in Rheumatology 11:281-288.

317

Fang, F. C , S. J. Libby, M . E . Castor, and A . M . Fung. 2005. Isocitrate
lyase (AceA) is required for Salmonella persistence but not for acute lethal
infection in mice. Infect I m m u n 73:2547-9.
Farmer, P. 1996. Social inequalities and emerging infectious diseases. Emerg
Infect Dis 2:259-69.
Farmer, P. and N. G. Campos. 2004. Rethinking medical ethics: a view from
below. Developing World Bioeth 4:17-41.
Farmer, P., S. Robin, S. L. Ramilus, and J. Y. Kim. 1991. Tuberculosis,
poverty, and "compliance": lessons from rural Haiti. Semin Respir Infect
6:254-60.
Fauci, A. S. 1996. Host factors and the pathogenesis of HIV-induced disease.
Nature 384:529-34.
Feldman, M., R. Bryan, S. Rajan, L. Scheffler, S. Brunnert, H. Tang, and
A . Prince. 1998. Role of flagella in pathogenesis of Pseudomonas aeruginosa
pulmonary infection. Infect I m m u n 66:43-51.
Feldman, W. H., and A. H. Baggentoss. 1938. The residual infectivity of the
primary complex of tuberculosis. A m . J. Pathol. 14:473-490.
Feldman, W. H., and A. H. Baggentoss. 1939. The occurrence of virulent
tubercle bacilli in presumably non-tuberculous lung tissue. A m . J. Pathol.
15:501.
Feng, C. G., A. G. Bean, H. Hooi, H. Briscoe, and W. J. Britton. 1999.
Increase in g a m m a interferon-secreting CD8(+), as well as CD4(+), T cells in
lungs following aerosol infection with Mycobacterium tuberculosis. Infect
I m m u n 67:3242-7.
Feng, C. G., C. M. Collazo-Custodio, M. Eckhaus, S. Hieny, Y. Belkaid, K.
Elkins, D. Jankovic, G . A . Taylor, and A . Sher. 2004. Mice deficient in
L R G - 4 7 display increased susceptibility to mycobacterial infection associated
with the induction of lymphopenia. J Immunol 172:1163-8.
Feng, C. G., D. Jankovic, M. Kullberg, A. Cheever, C. A. Scanga, S. Hieny,
P. Caspar, G . S. Y a p , and A . Sher. 2005. Maintenance of Pulmonary Thl
Effector Function in Chronic Tuberculosis Requires Persistent IL-12
Production. J Immunol 174:4185-4192.

318

Fenner, F. and B. Fantini. 1999. Biological Control of Vertebrate Pests: The
History of Myxomatosis - an Experiment in Evolution. C A B I Publishing, N e w
York, N Y .
Ferrari, G., H. Langen, M. Naito, and J. Pieters. 1999. A coat protein on
phagosomes involved in the intracellular survival of mycobacteria. Cell
97:435-47.
Fidock, D. A., P. J. Rosenthal, S. L. Croft, R. Brun, and S. Nwaka. 2004.
Antimalarial drug discovery: efficacy models for compound screening. Nat
Rev Drug Discov 3:509-20.
Fields, P. I., R. V. Swanson, C. G. Haidaris, and F. Heffron. 1986. Mutants
of Salmonella typhimurium that cannot survive within the macrophage are
avirulent. Proc Natl Acad Sci U S A 83:5189-93.
Figueroa, J. E. and P. Densen. 1991. Infectious diseases associated with
complement deficiencies. Clin. Microbiol. Rev. 4: 359-395
Fikrig, E., H. Tao, F. S. Kantor, S. W. Barthold, and R. A. Flavell. 1993.
Evasion of protective immunity by Borrelia burgdorferi by truncation of outer
surface protein B. Proc Natl Acad Sci U S A 90:4092-6.
Fikrig, E., L. K. Bockenstedt, S. W. Barthold, M. Chen, H. Tao, P. AliSalaam, S. R. Telford, and R. A . Flavell. 1994. Sera from patients with
chronic L y m e disease protect mice from L y m e borreliosis. J Infect Dis
169:568-74.
Fikrig, E., M. Chen, S. W. Barthold, J. Anguita, W. Feng, S. R. Telford,
3rd, and R. A . Flavell. 1999. Borrelia burgdorferi erpT expression in the
arthropod vector and murine host. M o l Microbiol 31:281-90.
Finken, M., P. Kirschner, A. Meier, A. Wrede, and E. C. Bottger. 1993.
Molecular basis of streptomycin resistance in Mycobacterium tuberculosis:
alterations of theribosomalprotein S12 gene and point mutations within a
functional 16S ribosomal R N A pseudoknot. M o l Microbiol 9:1239-46.
Fischer, E. and U. Sauer. 2003. A novel metabolic cycle catalyzes glucose
oxidation and anaplerosis in hungry Escherichia coli. J Biol C h e m 278:4644651.
Fitzgerald, T. J. 1981. Pathogenesis and immunology of Treponema pallidum.
A n n u Rev Microbiol 35:29-54.

319

Fitzgerald, T. J., L. A . Repesh, D. R. Blanco, and J. N . Miller. 1984.
Attachment of Treponema pallidum to fibronectin, laminin, collagen IV, and
collagen I, and blockage of attachment by i m m u n e rabbit IgG. Br J Vener Dis
60:357-63.
Fleischmann, R. D., D. Alland, J. A. Eisen, L. Carpenter, O. White, J.
Peterson, R. DeBoy, R. Dodson, M . G w i n n , D. Haft, E . Hickey, J. F.
Kolonay, W . C. Nelson, L. A . U m a y a m , M . Ermolaeva, S. L. Salzberg, A .
Delcher, T. Utterback, J. W e i d m a n , H . Khouri, J. Gill, A . Mikula, W .
Bishai, W . R. Jacobs Jr, Jr., J. C. Venter, and C. M . Fraser. 2002. Wholegenome comparison of Mycobacterium tuberculosis clinical and laboratory
strains. J Bacteriol 184:5479-90.
Flesch, I. E., and S. H. Kaufmann. 1990. Stimulation of antibacterial
macrophage activities by B-cell stimulatory factor 2 (interleukin-6). Infect
I m m u n 58:269-71.
Flesch, I. E., and S. H. Kaufmann. 1991. Mechanisms involved in
mycobacterial growth inhibition by g a m m a interferon-activated bone marrow
macrophages: role of reactive nitrogen intermediates. Infect I m m u n 59:3213-8.
Flesch, I. E., J. H. Hess, S. Huang, M. Aguet, J. Rothe, H. Bluethmann,
and S. H . K a u f m a n n . 1995. Early interleukin 12 production by macrophages
in response to mycobacterial infection depends on interferon g a m m a and tumor
necrosis factor alpha. J Exp M e d 181:1615-21.
Flynn, J. L. 2004. Immunology of Tuberculosis and implications in vaccine
development. Tuberculosis 84:93-101.
Flynn, J. L., and J. Chan. 2001. Immunology of Tuberculosis. Annu Rev
Immunol 19:93-129.
Flynn, J. L., and J. Chan. 2003. Immune evasion by Mycobacterium
tuberculosis: living with the enemy. Curr Opin Immunol. 15:450-455.
Flynn, J. L., C. A. Scanga, K. E. Tanaka, and J. Chan. 1998. Effects of
aminoguanidine on latent murine tuberculosis. J Immunol 160:1796-803.
Flynn, J. L., J. Chan, K. J. Triebold, D. K. Dalton, T. A. Stewart, and B.
R. Bloom. 1993. A n essential role for interferon g a m m a in resistance to
Mycobacterium tuberculosis infection. J Exp M e d 178:2249-54.

320

Flynn, J. L., M . M . Goldstein, J. C h a n , K . J. Triebold, K . Pfeffer, C. J.
Lowenstein, R. Schreiber, T. W . M a k , and B. R. Bloom. 1995. T u m o r
necrosis factor-alpha is required in the protective i m m u n e response against
Mycobacterium tuberculosis in mice. Immunity 2:561-72.
Flynn, J. L., M. M. Goldstein, K. J. Triebold, B. Roller, and B. R. Bloom.
1992. Major histocompatibility complex class I-restricted T cells are required
for resistance to Mycobacterium tuberculosis infection. Proc Natl Acad Sci
U S A 89:12013-7.
Flynn, J. L., S. V. Capuano, D. Croix, S. Pawar, A. Myers, A. Zinovik, and
E . Klein. 2003. Non-human primates: a model for Tuberculosis research.
Tuberculosis 83:116-118.
Foster, J. W. 1995. Low pH adaptation and the acid tolerance response of
Salmonella typhimurium. Crit Rev Microbiol 21:215-37.
Fraenkel, D. G. 1996. Glycolysis, p. 189-198. In: F. C. Neidhardt, R. Curtiss,
m , J. L. Ingraham, E.C.C. Lin, K. B. L o w , B. Magasanik, W . S. Reznikoff, M .
Riley, M . Schaechter, and H. E. Umbarger (Ed.), Escherichia coli and
Salmonellae: cellular and molecular biology, 2nd ed. A S M Press, Washington,
D.C.
Fraenkel, D. G., and B. L. Horecker. 1965. Fructose 1,6-diphosphatase adn
acid hexose phosphatase of Escherichia coli. J. Bacteriol. 90:837-842.
Fraenkel, D. G., and S. R. Levisohn. 1967. Glucose and gluconate
metabolism in an Escherichia coli mutant lacking phosphoglucose isomerase. J
Bacteriol 93:1571-8.
Fraser, C. M., S. Casjens, W. M. Huang, G. G. Sutton, R. Clayton, R.
Lathigra, O . White, R. A . Retchum, R. Dodson, E . R. Hickey, M . G w i n n ,
B. Dougherty, J. F. T o m b , R. D. Fleischmann, D. Richardson, J. Peterson,
A . R. Rerlavage, J. Quackenbush, S. Salzberg, M . Hanson, R. van Vugt, N .
Palmer, M . D. A d a m s , J. Gocayne, J. C. Venter, and et al. 1997. Genomic
sequence of a L y m e disease spirochaete, Borrelia burgdorferi. Nature
390:580-6.
Fraser, C. M., S. J. Norris, G. M. Weinstock, O. White, G. G. Sutton, R.
Dodson, M . G w i n n , E . R. Hickey, R. Clayton, R. A . Retchum, E .
Sodergren, J. M . H a r d h a m , M . P. M c L e o d , S. Salzberg, J. Peterson, H .
Rhalak, D. Richardson, J. R. Howell, M . C h i d a m b a r a m , T. Utterback, L.
M c D o n a l d , P. Artiach, C. B o w m a n , M . D. Cotton, J. C. Venter, and et al.

321

1998. Complete genome sequence of Treponema pallidum, the syphilis
spirochete. Science 281:375-88.
Fratazzi, C, R. D. Arbeit, C. Carini, M. R. Balcewicz-Sablinska, J. Reane,
H . Rornfeld, and H . G. Remold. 1999. Macrophage apoptosis in
mycobacterial infections. J Leukoc Biol 66:763-4.
Fratti, R. A., J. Chua, I. Vergne, and V. Deretic. 2003. Mycobacterium
Tuberculosis glycosylated phosphatidylinositol causes phagosome maturation
arrest. Proc Natl Acad Sci U S A 100:5437-42.
Fry, B., T. Zhu, M. M. Domach, R. R. Roepsel, C. Phalakornkule, and M.
M . Ataai. 2000. Characterization of Growth and Acid Formation in a Bacillus
subtilis Pyruvate Kinase Mutant. Appl. Environ. Microbiol. 66:4045-4049.
Fu, Y. and J. E. Galan. 1999. A salmonella protein antagonizes Rac-1 and
Cdc42 to mediate host-cell recovery after bacterial invasion. Nature 401:293-7.
Fuhrer, T., E. Fischer, and U. Sauer. 2005. Experimental Identification and
Quantification of Glucose Metabolism in Seven Bacterial Species. J. Bacteriol.
187:1581-1590.
Fulton, S. A., J. M. Johnsen, S. F. Wolf, D. S. Sieburth, and W. H. Boom.
1996. Interleukin-12 production by h u m a n monocytes infected with
Mycobacterium tuberculosis: role of phagocytosis. Infect I m m u n 64:2523-31.
Gansert, J. L., V. Riessler, M. Engele, F. Wittke, M. Rollinghoff, A. M.
Rrensky, S. A . Porcelli, R. L. Modlin, and S. Stenger. 2003. H u m a n N K T
cells express granulysin and exhibit antimycobacterial activity. J Immunol
170:3154-61.
Garnett, G. P., and R. C. Brunham. 1999. Magic bullets need accurate guns-syphilis eradication, elimination, and control. Microbes Infect 1:395-404.
Garnett, G. P., R. J. Mertz, L. Finelli, W. C. Levine, and M. E. St Louis.
1999. The transmission dynamics of gonorrhoea: modelling the reported
behaviour of infected patients from Newark, N e w Jersey. Philos Trans R Soc
Lond B Biol Sci 354:787-97.
Garnett, G. P., S. O. Aral, D. V. Hoyle, W. Cates, Jr., and R. M. Anderson.
1997. The natural history of syphilis. Implications for the transmission
dynamics and control of infection. Sex Transm Dis 24:185-200.

322

Garnier, T., R. Eiglmeier, J. C . C a m u s , N . Medina, H . Mansoor, M . Pryor,
S. Duthoy, S. Grondin, C. Lacroix, C. M o n s e m p e , S. Simon, B. Harris, R.
Atkin, J. Doggett, R. M a y e s , L. Reating, P. R. Wheeler, J. Parkhill, B. G .
Barrell, S. T. Cole, S. V . Gordon, and R. G. Hewinson. 2003. The complete
genome sequence of Mycobacterium bovis. Proc Natl Acad Sci U S A
100:7877-82.
Gatfield, J. and J. Pieters. 2000. Essential role for cholesterol in entry of
mycobacteria into macrophages. Science 288:1647-50.
Gazdik, M. A. and R. A. McDonough. 2005. Identification of Cyclic AMPRegulated Genes in Mycobacterium tuberculosis Complex Bacteria under
Low-Oxygen Conditions. J Bacteriol 187:2681-92.
Gjestland, T. 1955. The Oslo study of untreated syphilis - an epidemiologic
investigation of the natural course of the syphilitic infection based upon a restudy of the Boeck-Bruusgaard material. Acta Dermatol. Vener. 35 (Suppl.
34): 1-368
Gern, L. and P. F. Humair. 1998. Natural history of Borrelia burgdorferi
sensu lato. W e i n Klin Wochenschr. 110: 856-858.
Gerstmeir, R., A. Cramer, P. Dangel, S. Schaffer, and B. J. Eikmanns.
2004. R a m B , a Novel Transcriptional Regulator of Genes Involved in Acetate
Metabolism of Corynebacterium glutamicum. J. Bacteriol. 186:2798-2809.
Ghinsberg, R. C. and Y. Nitzan. 1992. Is syphilis an incurable disease? Med
Hypotheses 39:35-40.
Gibbs, C. P., B. Y. Reimann, E. Schultz, A. Kaufmann, R. Haas, and T. F.
Meyer. 1989. Reassortment of pilin genes in Neisseria gonorrhoeae occurs by
two distinct mechanisms. Nature 338:651-2.
Gil, D. P., L. G. Leon, L. I. Correa, J. R. Maya, S. C. Paris, L. F. Garcia,
and M . Rojas. 2004. Differential induction of apoptosis and necrosis in
monocytes from patients with tuberculosis and healthy control subjects. J
Infect Dis 189:2120-8.
Gilbert, P., P. J. Collier, and M. R. Brown. 1990. Influence of growth rate
on susceptibility to antimicrobial agents: biofilms, cell cycle, dormancy, and
stringent response. Antimicrob Agents Chemother 34:1865-8.
Gilman, R. H. 1989. General considerations in the management of typhoid

323

fever and dysentery. Scand J Gastroenterol Suppl 169: 11-18.
Gimenez, R., M. F. Nunez, J. Badia, J. Aguilar, and L. Baldoma. 2003. The
gene yjcG, cotranscribed with the gene acs, encodes an acetate permease in
Escherichia coli. J Bacteriol 185:6448-55.
Glickman, M. S., and W. R. Jacobs, Jr. 2001. Microbial pathogenesis of
Mycobacterium tuberculosis: d a w n of a discipline. Cell 104:477-85.
Goldman, D. and M. J. Wagner. 1962. Enzyme Systems in the Mycobacteria.
Biochimica et Biophysica A C T A 65:197-306.
Gomez, J. E. and J. D. McRinney. 2004. M. Tuberculosis persistence,
latency, and drug tolerance. Tuberculosis 84:29-44.
Gomez, J. E. and W. R. Bishai. 2000. whmD is an essential mycobacterial
gene required for proper septation and cell division. Proc Natl Acad Sci U S A
97:8554-9.
Gotschlich, E. C. 1994. Genetic locus for the biosynthesis of the variable
portion of Neisseria gonorrhoeae lipooligosaccharide. J Exp M e d 180:218190.
Gourdon, P., M. F. Baucher, N. D. Lindley, and A. Guyonvarch. 2000.
Cloning of the malic enzyme gene from Corynebacterium glutamicum and role
of the enzyme in lactate metabolism. Appl Environ Microbiol 66:2981-7.
Govan, J. R., and V. Deretic. 1996. Microbial pathogenesis in cystic fibrosis:
mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev
60:539-74.
Graham, J. E. and J. E. Clark-Curtiss. 1999. Identification of
Mycobacterium tuberculosis R N A s synthesized in response to phagocytosis by
h u m a n macrophages by selective capture of transcribed sequences (SCOTS).
Proc Natl Acad Sci U S A 96:11554-9.
Grassly, N. C, C. Fraser, and G. P. Garnett. 2005. Host immunity and
synchronized epidemics of syphilis across the United States. Nature 433:41721.
Gray, C. T., J. W. Wimpenny, and M. R. Mossman. 1966. Regulation of
metabolism in facultative bacteria. II. Effects of aerobiosis, anaerobiosis and
nutrition on the formation of Krebs cycle enzymes in Escherichia coli.

324

Biochim Biophys Acta 117:33-41.
Gray-Owen, S. D., C. Dehio, T. Rudel, M. Naumann, and T. F. Meyer.
2001. Neisseria, p. 559-600. In: E.A. Groisman (Ed.), Principles of Bacterial
Pathogenesis. Academic Press, San Diego, C A .
Grigg, E. R. N. 1958. The arcana of tuberculosis, with a brief epidemiologic
history of the disease in the U S A . A m . Rev. Tuberc. Pulm. Dis. 78:151-172,
426-453, 583-603.
Groisman, E. A., and H. Ochman. 1997. How Salmonella became a
pathogen. Trends Microbiol 5:343-9.
Grosset, J. 2003. Mycobacterium tuberculosis in the extracellular
compartment: an underestimated adversary. Antimicrob Agents Chemother
47:833-6.
Guermonprez, P., J. Valladeau, L. Zitvogel, C. Thery, and S. Amigorena.
2002. Antigen presentation and T cell stimulation by dendritic cells. A n n u Rev
Immunol 20:621-67.
Guest, J. R. and G. C. Russell. 1992. Complexes and complexities of the
citric acid cycle in Escherichia coli. Curr Top Cell Regul 33:231-47.
Gui, L., A. Sunnarborg, and D. C. LaPorte. 1996b. Regulated expression of
a repressor protein: FadR activates iclR. J Bacteriol 178:4704-9.
Gui, L., A. Sunnarborg, B. Pan, and D. C. LaPorte. 1996a. Autoregulation
of iclR, the gene encoding the repressor of the glyoxylate bypass operon. J
Bacteriol 178:321-4.
Gupta, N. R. and B. Vennesland. 1964. Glyoxylate Carboligase of
Escherichia coli: A Flavoprotein. J Biol C h e m 239:3787-9.
Gupta, R., N. Gupta, and P. Rathi. 2004. Bacterial lipases: an overview of
production, purification and biochemical properties. Appl Microbiol
Biotechnol 64:763-81.
Gupta, U. D., and V. M. Ratoch. 1997. Understanding the phenomenon of
persistence in mycobacterial infections. Indian J Lepr 69:385-393.
Gylfe, A., S. Bergstrom, J. Lundstrom, and B. Olsen. 2000. Reactivation of
Borrelia infection in birds. Nature 403:724-725

325

Haake, D. A . and M . A . Lovett. 1990. Interactional invasion of endothelial
monolayers by Treponema pallidum. P. 297-315. In: B. H. Iglewski, V. L.
Clark (Ed.), Molecular Basis of Bacterial Pathogenesis. Academic Press Inc.,
San Diego, C A .
Haas, F., and S. S. Haas. 1996. The origins of Mycobacterium tuberculosis
and the notion of its contagiousness, p. 3-19. In: W . N . R o m and S. Garay
(Ed.), Tuberculosis. Little, B r o w n & Co., Boston, M A .
Hagblom, P., E. Segal, E. Billyard, and M. So. 1985. Intragenic
recombination leads to pilus antigenic variation in Neisseria gonorrhoeae.
Nature 315:156-8.
Halarnkar, P. P., and G.J. Blomquist. 1989. Comparative aspects of
propionate metabolism. C o m p Biochem Physiol B. 92:227-31.
Handsfield, H. H., T. O. Lipman, J. P. Harnisch, E. Tronca, and R. R.
Holmes. 1974. Asymptomatic gonorrhea in men. Diagnosis, natural course,
prevalence and significance. N Engl J M e d 290:117-23.
Hansen, E. J., and E. Juni. 1975. Isolation of mutants of Escherichia coli
lacking N A D - and NADP-linked malic. Biochem Biophys Res Cornmun
65:559-66.
Hardt, W. D., L. M. Chen, R. E. Schuebel, X. R. Bustelo, and J. E. Galan.
1998. S. typhimurium encodes an activator of R h o GTPases that induces
membrane ruffling and nuclear responses in host cells. Cell 93:815-26.
Hassett, D. J., J. F. Ma, J. G. Elkins, T. R. McDermott, U. A. Ochsner, S.
E . West, C. T. H u a n g , J. Fredericks, S. Burnett, P. S. Stewart, G .
McFeters, L. Passador, and B. H . Iglewski. 1999. Q u o r u m sensing in
Pseudomonas aeruginosa controls expression of catalase and superoxide
dismutase genes and mediates biofilm susceptibility to hydrogen peroxide. M o l
Microbiol 34:1082-93.
Hayashi, M., H. Mizoguchi, N. Shiraishi, M. Obayashi, S. Nakagawa, J.
Imai, S. Watanabe, T. Ota, and M . Ikeda. 2002. Transcriptome analysis of
acetate metabolism in Corynebacterium glutamicum using a newly developed
metabolic array. Biosci Biotechnol Biochem 66:1337-44.
Hayashi, S. I., and E. C. Lin. 1967. Purification and properties of glycerol
kinase from Escherichia coli. J Biol C h e m 242:1030-5.

326

H e m m e r , B., B. Gran, Y . Zhao, A . Marques, J. Pascal, A . Tzou, T. R o n d o ,
I. Cortese, B. Bielekova, S. E . Straus, H . F. McFarland, R. Houghten, R.
Simon, C . Pinilla, and R. Martin. 1999. Identification of Candidate T-cell
Epitopes and Molecular Mimics in Chronic L y m e Disease. Nat M e d 5:13751382.
Hernandez-Pando, R., M. Jeyanathan, G. Mengistu, D. Aguilar, H.
Orozco, M . Harboe, G. A . Rook, and G. Bjune. 2000. Persistence of D N A
from Mycobacterium tuberculosis in superficially normal lung tissue during
latent infection. Lancet 356:2133-8.
Hessel, L., H. Debois, M. Fletcher, and R. Dumas. 1999. Experience with
Salmonella typhi Vi capsular polysaccharide vaccine. Eur J Clin Microbiol
Infect Dis 18:609-620.
Hesslinger, C, S. A. Fairhurst, and G. Sawers. 1998. Novel keto acid
formate-lyase and propionate kinase enzymes are components of an anaerobic
pathway in Escherichia coli that degrades L-threonine to propionate. M o l
Microbiol 27:477-92.
Heymann, S. J., T. F. Brewer, M. E. Wilson, and H. V. Fineberg. 1999. The
need for global action against multidrug-resistant tuberculosis. J A M A
281:2138-40.
Hisert, R. B., M. A. Rirksey, J. E. Gomez, A. O. Sousa, J. S. Cox, W. R.
Jacobs, Jr., C. F. Nathan, and J. D. McRinney. 2004. Identification of
Mycobacterium
tuberculosis
counterimmune
(cim)
mutants
in
immunodeficient mice by differential screening. Infect I m m u n 72:5315-21.
Hobbs, M. M., T. M. Alcorn, R. H. Davis, W. Fischer, J. C. Thomas, I.
Martin, C. Ison, P. F. Sparling, and M . S. Cohen. 1999. Molecular typing of
Neisseria gonorrhoeae causing repeated infections: evolution of porin during
passage within a community. J Infect Dis 179:371-81.
Hoge, C. W., L. Fisher, H. D. Donnell, Jr., D. R. Dodson, G. V. Tomlinson,
Jr., R. F. Breiman, A . B. Bloch, and R. C. Good. 1994. Risk factors for
transmission of Mycobacterium tuberculosis in a primary school outbreak: lack
of racial difference in susceptibility to infection. A m J Epidemiol 139:520-30.
Hoiseth, S. R., and B. A. Stocker. 1981. Aromatic-dependent Salmonella
typhimurium are non-virulent and effective as live vaccines. Nature 291:238-9.

327

H o l m s , H . 1996. Flux analysis and control of the central metabolic pathways
in Escherichia coli. F E M S Microbiol Rev 19:85-116.
Hondalus, M. R., S. Bardarov, R. Russell, J. Chan, W. R. Jacobs, Jr., and
B. R. Bloom. 2000. Attenuation of and protection induced by a leucine
auxotroph of Mycobacterium tuberculosis. Infect I m m u n 68:2888-98.
Honer zu Bentrup, R., A. Miczak, D. L. Swenson, and D. G. Russell. 1999.
Characterization of activity and expression of isocitrate lyase in
Mycobacterium avium and Mycobacterium tuberculosis. J Bacteriol 181:71617.
Hopper, S., B. Vasquez, A. Merz, S. Clary, J. S. Wilbur, and M. So. 2000.
Effects of the immunoglobulin A l protease on Neisseria gonorrhoeae
trafficking across polarized T 8 4 epithelial monolayers. Infect I m m u n 68:90611.
Hornick, R. B. 1985. Selective primary health care: strategies for control of
disease in the developing world. X X . Typhoid fever. Rev Infect Dis 7:536-46.
Hornick, R. B., S. E. Greisman, T. E. Woodward, H. L. DuPont, A. T.
Dawkins, and M . J. Snyder. 1970. Typhoid fever: pathogenesis and
immunologic control. N Engl J M e d 283:739-46.
Horswill, A. R., and J. C. Escalante-Semerena. 1997. Propionate catabolism
in Salmonella typhimurium L T 2 : two divergently transcribed units comprise
the prp locus at 8.5 centisomes, prpR encodes a m e m b e r of the sigma-54
family of activators, and the p r p B C D E genes constitute an operon. J Bacteriol
179:928-40.
Horswill, A. R., and J. C. Escalante-Semerena. 1999. Salmonella
typhimurium L T 2 catabolizes propionate via the 2-methylcitric acid cycle. J
Bacteriol 181:5615-23.
Hu, L. T. and M. S. Rlempner. 1997. Host-pathogen interactions in the
immunopathogenesis of L y m e disease. J Clin Immunol 17:354-365
liver, D., H. Rallstrom, S. Normark, and A. B. Jonsson. 1998. Transcellular
passage of Neisseria gonorrhoeae involves pilus phase variation. Infect I m m u n
66:469-73.
Iuchi, S. and E. C. Lin. 1988. arcA (dye), a global regulatory gene in
Escherichia coli mediating repression of enzymes in aerobic pathways. Proc

328

Natl Acad Sci U S A 85:1888-92.
Iuchi, S. and E. C. Lin. 1991. Adaptation of Escherichia coli to respiratory
conditions: regulation of gene expression. Cell 66:5-7.

Jarvis, G. A. 1995. Recognition and control of neisserial infection by antibody
and complement. Trends Microbiol 3:198-201.
Jensen, E. T., A. Rharazmi, R. Lam, J. W. Costerton, and N. Hoiby. 1990.
H u m a n polymorphonuclear leukocyte response to Pseudomonas aeruginosa
grown in biofilms. Infect I m m u n 58:2383-5.
Jerse, A. E., M. S. Cohen, P. M. Drown, L. G. Whicker, S. F. Isbey, H. S.
Seifert, and J. G. Cannon. 1994. Multiple gonococcal opacity proteins are
expressed during experimental urethral infection in the male. J Exp M e d
179:911-20.
Johnson, W. D., Jr., E. W. Hook, E. Lindsey, and D. Raye. 1973. Treatment
of chronic typhoid carries with ampicillin. Antimicrobial Agents
Chemotherapy 3:439-440.
Jones, B. D. 1997. Host responses to pathogenic Salmonella infection. Genes
D e v 11:679-87.
Jones, B. D., and S. Falkow. 1996. Salmonellosis: host immune responses and
bacterial virulence determinants. A n n u Rev Immunol 14:533-61.
Junqueira-Ripnis, A. P., A. Kipnis, A. Jamieson, M. G. Juarrero, A.
Diefenbach, D. H . Raulet, J. Turner, and I. M . O r m e . 2003. N K Cells
Respond to Pulmonary Infection with Mycobacterium tuberculosis, but Play a
Minimal Role in Protection J Immunol 171:6039-6045.
Rakuda, H., R. Hosono, R. Shiroishi, and S. Ichihara. 1994. Identification
and
characterization
of
the
ackA
(acetate
kinase
A)-pta
(phosphotransacetylase) operon and complementation analysis of acetate
utilization by an ackA-pta deletion mutant of Escherichia coli. J Biochem
116:916-22.
Rallstrom, H., M. R. Liszewski, J. P. Atkinson, and A. B. Jonsson. 1997.
M e m b r a n e cofactor protein ( M C P or C D 4 6 ) is a cellular pilus receptor for
pathogenic Neisseria. M o l Microbiol 25:639-47.
Rallstrom, H., M. S. Islam, P. O. Berggren, and A. B. Jonsson. 1998. Cell

329

signaling by the type IV pili of pathogenic Neisseria. J Biol C h e m 273:2177782.
Ranai, R. 1966. Experimental Studies on Host-Parasite Equilibrium in
tuberculosis Infection, in Relation to Vaccination and Chemotherapy. 19:181199.
Ranai, R. and E. Rondo. 1974. Chemistry and biology of mycobacteria
grown in vivo. Jpn J M e d Sci Biol 27:135-60.
Rannan, R. B., V. M. Ratoch, V. P. Bharadwaj, V. D. Sharma, A. R.
Datta, and C. T. Shivannavar. 1985. Metabolic studies on mycobacteria~H.
Glyoxylate by-pass ( T C A cycle) enzymes of slow and fast growing
mycobacteria. Indian J Lepr 57:542-8.
Raplan, G., F. A. Post, A. L. Moreira, H. Wainwright, B. N. Rreiswirth,
M . Tanverdi, B. M a t h e m a , S. V . R a m a s w a m y , G . Walther, L. M . Steyn, C.
E . Barry, 3rd, and L. G. Bekker. 2003. Mycobacterium tuberculosis growth
at the cavity surface: a microenvironment with failed immunity. Infect I m m u n
71:7099-108.
Rarakousis, P. C, T. Yoshimatsu, G. Lamichhane, S. C. Woolwine, E. L.
Nuermberger, J. Grosset, and W . R. Bishai. 2004. Dormancy Phenotype
Displayed by Extracellular Mycobacterium tuberculosis within Artificial
Granulomas in Mice. J Exp M e d 200:647-657.
Rarakousis, P. C, W. R. Bishai, and S. E. Dorman. 2004. Mycobacterium
tuberculosis cell envelope lipids and the host i m m u n e response. Cell Microbiol
6:105-16.
Rather, B., R. Stingl, M. E. van der Rest, R. Altendorf, and D. Molenaar.
2000. Another Unusual Type of Citric Acid Cycle E n z y m e in Helicobacter
pylori: the Malate:Quinone Oxidoreductase. J. Bacteriol. 182:3204-3209.
Ratoch, V. M., V. D. Sharma, R. B. Rannan, A. R. Datta, C. T.
Shivannavar, and V. P. Bharadwaj. 1987. Metabolic studies on
mycobacteria. III. Demonstration of key enzymes of T C A cycle in M . leprae.
Indian J Lepr 59:152-7.
Raye, D., J. G. Merselis, Jr., S. Connolly, and E. W. Hook. 1967. Treatment
of chronic enteric carriers of Salmonella typhosa with ampicillin. A n n N Y
Acad Sci 145:429-35.

330

Reane, J., H . G . Remold, and H . Rornfeld. 2000. Virulent Mycobacterium
tuberculosis Strains Evade Apoptosis of Infected Alveolar Macrophages. J
Immunol 164:2016-2020.
Reating, L. A., P. R. Wheeler, H. Mansoor, J. R. Inwald, J. Dale, R. G.
Hewinson, and G. S.V. 2005. The pyruvate requirement of some members of
the Mycobacterium tuberculosis complex is due to an inactive pyruvate kinase:
implications for in vivo growth. Mol. Microbiol. 56:163-74.
Reeling, M. J. 1997. Modelling the persistence of measles. Trends. Microbiol.
5:513-518.
Reeling, P. J., and B. T. Grenfell. 1997. Disease extinction and community
size: modelling the persistence of measles. Science 275:65-67.
Kellogg, D. S., W. L. Peacock, W. E. Deacon, L. Brown, and C. I. Pirkle.
1963. Neisseria gonorrhoeae. I. Virulence genetically linked to clonal
variation. J Bacteriol 85:1274.
Rerle, R. R., J. R. Mascola, and T. A. Miller. 1992. Disseminated
gonococcal infection. A m . Fam. Physician 45:209-214
Kilian, M., J. Reinholdt, H. Lomholt, R. Poulsen, and E. V. Frandsen.
1996. Biological significance of IgAl proteases in bacterial colonization and
pathogenesis: critical evaluation of experimental evidence. A P M I S 104:321338
Kilian, M., J. Mestecky, and M. W. Russell. 1988. Defense mechanisms
involving Fc-dependent functions of immunoglobulin A and their subversion
by bacterial immunoglobulin A proteases. Microbiol Rev 52:296-303.
Kim, H. J., T. H. Rim, Y. Rim, and H. S. Lee. 2004. Identification and
characterization of glxR, a gene involved in regulation of glyoxylate bypass in
Corynebacterium glutamicum. J Bacteriol 186:3453-60.
Rindler, V., A. P. Sappino, G. E. Grau, P. F. Piguet, and P. Vassalli. 1989.
The inducing role of tumor necrosis factor in the development of bactericidal
granulomas during B C G infection. Cell 56:731-40.
Kitten. T. and A. G. Barbour. 1990. Juxtaposition of expressed variable
antigens with a conserved telomere in the bacterium Borrelia hermsii. Proc
Natl Acad Sci U S A 87: 6077-81.

331

Ritten, T. and A . G. Barbour. 1992. The relapsing fever agent Borrelia
hermsii has multiple copies of its chromosome and linear plasmids. Genetics
132:311-24.
Rlempner, M. S., and B. T. Huber. 1999. Is it thee or me?~autoimmunity in
L y m e disease. Nat M e d 5:1346-7.
Roch, R. 1882. Classics in infectious diseases. The etiology of Tuberculosis:
Robert Koch. Reviews in Infectious Diseases 4:1270-4.
Rolattukudy, P. E., N. D. Fernandes, A. R. Azad, A. M. Fitzmaurice, and
T. D. Sirakova. 1997. Biochemistry and molecular genetics of cell-wall lipid
biosynthesis in mycobacteria. M o l Microbiol 24:263-70.
Rondo, E., and R. Ranai. 1976. An attempt to cultivate mycobacteria in
simple synthetic liquid medium containing lecithin-cholesterol liposomes. Jpn
J M e d Sci Biol 29:109-21.
Rondo, E., R. Ranai, R. Nishimura, and T. Tsumita. 1970. Analysis of
host-originated lipids associated with "in vivo grown tubercle bacilli". Jpn J
M e d Sci Biol 23:315-26.
Rondo, E., R. Suzuki, R. Ranai, and T. Yasuda. 1985. Liposomesmycobacteria incubation systems as a partial model of host-parasite interaction
at cell membrane level. Jpn J M e d Sci Biol 38:169-80.
Ropanoff, D. E., D. E. Snider, Jr., and M. Johnson. 1988. Recurrent
Tuberculosis: w h y do patients develop disease again? A United States Public
Health Service cooperative survey. A m J Public Health 78:30-3.
Romberg, H. L. 1966. The role and control of the glyoxylate cycle in
Escherichia coli. Biochem J 99:1-11.
Romberg, H. L., and H. A. Rrebs. 1957. Synthesis of cell constituents from
C2-units by a modified tricarboxylic acid cycle. Nature 179:988-991.
Romberg, H. L., and J. R. Sadler. 1960. Microbial oxidation of glycollate
via a dicarboxylic acid cycle. Nature 185:153-5.
Romberg, H. L. and J. Smith. 1970. Role of phosphofructokinase in the
utilization of glucose by Escherichia coli. Nature 227:44-6.
Rornfeld, H., G. Mancino, and V. Colizzi. 1999. The Role of Macrophage

332

Cell Death in Tuberculosis. Cell Death and Differentiation 6:71-78.
Rreft, J., J. A. Vazquez-Boland, S. Altrock, G. Dominguez-Bernal, and W.
Goebel. 2002. Pathogenicity islands and other virulence elements in Listeria.
Curr Top Microbiol Immunol 264:109-25.
Rretzschmar, U., A. Ruckert, J.-H. Jeoung, and H. Gorisch. 2002.
Malate: quinone oxidoreductase is essential for growth on ethanol or acetate in
Pseudomonas aeruginosa. Microbiology 148:3839-3847.
Rrozowski, Z. 1994. The short-chain alcohol dehydrogenase superfamily:
variations on a c o m m o n theme. J. Steroid. Biochem. Mol. Biol. 51:125-30.
Runau, W. H., V. Dommes, and H. Schulz. 1995. beta-oxidation of fatty
acids in mitochondria, peroxisomes, and bacteria: a century of continued
progress. Prog Lipid Res 34:267-342.
Kuiper, H., A. P. van Dam, L. Spanjaard, B. M. de Jongh, A.
Widjojokusumo, T. C. Ramselaar, I. Cairo, R. Vos, and J. Dankert. 1994.
Isolation of Borrelia burgdorferi from biopsy specimens taken from healthylookin skin of patients with L y m e borreliosis. Clin Microbiol 32:715-720.
Rupsch, E. M., B. Rnepper, T. Ruroki, I. Heuer, and T. F. Meyer. 1993.
Variable opacity (Opa) outer membrane proteins account for the cell tropisms
displayed by Neisseria gonorrhoeae for h u m a n leukocytes and epithelial cells.
E m b o J 12:641-50.
Russell, E. L., R. Rishony, N. Q. Balaban, and S. Leibler. 2005. Bacterial
Persistence: A Model of Survival in Changing Environments. Genetics.
Laochumroonvorapong, P., S. Paul, C. Manca, V. H. Freedman, and G.
Raplan. 1997. Mycobacterial growth and sensitivity to H 2 0 2 killing in h u m a n
monocytes in vitro. Infect I m m u n 65:4850-7.
Lawrence, J. R., D. R. Rorber, B. D. Hoyle, J. W. Costerton, and D. E.
Caldwell. 1991. Optical sectioning of microbial biofilms. J Bacteriol
173:6558-67.
Lecuit, M. and P. Cossart. 2002. Genetically-modified-animal models for
h u m a n infections: the Listeria paradigm. Trends M o l M e d 8:537-42.
Lee, S. R., J. D. Newman, and J. D. Reasling. 2005. Catabolite Repression of
the Propionate Catabolic Genes in Escherichia coli and Salmonella enterica:

333

Evidence for Involvement of the Cyclic A M P Receptor Protein. J Bacteriol
187:2793-800.
Lertmemongkolchai, G., G. Cai, C. A. Hunter, and G. J. Bancroft. 2001.
Bystander Activation of C D 8 + T Cells Contributes to the Rapid Production of
IFN-y in Response to Bacterial Pathogens. J Immunol 166:1097-1105.
Lewinski, M. A., J. N. Miller, M. A. Lovett, and D. R. Blanco. 1999.
Correlation of immunity in experimental syphilis with serum-mediated
aggregation of Treponema pallidum rare outer membrane proteins. Infect
I m m u n 67:3631-6.
Li, Z., C. Relley, F. Collins, D. Rouse, and S. Morris. 1998. Expression of
katG in Mycobacterium tuberculosis is associated with its growth and
persistence in mice and guinea pigs. J Infect Dis 177:1030-5.
Liang, F. T., M. B. Jacobs, L. C. Bowers, and M. T. Philipp. 2002. An
i m m u n e evasion mechanism for spirochetal persistence in L y m e borreliosis. J
Exp M e d 195:415-22.
Lin, E. C. C. 1996. Dissimilatory pathways for sugars, polyols, and
carboxylates, p. 307-342. In: F. C. Neidhardt, J. L. Ingraham, K. B. L o w , B.
Magasanik, M . Schaechter, and H. E. Umbarger (ed.), Escherichia coli and
Salmonella: cellular and molecular biology, 2nd ed., vol. 1. A S M Press,
Washington, D.C.
Lin, L., P. Ayala, J. Larson, M. Mulks, M. Fukuda, S. Carlsson, C. Enns,
and M . So. 1997. The Neisseria Type 2 IgAl Protease Cleaves L A M P 1 and
Promotes Survival of Bacteria Within Epithelial Cells. Molecular
Microbiology 24:1083-1094.
Liu, J. Q., T. Dairi, N. Itoh, M. Rataoka, and S. Shimizu. 2003a. A novel
enzyme, D-3-hydroxyaspartate aldolase from Paracoccus denitrificans IFO
13301: purification, characterization, and gene cloning. Appl Microbiol
Biotechnol 62:53-60.
Liu, R., Y. Jinzhi, and D. G. Russell. 2003b. pckA-deficient Mycobacterium
bovis B C G shows attenuated virulence in mice and in macrophages.
Microbiology 149:1829-1835.
Livey, I., C. P. Gibbs, R. Schuster, and F. Dorner. 1995. Evidence for lateral
transfer and recombination in O s p C variation in L y m e disease Borrelia. M o l
Microbiol 18:257-69.

334

Lorenz, M . C. and G . R. Fink. 2001. The glyoxylate cycle is required for
fungal virulence. Nature 412:83-6.
Lorenz, M. C, J. A. Bender, and G. R. Fink. 2004. Transcriptional
Response of Candida albicans upon Internalization by Macrophages.
Eukaryotic Cell 3:1076-1087.
Lukehart, S. A . 1982. Activation of macrophages by products of lymphocytes
from normal and syphilitic rabbits. Infect I m m u n 37:64-9.
Lukehart, S. A., and J. N. Miller. 1978. Demonstration of the in vitro
phagocytosis of Treponema pallidum by rabbit peritoneal macrophages. J
Immunol 121:2014-24.
Lukehart, S. A., J. M. Shaffer, and S. A. Baker-Zander. 1992. A
subpopulation of Treponema pallidum is resistant to phagocytosis: possible
mechanism of persistence. J Infect Dis 166:1449-53.
Lukehart, S. A., S. A. Baker-Zander, and S. Sell. 1980a. Characterization of
lymphocyte responsiveness in early experimental syphilis. I. In vitro response
to mitogens and Treponema pallidum antigens. J Immunol 124:454-60.
Lukehart, S. A., S. A. Baker-Zander, R. M. Lloyd, and S. Sell. 1980b.
Characterization of lymphocyte responsiveness in early experimental syphilis.
U. Nature of cellular infiltration and Treponema pallidum distribution in
testicular lesions. J Immunol 124:461-7.
Lundberg, B. E., R. E. Wolf, M. C. Dinauer, Y. Xu, and F. C. Fang. 1999.
Glucose 6-phosphate dehydrogenase is required for Salmonella typhimurium
virulence and resistance to reactive oxygen and nitrogen intermediates. Infect
I m m u n 67:436-8.
Lurie, M. B. 1939a. Studies on the mechanism of immunity in tuberculosis:
the role of extracellular factors and local immunity in the fixation and
inhibition of growth of tubercle bacilli. J Exp M e d 69:555-578.
Lurie, M. B. 1939b. Studies on the mechanism of immunity in tuberculosis:
the mobilization of mononuclear phagocytes in normal and immunized animals
and their relative capacities for division and phagocytosis. J Exp M e d 69:579599.
Lurie, M. B. 1964. Resistance to Tuberculosis: Experimental Studies in Native
and Acquired Defensive Mechanisms. Harvard University Press, Cambridge,

335

MA.
Lurie, M. B., and Zappasodi. 1942. Studies on the mechanism of immunity in
tuberculosis. The fate of tubercle bacilli ingested by mononuclear phagocytes
derived from normal and immunized animals. J Exp M e d 75:247-267.
Luttik, M. A., P. Rotter, F. A. Salomons, I. J. van der Rlei, J. P. van
Dijken, and J. T. Pronk. 2000. The Saccharomyces cerevisiae I C L 2 gene
encodes a mitochondrial 2-methylisocitrate lyase involved in propionylcoenzyme A metabolism. J Bacteriol 182:7007-13.
Lynch, A. S. and E. C. C. Lin. 1996. Responses to molecular oxygen. In F. C.
Neidhardt, R. Curtiss III, J. L. Ingraham, E. C. C. Lin,
Mackaness, G. B. 1968. The immunology of antituberculosis immunity. J Exp
M e d 97:337-344.
MacMicking, J. D. 2005. Immune control of phagosomal bacteria by p47
GTPases. Curr Opin Microbiol 8:74-82.
MacMicking, J. D., G. A. Taylor, and J. D. McRinney. 2003. Immune
control of tuberculosis by IFN-y-inducible LRG-47. Science 302:654-9.
MacMicking, J. D., R. J. North, R. LaCourse, J. S. Mudgett, S. R. Shah,
and C. F. Nathan. 1997. Identification of nitric oxide synthase as a protective
locus against tuberculosis. Proc Natl Acad Sci U S A 94:5243-8.
MacMicking, J., Q. W. Xie, and C. Nathan. 1997. Nitric oxide and
macrophage function. A n n u Rev Immunol 15:323-50.
Maggio-Hall, L. A., and N. P. Reller. 2004. Mitochondrial beta-oxidation in
Aspergillus nidulans. M o l Microbiol 54:1173-85.
Mahenthiralingam, E. and D. P. Speert. 1995. Nonopsonic phagocytosis of
Pseudomonas aeruginosa by macrophages and polymorphonuclear leukocytes
requires the presence of the bacterial flagellum. Infect I m m u n 63:4519-23.
Mahenthiralingam, E., M. E. Campbell, and D. P. Speert. 1994.
Nonmotility and phagocytic resistance of Pseudomonas aeruginosa isolates
from chronically colonized patients with cystic fibrosis. Infect I m m u n 62:596605.
Malik, Z. A., G. M. Denning, and D. J. Rusner. 2000. Inhibition of Ca(2+)

336

signaling by Mycobacterium
phagosome-lysosome
fusion

tuberculosis is associated with reduced
and
increased
survival within
human

macrophages. J Exp M e d 191:287-302.
Malik, Z. A., S. S. Iyer, and D. J. Rusner. 2001. Mycobacterium tuberculosis
phagosomes exhibit altered calmodulin-dependent signal transduction:
contribution to inhibition of phagosome-lysosome fusion and intracellular
survival in h u m a n macrophages. J Immunol 166:3392-401.
Maloy, S. R., and W. D. Nunn. 1982. Genetic regulation of the glyoxylate
shunt in Escherichia coli K-12. J Bacteriol 149:173-80.
Manabe, Y. C, and W. R. Bishai. 2000. Latent Mycobacterium tuberculosispersistence, patience, and winning by waiting. Nat M e d 6:1327-9.
Manca, C, M. B. Reed, S. Freeman, B. Mathema, B. Rreiswirth, C. E.
Barry, III, and G . Raplan. 2004. Differential Monocyte Activation Underlies
Strain-Specific Mycobacterium tuberculosis Pathogenesis. Infect. I m m u n .
72:5511-5514.
Manca, C, S. Paul, C. E. Barry, 3rd, V. H. Freedman, and G. Raplan.
1999. Mycobacterium tuberculosis catalase and peroxidase activities and
resistance to oxidative killing in h u m a n monocytes in vitro. Infect I m m u n
67:74-9.
Mandrell, R. E. and M. A. Apicella. 1993. Lipo-oligosaccharides (LOS) of
mucosal pathogens: molecular mimicry and host-modification of L O S .
Immunobiol 187:382-402
Manganelli, R., S. Tyagi, and I. Smith. 2001. p, 295-310. In: T. Parish & N.
Stoker (Ed.) Mycobacterium tuberculosis Protocols. H u m a n a Press, Totowa,
N e w Jersey.
Marconi, R. T., M. E. Ronkel, and C. F. Garon. 1993. Variability of osp
genes and gene products among species of L y m e disease spirochetes. Infect
I m m u n 61:2611-7.
Matin, A., and M. R. Matin. 1982. Cellular levels, excretion, and synthesis
rates of cyclic A M P in Escherichia coli grown in continuous culture. J
Bacteriol 149:801-7.
McCleary, W. and J. Stock. 1994. Acetyl phosphate and the activation of
two-component response regulators. J. Biol. C h e m . 269:31567-31572.

337

M c C o r m a c k , W . , R. Stumacher, R. Johnson, and A . Donner. 1977. Clinical
Spectrum of Gonococcal Infection in W o m e n . The Lancet 1:1182-1185.
McCune, R. M., and R. Tompsett. 1956. Fate of Mycobacterium tuberculosis
in mouse tissues as determined by the microbial enumeration technique. I. The
persistence of drug-susceptible tubercle bacilli in the tissues despite prolonged
antimicrobial therapy. J Exp M e d 104:737-762.
McCune, R. M., R. Tompsett, and W. McDermott. 1956. Fate of
Mycobacterium tuberculosis in mouse tissues as determined by the microbial
enumeration techinque. II. The conversion of tuberculous infection to the latent
state by the administariton of pyrazinamide and a companion drug. J Exp M e d
104:763-801.
McCune, R. M., S. H. Lee, R. Deuschele, and W. McDermott. 1957.
Ineffectiveness of isoniazid in modifying the phenomenon of microbial
persistence. A m . Rev. Tuberc. Pulm. Dis. 76: 1106-1109
McCune, R. M., F. M. Feldmann, H. P. Lambert, and W. McDermott.
1966a. Microbial persistence. I. The capacity of tubercle bacilli to survive
sterilization in mouse tissues. J Exp M e d 123:445-468.
McCune, R. M., F. M. Feldmann, and W. McDermott. 1966b. Microbial
persistence. II. Characteristics of the sterile state of tubercle bacilli. J Exp M e d
123:469-486.
McDermott, W. 1958. Microbial Persistence. Yale J. Biol. Med. 30:257-291.
McGrath, J. W. 1988. Social networks of disease spread in the Lower Illinois
Valley: a stimulation approach. A m . J. Phys. Anthropol. 77:483-496.
McRinney, J. D., R. Honer zu Bentrup, E. J. Munoz-Elias, A. Miczak, B.
C h e n , W . T. C h a n , D. Swenson, J. C. Sacchettini, W . R. Jacobs, Jr., and D.
G. Russell. 2000. Persistence of Mycobacterium tuberculosis in macrophages
and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature
406:735-738.
McRinney, J. D. 2000. In vivo Veritas: the search for TB drug targets goes
live. Nat M e d 6:1330-3.
McLean, R. J., M. Whiteley, D. J. Stickler, and W. C. Fuqua. 1997.
Evidence of autoinducer activity in naturally occurring biofilms. F E M S

338

Microbiol Lett 154:259-63.
Mdluli, R., R. A. Slayden, Y. Zhu, S. Ramaswamy, X. Pan, D. Mead, D. D.
Crane, J. M . Musser, and C. E . Barry, 3rd. 1998. Inhibition of a
Mycobacterium tuberculosis beta-ketoacyl A C P synthase by isoniazid. Science
280:1607-10.
Medlar, E. M. 1948. The Pathogenesis of Minimal Pulmonary Tuberculosis.
American Review of Tuberculosis 58:583-611.
Medlar, E. M., S. Bernstein, and D. M. Steward. 1952. A bacteriologic
study of resected tuberculosis lesions. A m . Rev. Tuberc. 66:36-43.
Meier, J. T., M. I. Simon, and A. G. Barbour. 1985. Antigenic variation is
associated with D N A rearrangements in a relapsing fever Borrelia. Cell
41:403-9.
Meleney, H. E. 1928. Relapse phenomena of Spironema recurrentis. J Exp
M e d 48:65.
Mert, A., M. Bilir, F. Tabak, R. Ozaras, R. Ozturk, H. Senturk, H. Aki, N.
Seyhan, T. Rarayel, and Y . Aktuglu. 2001. Miliary tuberculosis: clinical
manifestations, diagnosis and outcome in 38 adults. Respirology 6:217-24.
Meyer, T. F., C. P. Gibbs, and R. Haas. 1990. Variation and control of
protein expression in Neisseria. A n n u Rev Microbiol 44:451-77.
Middlebrook, G. 1952. Sterilization of tubercle bacilli by isonicotinic acid
hydrazide and the incidence of variants resistant to the drug in vitro. A m . Rev.
Tuberc. Pulm. Dis. 65:765-767.
Miller, B. H., R. A. Fratti, J. F. Poschet, G. S. Timmins, S. S. Master, M.
Burgos, M . A . Marietta, and V . Deretic. 2004. Mycobacteria Inhibit Nitric
Oxide Synthase Recruitment to Phagosomes during Macrophage Infection.
Infect. I m m u n . 72:2872-2878.
Miller, S. I., A. M. Rukral, and J. J. Mekalanos. 1989. A two-component
regulatory system (phoP phoQ) controls Salmonella typhimurium virulence.
Proc Natl Acad Sci U S A 86:5054-8.
Minor, S. Y. and E. C. Gotschlich. 2000. The genetics of LPS synthesis by
the gonococcus, p. 111-131. In: J. B. Goldberg (Ed.), Genetics of Bacterial
Polysaccharides. C R C Press, Inc., Boca Raton, FL.

339

M o r a n , A . P., M . M . Prendegast, and B . J. Appelmelk. 1996. Molecular
mimicry of
host structures by bacterial lipopolysaccharides and its
contribution to disease. F E M S Immunol M e d Microbiol 16: 105-115.
Mitchison, D. A. 1979. Basic Mechanisms of Chemotherapy. Chest 76:771781.
Mitchison, D. A . 1980. Treatment of tuberculosis. J. Royal. Coll. Phys.
London 14:91-99.
Mitchison, D. A. 2004. The search for new sterilizing anti-tuberculosis drugs.
Front Biosci 9:1059-72.
Modilevsky, T., F. R. Sattler, and P. F. Barnes. 1989. Mycobacterial disease
in patients with h u m a n immunodeficiency virus infection. Arch Intern M e d
149:2201-5.
Mogues, T., M. E. Goodrich, L. Ryan, R. LaCourse, and R. J. North. 2001.
The Relative Importance of T Cell Subsets in Immunity and Immunopathology
of Airborne Mycobacterium tuberculosis Infection in Mice. J Exp M e d
193:271-280.
Molenaar, D., M. E. van der Rest, A. Drysch, and R. Yucel. 2000.
Functions
of the
Membrane-Associated
and
Cytoplasmic
Malate
Dehydrogenases in the Citric Acid Cycle of Corynebacterium glutamicum. J.
Bacteriol. 182:6884-6891.
Molina, I., M. T. Pellicer, J. Badia, J. Aguilar, and L. Baldoma. 1994.
Molecular characterization of Escherichia coli malate synthase G.
Differentiation with the malate synthase A isoenzyme. Eur J Biochem
224:541-8.
Mombaerts, P., J. Lacomini, R. S. Johnson, R. Herrup, S. Tonegawa, and
V . E . Papaioannou. 1992. RAG-1-deficient mice have no mature B and T
lymphocytes. Cell 68:869-877.
Monack, D. M., D. M. Bouley, and S. Falkow. 2004. Salmonella
typhimurium persists within macrophages in the mesenteric lymph nodes of
chronically infected Nrampl+/+ mice and can be reactivated by IFN-y
neutralization. J Exp M e d 199:231-41.
Moore, M., E. McCray, and I. M. Onorato. 1996. Drug resistance among
reported U.S. cases of tuberculosis, 1993-1994. American J Resp Crit Care

340

M e d 153:A334.
Morgan, C. A., S. A. Lukehart, and W. C. Van Voorhis. 2003. Protection
against syphilis correlates with specificity of antibodies to the variable regions
of Treponema pallidum repeat protein K. Infect I m m u n 71:5605-12.
Morse, D., D. R. Brothwell, and P. J. Ucko. 1964. Tuberculosis in Ancient
Egypt. A m Rev Respir Dis 90:524-41.
Movahedzadeh, F., S. C. Rison, P. R. Wheeler, S. L. Kendall, T. J. Larson,
and N . G . Stoker. 2004. The Mycobacterium tuberculosis R v 1099c gene
encodes a GlpX-like class II fructose 1,6-bisphosphatase. Microbiology
150:3499-505.
Moxon, E. R., P. B. Rainey, M. A. Nowak, and R. E. Lenski. 1994.
Adaptive evolution of highly mutable loci in pathogenic bacteria. Curr Biol
4:24-33.
Moyed, H. S. and R. P. Bertrand. 1983. hip A, a newly recognized gene of
Escherichia coli K-12 that affects frequency of persistence after inhibition of
murein synthesis. J Bacteriol 155:768-75.
Mukhopadhyay, B. and E. Purwantini. 2000. Pyruvate carboxylase from
Mycobacterium smegmatis: stabilization, rapid purification, molecular and
biochemical characterization and regulation of the cellular level. Biochim
Biophys Acta 1475:191-206.
Munoz-Elias, E. J., and J. D. McRinney. 2002. Bacterial Persistence:
Strategies for Survival, p. 331-355. In: S. Kaufmann, A. Sher, and R. A h m e d
(Ed.), Immunology of Infectious Diseases. A S M Press, Washington, D.C.
Munoz-Elias, E. J., J. Timm, T. Botha, W. T. Chan, J. E. Gomez, and J. D.
M c R i n n e y . 2005. Replication dynamics of Mycobacterium tuberculosis in
chronically infected mice. Infect I m m u n 73:546-551.
Munoz-Elias, E. J., and J. D. McRinney. 2005. Mycobacterium tuberculosis
isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence.
Nat M e d 11:638-644.
Murray, P. J. 1999. Defining the requirements for immunological control of
mycobacterial infections. Trends Microbiol 7:366-72.
Murthy, P. S., M. Sirsi, and T. Ramakrishnan. 1973. Effect of age on the

341

enzymes

of

tricarboxylic

acid

and

related

cycles

in

Mycobacterium

tuberculosis H37Rv. A m Rev Respir Dis 108:689-90.
Muttucumaru, D. G., G. Roberts, J. Hinds, R. A. Stabler, and T. Parish.
2004. Gene expression profile of Mycobacterium tuberculosis in a nonreplicating state. Tuberculosis 84:239-46.
Nagabhushanam, V., A. Solache, L.-M. Ting, C. J. Escaron, J. Y. Zhang,
and J. D. Ernst. 2003. Innate Inhibition of Adaptive Immunity:
Mycobacterium tuberculosis-Induced IL-6 Inhibits Macrophage Responses to
IFN-y. J Immunol 171:4750-4757.
Nassif, X. and M. So. 1995. Interaction of pathogenic Neisseriae with
nonphagocytic cells. Clin Microbiol Rev 8:376-88.
Nassif, X., C. Pujol, P. Morand, and E. Eugene. 1999. Interactions of
pathogenic Neisseria with host cells. Is it possible to assemble the puzzle? M o l
Microbiol 32:1124-32.
Nathan, C. 1992. Nitric oxide as a secretory product of mammalian cells.
Faseb J 6:3051-64.
Nathan, C. 2004. Antibiotics at the crossroads. Nature 431:899-902.
Nathan, C. F. and Ehrt, S. 2004. Nitric Oxide in Tuberculosis, p. 215-235. In:
W . N . R o m and S. M . Garay ((ed.), Tuberculosis, 2nd ed. Lippincott Williams
and Wilkins, Philadelphia, P A .
Nathan, C. and M . U. Shiloh. 2000. Reactive oxygen and nitrogen
intermediates in the relationship between mammalian hosts and microbial
pathogens. Proc Natl Acad Sci U S A 97:8841-8848.
Nathan, C, and Q. W. Xie. 1994. Regulation of biosynthesis of nitric oxide. J
Biol C h e m 269:13725-8.
Naumann, M., S. Wessler, C. Bartsch, B. Wieland, and T. F. Meyer. 1997.
Neisseria gonorrhoeae epithelial cell interaction leads to the activation of the
transcription factors nuclear factor kappaB and activator protein 1 and the
induction of inflammatory cytokines. J Exp M e d 186:247-258.
Neveling, U., S. Bringer-Meyer, and H. Sahm. 1998. Gene and subunit
organization of bacterial pyruvate dehydrogenase complexes. Biochim Biophys
Acta 1385:367-372.

342

N g , V. H., J. S. Cox, A . O . Sousa, J. D. MacMicking, and J. D. M c R i n n e y .
2004. Role of KatG catalase-peroxidase in mycobacterial pathogenesis:
countering the phagocyte oxidative burst. M o l Microbiol 52:1291-1302.
Nopponpunth, V., W. Sirawaraporn, P. J. Greene, and D. V. Santi. 1999.
Cloning and expression of Mycobacterium tuberculosis and Mycobacterium
leprae dihydropteroate synthase in Escherichia coli. J Bacteriol 181:68146821.
Norris, S. J., J. R. Howell, S. A. Garza, M. S. Ferdows, and A. G. Barbour.
1995. High- and low-infectivity phenotypes of clonal populations of in vitrocultured Borrelia burgdorferi. Infect I m m u n 63: 2206-2212.
North, R. J. 1974. T cell dependence of macrophage activation and
mobilization during infection with Mycobacterium tuberculosis. Infect I m m u n
10:66-71.
North, R. J., and Y. J. Jung. 2004. Immunity to tuberculosis. Annu. Rev.
Immunol. 22:599-623.
Notley-McRobb, L., A. Death, and T. Ferenci. 1997. The relationship
between external glucose concentration and c A M P levels inside Escherichia
coli: implications for models of phosphotransferase-mediated regulation of
adenylate cyclase. Microbiology 143 (Pt 6): 1909-18.
Nunez-Martinez, O., C. Ripoll Noiseux, J. A. Carneros Martin, V.
Gonzalez Lara, and H . G . Gregorio M a r a n o n . 2001. Reactivation
tuberculosis in a patient with anti-TNF-alpha treatment. A m J Gastroenterol
96:1665-6.
Nunez, M. F., M. T. Pellicer, J. Badia, J. Aguilar, and L. Baldoma. 2001.
Biochemical characterization of the 2-ketoacid reductases encoded by y c d W
and yiaE genes in Escherichia coli. Biochem J 354:707-715.
Nyka, W. 1962. Studies on the infective particle in air-borne tuberculosis. I.
Observations in mice infected with a bovine strain of M . tuberculosis. A m .
Rev. Respir. Dis. 85:33-9.
Ochman, H., F. C. Soncini, F. Solomon, and E. A. Groisman. 1996.
Identification of a pathogenicity island required for Salmonella survival in host
cells. Proc Natl Acad Sci U S A 93:7800-7804.

343

O c h m a n , H., J. G. Lawrence, and E . A . Groisman. 2000. Lateral gene
transfer and the nature of bacterial innovation. Nature 405:299-304.
Oddo, M., T. Renno, A. Attinger, T. Bakker, H. R. MacDonald, and P. R.
Meylan. 1998. Fas ligand-induced apoptosis of infected h u m a n macrophages
reduces the viability of intracellular Mycobacterium tuberculosis. J Immunol
160:5448-54.
Oh, M.-R., L. Rohlin, R. C. Rao, and J. C. Liao. 2002. Global Expression
Profiling of Acetate-grown Escherichia coli. J. Biol. C h e m . 277:13175-13183.
Oliver, A., R. Canton, P. Campo, F. Baquero, and J. Blazquez. 2000. High
frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung
infection. Science 288:1251-4.
Opie, E. L. and J. D. Aronson. 1927. Tubercle bacilli in latent tuberculous
lesions and in lung tissue without tuberculous lesions. Archives of Pathology
4:1-21.
Oriel, J. D. 1991. Noeggerath and "latent gonorrhea". Sex Transm Dis 18:8991.
Orme, I. M. 1988. A mouse model of the recrudescence of latent tuberculosis
in the elderly. American Review of Respiratory Disease 137:716-8.
Orme, I. M. and F. M. Collins. 1994. Mouse model of tuberculosis, p. 113134. In: B.R. Bloom (Ed.), Tuberculosis, Pathogenesis, Protection and
Control. A S M Press, Washington D.C.
Orme, I., E. D. Roberts, J. P. Griffen, and J. S. Abrams. 1993. Cytokine
secretion by C D 4 T lymphocytes acquired in response to Mycobacterium
tuberculosis infection. J. Immunol. 151:518-525.
Ornston, L. N., and M. R. Ornston. 1969. Regulation of glyoxylate
metabolism in Escherichia coli K-12. J Bacteriol 98:1098-108.
Oksi, J., J. Savolainen, J. Pene, J. Bousquet, P. Laippala, and M. R.
Viljanen. 1996. Decreased interleukin-4 and increased g a m m a interferon
production by peripheral blood mononuclear cells of patients with L y m e
borreliosis. Infect I m m u n 64:3620-3623
O'Toole, G. A., and R. Rolter. 1998. Flagellar and twitching motility are
necessary for Pseudomonas aeruginosa biofilm development. M o l Microbiol

344

30:295-304.
O'Toole, G. A., R. A. Gibbs, P. W. Hager, P. V. Phibbs, Jr., and R. Rolter.
2000. The global carbon metabolism regulator Cre is a component of a signal
transduction pathway required for biofilm development by Pseudomonas
aeruginosa. J Bacteriol 182:425-31.
Ottenhoff, T. H., F. A. Verreck, E. G. Lichtenauer-Raligis, M. A. Hoeve,
O . Sanal, and J. T. van Dissel. 2002. Genetics, cytokines and h u m a n
infectious disease: lessons from weakly pathogenic mycobacteria and
salmonellae. Nat Genet 32:97-105.
Ovcinnikov, N. M., and V. V. Delektorskij. 1972. Electron microscopy of
phagocytosis in syphilis and yaws. Br J Vener Dis 48:227-48.
Pachner, A. R., E. Delaney, and T. O'Neill. 1995. Neuroborreliosis in the
nonhuman primate: Borrelia burgdorferi persists in the central nervous system.
A n n Neurol 38:667-9.
Pang, T. 1998. Genetic dynamics of Salmonella typhi—diversity in clonality.
Trends Microbiol 6:339-42.
Pang, T., M. M. Levine, B. Ivanoff, J. Wain, and B. B. Finlay. 1998.
Typhoid fever—important issues still remain. Trends Microbiol 6:131-3.
Parish, T. and N. G. Stoker. 2000. glnE is an essential gene in
Mycobacterium tuberculosis. J Bacteriol 182: 5715-20.
Parish, T. and N. G. Stoker. 2002. The common aromatic amino acid
biosynthesis pathway
is essential in Mycobacterium
tuberculosis.
Microbiology 148:3069-77.
Park, S. J., G. Chao, and R. P. Gunsalus. 1997. Aerobic regulation of the
s u c A B C D genes of Escherichia coli, which encode alpha-ketoglutarate
dehydrogenase and succinyl coenzyme A synthetase: roles of ArcA, Fnr, and
the upstream s d h C D A B promoter. J Bacteriol 179:4138-4142.
Parsons, N. J., J. R. Andrade, P. V. Patel, J. A. Cole, and H. Smith. 1989.
Sialylation of lipopolysaccharide and loss of absorption of bactericidal
antibody during conversion of gonococci to serum resistance by cytidine 5'monophospho-N-acetyl neuraminic acid. Microb Pathog 7:63-72.
Parvin, R., S. V. Pande, and T. A. Venkitasubramanian. 1966. Acetate

345

metabolism in mycobacteria. Can J Biochem 44:355-361.
Pavelka, M. S., Jr., and W. R. Jacobs, Jr. 1999. Comparison of the
construction of unmarked deletion mutations in Mycobacterium smegmatis,
Mycobacterium
bovis bacillus calmette-Guerin, and
Mycobacterium
tuberculosis H 3 7 R v by allelic exchange. J Bacteriol 181:4780-4789.
Paavonen, J. 1998. Pelvic inflammatory disease - from diagnosis to
prevention. Dermtol Clin 16:747-756.
Pawlotsky, J. M. 2004. Pathophysiology of hepatitis C virus infection and
related liver disease. Trends Microbiol 12:96-102.
Peekhaus, N., and T. Conway. 1998. What's for Dinner?: Entner-Doudoroff
Metabolism in Escherichia coli. J. Bacteriol. 180: 3495-3502.
Pellicer, M. T., C. Fernandez, J. Badia, J. Aguilar, E. C. Lin, and L.
Baldom. 1999. Cross-induction of glc and ace operons of Escherichia coli
attributable to pathway intersection. Characterization of the glc promoter. J
Biol C h e m 274:1745-1752.
Peng, L. and R. Shimizu. 2003. Global metabolic regulation analysis for
Escherichia coli K 1 2 based on protein expression by 2-dimensional
electrophoresis and enzyme activity measurement. Appl Microbiol Biotechnol
61: 163-178.
Peng, L., M. J. Arauzo-Bravo, and R. Shimizu. 2004. Metabolic flux
analysis for a ppc mutant Escherichia coli based on 13C-labelling experiments
together with enzyme activity assays and intracellular metabolite
measurements. F E M S Microbiol Lett 235:17-23.
Penningon, P. M., D. Cadavid, J. Bunikis, S. J. Norris, and A. G. Barbour.
1999. Extensive interplasmidic duplications change the virulence phenotype of
the relapsing fever agent Borrelia turicatae. M o l Microbiol 34:1120-1132.
Perriens, J. H., M. E. St Louis, Y. B. Mukadi, C. Brown, J. Prignot, F.
Pouthier, F. Portaels, J. C . Willame, J. R. Mandala, M . Raboto, R. W .
Ryder, G. Roscigno, and P. Piot. 1995. Pulmonary tuberculosis in HIVinfected patients in Zaire. A controlled trial of treatment for either 6 or 12
months. N Engl J M e d 332:779-784.
Persing, D. H., D. Mathiesen, D. Podzorski, and S. W. Barthold. 1994.
Genetic stability of Borrelia burgdorferi recovered from chronically infected

346

immunocompetent mice. Infect I m m u n 62:3521-3527.
Pertierra, A. G. and R. A. Cooper. 1977. Pyruvate formation during the
catabolism of simple hexose sugars by Escherichia coli: studies with pyruvate
kinase-negative mutants. J. Bacteriol.: 1208-1214.
Peters-Wendisch, P., C. Rreutzer, J. Kalinowski, M. Patek, H. Sahm, and
B. Eikmanns. 1998. Pyruvate carboxylase from Corynebacterium glutamicum:
characterization, expression and inactivation of the pyc gene. Microbiology
144:915-927.
Philipp, M. T. 1998. Studies on OspA: a source of new paradigms in Lyme
disease research. Trends Microbiol 6:44-47.
Piddington, D. L., F. C. Fang, T. Laessig, A. M. Cooper, I. M. Orme, and
N . A . Buchmeier. 2001. Cu,Zn superoxide dismutase of Mycobacterium
tuberculosis contributes to survival in activated macrophages that are
generating an oxidative burst. Infect I m m u n 69:4980-4987.
Plasterk, R. H., M. I. Simon, and A. G. Barbour. 1985. Transposition of
structural genes to an expression sequence on a linear plasmid causes antigenic
variation in the bacterium Borrelia hermsii. Nature 318:257-63.
Plaut, G.W., Beach, R.L., and Aogaichi, T. 1975. Alpha-methylisocitrate. A
selective inhibitor of TPN-linked isocitrate dehydrogenase from bovine heart
and rat liver. J Biol C h e m 250: 6351-6354.
Ponce, E., A. Martinez, F. Bolivar, and F. Valle. 1998. Stimulation of
glucose catabolism through the pentose pathway by the absence of the two
pyruvate kinase isoenzymes in Escherichia coli. Biotechnol Bioeng 58:292-5.
Post, F. A., P. A. Willcox, B. Mathema, L. M. Steyn, R. Shean, S. V.
R a m a s w a m y , E . A . Graviss, E . Shashkina, B. N . Rreiswirth, and G .
Kaplan. 2004. Genetic polymorphism in Mycobacterium tuberculosis isolates
from patients with chronic multidrug-resistant tuberculosis. J Infect Dis
190:99-106.
Pratt, L. A. and R. Rolter. 1999. Genetic analyses of bacterial biofilm
formation. Curr Opin Microbiol 2:598-603.
Pronk, J. T., A. van der Linden-Beuman, C. Verduyn, W. A. Scheffers,
and J. P. van Dijken. 1994. Propionate metabolism in Saccharomyces
cerevisiae: implications for the metabolon hypothesis. Microbiology 140:717-

347

22.
Pym, A. S., B. Saint-Joanis, and S. T. Cole. 2002. Effect of katG mutations
on the virulence of Mycobacterium tuberculosis and the implication for
transmission in humans. Infect I m m u n 70:4955-60.
Quetel, C. 1990. History of Syphilis. John Hopkins University Press,
Baltimore, M D .
Radolf, J. D. 1994. Role of outer membrane architecture in immune evasion
by Treponema pallidum and Borrelia burgdorferi. Trends Microbiol 2:307-11.
Radolf, J. D. 1995. Treponema pallidum and the quest for outer membrane
proteins. M o l Microbiol 16:1067-73.
Radolf, J. D., M. V. Norgard, and W. W. Schulz. 1989. Outer membrane
ultrastructure explains the limited antigenicity of virulent Treponema pallidum.
Proc Natl Acad Sci U S A 86:2051-5.
Ram, S., F. G. Mackinnon, S. Gulati, D. P. McQuillen, U. Vogel, M.
Frosch, C . Elkins, H . R. Guttormsen, L. M . Wetzler, M . O p p e r m a n n , M .
R. Pangburn, and P. A . Rice. 1999. The contrasting mechanisms of serum
resistance of Neisseria gonorrhoeae and group B Neissseria meningitidis. M o l
Microbiol 36: 915-928
Ranes, M., J. Rauzier, M. Lagranderie, M. Gheorghiu, and B. Gicquel.
1990. Functional Analysis of pAL5000, a Plasmid from Mycobacterium
Rathman, M., L. P. Barker, and S. Falkow. 1997. The unique trafficking
pattern of Salmonella typhimurium-containing phagosomes in murine
macrophages is independent of the mechanism of bacterial entry. Infect I m m u n
65:1475-85.
Rathman, M., M. D. Sjaastad, and S. Falkow. 1996. Acidification of
phagosomes containing Salmonella typhimurium in murine macrophages.
Infect I m m u n 64:2765-73.
Ravetch, J. V. and L. L. Lanier. 2000. Immune inhibitory receptors. Science
290:84-9.
Raviglione, M. C, D. E. Snider, Jr., and A. Rochi. 1995. Global
epidemiology of Tuberculosis. Morbidity and mortality of a worldwide
epidemic. Jama 273:220-6.

348

Raynaud, C , C. Guilhot, J. Rauzier, Y . Bordat, V . Pelicic, R. Manganelli,
I. Smith, B. Gicquel, and M . Jackson. 2002. Phospholipases C are involved
in the virulence of Mycobacterium tuberculosis. M o l Microbiol 45:203-17.
Reed, M. B., P. Domenech, C. Manca, H. Su, A. R. Barczak, B. N.
Rreiswirth, G . Raplan, and C. E . Barry, 3rd. 2004. A glycolipid of
hypervirulent tuberculosis strains that inhibits the innate i m m u n e response.
Nature 431:84-7.
Rees, R., and P. D'Arcy Hart. 1961. Analysis of the Host-Parasite
Equilibrium in Chronic Murine Tuberculosis by Total and Viable Bacillary
Counts. Brit. J. Exp. Pathol. 42:83-88.
Restrepo, B. I. and A. G. Barbour. 1994. Antigen diversity in the bacterium
B. hermsii through somatic mutations in rearranged v m p genes. Cell 78:86776.
Restrepo, B. I., C. J. Carter, and A. G. Barbour. 1994. Activation of a vmp
pseudogene in Borrelia hermsii: an alternate mechanism of antigenic variation
during relapsing fever. M o l Microbiol 13:287-99.
Rhen, M., S. Eriksson, and S. Pettersson. 2000. Bacterial adaptation to host
innate immunity responses. Curr Opin Microbiol 3:60-64.
Rhoades, E. R., A. A. Frank, and I. M. Orme. 1997. Progression of chronic
pulmonary tuberculosis in mice aerogenically infected with virulent
Mycobacterium tuberculosis. Tuber Lung Dis 78:57-66.
Rich, A. R., A. M. Chesney, and T. B. Turner. 1933. Experiments
demonstrating that acquired immunity in syphilis is not dependent upon
allergic inflammation. John Hopkins Hosp. Bull. 52:179-202.
Roberts, E. D., R. P. Bohm, Jr., F. B. Cogswell, H. N. Lanners, R. C.
Lowrie, Jr., L. Povinelli, J. Piesman, and M . T. Philipp. 1995. Chronic
L y m e disease in the rhesus monkey. Lab Invest 72:146-60.
Rodriguez, G. M., and I. Smith. 2003. Mechanisms of iron regulation in
mycobacteria: role in physiology and virulence. M o l Microbiol 47:1485-94.
Romano, A. H. 1970. Distribution of the phosphoenolpyruvate: glucose
phosphotransferase system in bacteria. J. Bacteriol. 104:808-813.

349

R o m a n o , A . H., and T. C o n w a y . 1996. Evolution of carbohydrate metabolic
pathways. 14th Forum in Microbiology:448-455.
Rothbard, J. B., R. Fernandez, L. Wang, N. N. Teng, and G. R. Schoolnik.
1985. Antibodies to peptides corresponding to a conserved sequence of
gonococcal pilins block bacterial adhesion. Proc Natl Acad Sci U S A 82:915-9.
Rowe, B., L. R. Ward, and E. J. Threlfall. 1997. Multidrug-resistant
Salmonella typhi: a worldwide epidemic. Clin Infect Dis 24 Suppl 1:S 106-9.
Rozen, S., and H. Skaletsky. 2000. Primer3 on the WWW for general users
and for biologist programmers. Methods M o l Biol 132:365-86.
R u d e , T. H., D. L. Toffaletti, G . M . Cox, and J. R. Perfect. 2002.
Relationship of the glyoxylate pathway to the pathogenesis of Cryptococcus
neoformans. Infect I m m u n 70:5684-94.
Rudenko, G. M. M. Cross, and P. Borst. 1998. Changing the end: antigenic
variation orchestrated at the telomeres of African trypanosomes. Trends
Microbiol. 6: 113-116.
Runquist, M. and N. J. Rruger. 1999. Control of gluconeogenesis by
isocitrate lyase in endosperm of germinating castor bean seedlings. Plant J
19:423-31.
Russell, D. G. 2001. Mycobacterium tuberculosis: here today and here to stay.
Nat. Rev. Mol. Cell Biol. 2:1.
Russell, D. G., J. Dant, and S. Sturgill-Roszycki. 1996. Mycobacterium
avium- and Mycobacterium tuberculosis-containing vacuoles are dynamic,
fusion-competent vesicles that are accessible to glycosphingolipids from the
host cell plasmalemma. J Immunol 156:4764-73.
Saier, M., Jr. and T. Ramseier. 1996. The catabolite repressor/activator (Cra)
protein of enteric bacteria. J. Bacteriol. 178:3411-3417.
Saint Girons, I. and A. G. Barbour. 1991. Antigenic variation in Borrelia.
Res Microbiol 142: 711-717.
Saito, H., H. Tomioka, T. Watanabe, and T. Yoneyama. 1983.
Mycobacteriocins produced by rapidly growing mycobacteria are Tweenhydrolyzing esterases. J Bacteriol 153:1294-300.
Saitou, N., and M. Nei. 1987. The neighbor-joining method: a new method for

350

reconstructing phylogenetic trees. M o l Biol Evol 4:406-25.
Salo, W. L., A. C. Aufderheide, J. Buikstra, and T. A. Holcomb. 1994.
Identification of Mycobacterium tuberculosis D N A in a pre-Columbian
Peruvian m u m m y . Proc Natl Acad Sci U S A 91:2091-4.
Santangelo, R. T., M. H. Nouri-Sorkhabi, T. C. Sorrell, M. Cagney, S. C.
Chen, P. W . Ruchel, and L. C. Wright. 1999. Biochemical and functional
characterisation of secreted phospholipase activities from Cryptococcus
neoformans in their naturally occurring state. J M e d Microbiol 48:731-40.
Sassetti, C. M. and E. J. Rubin. 2003. Genetic requirements for
mycobacterial survival during infection. Proc Natl Acad Sci U S A 100:1298912994.
Sassetti, C. M., D. H. Boyd, and E. J. Rubin. 2003. Genes required for
mycobacterial growth defined by high density mutagenesis. M o l Microbiol
48:77-84.
Saunders, B. M., H. Briscoe, and W. J. Britton. 2004. T cell-derived tumour
necrosis factor is essential, but not sufficient, for protection against
Mycobacterium tuberculosis infection. Clin Exp Immunol 137:279-287.
Scanga, C. A., V. P. Mohan, H. Joseph, R. Yu, J. Chan, and J. L. Flynn.
1999. Reactivation of latent tuberculosis: variations on the Cornell murine
model. Infect I m m u n 67:4531-8.
Scanga, C. A., V. P. Mohan, R. Tanaka, D. Alland, J. L. Flynn, and J.
C h a n . 2001. The inducible nitric oxide synthase locus confers protection
against aerogenic challenge of both clinical and laboratory strains of
Mycobacterium tuberculosis in mice. Infect I m m u n 69:7711-7.
Schaible, U. E., S. Sturgill-Roszycki, P. H. Schlesinger, and D. G. Russell.
1998. Cytokine activation leads to acidification and increases maturation of
Mycobacterium av/wra-containing phagosomes in murine macrophages. J
Immunol 160:1290-6.
Scherer, C. A. and S. I. Miller. 2001. Molecular Pathogenesis of
Salmonellae, p. 265-333. In: E. A. Groisman (Ed.), Principles of Bacterial
Pathogenesis. Academic Press, San Diego, C A .
Schlesinger, L. S. 1993. Macrophage phagocytosis of virulent but not
attenuated strains of Mycobacterium tuberculosis is mediated by mannose

351

receptors in addition to complement receptors. J Immunol 150:2920-30.
Schlesinger, L. S., C. G. Bellinger-Rawahara, N. R. Payne, and M. A.
Horwitz. 1990. Phagocytosis of Mycobacterium tuberculosis is mediated by
h u m a n monocyte complement receptors and complement component C3. J
Immunol 144:2771-80.
Schloss, J. V., and W. W. Cleland. 1982. Inhibition of isocitrate lyase by 3nitropropionate, a reaction-intermediate analogue. Biochemistry 21:4420-7.
Schnappinger, D., S. Ehrt, M. I. Voskuil, Y. Liu, J. A. Mangan, I. M.
M o n a h a n , G. Dolganov, B. Efron, P. D. Butcher, C. Nathan, and G . R.
Schoolnik. 2003. Transcriptional Adaptation of Mycobacterium tuberculosis
within Macrophages: Insights into the Phagosomal Environment. J Exp M e d
198:693-704.
Schneider, H., J. M. Griffiss, J. W. Boslego, P. J. Hitchcock, R. M. Zahos,
and
M.
A.
Apicella.
1991. Expression
of
paragloboside-like
lipooligosaccharides m a y be a necessary component of gonococcal
pathogenesis in men. J Exp M e d 174:1601-5.
Schryvers, A., E. Lohmeier, and J. H. Weiner. 1978. Chemical and
functional properties of the native and reconstituted forms of the membranebound, aerobic glycerol-3-phosphate dehydrogenase of Escherichia coli. J Biol
C h e m 253:783-8.
Schuhardt, V. T., and M. Wilkerson. 1951. Relapse Phenomena in Rats
Infected with Single Spirochetes (Borrelia recurrentis Var. turicatae). J
Bacteriol 62:215-219.
Schwan, T. G., and B. J. Hinnebusch. 1998. Bloodstream- versus tickassociated variants of a relapsing fever bacterium. Science 280:1938-40.
Sebbane, F., C. Jarrett, J. R. Linkenhoker, and B. J. Hinnebusch. 2004.
Evaluation of the Role of Constitutive Isocitrate Lyase Activity in Yersinia
pestis Infection of the Flea Vector and Mammalian Host. Infect. I m m u n .
72:7334-7337.
Segal, B. H., L. Ding, and S. M. Holland. 2003. Phagocyte NADPH oxidase,
but not inducible nitric oxide synthase, is essential for early control of
Burkholderia cepacia and Chromobacterium violaceum infection in mice.
Infect I m m u n 71:205-10.

352

Segal, E., E . Billyard, M . So, S. Storzbach, and T. F. Meyer. 1985. Role of
chromosomal rearrangement in N. gonorrhoeae pilus phase variation. Cell
40:293-300.
Segal, W., and H. Bloch. 1956. Biochemical Differentiation of
Mycobacterium tuberculosis G r o w n in vivo and in vitro. J Bacteriol 72:132141.
Seifert, H. S. 1996. Questions about gonococcal pilus phase- and antigenic
variation. M o l Microbiol 21:433-40.
Seifert, H. S., C. J. Wright, A. E. Jerse, M. S. Cohen, and J. G. Cannon.
1994. Multiple gonococcal pilin antigenic variants are produced during
experimental h u m a n infections. J Clin Invest 93:2744-9.
Seiler, P., T. Ulrichs, S. Bandermann, L. Pradl, S. Jorg, V. Rrenn, L.
Morawietz, S. H . R a u f m a n n , and P. Aichele. 2003. Cell-wall alterations as
an attribute of Mycobacterium tuberculosis in latent infection. J Infect Dis
188:1326-31.
Sell, S., D. Gamboa, S. A. Baker-Zander, S. A. Lukehart, and J. N. Miller.
1980. Host response to Treponema pallidum in intradermally-infected rabbits:
evidence for persistence of infection at local and distant sites. J Invest
Dermatol 75:470-5.
Sepkowitz, R. A., J. Raffalli, L. Riley, T. E. Riehn, and D. Armstrong.
1995. Tuberculosis in the A D D S era. Clin Microbiol Rev 8:180-99.
Serbina, N. V., and J. L. Flynn. 1999. Early emergence of CD8(+) T cells
primed for production of type 1 cytokines in the lungs of Mycobacterium
tuberculosis-infected mice. Infect I m m u n 67:3980-8.
Serbina, N. V., C. C. Liu, C. A. Scanga, and J. L. Flynn. 2000. CD8+ CTL
from lungs of Mycobacterium tuberculosis-infected mice express perforin in
vivo and lyse infected macrophages. J Immunol 165:353-63.
Serbina, N. V., V. Lazarevic, and J. L. Flynn. 2001. CD4(+) T cells are
required for the development of cytotoxic CD8(+) T cells during
Mycobacterium tuberculosis infection. J Immunol 167:6991-7000.
Seshadri, R., P. S. Murthy, and T. A. Venkitasubramanian. 1972. Malate
metabolism in mycobacteria. Biochem J 128:62P.

353

Seshadri, R., P. S. Murthy, and

T. A . Venkitasubramanian. 1976.

Isociatrate lyase in mycobacteria. Indian J Biochem Biophys 13:95-6.
Sever, J. L. and G. P. Youmans. 1957. Enumeration of viable tubercle bacilli
from the organs of nonimmunized and immunized mice. A m . Rev. Tuberc.
Pulm. Dis. 76:616-635.
Shafer, W. M. and R. F. Rest. 1989. Interactions of gonococci with
phagocytic cells. A n n u Rev Microbiol 43:121-45.
Sharma, V. D., V. M. Ratoch, A. R. Datta, R. B. Rannan, C. T.
Shivannavar, and V . P. Bharadwaj. 1985. Metabolic studies on
mycobacteria-I. Demonstration of key enzymes of glycolysis and tricarboxylic
acid cycle on polyacrylamide gels. Indian J Lepr 57:534-41.
Sharma, V., S. Sharma, R. Hoener zu Bentrup, J. D. McRinney, D. G.
Russell, W . R. Jacobs, Jr., and J. C. Sacchettini. 2000. Structure of isocitrate
lyase, a persistence factor of Mycobacterium tuberculosis. Nat Struct Biol
7:663-8.
Shi, L., Y. J. Jung, S. Tyagi, M. L. Gennaro, and R. J. North. 2003.
Expression of Thl-mediated immunity in mouse lungs induces a
Mycobacterium
tuberculosis
transcription
pattern
characteristic
of
nonreplicating persistence. Proc Natl Acad Sci U S A 100:241-6.
Shibata, Y., P. Y. Berclaz, Z. C. Chroneos, M. Yoshida, J. A. Whitsett, and
B. C . Trapnell. 2001. G M - C S F regulates alveolar macrophage differentiation
and innate immunity in the lung through PU.l. Immunity 15:557-67.
Shukla, V. R., H. Singh, M. Pandey, S. R. Upadhyay, and G. Nath. 2000.
Carcinoma of the gallbladder - is it a sequel of typhoid? Dig Dis Sci 45: 900903.
Sigal, L. H . 1997. L y m e disease: a review of aspects of its immunology and
immunopathogenesis. A n n u Rev Immunol 15:63-92.
Simon, V. and D. D. Ho. 2003. HIV-1 dynamics in vivo: implications for
therapy. Nat Rev Microbiol 1:181-90.
Sinai, A. P. and R. A. Joiner. 1997. Safe haven: the cell biology of
nonfusogenic pathogen vacuoles. A n n u Rev Microbiol 51:415-62.
Singh, A. E., and B. Romanowski. 1999. Syphilis: review with emphasis on
clinical, epidemiologic, and some biologic features. Clin Microbiol Rev

354

12:187-209.
Slauch, J., R. Taylor, and S. Maloy. 1997. Survival in a cruel world: how
Vibrio cholerae and Salmonella respond to an unwilling host. Genes D e v
11:1761-74.
Smith, C. V., C. C. Huang, A. Miczak, D. G. Russell, J. C. Sacchettini, and
R . H o n e r zu Bentrup. 2003. Biochemical and structural studies of malate
synthase from Mycobacterium tuberculosis. J Biol C h e m 278:1735-43.
Smith, D. A., T. Parish, N. G. Stoker, and G. J. Bancroft. 2001.
Characterization of Auxotrophic Mutants of Mycobacterium tuberculosis and
Their Potential as Vaccine Candidates. Infect I m m u n 69:1142-1150.
Smith, H. 2000. Questions about the behaviour of bacterial pathogens in vivo.
Philos Trans R Soc Lond B Biol Sci 355:551-64.
Smith, H., N. Parsons, and J. Cole. 1995. Sialylation of Neisserial
Lipopolysacchari.de:
A
Major Influence on Pathogenicity. Microbe
Pathogenicity 19:365-377.
Sousa, A. O., R. J. Mazzaccaro, R. G. Russell, F. R. Lee, O. C. Turner, S.
H o n g , L. V a n Raer, and B. R. Bloom. 2000. Relative contributions of
distinct M H C class I-dependent cell populations in protection to tuberculosis
infection in mice. Proc Natl Acad Sci U S A 97:4204-8.
Spencer, M. E., and J. R. Guest. 1987. Regulation of citric acid cycle genes
in facultative bacteria. Microbiol Sci 4:164-8.
Stamm, L. M., J. H. Morisaki, L.-Y. Gao, R. L. Jeng, R. L. McDonald, R.
Roth, S. Takeshita, J. Heuser, M . D. Welch, and E . J. B r o w n . 2003.
Mycobacterium marinum Escapes from Phagosomes and Is Propelled by
Actin-based Motility. J Exp M e d 198:1361-1368.
Steere, A. C. 1989. Lyme disease. N Engl J Med 321:586-96.
Stenger, S., D. A. Hanson, R. Teitelbaum, P. Dewan,
Froelich, T. G a n z , S. Thoma-Uszynski, A . Melian,
Porcelli, B. R. Bloom, A . M . Rrensky, and R. L.
antimicrobial activity of cytolytic T cells mediated by

R. R. Niazi, C. J.
C. Bogdan, S. A .
Modlin. 1998. A n
granulysin. Science

282:121-5.
Stern, A., M. Brown, P. Nickel, and T. F. Meyer. 1986. Opacity genes in

355

Neisseria gonorrhoeae: control of phase and antigenic variation. Cell 47: 6171.
Stern, A., P. Nickel, T. F. Meyer, and M. So. 1984. Opacity determinants of
Neisseria gonorrhoeae: gene expression and chromosomal linkage to the
gonococcal pilus gene. Cell 37:447-56.
Stevenson, B., L. R. Bockenstedt, and S. W. Barthold. 1994. Expression and
gene sequence of outer surface protein C of Borrelia burgdorferi reisolated
from chronically infected mice. Infect I m m u n 62:3568-3571.
Stewart, G. R., B. D. Robertson, and D. B. Young. 2003. Tuberculosis: a
problem with persistence. Nat Rev Microbiol 1:97-105.
Stickler, D. J., N. S. Morris, R. J. McLean, and C. Fuqua. 1998. Biofilms
on indwelling urethral catheters produce quorum-sensing signal molecules in
situ and in vitro. Appl Environ Microbiol 64:3486-90.
Stoenner, H. G., T. Dodd, and C. Larsen. 1982. Antigenic variation of
Borrelia hermsii. J Exp M e d 156:1297-311.
Stover, C. R., V. F. de la Cruz, T. R. Fuerst, J. E. Burlein, L. A. Benson, L.
T. Bennett, G . P. Bansal, J. F. Young, M . H . Lee, G. F. Hatfull, and et al.
1991. N e w use of B C G for recombinant vaccines. Nature 351:456-60.
Sturgill-Roszycki, S., P. H. Schlesinger, P. Chakraborty, P. L. Haddix, H.
L. Collins, A . R. Fok, R. D. Allen, S. L. Gluck, J. Heuser, and D. G .
Russell. 1994. Lack of acidification in Mycobacterium phagosomes produced
by exclusion of the vesicular proton-ATPase. [published erratum appears in
Science 1994 M a r 11;263(5152):1359]. Science 263:678-81.
Sturgill-Roszycki, S., U. E. Schaible, and D. G. Russell. 1996.
Mycobacterium-containing phagosomes are accessible to early endosomes and
reflect a transitional state in normal phagosome biogenesis. E m b o J 15:6960-8.
Suk, R., S. Das, W. Sun, B. Jwang, S. W. Barthold, R. A. Flavell, and E.
Fikrig. 1995. Borrelia burgdorferi genes selectively expressed in the infected
host. Proc Natl Acad Sci U S A 92:4269-73.
Sukupohi, S., A. Edelstein, M. Rhen, S. J. Normark, and J. D. Pfeifer.
1997. Development of a murine model of chronic Salmonella infection. Infect
I m m u n 65:838-42.

356

Suter, E . 1961. Pasive transfer of acquired resistance to infection with
Mycobacterium tuberculosis by means of cells. American Review of
Respiratory Disease 83:535-543.
Swanson, J. 1973. Studies on gonococcus infection. IV. Pili: their role in
attachment of gonococci totissueculture cells. J Exp M e d 137:571-89.
Swanson, J., O. Barrera, J. Sola, and J. Boslego. 1988. Expression of outer
membrane protein II by gonococci in experimental gonorrhea. J Exp M e d
168:2121-9.
Sweany, H. C, S. A. Levinson, and A. M. S. Stadnichenko. 1943.
Tuberculous Infection in People Dying of Causes other than tuberculosis.
American Review of Tuberculosis 47:131-173.
Tabuchi, T., and H. Uchiyama. 1975. Methylcitrate condensing and
methylisocitrate cleaving enzymes; evidence for the pathway of oxidation of
propionyl-CoA to pyruvate via C7-tricarboxylic acids. Agr. Biol. C h e m .
39:2035-42.
Tabuchi, T., and N. Serizawa. 1975. A Hypothetical Cyclic Pathway for the
Metabolism of Odd-carbon n-Alkanes or Propionyl-CoA via Seven-carbon
Tricarboxylic Acids in Yeasts. Agr. Biol. Chem. 39:1055-1061.
Tailleux, L., O. Schwartz, J.-L. Herrmann, E. Pivert, M. Jackson, A.
A m a r a , L. Legres, D. Dreher, L. P. Nicod, J. C. Gluckman, P. H .
Lagrange, B. Gicquel, and O . Neyrolles. 2003. D C - S I G N Is the Major
Mycobacterium tuberculosis Receptor on H u m a n Dendritic Cells. J Exp M e d
197:121-127.
Tascon, R. E., E. Stavropoulos, R. V. Lukacs, and M. J. Colston. 1998.
Protection against Mycobacterium tuberculosis infection by C D 8 + T cells
requires the production of g a m m a interferon. Infect I m m u n 66:830-4.
Telenti, A., P. Imboden, F. Marchesi, D. Lowrie, S. Cole, M. J. Colston, L.
Matter, R . Schopfer, and T. B o d m e r . 1993. Detection of rifampicinresistance mutations in Mycobacterium tuberculosis. Lancet 341:647-50.
Textor, S., V. F. Wendisch, A. A. De Graaf, U. Muller, M. I. Linder, D.
Linder, and W . Buckel. 1997. Propionate oxidation in Escherichia coli:
evidence for operation of a methylcitrate cycle in bacteria. Arch Microbiol
168:428-36.

357

Theodore, T. S., and E . Englesberg. 1964. Mutant of Salmonella
typhimurium
Deficient
in
the
Carbon
Dioxide-Fixing
Enzyme
Phosphoenolpyruvic Carboxylase. J Bacteriol 88:946-55.
Thompson, J. D., D. G. Higgins, and T. J. Gibson. 1994. CLUSTAL W:
improving the sensitivity of progressive multiple sequence alignment through
sequence weighting, position-specific gap penalties and weight matrix choice.
Nucleic Acids Res 22:4673-80.
Timm, J., F. A. Post, L. G. Bekker, G. B. Walther, H. C. Wainwright, R.
Manganelli, W . T. C h a n , L. Tsenova, B. Gold, I. Smith, G . Raplan, and J.
D. M c R i n n e y . 2003. Differential expression of iron-, carbon-, and oxygenresponsive mycobacterial genes in the lungs of chronically infected mice and
tuberculosis patients. Proc Natl Acad Sci U S A 100:14321-6.
Tian, J., Bryk, R., Itoh, M., Suematsu, M., and Nathan, C. (2005) Variant
tricarboxylic acid cyclein Mycobacterium tuberculosis: identification of
a-ketoglutarate decarboxylase. Proc Natl Acad Sci U S A 102: 10670-10675.
Ting, L. M., A. C. Rim, A. Cattamanchi, and J. D. Ernst. 1999.
Mycobacterium tuberculosis inhibits IFN-y transcriptional responses without
inhibiting activation of S T A T 1 . J Immunol 163:3898-906.
Tomb, J. F., O. White, A. R. Rerlavage, R. A. Clayton, G. G. Sutton, R. D.
Fleischmann, R. A . Retchum, H . P. Rlenk, S. Gill, B. A . Dougherty, R.
Nelson, J. Quackenbush, L. Zhou, E . F. Rirkness, S. Peterson, B. Loftus,
D. Richardson, R. Dodson, H . G . Rhalak, A . Glodek, R. M c K e n n e y et al.,
1997. The complete genome sequence of the gastric pathogen Helicobacter
pylori. Nature 388:539-47.

Trinchieri, G. 2003. Interleukin-12 and the regulation of innate resistance and
adaptive immunity. Nat Rev Immunol 3:133-46.
Trivedi, O. A., P. Arora, V. Sridharan, R. Tickoo, D. Mohanty, and R. S.
Gokhale. 2004. Enzymic activation and transfer of fatty acids as acyladenylates in mycobacteria. Nature 428:441-5.
Tuckman, D., R. J. Donnelly, F. X. Zhao, W. R. Jacobs, Jr., and N. D.
Connell. 1997. Interruption of the phosphoglucose isomerase gene results in
glucose auxotrophy in Mycobacterium smegmatis. J Bacteriol 179:2724-30.
Tyagi, S., and F. R. Rramer. 1996. Molecular beacons: probes that fluoresce
upon hybridization. Nat Biotechnol 14:303-8.

358

Uchiya, R., M . A . Barbieri, R. Funato, A . H . Shah, P. D. Stahl, and E . A .
Groisman. 1999. A Salmonella virulence protein that inhibits cellular
trafficking. E m b o J 18:3924-33.
Utley, M., D. P. Franklin, R. A. Rrogfelt, D. C. Laux, and P. S. Cohen.
1998. A Salmonella typhimurium mutant unable to utilize fatty acids and
citrate is avirulent and immunogenic in mice. F E M S Microbiol Lett 163:12934.
Valdivia, R. H., and S. Falkow. 1997. Fluorescence-based isolation of
bacterial genes expressed within host cells. Science 277:2007-11.
Valentine, P. J., B. P. Devore, and F. Heffron. 1998. Identification of three
highly attenuated Salmonella typhimurium mutants that are more immunogenic
and protective in mice than a prototypical aroA mutant. Infect I m m u n 66:337883.
Valway, S. E., M. P. Sanchez, T. F. Shinnick, I. Orme, T. Agerton, D. Hoy,
J. S. Jones, H . Westmoreland, and I. M . Onorato. 1998. A n outbreak
involving extensive transmission of a virulent strain of Mycobacterium
tuberculosis. N Engl J M e d 338:633-9.
van den Berg, M. A., P. de Jong-Gubbels, C. J. Rortland, J. P. van Dijken,
J. T. Pronk, and H . Y . Steensma. 1996. The T w o Acetyl-coenzyme A
Synthetases of Saccharomyces cerevisiae Differ with Respect to Kinetic
Properties and Transcriptional Regulation. J. Biol. Chem. 271:28953-28959.
van der Rest, M. E., C. Frank, and D. Molenaar. 2000. Functions of the
membrane-associated and cytoplasmic malate dehydrogenases in the citric acid
cycle of Escherichia coli. J Bacteriol 182:6892-9.
van Hyningen, T. K., H. L. Collins, and D. G. Russell. 1997. IL-6 produced
by macrophages infected with Mycobacterium species suppresses T cell
responses. J. Immunol. 158:330-337.
van Putten, J. P. 1993. Phase variation of lipopolysaccharide directs
interconversion of invasive and immuno-resistant phenotypes of Neisseria
gonorrhoeae. E m b o J 12:4043-51.
van Putten, J. P., and B. D. Robertson. 1995. Molecular mechanisms and
implications for infection of lipopolysaccharide variation in Neisseria. M o l
Microbiol 16:847-53.

359

van Voorhis, W . C , L. R. Barrett, J. M . Nasio, F. A . P l u m m e r , and S. A .
Lukehart. 1996a. Lesions of primary and secondary syphilis contain activated
cytolytic T cells. Infect I m m u n 64:1048-1050.
van Voorhis, W. C, L. R. Barrett, D. M. Roelle, J. M. Nasio, F. A.
P l u m m e r , and S. A . Lukehart. 1996b. Primary and secondary syphilis lesions
contain m R N A for Thl cytokines. J Infect Dis 173: 491-495.
Vandiviere, H. M., W. E. Loring, I. Melvin, and S. Willis. 1956. The
Treated Pulmonary Lesion and its Tubercle Bacillus. A m J M e d Sci 232:30-37.
V a n h a m , G., Z. Toossi, C. S. Hirsch, R. S. Wallis, S. R. Schwander, E . A .
Rich, and J. J. Ellner. 1997. Examining a paradox in the pathogenesis of
h u m a n pulmonary tuberculosis: i m m u n e activation and suppression/anergy.
Tuberc Lung Dis 78:145-158.
Vanni, P., E. Giachetti, G. Pinzauti, and B. A. McFadden. 1990.
Comparative Structure, Function and Regulation of Isocitrate Lyase, an
Important Assimilatory Enzyme. C o m p Biochem Physiol 95B:431-458.
Vazquez-Torres, A., and F. C. Fang. 2001. Oxygen-dependent antiSalmonella activity of macrophages. Trends Microbiol 9:29-33.
Vazquez-Torres, A., J. Jones-Carson, A. J. Baumler, S. Falkow, R.
Valdivia, W . B r o w n , M . Le, R. Berggren, W . T. Parks, and F. C. Fang.
1999. Extraintestinal dissemination of Salmonella by CD18-expressing
phagocytes. Nature 401:804-8.
Vazquez-Torres, A., J. Jones-Carson, P. Mastroeni, H. Ischiropoulos, and
F. C . Fang. 2000. Antimicrobial actions of the N A D P H phagocyte oxidase and
inducible nitric oxide synthase in experimental salmonellosis. I. Effects on
microbial killing by activated peritoneal macrophages in vitro. J Exp M e d
192:227-36.
Velayudhan, J., and D. J. Relly. 2002. Analysis of gluconeogenic and
anaplerotic enzymes in Campylobacter jejuni: an essential role for
phosphoenolpyruvate carboxykinase. Microbiology 148:685-694.
Vergne, I., J. Chua, and V. Deretic. 2003. Tuberculosis Toxin Blocking
Phagosome Maturation Inhibits a Novel Ca2+/Calmodulin-PI3K h V P S 3 4
Cascade. J Exp M e d 198:653-659.
Verreck, F. A. W., T. de Boer, D. M. L. Langenberg, M. A. Hoeve, M.

360

R r a m e r , E . Vaisberg, R. Kastelein, A . Kolk, R. de Waal-Malefyt, and T.
H . M . Ottenhoff. 2004. H u m a n IL-23-producing type 1 macrophages promote
but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria.
Proc Natl Acad Sci U S A 101:4560-4565.
Vinopal, R. T., and D. G. Fraenkel. 1974. Phenotypic suppression of
phosphofructokinase mutations in Escherichia coli by constitutive expression
of the glyoxylate shunt. J Bacteriol 118:1090-100.
Vinopal, R. T., and D. G. Fraenkel. 1975. PfkB and pfkC loci of Escherichia
coli. J Bacteriol 122:1153-61.
Vinopal, R. T., D. Clifton, and D. G. Fraenkel. 1975. PfkA locus of
Escherichia coli. J Bacteriol 122:1162-71.
Vogel, U. and M. Frosch. 1999. Mechanisms of neisserial serum resistance.
M o l Microbiol 32:1133-1139.
Voskuil, M. I., D. Schnappinger, R. C. Visconti, M. I. Harrell, G. M.
Dolganov, D. R. Sherman, and G. R. Schoolnik. 2003. Inhibition of
Respiration by Nitric Oxide Induces a Mycobacterium tuberculosis Dormancy
Program. J Exp M e d 198:705-713.
Voskuil, M. I., R. C. Visconti, and G. R. Schoolnik. 2004. Mycobacterium
tuberculosis gene expression during adaptation to stationary phase and lowoxygen dormancy. Tuberculosis (Edinb) 84:218-27.
Wall, D., and D. Raiser. 1999. Type IV pili and cell motility. Mol Microbiol
32:1-10.
Wallace, J. G. 1961. The heat resistance of tubercle bacilli in the lungs of
infected mice. A m . Rev. Resp. Dis. 83:866-871.
Walsh, C. 2003. Where will new antibiotics come from? Nat Rev Microbiol
1:65-70.
Walsh, R., and D. E. Roshland, Jr. 1984. Determination of flux through the
branch point of two metabolic cycles. The tricarboxylic acid cycle and the
glyoxylate shunt. J Biol C h e m 259:9646-54.
Walsh, R., and D. E. Roshland, Jr. 1985. Branch point control by the
phosphorylation state of isocitrate dehydrogenase. A quantitative examination
of fluxes during a regulatory transition. J Biol C h e m 260:8430-7.

361

W a n g , C. H., C. Y . Liu, H . C. Lin, C. T. Y u , R. F. C h u n g , and H . P. R u o .
1998. Increased exhaled nitric oxide in active pulmonary tuberculosis due to
inducible N O synthase upregulation in alveolar macrophages. Eur Respir J
11:809-15.
Wang, Z.-X., C. Bramer, and A. Steinbuchel. 2003a. Two phenotypically
compensating isocitrate dehydrogenases in Ralstonia eutropha. F E M S
Microbiology Letters 227:9-16.
Wang, Z.-Y., C. R. Thornton, M. J. Rershaw, L. Debao, and N. J. Talbot.
2003b. The glyoxylate cycle is required for temporal regulation of virulence by
the plant pathogenic fungus Magnaporthe grisea. M o l Microbiol 47:16011612.
Warren, W. A. 1970. Catalysis of both oxidation and reduction of glyoxylate
by pig heart lactate dehydrogenase isoenzyme 1. J. Biol. Chem. 245:16751681.
Watnick, P. I., and R. Rolter. 1999. Steps in the development of a Vibrio
cholerae El Tor biofilm. M o l Microbiol 34:586-95.
Wayne, L. G. 1994. Cultivation of M. tuberculosis for research purposes, p.
73-83. In: B.R. Bloom (Ed.) Tuberculosis: Pathogenesis, Protection & Control.
A S M Press, Washington, D.C.
Wayne, L. G., and C. D. Sohaskey. 2001. Nonreplicating persistence of
Mycobacterium tuberculosis. A n n u Rev Microbiol 55:139-63.
Wayne, L. G., and D. Salkin. 1956. The bacteriology of resected tuberculous
pulmonary lesions. A m . Rev. Tuberc. Pulm. Dis. 74:376-387.
Wayne, L. G., and L. G. Hayes. 1996. An in vitro model for sequential study
of shiftdown of Mycobacterium tuberculosis through two stages of
nonreplicating persistence. Infect I m m u n 64:2062-9.
Weinrauch, Y., and A. Zychlinsky. 1999. The induction of apoptosis by
bacterial pathogens. Annu. Rev. Microbiol. 53:155-187.
Wendisch, V. F., A. A. de Graaf, H. Sahm, and B. J. Eikmanns. 2000.
Quantitative determination of metabolic fluxes during coutilization of two
carbon sources: comparative analyses with Corynebacterium glutamicum
during growth on acetate and/or glucose. J Bacteriol 182:3088-96.

362

Wengenack, N . L., M . P. Jensen, F. Rusnak, and M . R. Stem. 1999.
Mycobacterium tuberculosis KatG is a peroxynitritase. Biochem Biophys Res
C o m m u n 256:485-7.
Wheeler, P. R. 1984. Oxidation of carbon sources through the tricarboxylic
acid cycle in Mycobacterium leprae grown in armadillo liver. J G e n Microbiol
130:381-9.
Wheeler, P. R., and C. Ratledge. 1988. Use of carbon sources for lipid
biosynthesis in Mycobacterium leprae: a comparison with other pathogenic
mycobacteria. J G e n Microbiol 134:2111-21.
WHO. 2004. World Health Report.
Wilske, B., A. G. Barbour, S. Bergstrom, N. Burman, B. I. Restrepo, P. A.
Rosa, T. Schwan, E . Soutschek, and R. Wallich. 1992. Antigenic variation
and strain heterogeneity in Borrelia spp. Res Microbiol 143:583-96.
Wolf, B., Y. E. Hsia, L. Sweetman, R. Gravel, D. J. Harris, and W. L.
N y h a n . 1981. Propionic acidemia: a clinical update. J Pediatr 99:835-46.
Wolfson, J. S., D. C. Hooper, G. L. McHugh, M. A. Bozza, and M. N.
Swartz. 1990. Mutants of Escherichia coli K-12 exhibiting reduced killing by
both quinolone and beta-lactam antimicrobial agents. Antimicrob Agents
Chemother 34:1938-43.
Xie, Q. W., H. J. Cho, J. Calaycay, R. A. Mumford, R. M. Swiderek, T. D.
Lee, A . Ding, T. Troso, and C. Nathan. 1992. Cloning and characterization
of inducible nitric oxide synthase from mouse macrophages. Science 256:2258.
Y a n g , Q . L. and E . C. Gotschlich. 1996. Variation of gonococcal
lipooligosaccharide structure is due to alterations in poly-G tracts in lgt genes
encoding glycosyl transferases. J Exp M e d 183:323-327.
Yildiz, F. H., and G. R. Schoolnik. 1999. Vibrio cholerae 01 El Tor:
identification of a gene cluster required for the rugose colony type,
exopolysaccharide production, chlorine resistance, and biofilm formation. Proc
Natl Acad Sci U S A 96:4028-33.
Zhang, J. R., and S. J. Norris. 1998a. Genetic variation of the Borrelia
burgdorferi gene vlsE involves cassette-specific, segmental gene conversion.
Infect I m m u n 66:3698-704.

363

Zhang, J. R., and S. J. Norris. 1998b. Kinetics and in vivo induction of
genetic variation of vlsE in Borrelia burgdorferi. Infect I m m u n 66:3689-97.
Zhang, J. R., J. M. Hardham, A. G. Barbour, and S. J. Norris. 1997.
Antigenic variation in L y m e disease Borreliae by promiscuous recombination
of VMP-like sequence cassettes. Cell 89:275-85.
Zhu, J., and J. J. Mekalanos. 2003. Quorum sensing-dependent biofilms
enhance colonization in Vibrio cholerae. D e v Cell 5:647-56.

364

